PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 24009852-6 2013 Enhanced catabolism of cellular polyamines by polyamine oxidases (PAO), spermine oxidase (SMO) or acetylpolyamine oxidase (AcPAO), increases cellular oxidative stress and generates hydrogen peroxide and a reactive toxic metabolite, acrolein, which covalently incorporates into lysine residues of cellular proteins. Acrolein 232-240 spermine oxidase Homo sapiens 72-88 24009852-6 2013 Enhanced catabolism of cellular polyamines by polyamine oxidases (PAO), spermine oxidase (SMO) or acetylpolyamine oxidase (AcPAO), increases cellular oxidative stress and generates hydrogen peroxide and a reactive toxic metabolite, acrolein, which covalently incorporates into lysine residues of cellular proteins. Acrolein 232-240 spermine oxidase Homo sapiens 90-93 22961095-0 2013 Involvement of interleukin-6-regulated nitric oxide synthase in hemorrhagic cystitis and impaired bladder contractions in young rats induced by acrolein, a urinary metabolite of cyclophosphamide. Acrolein 144-152 interleukin 6 Rattus norvegicus 15-28 23712027-10 2013 RESULTS: A 48 h exposure to acrolein (30 - 50 microM) did not significantly modify [Ca(2+)]i but significantly decreased forward scatter and increased annexin-V-binding. Acrolein 28-36 annexin A5 Homo sapiens 151-160 23712027-12 2013 Acrolein (50 microM) induced annexin-V-binding was significantly blunted in the nominal absence of extracellular Ca(2+). Acrolein 0-8 annexin A5 Homo sapiens 29-38 23712027-13 2013 Acrolein augmented the annexin-V-binding following treatment with Ca(2+) ionophore ionomycin (1 microM). Acrolein 0-8 annexin A5 Homo sapiens 23-32 22961095-4 2013 Acrolein instillation significantly increased the muscle contractions of rat bladder detrusor after 1 and 6 h but markedly decreased detrusor contractions after 24 h. Acrolein increased phosphorylated protein kinase C (pan-PKC) expressions in bladders after 1 and 6 h but inhibited it after 24 h. Inducible nitric oxide (NO) synthase (iNOS) protein expressions were markedly induced in bladders 24 h after acrolein treatment. Acrolein 0-8 nitric oxide synthase 2 Rattus norvegicus 335-339 22961095-4 2013 Acrolein instillation significantly increased the muscle contractions of rat bladder detrusor after 1 and 6 h but markedly decreased detrusor contractions after 24 h. Acrolein increased phosphorylated protein kinase C (pan-PKC) expressions in bladders after 1 and 6 h but inhibited it after 24 h. Inducible nitric oxide (NO) synthase (iNOS) protein expressions were markedly induced in bladders 24 h after acrolein treatment. Acrolein 167-175 nitric oxide synthase 2 Rattus norvegicus 335-339 22961095-5 2013 Twenty-four-hour acrolein instillation increased the levels of nitrite/nitrate and interleukin-6 (IL-6) in the urinary bladder. Acrolein 17-25 interleukin 6 Rattus norvegicus 83-96 22961095-5 2013 Twenty-four-hour acrolein instillation increased the levels of nitrite/nitrate and interleukin-6 (IL-6) in the urinary bladder. Acrolein 17-25 interleukin 6 Rattus norvegicus 98-102 22961095-8 2013 The increased detrusor contractions by 1-h acrolein treatment were significantly reversed by the PKC inhibitor RO32-0432, and the decreased detrusor contractions by 24-h acrolein treatment were significantly reversed by the iNOS inhibitor and IL-6-neutralizing antibody. Acrolein 170-178 nitric oxide synthase 2 Rattus norvegicus 224-228 22961095-8 2013 The increased detrusor contractions by 1-h acrolein treatment were significantly reversed by the PKC inhibitor RO32-0432, and the decreased detrusor contractions by 24-h acrolein treatment were significantly reversed by the iNOS inhibitor and IL-6-neutralizing antibody. Acrolein 170-178 interleukin 6 Rattus norvegicus 243-247 22961095-9 2013 Both the iNOS inhibitor and IL-6-neutralizing antibody effectively reversed the increased iNOS expression, decreased PKC phosphorylation, increased bladder weight, and hemorrhagic cystitis in rats 24 h after acrolein treatment. Acrolein 208-216 nitric oxide synthase 2 Rattus norvegicus 9-13 22961095-9 2013 Both the iNOS inhibitor and IL-6-neutralizing antibody effectively reversed the increased iNOS expression, decreased PKC phosphorylation, increased bladder weight, and hemorrhagic cystitis in rats 24 h after acrolein treatment. Acrolein 208-216 interleukin 6 Rattus norvegicus 28-32 22953919-3 2012 Moreover, direct trapping of acrolein by phloretin was found to be responsible for inhibiting the incorporation of carbonyl groups into BSA and oligomerisation in RNase A. Acrolein 29-37 ribonuclease A family member 1, pancreatic Homo sapiens 163-170 23328517-14 2012 CONCLUSION: Acrolein decreases the SUMO modification of GRs and reduces the inhibitory effect of dexamethasone on the transcription of MUC5AC. Acrolein 12-20 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 135-141 22928487-2 2012 Acrolein (40 muM) induced HPAEC mitochondrial generation of ROS, rotenone (2 mumol/L) blocked mitochondrial respiratory chain complex I, cesium chloride (CsCl, 40 mmol/L)blocked K(+)channels, and saline (0.9 g/dl) were used as control. Acrolein 0-8 latexin Homo sapiens 13-16 23039888-8 2012 Furthermore, the presence of MPO in tumour microenvironment was accompanied by the formation of acrolein only 5 h after tumour transplantation and its presence increased during tumour regression. Acrolein 96-104 myeloperoxidase Mus musculus 29-32 23026831-7 2012 Acrolein exposure rapidly and dramatically decreased intracellular glutathione and overall antioxidant capacity, and activated the stress-signaling MAP-kinases JNK, p42/44 and p38. Acrolein 0-8 mitogen-activated protein kinase 8 Homo sapiens 160-163 23026831-7 2012 Acrolein exposure rapidly and dramatically decreased intracellular glutathione and overall antioxidant capacity, and activated the stress-signaling MAP-kinases JNK, p42/44 and p38. Acrolein 0-8 erythrocyte membrane protein band 4.2 Homo sapiens 165-168 23026831-7 2012 Acrolein exposure rapidly and dramatically decreased intracellular glutathione and overall antioxidant capacity, and activated the stress-signaling MAP-kinases JNK, p42/44 and p38. Acrolein 0-8 mitogen-activated protein kinase 14 Homo sapiens 176-179 23026831-11 2012 Acrolein-induced cell death was attenuated by N-acetyl cysteine, phenyl-butyric acid, and caspase and JNK inhibitors. Acrolein 0-8 mitogen-activated protein kinase 8 Homo sapiens 102-105 22983351-0 2012 Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Acrolein 34-42 C-X-C motif chemokine ligand 8 Homo sapiens 51-55 22983351-0 2012 Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Acrolein 34-42 C-X-C motif chemokine ligand 8 Homo sapiens 56-61 22983351-0 2012 Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Acrolein 34-42 mitogen-activated protein kinase 1 Homo sapiens 81-84 22983351-0 2012 Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Acrolein 34-42 MAPK activated protein kinase 2 Homo sapiens 90-93 22983351-5 2012 Both CSE and acrolein induced p38 mitogen-activated protein kinase (MAPK) phosphorylation, accompanied by the phosphorylation of MAPK-activated kinase 2 (MK2), a known downstream substrate of the p38 MAPK, both in HBSMCs and in human airway epithelial cells. Acrolein 13-21 mitogen-activated protein kinase 1 Homo sapiens 30-33 22983351-5 2012 Both CSE and acrolein induced p38 mitogen-activated protein kinase (MAPK) phosphorylation, accompanied by the phosphorylation of MAPK-activated kinase 2 (MK2), a known downstream substrate of the p38 MAPK, both in HBSMCs and in human airway epithelial cells. Acrolein 13-21 mitogen-activated protein kinase 3 Homo sapiens 68-72 22983351-5 2012 Both CSE and acrolein induced p38 mitogen-activated protein kinase (MAPK) phosphorylation, accompanied by the phosphorylation of MAPK-activated kinase 2 (MK2), a known downstream substrate of the p38 MAPK, both in HBSMCs and in human airway epithelial cells. Acrolein 13-21 MAPK activated protein kinase 2 Homo sapiens 129-152 22983351-5 2012 Both CSE and acrolein induced p38 mitogen-activated protein kinase (MAPK) phosphorylation, accompanied by the phosphorylation of MAPK-activated kinase 2 (MK2), a known downstream substrate of the p38 MAPK, both in HBSMCs and in human airway epithelial cells. Acrolein 13-21 MAPK activated protein kinase 2 Homo sapiens 154-157 22983351-5 2012 Both CSE and acrolein induced p38 mitogen-activated protein kinase (MAPK) phosphorylation, accompanied by the phosphorylation of MAPK-activated kinase 2 (MK2), a known downstream substrate of the p38 MAPK, both in HBSMCs and in human airway epithelial cells. Acrolein 13-21 mitogen-activated protein kinase 1 Homo sapiens 196-199 22983351-6 2012 Furthermore, pharmacological inhibition of p38 MAPK or MK2 strongly accelerated the decay of IL-8 mRNA levels upon stimulation with CSE or acrolein and subsequent blockade of mRNA neosynthesis with actinomycin D in pulmonary structural cells (HBSMCs and airways epithelial cells) as well as in human alveolar macrophages. Acrolein 139-147 mitogen-activated protein kinase 1 Homo sapiens 43-46 22983351-6 2012 Furthermore, pharmacological inhibition of p38 MAPK or MK2 strongly accelerated the decay of IL-8 mRNA levels upon stimulation with CSE or acrolein and subsequent blockade of mRNA neosynthesis with actinomycin D in pulmonary structural cells (HBSMCs and airways epithelial cells) as well as in human alveolar macrophages. Acrolein 139-147 MAPK activated protein kinase 2 Homo sapiens 55-58 22983351-6 2012 Furthermore, pharmacological inhibition of p38 MAPK or MK2 strongly accelerated the decay of IL-8 mRNA levels upon stimulation with CSE or acrolein and subsequent blockade of mRNA neosynthesis with actinomycin D in pulmonary structural cells (HBSMCs and airways epithelial cells) as well as in human alveolar macrophages. Acrolein 139-147 C-X-C motif chemokine ligand 8 Homo sapiens 93-97 22906079-8 2012 RESULTS: In ARPE-19 cells exposed to acrolein and hyperglycemia there was reduced cell viability and an increase in the cell media of VEGF, TGFbeta1, and TGFbeta2, which was reversed by NBHA. Acrolein 37-45 vascular endothelial growth factor A Homo sapiens 134-138 22906079-8 2012 RESULTS: In ARPE-19 cells exposed to acrolein and hyperglycemia there was reduced cell viability and an increase in the cell media of VEGF, TGFbeta1, and TGFbeta2, which was reversed by NBHA. Acrolein 37-45 transforming growth factor beta 1 Homo sapiens 140-148 22906079-8 2012 RESULTS: In ARPE-19 cells exposed to acrolein and hyperglycemia there was reduced cell viability and an increase in the cell media of VEGF, TGFbeta1, and TGFbeta2, which was reversed by NBHA. Acrolein 37-45 transforming growth factor beta 2 Homo sapiens 154-162 22906079-9 2012 Acrolein/hyperglycemia-induced cell viability reduction and cytokine overproduction was also reduced by TGFbeta pathway blockade. Acrolein 0-8 transforming growth factor beta 1 Homo sapiens 104-111 22906079-10 2012 CONCLUSIONS: We conclude that the effect of acrolein on the reduction of viability and VEGF increase by ARPE-19 cells in hyperglycemic media is conducted through the TGFbeta signaling pathway. Acrolein 44-52 vascular endothelial growth factor A Homo sapiens 87-91 22906079-10 2012 CONCLUSIONS: We conclude that the effect of acrolein on the reduction of viability and VEGF increase by ARPE-19 cells in hyperglycemic media is conducted through the TGFbeta signaling pathway. Acrolein 44-52 transforming growth factor beta 1 Homo sapiens 166-173 23157870-0 2012 [Effect of acrolein exposure on the percentage of CD4+CD25+ regulatory T cells and expression of transcription factor Foxp3 in asthmatic rats]. Acrolein 11-19 Cd4 molecule Rattus norvegicus 50-53 22740640-2 2012 Quantitative real-time polymerase chain reaction analysis revealed a 2.5- to 3-fold induction of the hepatic ALDH1A1 mRNA in mice administered either acrolein (5 mg/kg acrolein p.o.) Acrolein 151-159 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 110-117 22740640-2 2012 Quantitative real-time polymerase chain reaction analysis revealed a 2.5- to 3-fold induction of the hepatic ALDH1A1 mRNA in mice administered either acrolein (5 mg/kg acrolein p.o.) Acrolein 169-177 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 110-117 22832791-2 2012 (5Z)-3,7-syn-7-(2-Trimethylsilylethoxy)methoxyocta-1,5-dien-3-ol 17 was prepared from the tin(iv) chloride promoted reaction of 4-(2-trimethylsilylethoxy)methoxypent-2-enyl(tributyl)stannane 16 with acrolein (1,5-syn : 1,5-anti = 96 : 4). Acrolein 199-207 synemin Homo sapiens 9-12 22869587-9 2012 Biochemical fractionation of acrolein- and hydralazine-treated cells revealed that hydralazine likely promoted Hsp90 migration from cytosol into other subcellular compartments. Acrolein 29-37 heat shock protein 90 alpha family class A member 1 Homo sapiens 111-116 22869587-10 2012 A role for Hsp90 mobilization in cytoprotection was confirmed by the finding that brief heat shock treatment suppressed acute acrolein toxicity in A549 cells. Acrolein 126-134 heat shock protein 90 alpha family class A member 1 Homo sapiens 11-16 22740640-5 2012 The levels of activator protein-1 (AP-1) mRNA and protein, as well as the amount of phosphorylated c-Jun were significantly increased in mouse liver or Hepa1c1c7 cells treated with either BHA or acrolein. Acrolein 195-203 jun proto-oncogene Mus musculus 14-33 22740640-5 2012 The levels of activator protein-1 (AP-1) mRNA and protein, as well as the amount of phosphorylated c-Jun were significantly increased in mouse liver or Hepa1c1c7 cells treated with either BHA or acrolein. Acrolein 195-203 jun proto-oncogene Mus musculus 99-104 23157870-0 2012 [Effect of acrolein exposure on the percentage of CD4+CD25+ regulatory T cells and expression of transcription factor Foxp3 in asthmatic rats]. Acrolein 11-19 forkhead box P3 Rattus norvegicus 118-123 23157870-8 2012 The percentage of CD4+CD25+ T cells ((3.26 +- 0.84)%) in OVA combined acrolein fog exposure group was remarkably lower than that in the aerosolized OVA exposure group and in the normal saline group (P < 0.01). Acrolein 70-78 Cd4 molecule Rattus norvegicus 18-21 23157870-10 2012 Further remarkable increase in IL-4 of both plasma and lung tissue was observed in the group exposed to both OVA and acrolein ((34.32 +- 6.21), (1.45 +- 0.32)ng/L) compared with the aerosolized OVA exposure group and the normal saline group (P < 0.05). Acrolein 117-125 interleukin 4 Rattus norvegicus 31-35 23157870-12 2012 Protein expression of Foxp3 in the aerosolized OVA group (8.07 +- 0.24) was lower than that in the normal saline group (10.25 +- 0.31) (P < 0.01), while the protein expression of Foxp3 in OVA combined acrolein fog exposure group (6.38 +- 0.32) was lower than that in the normal saline group and the aerosolized OVA exposure group (P < 0.01). Acrolein 204-212 forkhead box P3 Rattus norvegicus 22-27 22997880-8 2012 The liberation of cytochrome c from mitochondria to cytosol, the cleavages of the initiator caspase 9 and the effector caspase 3 have been observed after pretreatment with acrolein followed by H/ R in H9c2 cells. Acrolein 172-180 caspase 9 Rattus norvegicus 92-101 22836718-4 2012 At the same concentration (1 mmol/L), glycolaldehyde and acrolein had a stronger suppressive effect on fibrinogen activation than the other three RCCs. Acrolein 57-65 fibrinogen beta chain Homo sapiens 103-113 22997880-8 2012 The liberation of cytochrome c from mitochondria to cytosol, the cleavages of the initiator caspase 9 and the effector caspase 3 have been observed after pretreatment with acrolein followed by H/ R in H9c2 cells. Acrolein 172-180 caspase 3 Rattus norvegicus 119-128 22997880-9 2012 CONCLUSION: Acrolein could aggravate H/R injury and that this effect may be related, in part, to the modification of proteins involved the release of cytochrome c from mitochondria to cytosol and activation of caspases cascade reaction. Acrolein 12-20 caspase 9 Rattus norvegicus 210-218 22360685-6 2012 Acrolein could provoke similar effects only in MDA-MB 231 cells with a low trx1 expression. Acrolein 0-8 thioredoxin Homo sapiens 75-79 22522920-3 2012 The objective of the current study was to evaluate the effects of acrolein exposure (a prominent tobacco smoke toxin) on vectorial Cl(-) transport through the major apical anion channel cystic fibrosis transmembrane conductance regulator (CFTR) in sinonasal epithelium. Acrolein 66-74 cystic fibrosis transmembrane conductance regulator Mus musculus 239-243 22522920-10 2012 CONCLUSIONS: The present study demonstrates that acrolein has complex but pronounced interaction with the major apical Cl(-) transport mechanism that uses CFTR. Acrolein 49-57 cystic fibrosis transmembrane conductance regulator Mus musculus 155-159 22360685-7 2012 Simultaneous trx1 oxidation and trxR inactivation occurred only in the presence of Acrolein and resulted in a G2-M cell cycle arrest, without full CDC25 inhibition in MDA-MB 231 cells. Acrolein 83-91 thioredoxin Homo sapiens 13-17 22342303-11 2012 Finally, acrolein, an unsaturated aldehyde present in CSE, caused Src activation. Acrolein 9-17 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 54-57 21951103-0 2012 Melatonin suppresses acrolein-induced IL-8 production in human pulmonary fibroblasts. Acrolein 21-29 C-X-C motif chemokine ligand 8 Homo sapiens 38-42 21951103-6 2012 In this study, we investigated whether melatonin suppresses acrolein-induced IL-8 secretion in human pulmonary fibroblasts (HPFs). Acrolein 60-68 C-X-C motif chemokine ligand 8 Homo sapiens 77-81 21951103-7 2012 It was found that acrolein-induced IL-8 production was accompanied by increased levels of phosphorylation of Akt and extracellular signal-regulated kinases (ERK1/2) in HPFs, and that melatonin suppressed IL-8 production in HPFs. Acrolein 18-26 C-X-C motif chemokine ligand 8 Homo sapiens 35-39 21951103-7 2012 It was found that acrolein-induced IL-8 production was accompanied by increased levels of phosphorylation of Akt and extracellular signal-regulated kinases (ERK1/2) in HPFs, and that melatonin suppressed IL-8 production in HPFs. Acrolein 18-26 AKT serine/threonine kinase 1 Homo sapiens 109-112 21951103-7 2012 It was found that acrolein-induced IL-8 production was accompanied by increased levels of phosphorylation of Akt and extracellular signal-regulated kinases (ERK1/2) in HPFs, and that melatonin suppressed IL-8 production in HPFs. Acrolein 18-26 mitogen-activated protein kinase 3 Homo sapiens 157-163 21951103-7 2012 It was found that acrolein-induced IL-8 production was accompanied by increased levels of phosphorylation of Akt and extracellular signal-regulated kinases (ERK1/2) in HPFs, and that melatonin suppressed IL-8 production in HPFs. Acrolein 18-26 C-X-C motif chemokine ligand 8 Homo sapiens 204-208 21951103-8 2012 These results suggest that melatonin suppresses acrolein-induced IL-8 production via ERK1/2 and phosphatidylinositol 3-kinase (PI3K)/Akt signal inhibition in HPFs. Acrolein 48-56 C-X-C motif chemokine ligand 8 Homo sapiens 65-69 21951103-8 2012 These results suggest that melatonin suppresses acrolein-induced IL-8 production via ERK1/2 and phosphatidylinositol 3-kinase (PI3K)/Akt signal inhibition in HPFs. Acrolein 48-56 mitogen-activated protein kinase 3 Homo sapiens 85-91 21951103-8 2012 These results suggest that melatonin suppresses acrolein-induced IL-8 production via ERK1/2 and phosphatidylinositol 3-kinase (PI3K)/Akt signal inhibition in HPFs. Acrolein 48-56 AKT serine/threonine kinase 1 Homo sapiens 133-136 22339434-2 2012 In this work, it was determined that, among the three most studied human ALDH isoforms, ALDH2 showed the highest catalytic efficiency for oxidation of acrolein, 4-hydroxy-2-nonenal (4-HNE), and malondialdehyde. Acrolein 151-159 aldehyde dehydrogenase 1 family member A1 Homo sapiens 73-77 22339434-2 2012 In this work, it was determined that, among the three most studied human ALDH isoforms, ALDH2 showed the highest catalytic efficiency for oxidation of acrolein, 4-hydroxy-2-nonenal (4-HNE), and malondialdehyde. Acrolein 151-159 aldehyde dehydrogenase 2 family member Homo sapiens 88-93 22339434-6 2012 Formation of adducts of ALDH1A1 and ALDH2 with acrolein increased their K(d) values for NAD(+) by 2- and 3-fold, respectively. Acrolein 47-55 aldehyde dehydrogenase 1 family member A1 Homo sapiens 24-31 22339434-6 2012 Formation of adducts of ALDH1A1 and ALDH2 with acrolein increased their K(d) values for NAD(+) by 2- and 3-fold, respectively. Acrolein 47-55 aldehyde dehydrogenase 2 family member Homo sapiens 36-41 22342303-11 2012 Finally, acrolein, an unsaturated aldehyde present in CSE, caused Src activation. Acrolein 9-17 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 66-69 22296172-0 2012 Mukaiyama-Michael reactions with acrolein and methacrolein: a catalytic enantioselective synthesis of the C17-C28 fragment of pectenotoxins. Acrolein 33-41 cytokine like 1 Homo sapiens 106-109 22178192-7 2012 Indeed, modification of apoA-I by malondialdehyde (MDA) or acrolein also markedly impaired the lipoprotein"s ability to promote cellular cholesterol efflux by the ABCA1 pathway. Acrolein 59-67 apolipoprotein A1 Homo sapiens 24-30 22178192-7 2012 Indeed, modification of apoA-I by malondialdehyde (MDA) or acrolein also markedly impaired the lipoprotein"s ability to promote cellular cholesterol efflux by the ABCA1 pathway. Acrolein 59-67 ATP binding cassette subfamily A member 1 Homo sapiens 163-168 21778411-2 2012 Exposure of mice to acrolein at concentrations similar to those in cigarette smoke (5 ppm, 4 h) significantly suppressed alveolar macrophage responses to bacterial LPS, indicated by reduced induction of nitric oxide synthase 2, TNF-alpha, and IL-12p40. Acrolein 20-28 tumor necrosis factor Mus musculus 228-237 22001351-5 2012 Results show that AKR7A2 provides increased resistance to the cytotoxicity of 4-hydroxynonenal (HNE) and modest resistance to the cytotoxicity of trans, trans-muconaldehyde (MUC) and methyglyoxal, but provided no protection against crotonaldehyde and acrolein. Acrolein 251-259 aldo-keto reductase family 7 member A2 Homo sapiens 18-24 21778411-2 2012 Exposure of mice to acrolein at concentrations similar to those in cigarette smoke (5 ppm, 4 h) significantly suppressed alveolar macrophage responses to bacterial LPS, indicated by reduced induction of nitric oxide synthase 2, TNF-alpha, and IL-12p40. Acrolein 20-28 interleukin 12b Mus musculus 243-251 22905134-5 2012 In cultured human airway epithelial and smooth muscle cells and fibroblasts, acrolein and CS extract evoked IL-8 release, a response selectively reduced by TRPA1 antagonists. Acrolein 77-85 chemokine (C-X-C motif) ligand 15 Mus musculus 108-112 22905134-5 2012 In cultured human airway epithelial and smooth muscle cells and fibroblasts, acrolein and CS extract evoked IL-8 release, a response selectively reduced by TRPA1 antagonists. Acrolein 77-85 transient receptor potential cation channel subfamily A member 1 Homo sapiens 156-161 22905134-7 2012 However, only acrolein and CS, but not capsaicin or SP, released the keratinocyte chemoattractant (CXCL-1/KC, IL-8 analogue) in bronchoalveolar lavage (BAL) fluid of wild-type mice. Acrolein 14-22 chemokine (C-X-C motif) ligand 1 Mus musculus 99-105 22905134-7 2012 However, only acrolein and CS, but not capsaicin or SP, released the keratinocyte chemoattractant (CXCL-1/KC, IL-8 analogue) in bronchoalveolar lavage (BAL) fluid of wild-type mice. Acrolein 14-22 chemokine (C-X-C motif) ligand 15 Mus musculus 110-114 22675432-8 2012 RESULTS: Acute administration of acrolein caused a significant elevation of activated caspase 3, upregulation of VEGF expression and induced ER stress proteins in the lung tissue. Acrolein 33-41 caspase 3 Rattus norvegicus 86-95 22442701-8 2012 Furthermore, CS caused the formation of SR-B1-aldheydes adducts (acrolein and 4-hydroxy-2-nonenal) and the increase of its ubiquitination, which could be one of the causes of SR-B1 loss. Acrolein 65-73 scavenger receptor class B member 1 Homo sapiens 40-45 22084934-4 2011 To address these data gaps, we incubated purified human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with acrylamide (ACR), acrolein, or methylvinyl ketone (MVK). Acrolein 128-136 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 56-96 22675432-8 2012 RESULTS: Acute administration of acrolein caused a significant elevation of activated caspase 3, upregulation of VEGF expression and induced ER stress proteins in the lung tissue. Acrolein 33-41 vascular endothelial growth factor A Rattus norvegicus 113-117 22675432-10 2012 TUNEL staining and IHC for cleaved caspase 3 showed a large number of apoptotic septal cells in the acrolein-treated rat lungs. Acrolein 100-108 caspase 3 Rattus norvegicus 35-44 22675432-11 2012 Chronic acrolein administration cause the endoplasmic reticulum stress response manifested by significant upregulation of ATF4, CHOP and GADd34 expression. Acrolein 8-16 activating transcription factor 4 Rattus norvegicus 122-126 22675432-11 2012 Chronic acrolein administration cause the endoplasmic reticulum stress response manifested by significant upregulation of ATF4, CHOP and GADd34 expression. Acrolein 8-16 protein phosphatase 1, regulatory subunit 15A Rattus norvegicus 137-143 21903934-5 2011 Menthol, at a concentration (16 ppm) lower than in smoke of mentholated cigarettes, immediately abolished the irritation response to acrolein, an agonist of TRPA1, as did eucalyptol (460 ppm), another TRPM8 agonist. Acrolein 133-141 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 157-162 21868092-8 2011 Acrolein and mustard oil (MO)--at muM concentrations--induced a TRPA1-dependent iCGRP release; however, millimolar concentrations of mustard oil (>1mM) evoked iCGRP release by activating TRPV1, confirming recent evidence for TRPV1 agonism of high mustard oil concentrations. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 64-69 21868092-8 2011 Acrolein and mustard oil (MO)--at muM concentrations--induced a TRPA1-dependent iCGRP release; however, millimolar concentrations of mustard oil (>1mM) evoked iCGRP release by activating TRPV1, confirming recent evidence for TRPV1 agonism of high mustard oil concentrations. Acrolein 0-8 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 190-195 21868092-8 2011 Acrolein and mustard oil (MO)--at muM concentrations--induced a TRPA1-dependent iCGRP release; however, millimolar concentrations of mustard oil (>1mM) evoked iCGRP release by activating TRPV1, confirming recent evidence for TRPV1 agonism of high mustard oil concentrations. Acrolein 0-8 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 228-233 21908791-8 2011 Acrolein also induced myocyte hypertrophy (~2.2-fold increased myocyte area, P < 0.05), increased apoptosis (~7.5-fold), and disrupted endothelial nitric oxide synthase in the heart. Acrolein 0-8 nitric oxide synthase 3, endothelial cell Mus musculus 138-171 21454804-7 2011 Using mass spectrometry, irreversible oxidation of recombinant Grx1 by CSE and acrolein was demonstrated, which was associated with attenuated enzyme activity. Acrolein 79-87 glutaredoxin Mus musculus 63-67 21854768-0 2011 Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. Acrolein 0-8 TNF superfamily member 10 Homo sapiens 53-58 21854768-0 2011 Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. Acrolein 0-8 TNF receptor superfamily member 10b Homo sapiens 111-127 21854768-0 2011 Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. Acrolein 0-8 TNF receptor superfamily member 10b Homo sapiens 129-132 21854768-0 2011 Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. Acrolein 0-8 BCL2 apoptosis regulator Homo sapiens 157-162 21854768-4 2011 We investigated whether acrolein, an alpha,beta-unsaturated aldehyde, can potentiate TRAIL-induced apoptosis in human renal cancer cells. Acrolein 24-32 TNF superfamily member 10 Homo sapiens 85-90 21854768-5 2011 The combined treatment with acrolein and TRAIL significantly induced apoptosis, and stimulated of caspase-3 activity, DNA fragmentation, and cleavage of PARP. Acrolein 28-36 caspase 3 Homo sapiens 98-107 21854768-5 2011 The combined treatment with acrolein and TRAIL significantly induced apoptosis, and stimulated of caspase-3 activity, DNA fragmentation, and cleavage of PARP. Acrolein 28-36 collagen type XI alpha 2 chain Homo sapiens 153-157 21854768-6 2011 We found that acrolein down-regulated the protein level of Bcl-2 and Bcl-2 overexpression inhibited the cell death induced by the combined treatment with acrolein and TRAIL. Acrolein 14-22 BCL2 apoptosis regulator Homo sapiens 59-64 21854768-6 2011 We found that acrolein down-regulated the protein level of Bcl-2 and Bcl-2 overexpression inhibited the cell death induced by the combined treatment with acrolein and TRAIL. Acrolein 14-22 BCL2 apoptosis regulator Homo sapiens 69-74 21854768-6 2011 We found that acrolein down-regulated the protein level of Bcl-2 and Bcl-2 overexpression inhibited the cell death induced by the combined treatment with acrolein and TRAIL. Acrolein 14-22 TNF superfamily member 10 Homo sapiens 167-172 21854768-9 2011 Taken together, our results demonstrated that acrolein enhances TRAIL-induced apoptosis in Caki cells through down-regulation of Bcl-2 and ROS dependent up-regulation of DR5. Acrolein 46-54 TNF superfamily member 10 Homo sapiens 64-69 21854768-9 2011 Taken together, our results demonstrated that acrolein enhances TRAIL-induced apoptosis in Caki cells through down-regulation of Bcl-2 and ROS dependent up-regulation of DR5. Acrolein 46-54 BCL2 apoptosis regulator Homo sapiens 129-134 21854768-9 2011 Taken together, our results demonstrated that acrolein enhances TRAIL-induced apoptosis in Caki cells through down-regulation of Bcl-2 and ROS dependent up-regulation of DR5. Acrolein 46-54 TNF receptor superfamily member 10b Homo sapiens 170-173 21972382-3 2011 Transient receptor potential cation channel, subfamily A, member 1 (TRPA1) channels are nonselective cation channels that are activated by a range of natural products (eg, allyl isothiocyanate), a multitude of environmental irritants (eg, acrolein, which is present in air pollution, vehicle exhaust, and cigarette smoke), and inflammatory mediators (eg, cyclopentenone prostaglandins). Acrolein 239-247 transient receptor potential cation channel subfamily A member 1 Homo sapiens 0-66 21972382-3 2011 Transient receptor potential cation channel, subfamily A, member 1 (TRPA1) channels are nonselective cation channels that are activated by a range of natural products (eg, allyl isothiocyanate), a multitude of environmental irritants (eg, acrolein, which is present in air pollution, vehicle exhaust, and cigarette smoke), and inflammatory mediators (eg, cyclopentenone prostaglandins). Acrolein 239-247 transient receptor potential cation channel subfamily A member 1 Homo sapiens 68-73 21742783-3 2011 In vitro cigarette smoke extract (CSE) and one of its components, acrolein, inhibit the mammalian target of rapamycin (mTOR)/p70S6K pathway in human endothelial cells, and chemical inhibition of this pathway by rapamycin resulted in elevated MMP-1. Acrolein 66-74 mechanistic target of rapamycin kinase Homo sapiens 88-117 21742783-3 2011 In vitro cigarette smoke extract (CSE) and one of its components, acrolein, inhibit the mammalian target of rapamycin (mTOR)/p70S6K pathway in human endothelial cells, and chemical inhibition of this pathway by rapamycin resulted in elevated MMP-1. Acrolein 66-74 mechanistic target of rapamycin kinase Homo sapiens 119-123 21742783-4 2011 Moreover, the tissue inhibitor of metalloproteases-3 (TIMP-3), a major regulator of angiogenesis, is significantly downregulated in aortic endothelial cells treated with CSE, acrolein, or rapamycin. Acrolein 175-183 TIMP metallopeptidase inhibitor 3 Homo sapiens 14-60 21742783-3 2011 In vitro cigarette smoke extract (CSE) and one of its components, acrolein, inhibit the mammalian target of rapamycin (mTOR)/p70S6K pathway in human endothelial cells, and chemical inhibition of this pathway by rapamycin resulted in elevated MMP-1. Acrolein 66-74 ribosomal protein S6 kinase B1 Homo sapiens 125-131 21742783-3 2011 In vitro cigarette smoke extract (CSE) and one of its components, acrolein, inhibit the mammalian target of rapamycin (mTOR)/p70S6K pathway in human endothelial cells, and chemical inhibition of this pathway by rapamycin resulted in elevated MMP-1. Acrolein 66-74 matrix metallopeptidase 1 Homo sapiens 242-247 21527748-0 2011 Acrolein inhalation prevents vascular endothelial growth factor-induced mobilization of Flk-1+/Sca-1+ cells in mice. Acrolein 0-8 vascular endothelial growth factor A Mus musculus 29-63 21812108-0 2011 The effects of acrolein on the thioredoxin system: implications for redox-sensitive signaling. Acrolein 15-23 thioredoxin Homo sapiens 31-42 21812108-3 2011 This review focuses on the effects of acrolein on thioredoxin reductase (TrxR) and thioredoxin (Trx), which are major regulators of intracellular protein thiol redox balance. Acrolein 38-46 peroxiredoxin 5 Homo sapiens 50-71 21812108-3 2011 This review focuses on the effects of acrolein on thioredoxin reductase (TrxR) and thioredoxin (Trx), which are major regulators of intracellular protein thiol redox balance. Acrolein 38-46 peroxiredoxin 5 Homo sapiens 73-77 21812108-3 2011 This review focuses on the effects of acrolein on thioredoxin reductase (TrxR) and thioredoxin (Trx), which are major regulators of intracellular protein thiol redox balance. Acrolein 38-46 thioredoxin Homo sapiens 50-61 21812108-3 2011 This review focuses on the effects of acrolein on thioredoxin reductase (TrxR) and thioredoxin (Trx), which are major regulators of intracellular protein thiol redox balance. Acrolein 38-46 thioredoxin Homo sapiens 73-76 21812108-4 2011 Acrolein causes irreversible effects on TrxR and Trx, which are consistent with the formation of covalent adducts to selenocysteine and cysteine residues that are key to their activity. Acrolein 0-8 peroxiredoxin 5 Homo sapiens 40-44 21812108-4 2011 Acrolein causes irreversible effects on TrxR and Trx, which are consistent with the formation of covalent adducts to selenocysteine and cysteine residues that are key to their activity. Acrolein 0-8 thioredoxin Homo sapiens 40-43 21812108-7 2011 ASK1 promotes MAP kinase activation, and p38 activation contributes to apoptosis and a number of other acrolein-induced stress responses. Acrolein 103-111 mitogen-activated protein kinase kinase kinase 5 Homo sapiens 0-4 21812108-7 2011 ASK1 promotes MAP kinase activation, and p38 activation contributes to apoptosis and a number of other acrolein-induced stress responses. Acrolein 103-111 mitogen-activated protein kinase 14 Homo sapiens 41-44 21812108-8 2011 Overall, the disruption of the TrxR/Trx system by acrolein could be significant early and prolonged events that affect many aspects of redox-sensitive signaling and oxidant stress. Acrolein 50-58 peroxiredoxin 5 Homo sapiens 31-35 21812108-8 2011 Overall, the disruption of the TrxR/Trx system by acrolein could be significant early and prolonged events that affect many aspects of redox-sensitive signaling and oxidant stress. Acrolein 50-58 thioredoxin Homo sapiens 31-34 21527748-6 2011 Exposure to acrolein blocked vascular endothelial growth factor (VEGF)/AMD3100-stimulated mobilization of Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells and prevented VEGF-induced phosphorylation of Akt and endothelial nitric oxide synthase in the aorta. Acrolein 12-20 vascular endothelial growth factor A Mus musculus 166-170 21527748-6 2011 Exposure to acrolein blocked vascular endothelial growth factor (VEGF)/AMD3100-stimulated mobilization of Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells and prevented VEGF-induced phosphorylation of Akt and endothelial nitric oxide synthase in the aorta. Acrolein 12-20 thymoma viral proto-oncogene 1 Mus musculus 198-201 21527748-6 2011 Exposure to acrolein blocked vascular endothelial growth factor (VEGF)/AMD3100-stimulated mobilization of Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells and prevented VEGF-induced phosphorylation of Akt and endothelial nitric oxide synthase in the aorta. Acrolein 12-20 nitric oxide synthase 3, endothelial cell Mus musculus 206-239 21527748-0 2011 Acrolein inhalation prevents vascular endothelial growth factor-induced mobilization of Flk-1+/Sca-1+ cells in mice. Acrolein 0-8 kinase insert domain protein receptor Mus musculus 88-93 21527748-7 2011 CONCLUSIONS: Inhalation of acrolein increases apoptosis and suppresses the circulating levels of Flk-1(+)/Sca-1(+) cells while increasing these cells in the bone marrow and preventing their mobilization by VEGF. Acrolein 27-35 kinase insert domain protein receptor Mus musculus 97-102 21527748-0 2011 Acrolein inhalation prevents vascular endothelial growth factor-induced mobilization of Flk-1+/Sca-1+ cells in mice. Acrolein 0-8 lymphocyte antigen 6 complex, locus A Mus musculus 95-100 21527748-7 2011 CONCLUSIONS: Inhalation of acrolein increases apoptosis and suppresses the circulating levels of Flk-1(+)/Sca-1(+) cells while increasing these cells in the bone marrow and preventing their mobilization by VEGF. Acrolein 27-35 lymphocyte antigen 6 complex, locus A Mus musculus 106-111 21527748-7 2011 CONCLUSIONS: Inhalation of acrolein increases apoptosis and suppresses the circulating levels of Flk-1(+)/Sca-1(+) cells while increasing these cells in the bone marrow and preventing their mobilization by VEGF. Acrolein 27-35 vascular endothelial growth factor A Mus musculus 206-210 21527748-2 2011 Because exposure to these pollutants is associated with an increase in cardiovascular disease risk, we studied the effects of acrolein on Flk-1(+)/Sca-1(+) cells that are involved in vascular repair. Acrolein 126-134 kinase insert domain protein receptor Mus musculus 138-143 21527748-2 2011 Because exposure to these pollutants is associated with an increase in cardiovascular disease risk, we studied the effects of acrolein on Flk-1(+)/Sca-1(+) cells that are involved in vascular repair. Acrolein 126-134 lymphocyte antigen 6 complex, locus A Mus musculus 147-152 21527748-3 2011 METHODS AND RESULTS: In adult male C57BL/6 mice, inhalation of acrolein (1 part per million [ppm], 6 hours/day for 4 days or 5 ppm for 2 or 6 hours) led to the formation of protein-acrolein adducts in the bone marrow and diminished levels of plasma nitric oxide metabolites and circulating Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells. Acrolein 63-71 kinase insert domain protein receptor Mus musculus 290-295 21527748-3 2011 METHODS AND RESULTS: In adult male C57BL/6 mice, inhalation of acrolein (1 part per million [ppm], 6 hours/day for 4 days or 5 ppm for 2 or 6 hours) led to the formation of protein-acrolein adducts in the bone marrow and diminished levels of plasma nitric oxide metabolites and circulating Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells. Acrolein 63-71 lymphocyte antigen 6 complex, locus A Mus musculus 299-304 21527748-3 2011 METHODS AND RESULTS: In adult male C57BL/6 mice, inhalation of acrolein (1 part per million [ppm], 6 hours/day for 4 days or 5 ppm for 2 or 6 hours) led to the formation of protein-acrolein adducts in the bone marrow and diminished levels of plasma nitric oxide metabolites and circulating Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells. Acrolein 63-71 lymphocyte antigen 6 complex, locus A Mus musculus 316-321 21527748-4 2011 Acrolein exposure increased the number of apoptotic Flk-1(+)/Sca-1(+) cells in circulation and increased bone marrow-derived cells with endothelial characteristics (DiI-ac-low-density lipoprotein [DiI-acLDL]/UE-lectin and Flk-1(+)/Sca-1(+)) in culture. Acrolein 0-8 kinase insert domain protein receptor Mus musculus 52-57 21527748-4 2011 Acrolein exposure increased the number of apoptotic Flk-1(+)/Sca-1(+) cells in circulation and increased bone marrow-derived cells with endothelial characteristics (DiI-ac-low-density lipoprotein [DiI-acLDL]/UE-lectin and Flk-1(+)/Sca-1(+)) in culture. Acrolein 0-8 lymphocyte antigen 6 complex, locus A Mus musculus 61-66 21527748-4 2011 Acrolein exposure increased the number of apoptotic Flk-1(+)/Sca-1(+) cells in circulation and increased bone marrow-derived cells with endothelial characteristics (DiI-ac-low-density lipoprotein [DiI-acLDL]/UE-lectin and Flk-1(+)/Sca-1(+)) in culture. Acrolein 0-8 kinase insert domain protein receptor Mus musculus 222-227 21527748-4 2011 Acrolein exposure increased the number of apoptotic Flk-1(+)/Sca-1(+) cells in circulation and increased bone marrow-derived cells with endothelial characteristics (DiI-ac-low-density lipoprotein [DiI-acLDL]/UE-lectin and Flk-1(+)/Sca-1(+)) in culture. Acrolein 0-8 lymphocyte antigen 6 complex, locus A Mus musculus 231-236 21527748-5 2011 Deficits in the circulating levels of Flk-1(+)/Sca-1(+) cells were reversed after 7 days of recovery in acrolein-free air. Acrolein 104-112 kinase insert domain protein receptor Mus musculus 38-43 21527748-5 2011 Deficits in the circulating levels of Flk-1(+)/Sca-1(+) cells were reversed after 7 days of recovery in acrolein-free air. Acrolein 104-112 lymphocyte antigen 6 complex, locus A Mus musculus 47-52 21527748-6 2011 Exposure to acrolein blocked vascular endothelial growth factor (VEGF)/AMD3100-stimulated mobilization of Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells and prevented VEGF-induced phosphorylation of Akt and endothelial nitric oxide synthase in the aorta. Acrolein 12-20 vascular endothelial growth factor A Mus musculus 29-63 21527748-6 2011 Exposure to acrolein blocked vascular endothelial growth factor (VEGF)/AMD3100-stimulated mobilization of Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells and prevented VEGF-induced phosphorylation of Akt and endothelial nitric oxide synthase in the aorta. Acrolein 12-20 vascular endothelial growth factor A Mus musculus 65-69 21527748-6 2011 Exposure to acrolein blocked vascular endothelial growth factor (VEGF)/AMD3100-stimulated mobilization of Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells and prevented VEGF-induced phosphorylation of Akt and endothelial nitric oxide synthase in the aorta. Acrolein 12-20 kinase insert domain protein receptor Mus musculus 106-111 21527748-6 2011 Exposure to acrolein blocked vascular endothelial growth factor (VEGF)/AMD3100-stimulated mobilization of Flk-1(+)/Sca-1(+) but not Sca-1(+)-only cells and prevented VEGF-induced phosphorylation of Akt and endothelial nitric oxide synthase in the aorta. Acrolein 12-20 lymphocyte antigen 6 complex, locus A Mus musculus 115-120 20890592-5 2011 Acrolein inhibited NF-kappaB activity without altering cellular levels of the phosphorylated and nonphosphorylated forms of I-kappaBalpha, implying that the downregulatory effect of acrolein on cellular NF-kappaB activity in human skin cells is an I-kappaBalpha-independent activation pathway. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 19-28 21256123-3 2011 The catalytic efficiencies for metabolism of acrolein by Aldh1a1 was comparable to that of Aldh3a1 (V(max)/K(m)=23). Acrolein 45-53 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 57-64 21256123-3 2011 The catalytic efficiencies for metabolism of acrolein by Aldh1a1 was comparable to that of Aldh3a1 (V(max)/K(m)=23). Acrolein 45-53 aldehyde dehydrogenase family 3, subfamily A1 Mus musculus 91-98 21256123-9 2011 We demonstrated that knockdown of Aldh1a1 expression by siRNA caused Hepa-1c1c7 cells to be more sensitive to acrolein-induced cell death and resulted in increased accumulation of acrolein-protein adducts and caspase 3 activation. Acrolein 110-118 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 34-41 21256123-12 2011 In addition, hepatic cytosolic ALDH activity was induced by acrolein when 1mM NAD(+) was used as cofactor, suggesting an Aldh1a1-protective mechanism against acrolein toxicity in mice liver. Acrolein 60-68 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 31-35 21256123-12 2011 In addition, hepatic cytosolic ALDH activity was induced by acrolein when 1mM NAD(+) was used as cofactor, suggesting an Aldh1a1-protective mechanism against acrolein toxicity in mice liver. Acrolein 60-68 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 121-128 21256123-12 2011 In addition, hepatic cytosolic ALDH activity was induced by acrolein when 1mM NAD(+) was used as cofactor, suggesting an Aldh1a1-protective mechanism against acrolein toxicity in mice liver. Acrolein 158-166 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 31-35 21256123-12 2011 In addition, hepatic cytosolic ALDH activity was induced by acrolein when 1mM NAD(+) was used as cofactor, suggesting an Aldh1a1-protective mechanism against acrolein toxicity in mice liver. Acrolein 158-166 aldehyde dehydrogenase family 1, subfamily A1 Mus musculus 121-128 21306579-5 2011 CSE-evoked VEGF release was mimicked by its component acrolein at concentrations (10-100 microM) found in CSE, and prevented by the antioxidant and alpha,beta-unsaturated aldehyde scavenger, N-acetylcysteine (NAC). Acrolein 54-62 vascular endothelial growth factor A Homo sapiens 11-15 21306579-6 2011 Both CSE and acrolein (30 microM) induced VEGF mRNA expression in ASMC cultures, suggesting an effect at transcriptional level. Acrolein 13-21 vascular endothelial growth factor A Homo sapiens 42-46 20890592-0 2011 Acrolein, an I-kappaBalpha-independent downregulator of NF-kappaB activity, causes the decrease in nitric oxide production in human malignant keratinocytes. Acrolein 0-8 NFKB inhibitor alpha Homo sapiens 13-26 20890592-0 2011 Acrolein, an I-kappaBalpha-independent downregulator of NF-kappaB activity, causes the decrease in nitric oxide production in human malignant keratinocytes. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 56-65 20890592-6 2011 The results suggests that acrolein causes the decrease in nitric oxide production as an I-kappaBalpha-independent downregulator of NF-kappaB activity in human malignant keratinocytes, and acrolein-induced carcinogenesis may be associated with the modulation of cellular NF-kappaB activity. Acrolein 26-34 NFKB inhibitor alpha Homo sapiens 88-101 20890592-2 2011 The effect of acrolein on the activation of NF-kappaB in human malignant epidermal keratinocytes was examined to elucidate the molecular mechanism associated with this NF-kappaB-acrolein regulation and its consecutive sequence, nitric oxide (NO) production. Acrolein 14-22 nuclear factor kappa B subunit 1 Homo sapiens 44-53 20890592-3 2011 Acrolein significantly downregulated the cellular NF-kappaB activity up to 60% compared with control as well as the lipopolysaccharide (LPS)-induced NO production in a dose response manner at concentrations of 10~30 muM. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 50-59 20890592-3 2011 Acrolein significantly downregulated the cellular NF-kappaB activity up to 60% compared with control as well as the lipopolysaccharide (LPS)-induced NO production in a dose response manner at concentrations of 10~30 muM. Acrolein 0-8 latexin Homo sapiens 216-219 20890592-4 2011 To investigate the regulatory mechanism associated with this NF-kappaB-acrolein downregulation, the relative level of phosphorylation of I-kappaBalpha (serines-32 and -36), a principle regulator of NF-kappaB activation, represented by acrolein, was quantified. Acrolein 71-79 nuclear factor kappa B subunit 1 Homo sapiens 61-70 20890592-6 2011 The results suggests that acrolein causes the decrease in nitric oxide production as an I-kappaBalpha-independent downregulator of NF-kappaB activity in human malignant keratinocytes, and acrolein-induced carcinogenesis may be associated with the modulation of cellular NF-kappaB activity. Acrolein 26-34 nuclear factor kappa B subunit 1 Homo sapiens 131-140 20890592-6 2011 The results suggests that acrolein causes the decrease in nitric oxide production as an I-kappaBalpha-independent downregulator of NF-kappaB activity in human malignant keratinocytes, and acrolein-induced carcinogenesis may be associated with the modulation of cellular NF-kappaB activity. Acrolein 26-34 nuclear factor kappa B subunit 1 Homo sapiens 270-279 21371710-0 2011 Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Acrolein 17-25 apolipoprotein E Mus musculus 57-61 21167846-2 2011 TRC051384, a novel compound belonging to substituted 2-propen-1-one class is a potent inducer of heat shock protein 70 (HSP70). Acrolein 53-67 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 97-118 21167846-2 2011 TRC051384, a novel compound belonging to substituted 2-propen-1-one class is a potent inducer of heat shock protein 70 (HSP70). Acrolein 53-67 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 120-125 21423979-5 2011 The CH(2)CHCO fragment spontaneously decomposes to CH(2)CH + CO. A proportion of primary products CH(2)CH from the fission of bond C-C of propenal further decompose to CHCH + H but secondary dissociation HCO H + CO is negligibly small. Acrolein 138-146 churchill domain containing 1 Homo sapiens 168-172 21371710-11 2011 Plasma PF4 levels and accumulation of PF4 in atherosclerotic lesions was increased in the acrolein-fed mice. Acrolein 90-98 platelet factor 4 Mus musculus 7-10 21371710-11 2011 Plasma PF4 levels and accumulation of PF4 in atherosclerotic lesions was increased in the acrolein-fed mice. Acrolein 90-98 platelet factor 4 Mus musculus 38-41 21371710-12 2011 Incubation of endothelial cells with the plasma of acrolein-fed mice augmented transmigration of monocytic cells, which was abolished by anti-PF4 antibody treatment. Acrolein 51-59 platelet factor 4 Mus musculus 142-145 21371710-13 2011 CONCLUSIONS: Dietary exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Acrolein 33-41 apolipoprotein E Mus musculus 73-77 21036164-0 2011 Doxycycline attenuates acrolein-induced mucin production, in part by inhibiting MMP-9. Acrolein 23-31 solute carrier family 13 member 2 Rattus norvegicus 40-45 21309688-2 2011 Our purpose was to investigate the potential of acrolein to influence the release of transforming growth factor beta-2 (TGFbeta2) and vascular endothelial growth factor (VEGF), to assess the ability of N-benzylhydroxylamine (NBHA) to prevent the effect of acrolein on cytokine release and reduction of viable cells, and to explore the pathway by which acrolein might be causing the increase of VEGF. Acrolein 48-56 transforming growth factor beta 2 Homo sapiens 85-118 21309688-2 2011 Our purpose was to investigate the potential of acrolein to influence the release of transforming growth factor beta-2 (TGFbeta2) and vascular endothelial growth factor (VEGF), to assess the ability of N-benzylhydroxylamine (NBHA) to prevent the effect of acrolein on cytokine release and reduction of viable cells, and to explore the pathway by which acrolein might be causing the increase of VEGF. Acrolein 48-56 transforming growth factor beta 2 Homo sapiens 120-128 21309688-2 2011 Our purpose was to investigate the potential of acrolein to influence the release of transforming growth factor beta-2 (TGFbeta2) and vascular endothelial growth factor (VEGF), to assess the ability of N-benzylhydroxylamine (NBHA) to prevent the effect of acrolein on cytokine release and reduction of viable cells, and to explore the pathway by which acrolein might be causing the increase of VEGF. Acrolein 48-56 vascular endothelial growth factor A Homo sapiens 134-168 21309688-2 2011 Our purpose was to investigate the potential of acrolein to influence the release of transforming growth factor beta-2 (TGFbeta2) and vascular endothelial growth factor (VEGF), to assess the ability of N-benzylhydroxylamine (NBHA) to prevent the effect of acrolein on cytokine release and reduction of viable cells, and to explore the pathway by which acrolein might be causing the increase of VEGF. Acrolein 48-56 vascular endothelial growth factor A Homo sapiens 170-174 21320281-4 2011 METHODS: Thrombin and activated protein C (APC) generation were measured in defibrinated plasma exposed to acrolein-treated endothelial and smooth muscle cells. Acrolein 107-115 coagulation factor II Mus musculus 9-17 21320281-4 2011 METHODS: Thrombin and activated protein C (APC) generation were measured in defibrinated plasma exposed to acrolein-treated endothelial and smooth muscle cells. Acrolein 107-115 APC, WNT signaling pathway regulator Mus musculus 43-46 21320281-5 2011 Tissue factor (TF) activity was measured on acrolein-treated cells. Acrolein 44-52 coagulation factor III Mus musculus 0-13 21320281-5 2011 Tissue factor (TF) activity was measured on acrolein-treated cells. Acrolein 44-52 coagulation factor III Mus musculus 15-17 21320281-8 2011 RESULTS: Exposure of acrolein-treated endothelial and smooth muscle cells to defibrinated plasma increased thrombin generation in the plasma. Acrolein 21-29 coagulation factor II Mus musculus 107-115 21320281-9 2011 This was associated with enhanced phosphatidylserine exposure and/or increased TF activity on acrolein-treated cells. Acrolein 94-102 coagulation factor III Mus musculus 79-81 21320281-11 2011 In vivo, treatment of mice with cyclophosphamide and acrolein resulted in elevations of plasma TAT complex levels, whereas APC levels remained low. Acrolein 53-61 APC, WNT signaling pathway regulator Mus musculus 123-126 21187074-7 2011 Production of acrolein from spermine by spermine oxidase was clarified using spermine synthase-deficient Gy mice and transglutaminase 2-knockout mice, in which spermine content is negligible or spermidine/spermine N(1)-acetyltransferase activity is elevated. Acrolein 14-22 transglutaminase 2, C polypeptide Mus musculus 117-135 20525806-0 2011 Endothelial dysfunction and claudin 5 regulation during acrolein-induced lung injury. Acrolein 56-64 claudin 5 Homo sapiens 28-37 20525806-3 2011 A major irritant in smoke, acrolein can induce ALI possibly by altering CLDN5 expression. Acrolein 27-35 claudin 5 Homo sapiens 72-77 20525806-12 2011 The phosphatidylinositol 3-kinase inhibitor LY294002 diminished the acrolein-induced increased CLDN5 transcript. Acrolein 68-76 claudin 5 Homo sapiens 95-100 20525806-13 2011 Acrolein (300 nM) decreased CLDN5 transcripts, which were accompanied by increased FOXO1 and CTNNB1. Acrolein 0-8 claudin 5 Homo sapiens 28-33 20525806-13 2011 Acrolein (300 nM) decreased CLDN5 transcripts, which were accompanied by increased FOXO1 and CTNNB1. Acrolein 0-8 forkhead box O1 Homo sapiens 83-88 20525806-13 2011 Acrolein (300 nM) decreased CLDN5 transcripts, which were accompanied by increased FOXO1 and CTNNB1. Acrolein 0-8 catenin beta 1 Homo sapiens 93-99 21309688-6 2011 RESULTS: Acrolein was shown to reduce the number of viable ARPE-19 cells and to upregulate the release of the proangiogenic cytokines TGFbeta2 and VEGF. Acrolein 9-17 transforming growth factor beta 2 Homo sapiens 134-142 21309688-6 2011 RESULTS: Acrolein was shown to reduce the number of viable ARPE-19 cells and to upregulate the release of the proangiogenic cytokines TGFbeta2 and VEGF. Acrolein 9-17 vascular endothelial growth factor A Homo sapiens 147-151 21309688-7 2011 Co-treatment with 200 muM NBHA significantly reduced the effects of acrolein on viable cell number and TGFbeta2 release. Acrolein 68-76 transforming growth factor beta 2 Homo sapiens 103-111 21309688-8 2011 Pretreatment of the cells with SIS3 partially blocked the action of acrolein on decreased viable cell number and VEGF upregulation, suggesting that part of the effects of acrolein are mediated by the increased levels of TGFbeta and its signaling. Acrolein 68-76 vascular endothelial growth factor A Homo sapiens 113-117 21309688-9 2011 CONCLUSIONS: Our results suggest that the action of acrolein on the reduction of viability and VEGF increase by ARPE-19 cells is partially mediated by TGFbeta2. Acrolein 52-60 vascular endothelial growth factor A Homo sapiens 95-99 21309688-9 2011 CONCLUSIONS: Our results suggest that the action of acrolein on the reduction of viability and VEGF increase by ARPE-19 cells is partially mediated by TGFbeta2. Acrolein 52-60 transforming growth factor beta 2 Homo sapiens 151-159 21036164-0 2011 Doxycycline attenuates acrolein-induced mucin production, in part by inhibiting MMP-9. Acrolein 23-31 matrix metallopeptidase 9 Rattus norvegicus 80-85 21036164-2 2011 The aim of this study was to investigate whether doxycycline, a tetracycline antibiotic that inhibits MMPs, attenuates mucus production and synthesis of mucin MUC5AC in acrolein-exposed rats. Acrolein 169-177 matrix metallopeptidase 9 Rattus norvegicus 102-106 21036164-2 2011 The aim of this study was to investigate whether doxycycline, a tetracycline antibiotic that inhibits MMPs, attenuates mucus production and synthesis of mucin MUC5AC in acrolein-exposed rats. Acrolein 169-177 solute carrier family 13 member 2 Rattus norvegicus 153-158 21036164-2 2011 The aim of this study was to investigate whether doxycycline, a tetracycline antibiotic that inhibits MMPs, attenuates mucus production and synthesis of mucin MUC5AC in acrolein-exposed rats. Acrolein 169-177 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 159-165 21036164-5 2011 The increase in levels of MMP-9 mRNA and protein in airway epithelium after acrolein exposure was accompanied by an increase in MUC5AC mRNA expression. Acrolein 76-84 matrix metallopeptidase 9 Rattus norvegicus 26-31 21036164-5 2011 The increase in levels of MMP-9 mRNA and protein in airway epithelium after acrolein exposure was accompanied by an increase in MUC5AC mRNA expression. Acrolein 76-84 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 128-134 21036164-6 2011 Doxycycline significantly prevented these increases in acrolein-induced expression of MMP-9 and MUC5AC and attenuated mucus production in tracheal epithelium. Acrolein 55-63 matrix metallopeptidase 9 Rattus norvegicus 86-91 21036164-6 2011 Doxycycline significantly prevented these increases in acrolein-induced expression of MMP-9 and MUC5AC and attenuated mucus production in tracheal epithelium. Acrolein 55-63 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 96-102 21036164-7 2011 These results indicate that doxycycline attenuated acrolein-induced mucin synthesis, in part by inhibiting expression of MMP-9. Acrolein 51-59 solute carrier family 13 member 2 Rattus norvegicus 68-73 21036164-7 2011 These results indicate that doxycycline attenuated acrolein-induced mucin synthesis, in part by inhibiting expression of MMP-9. Acrolein 51-59 matrix metallopeptidase 9 Rattus norvegicus 121-126 21422526-8 2011 A treatment with 20 muM of acrolein for 30 min activated NF-kappaB, Nrf2, and heme oxygenase-1 while after 24 hrs of exposure, their induction was observed with the subtoxic and toxic concentrations of acrolein except for NF-kappaB. Acrolein 27-35 NFE2 like bZIP transcription factor 2 Rattus norvegicus 68-72 20971184-4 2011 H(2)O(2) and N-ethylmaleimide (NEM) showed no cross-protection against each other, whereas another thiol-reactive chemical, acrolein, elicited Yap1-dependent cross-protection against NEM, but not H(2)O(2). Acrolein 124-132 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 143-147 20971184-5 2011 Either Cys620 or Cys629 was sufficient for activation of Yap1 by NEM or acrolein; Cys598 was dispensable for this activation mechanism. Acrolein 72-80 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 57-61 21422526-8 2011 A treatment with 20 muM of acrolein for 30 min activated NF-kappaB, Nrf2, and heme oxygenase-1 while after 24 hrs of exposure, their induction was observed with the subtoxic and toxic concentrations of acrolein except for NF-kappaB. Acrolein 27-35 heme oxygenase 1 Rattus norvegicus 78-94 21422526-9 2011 Sirt-1 was also up-regulated after 24 hrs of exposure with acrolein. Acrolein 59-67 sirtuin 1 Rattus norvegicus 0-6 21422526-10 2011 Acrolein also induced the phosphorylation of p66shc and of ERK1/2 after 30 min of treatment. Acrolein 0-8 SHC adaptor protein 1 Rattus norvegicus 45-51 21422526-10 2011 Acrolein also induced the phosphorylation of p66shc and of ERK1/2 after 30 min of treatment. Acrolein 0-8 mitogen activated protein kinase 3 Rattus norvegicus 59-65 21075522-2 2011 TRPA1 receptors are targeted by pungent compounds from mustard and garlic and environmental irritants such as formaldehyde and acrolein. Acrolein 127-135 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 0-5 21265100-0 2010 [Study on the change of angiotensin II expression in rat lung exposure to acrolein]. Acrolein 74-82 angiotensinogen Rattus norvegicus 24-38 20149621-5 2010 Hydroxytyrosol treatment simultaneously protected against acrolein-induced inhibition of nuclear factor-E2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor coactivator 1 alpha (PPARGC1alpha) in ARPE-19 cells. Acrolein 58-66 NFE2 like bZIP transcription factor 2 Homo sapiens 125-129 20149621-5 2010 Hydroxytyrosol treatment simultaneously protected against acrolein-induced inhibition of nuclear factor-E2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor coactivator 1 alpha (PPARGC1alpha) in ARPE-19 cells. Acrolein 58-66 PPARG coactivator 1 alpha Homo sapiens 199-211 20153624-5 2010 Acrolein, a major component of cigarette smoke and also a product of lipid peroxidation, at 75 mumol/L over 24 h, caused significant loss of ARPE-19 cell viability, increased oxidative damage, decreased antioxidant defense, inactivation of the Keap1/Nrf2 pathway, and mitochondrial dysfunction. Acrolein 0-8 kelch like ECH associated protein 1 Homo sapiens 244-249 20153624-5 2010 Acrolein, a major component of cigarette smoke and also a product of lipid peroxidation, at 75 mumol/L over 24 h, caused significant loss of ARPE-19 cell viability, increased oxidative damage, decreased antioxidant defense, inactivation of the Keap1/Nrf2 pathway, and mitochondrial dysfunction. Acrolein 0-8 NFE2 like bZIP transcription factor 2 Homo sapiens 250-254 21265103-6 2010 RESULTS: Increased immunostaining, protein level and mRNA expression of IL-1beta and IL-6 were found in rat lung at 3 weeks and reached to the peak at 6 weeks post exposure to acrolein. Acrolein 176-184 interleukin 6 Rattus norvegicus 85-89 21265100-1 2010 OBJECTIVE: To investigate the changes of angiotensin II (Ang II) expression in a rat model of mucus hypersecretion induced by acrolein. Acrolein 126-134 angiotensinogen Rattus norvegicus 41-55 21265103-8 2010 CONCLUSION: Enalapril, as a ACE inhibitor, could protect the airway from inflammation injury in acrolein-treated rats via the down-regulation of IL-1beta and IL-6 expression. Acrolein 96-104 angiotensin I converting enzyme Rattus norvegicus 28-31 21265103-8 2010 CONCLUSION: Enalapril, as a ACE inhibitor, could protect the airway from inflammation injury in acrolein-treated rats via the down-regulation of IL-1beta and IL-6 expression. Acrolein 96-104 interleukin 1 beta Rattus norvegicus 145-153 21265103-8 2010 CONCLUSION: Enalapril, as a ACE inhibitor, could protect the airway from inflammation injury in acrolein-treated rats via the down-regulation of IL-1beta and IL-6 expression. Acrolein 96-104 interleukin 6 Rattus norvegicus 158-162 21265100-1 2010 OBJECTIVE: To investigate the changes of angiotensin II (Ang II) expression in a rat model of mucus hypersecretion induced by acrolein. Acrolein 126-134 angiotensinogen Rattus norvegicus 57-63 21265100-7 2010 CONCLUSION: The increase of Ang II expression, which associated to pulmonary mucus hypersecretion, might play a role in the lung injury induced by acrolein exposure. Acrolein 147-155 angiotensinogen Rattus norvegicus 28-34 21265101-0 2010 [Effects of acrolein exposure on the expression of Muc5ac in the airway of rats]. Acrolein 12-20 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 51-57 21265101-1 2010 OBJECTIVE: To explore the changes of Muc5ac expression in a rat model of mucus hypersecretion induced by acrolein. Acrolein 105-113 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 37-43 21265101-6 2010 CONCLUSION: The pulmonary mucus hypersecretion is associated to the increase of intrinsic Muc5ac expression in the rat airway exposure to acrolein. Acrolein 138-146 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 90-96 21265102-7 2010 CONCLUSION: Enalapril (ACE inhibitor) treatment could effectively decrease pulmonary mucus hypersecretion in acrolein-treated rats, which may be related to the downregulation of NF-kappaB expression. Acrolein 109-117 angiotensin I converting enzyme Rattus norvegicus 23-26 21265103-0 2010 [Effects of enalapril on IL-1beta, IL-6 expression in rat lung exposure to acrolein]. Acrolein 75-83 interleukin 6 Rattus norvegicus 35-39 21265103-1 2010 OBJECTIVE: To investigate the effects of enalapril on the expressions of IL-1beta and IL-6 in the lung of rats treated with acrolein inhalation. Acrolein 124-132 interleukin 1 beta Rattus norvegicus 73-81 21265103-1 2010 OBJECTIVE: To investigate the effects of enalapril on the expressions of IL-1beta and IL-6 in the lung of rats treated with acrolein inhalation. Acrolein 124-132 interleukin 6 Rattus norvegicus 86-90 21265103-6 2010 RESULTS: Increased immunostaining, protein level and mRNA expression of IL-1beta and IL-6 were found in rat lung at 3 weeks and reached to the peak at 6 weeks post exposure to acrolein. Acrolein 176-184 interleukin 1 beta Rattus norvegicus 72-80 20385619-4 2010 CSE and aldehydes dose and time dependently decreased SIRT1 protein levels, with EC(50) of 1% for CSE and 30 microM for acrolein at 6 h, and >80% inhibition at 24 h with CSE, which was regulated by modulation of intracellular thiol status of the cells. Acrolein 120-128 sirtuin 1 Mus musculus 54-59 20678513-7 2010 Exposure to acrolein also led to an increase in the indices of platelet activation such as the formation of platelet-leukocyte aggregates in the blood, plasma PF4 levels, and increased platelet-fibrinogen binding. Acrolein 12-20 platelet factor 4 Mus musculus 159-162 20491941-2 2010 In this study, Fps1p loss was shown to confer resistances to acetic acid, acrolein and allyl alcohol, not just in S. cerevisiae but also in the osmotolerant spoilage yeast Zygosaccharomyces rouxii. Acrolein 74-82 Fps1p Saccharomyces cerevisiae S288C 15-20 20359552-0 2010 Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Acrolein 23-31 solute carrier family 13 member 2 Rattus norvegicus 40-45 20601631-7 2010 TRPA1, a TRP ion channel expressed in chemosensory C-fibers, is activated by almost all oxidizing and electrophilic chemicals, including chlorine, acrolein, tear gas agents, and methyl isocyanate, the highly noxious chemical released in the Bhopal disaster. Acrolein 147-155 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 0-5 20302565-6 2010 In AD, the activity of the glutathione-S-transferase, the main enzyme responsible for the detoxification of acrolein is significantly decreased in hippocampus. Acrolein 108-116 glutathione S-transferase kappa 1 Homo sapiens 27-52 20302565-8 2010 Acrolein could modulate tau phosphorylation through different pathways. Acrolein 0-8 microtubule associated protein tau Homo sapiens 24-27 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Acrolein 50-58 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 91-97 20359552-2 2010 Since the small G-protein Ras is known to modulate cellular functions in the lung, we sought to investigate whether the Ras inhibitor simvastatin could attenuate acrolein-induced mucin production in rat airways. Acrolein 162-170 solute carrier family 13 member 2 Rattus norvegicus 179-184 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Acrolein 50-58 solute carrier family 13 member 2 Rattus norvegicus 98-103 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Acrolein 50-58 epidermal growth factor receptor Rattus norvegicus 140-144 20153347-0 2010 Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway. Acrolein 0-8 arachidonate 5-lipoxygenase Mus musculus 19-33 20359552-9 2010 In vitro, simvastatin pretreatment attenuated the acrolein-induced significant increase in MUC5AC mucin expression, Ras-GTPase activity and EGFR/ERK phosphorylation. Acrolein 50-58 Eph receptor B1 Rattus norvegicus 145-148 20359552-11 2010 Our results suggest that simvastatin may attenuate acrolein-induced mucin protein synthesis in the airway and airway inflammation, possibly by blocking ERK activation mediated by Ras protein isoprenylation. Acrolein 51-59 solute carrier family 13 member 2 Rattus norvegicus 68-73 20359552-11 2010 Our results suggest that simvastatin may attenuate acrolein-induced mucin protein synthesis in the airway and airway inflammation, possibly by blocking ERK activation mediated by Ras protein isoprenylation. Acrolein 51-59 Eph receptor B1 Rattus norvegicus 152-155 20153347-7 2010 In addition, acrolein-evoked 5-LO expression was also inhibited by inhibition of EGFR pathway, but not by inhibition of PDGFR pathway. Acrolein 13-21 epidermal growth factor receptor Mus musculus 81-85 20153347-8 2010 These observations suggest that acrolein has a profound effect on the 5-LO pathway via an EGFR-mediated activation of ERK pathway, leading to acute ischemic syndromes through the generation of LTB(4), subsequent MMP-9 production and plaque rupture. Acrolein 32-40 epidermal growth factor receptor Mus musculus 90-94 20153347-0 2010 Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway. Acrolein 0-8 Eph receptor B2 Mus musculus 89-92 20153347-8 2010 These observations suggest that acrolein has a profound effect on the 5-LO pathway via an EGFR-mediated activation of ERK pathway, leading to acute ischemic syndromes through the generation of LTB(4), subsequent MMP-9 production and plaque rupture. Acrolein 32-40 Eph receptor B2 Mus musculus 118-121 20153347-8 2010 These observations suggest that acrolein has a profound effect on the 5-LO pathway via an EGFR-mediated activation of ERK pathway, leading to acute ischemic syndromes through the generation of LTB(4), subsequent MMP-9 production and plaque rupture. Acrolein 32-40 matrix metallopeptidase 9 Mus musculus 212-217 20153347-4 2010 Acrolein-evoked 5-LO expression was blocked by pharmacological inhibition of the ERK pathway, but not by inhibitors for JNK and p38 MAPK pathways. Acrolein 0-8 Eph receptor B2 Mus musculus 81-84 20153347-5 2010 In line with these results, acrolein exclusively increased the phosphorylation of ERK among these MAPK, suggesting a role for the ERK pathway in acrolein-induced 5-LO expression with subsequent production of LTB(4). Acrolein 28-36 Eph receptor B2 Mus musculus 82-85 20153347-5 2010 In line with these results, acrolein exclusively increased the phosphorylation of ERK among these MAPK, suggesting a role for the ERK pathway in acrolein-induced 5-LO expression with subsequent production of LTB(4). Acrolein 28-36 Eph receptor B2 Mus musculus 130-133 20153347-5 2010 In line with these results, acrolein exclusively increased the phosphorylation of ERK among these MAPK, suggesting a role for the ERK pathway in acrolein-induced 5-LO expression with subsequent production of LTB(4). Acrolein 145-153 Eph receptor B2 Mus musculus 82-85 20153347-5 2010 In line with these results, acrolein exclusively increased the phosphorylation of ERK among these MAPK, suggesting a role for the ERK pathway in acrolein-induced 5-LO expression with subsequent production of LTB(4). Acrolein 145-153 Eph receptor B2 Mus musculus 130-133 20153347-6 2010 Among the receptor tyrosine kinases including epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR), acrolein-evoked ERK phosphorylation was attenuated by AG1478, an EGFR inhibitor, but not by AG1295, a PDGFR inhibitor. Acrolein 139-147 epidermal growth factor receptor Mus musculus 46-78 20153347-6 2010 Among the receptor tyrosine kinases including epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR), acrolein-evoked ERK phosphorylation was attenuated by AG1478, an EGFR inhibitor, but not by AG1295, a PDGFR inhibitor. Acrolein 139-147 epidermal growth factor receptor Mus musculus 80-84 20153347-6 2010 Among the receptor tyrosine kinases including epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR), acrolein-evoked ERK phosphorylation was attenuated by AG1478, an EGFR inhibitor, but not by AG1295, a PDGFR inhibitor. Acrolein 139-147 platelet derived growth factor receptor, beta polypeptide Mus musculus 90-129 20153347-6 2010 Among the receptor tyrosine kinases including epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR), acrolein-evoked ERK phosphorylation was attenuated by AG1478, an EGFR inhibitor, but not by AG1295, a PDGFR inhibitor. Acrolein 139-147 platelet derived growth factor receptor, beta polypeptide Mus musculus 131-136 20153347-6 2010 Among the receptor tyrosine kinases including epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR), acrolein-evoked ERK phosphorylation was attenuated by AG1478, an EGFR inhibitor, but not by AG1295, a PDGFR inhibitor. Acrolein 139-147 Eph receptor B2 Mus musculus 155-158 20153347-6 2010 Among the receptor tyrosine kinases including epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR), acrolein-evoked ERK phosphorylation was attenuated by AG1478, an EGFR inhibitor, but not by AG1295, a PDGFR inhibitor. Acrolein 139-147 epidermal growth factor receptor Mus musculus 204-208 20153347-6 2010 Among the receptor tyrosine kinases including epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR), acrolein-evoked ERK phosphorylation was attenuated by AG1478, an EGFR inhibitor, but not by AG1295, a PDGFR inhibitor. Acrolein 139-147 platelet derived growth factor receptor, beta polypeptide Mus musculus 241-246 19661247-2 2009 Previously, we reported that acrolein levels found in COPD sputum could activate matrix metalloproteinase-9 (MMP9). Acrolein 29-37 matrix metallopeptidase 9 Mus musculus 81-107 20060463-7 2010 Acrolein treatment also increased the percentage of MUC5AC positive cells. Acrolein 0-8 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 52-58 19686041-6 2010 Acrolein also elicited redistribution of several chaperones (Hsp40, -70, -90, and -110) to intermediate filament fractions, suggesting chaperone-mediated autophagy contributes to the triage of acrolein-adducted proteins. Acrolein 0-8 DnaJ heat shock protein family (Hsp40) member B1 pseudogene 1 Homo sapiens 61-86 20393600-0 2010 Acrolein induces apoptosis through the death receptor pathway in A549 lung cells: role of p53. Acrolein 0-8 tumor protein p53 Homo sapiens 90-93 20393600-5 2010 Exposure of cells to acrolein (0-50 micromol/L) mainly caused apoptosis, which was manifested by execution phase events such as condensation of nuclear chromatin, phosphatidylserine externalization, and poly(ADP-ribose) polymerase (PARP) cleavage. Acrolein 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 203-230 20393600-5 2010 Exposure of cells to acrolein (0-50 micromol/L) mainly caused apoptosis, which was manifested by execution phase events such as condensation of nuclear chromatin, phosphatidylserine externalization, and poly(ADP-ribose) polymerase (PARP) cleavage. Acrolein 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 232-236 20393600-7 2010 Acrolein triggered the death receptor pathway of apoptosis, causing elevation of Fas ligand (FasL) and translocation of adaptor protein Fas-associated death domain to the plasma membrane. Acrolein 0-8 Fas ligand Homo sapiens 81-91 20393600-7 2010 Acrolein triggered the death receptor pathway of apoptosis, causing elevation of Fas ligand (FasL) and translocation of adaptor protein Fas-associated death domain to the plasma membrane. Acrolein 0-8 Fas ligand Homo sapiens 93-97 20393600-8 2010 Acrolein caused activation of caspase-8, caspase-2, caspase-7, and the cross-talk pathway mediated by Bid cleavage. Acrolein 0-8 caspase 8 Homo sapiens 30-39 20393600-8 2010 Acrolein caused activation of caspase-8, caspase-2, caspase-7, and the cross-talk pathway mediated by Bid cleavage. Acrolein 0-8 caspase 2 Homo sapiens 41-50 20393600-8 2010 Acrolein caused activation of caspase-8, caspase-2, caspase-7, and the cross-talk pathway mediated by Bid cleavage. Acrolein 0-8 caspase 7 Homo sapiens 52-61 20393600-8 2010 Acrolein caused activation of caspase-8, caspase-2, caspase-7, and the cross-talk pathway mediated by Bid cleavage. Acrolein 0-8 BH3 interacting domain death agonist Homo sapiens 102-105 20393600-9 2010 Activation of p53 and increased expression of p53-upregulated modulator of apoptosis (PUMA) occurred in response to acrolein. Acrolein 116-124 tumor protein p53 Homo sapiens 14-17 20393600-9 2010 Activation of p53 and increased expression of p53-upregulated modulator of apoptosis (PUMA) occurred in response to acrolein. Acrolein 116-124 tumor protein p53 Homo sapiens 46-49 19729665-7 2009 MEASUREMENTS AND MAIN RESULTS: We demonstrated that TRPA1 agonists such as acrolein activate cloned human TRPA1 channels in HEK293 cells and also vagal sensory nerves in murine, guinea pig, and human tissues. Acrolein 75-83 transient receptor potential cation channel subfamily A member 1 Homo sapiens 52-57 19729665-7 2009 MEASUREMENTS AND MAIN RESULTS: We demonstrated that TRPA1 agonists such as acrolein activate cloned human TRPA1 channels in HEK293 cells and also vagal sensory nerves in murine, guinea pig, and human tissues. Acrolein 75-83 transient receptor potential cation channel subfamily A member 1 Homo sapiens 106-111 20419599-4 2010 TRPA1 is targeted by a series of byproducts of oxidative and nitrative stress, including acrolein, 4-hydroxy-2-nonenal and hydrogen peroxide. Acrolein 89-97 transient receptor potential cation channel subfamily A member 1 Homo sapiens 0-5 21504135-9 2010 A treatment with 10 muM of acrolein for 30 min activated NFkappaB while this activation was suppressed after a 24 hrs of treatment. Acrolein 27-35 nuclear factor kappa B subunit 1 Homo sapiens 57-65 21504135-10 2010 In contrast, Nrf2 was activated only after 24 hrs of acrolein exposure. Acrolein 53-61 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 21504135-11 2010 Consequently, the expression of heme oxygenase-1 and gamma-glutamyl-cysteine-synthase were elevated after 24 hrs of acrolein treatment. Acrolein 116-124 heme oxygenase 1 Homo sapiens 32-48 21504135-12 2010 Sirt-1 was also upregulated after 24 hrs of acrolein treatment. Acrolein 44-52 sirtuin 1 Homo sapiens 0-6 21504135-14 2010 Acrolein, at 10 muM, induced the phosphorylation of p66Shc and ERK1/2 only after a short period of treatment. Acrolein 0-8 mitogen-activated protein kinase 3 Homo sapiens 63-69 19845671-7 2009 Acrolein and crotonaldehyde, two alpha,beta-unsaturated aldehydes recently identified as TRPA1 stimulants and contained in cigarette smoke, air pollution or produced endogenously by oxidative stress, caused a remarkable tussive effect, a response that was selectively inhibited by HC-030031. Acrolein 0-8 transient receptor potential cation channel subfamily A member 1 Cavia porcellus 89-94 19661247-2 2009 Previously, we reported that acrolein levels found in COPD sputum could activate matrix metalloproteinase-9 (MMP9). Acrolein 29-37 matrix metallopeptidase 9 Mus musculus 109-113 19661247-7 2009 MEASUREMENTS AND MAIN RESULTS: In a cell-free system, acrolein, in concentrations equal to those found in COPD sputum, directly adducted cysteine 319 in the MMP14 hemopexin-like domain and activated MMP14. Acrolein 54-62 matrix metallopeptidase 14 (membrane-inserted) Mus musculus 157-162 19661247-7 2009 MEASUREMENTS AND MAIN RESULTS: In a cell-free system, acrolein, in concentrations equal to those found in COPD sputum, directly adducted cysteine 319 in the MMP14 hemopexin-like domain and activated MMP14. Acrolein 54-62 matrix metallopeptidase 14 (membrane-inserted) Mus musculus 199-204 19661247-10 2009 In mouse lung, acrolein or tobacco smoke increased lung MMP14 activity and protein. Acrolein 15-23 matrix metallopeptidase 14 (membrane-inserted) Mus musculus 56-61 19661247-11 2009 In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Acrolein 10-18 matrix metallopeptidase 14 (membrane-inserted) Mus musculus 27-32 19661247-11 2009 In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Acrolein 10-18 epidermal growth factor receptor Mus musculus 66-98 19661247-11 2009 In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Acrolein 10-18 epidermal growth factor receptor Mus musculus 100-104 19661247-11 2009 In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Acrolein 10-18 epidermal growth factor receptor Mus musculus 129-133 19661247-11 2009 In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Acrolein 10-18 mitogen-activated protein kinase 8 Mus musculus 231-236 19661247-11 2009 In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor. Acrolein 10-18 mitogen-activated protein kinase 14 Mus musculus 259-265 19661247-13 2009 In acrolein-exposed mice or transgenic mice with lung-specific transforming growth factor-alpha (an EGFR ligand) expression, lung MMP14 and MUC5AC levels increased and these effects were inhibited by a EGFR inhibitor, erlotinib. Acrolein 3-11 epidermal growth factor receptor Mus musculus 100-104 19661247-13 2009 In acrolein-exposed mice or transgenic mice with lung-specific transforming growth factor-alpha (an EGFR ligand) expression, lung MMP14 and MUC5AC levels increased and these effects were inhibited by a EGFR inhibitor, erlotinib. Acrolein 3-11 matrix metallopeptidase 14 (membrane-inserted) Mus musculus 130-135 19661247-13 2009 In acrolein-exposed mice or transgenic mice with lung-specific transforming growth factor-alpha (an EGFR ligand) expression, lung MMP14 and MUC5AC levels increased and these effects were inhibited by a EGFR inhibitor, erlotinib. Acrolein 3-11 mucin 5, subtypes A and C, tracheobronchial/gastric Mus musculus 140-146 19661247-13 2009 In acrolein-exposed mice or transgenic mice with lung-specific transforming growth factor-alpha (an EGFR ligand) expression, lung MMP14 and MUC5AC levels increased and these effects were inhibited by a EGFR inhibitor, erlotinib. Acrolein 3-11 epidermal growth factor receptor Mus musculus 202-206 19661247-14 2009 CONCLUSIONS: Taken together, these findings implicate acrolein-induced MMP14 expression and activity in mucin production in COPD. Acrolein 54-62 matrix metallopeptidase 14 (membrane-inserted) Mus musculus 71-76 19608619-5 2009 Activation of NRF2, by KEAP1 knockdown, caused a 75% increase in the amount of glutathione in HaCaT cells and a 1.4- to 1.6-fold increase in their resistance to the electrophiles acrolein, chlorambucil and cumene hydroperoxide (CuOOH), as well as the redox-cycling agent menadione. Acrolein 179-187 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 19507004-3 2009 Furthermore, the TRPA1 agonists AITC, CA, and acrolein concentration dependently evoked an increase in intracellular Ca(2+) influx and the release of 5-HT in QGP-1 cells. Acrolein 46-54 transient receptor potential cation channel subfamily A member 1 Homo sapiens 17-22 19507004-5 2009 These results indicate that the Ca(2+) influx increase and 5-HT release induced by AITC, CA and acrolein in QGP-1 cells were mediated by TRPA1, and that the QGP-1 cell line could be a new model for the investigation of TRPA1 function in the human EC cell. Acrolein 96-104 transient receptor potential cation channel subfamily A member 1 Homo sapiens 137-142 19507004-5 2009 These results indicate that the Ca(2+) influx increase and 5-HT release induced by AITC, CA and acrolein in QGP-1 cells were mediated by TRPA1, and that the QGP-1 cell line could be a new model for the investigation of TRPA1 function in the human EC cell. Acrolein 96-104 transient receptor potential cation channel subfamily A member 1 Homo sapiens 219-224 19596284-7 2009 Exposure to acrolein (<15microM, 30min) activated the survival factor AKT, which led to phosphorylation of Bad and induction of antiapoptosis proteins cIAP1/2. Acrolein 12-20 AKT serine/threonine kinase 1 Homo sapiens 73-76 19596284-7 2009 Exposure to acrolein (<15microM, 30min) activated the survival factor AKT, which led to phosphorylation of Bad and induction of antiapoptosis proteins cIAP1/2. Acrolein 12-20 baculoviral IAP repeat containing 2 Homo sapiens 154-161 19596284-10 2009 Acrolein (3-27microM, 30-60min) activated early stage processes in the mitochondrial pathway of apoptosis, such as Bax translocation to mitochondria, cytochrome c release, caspase-9 activation, and translocation of apoptosis-inducing factor to the nucleus. Acrolein 0-8 BCL2 associated X, apoptosis regulator Homo sapiens 115-118 19596284-10 2009 Acrolein (3-27microM, 30-60min) activated early stage processes in the mitochondrial pathway of apoptosis, such as Bax translocation to mitochondria, cytochrome c release, caspase-9 activation, and translocation of apoptosis-inducing factor to the nucleus. Acrolein 0-8 cytochrome c, somatic Homo sapiens 150-162 19596284-10 2009 Acrolein (3-27microM, 30-60min) activated early stage processes in the mitochondrial pathway of apoptosis, such as Bax translocation to mitochondria, cytochrome c release, caspase-9 activation, and translocation of apoptosis-inducing factor to the nucleus. Acrolein 0-8 caspase 9 Homo sapiens 172-181 19596284-11 2009 Acrolein (10-50microM) triggered later stage processes such as activation of caspases-3, -7 and -6, phosphatidylserine externalization and cleavage of poly(ADP)ribose polymerase after longer times (2h). Acrolein 0-8 caspase 3 Homo sapiens 77-98 19596284-11 2009 Acrolein (10-50microM) triggered later stage processes such as activation of caspases-3, -7 and -6, phosphatidylserine externalization and cleavage of poly(ADP)ribose polymerase after longer times (2h). Acrolein 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 151-177 19696094-3 2009 Herein, we tested the hypothesis that glutathione S-transferase P (GSTP), the GST isoform that displays high catalytic efficiency with acrolein, protects against CY-induced urotoxicity by detoxifying acrolein. Acrolein 135-143 glutathione S-transferase pi 1 Homo sapiens 67-71 19696094-3 2009 Herein, we tested the hypothesis that glutathione S-transferase P (GSTP), the GST isoform that displays high catalytic efficiency with acrolein, protects against CY-induced urotoxicity by detoxifying acrolein. Acrolein 200-208 glutathione S-transferase pi 1 Homo sapiens 67-71 19729010-0 2009 Effects of acrolein, a natural occurring aldehyde, on the anticoagulant serpin antithrombin. Acrolein 11-19 serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 Mus musculus 79-91 19729010-1 2009 We studied the effect of acrolein, an alpha,beta-unsaturated aldehyde that causes adduct-modification of lysine, cysteine, and histidine residues, on antithrombin, a key anticoagulant serpin. Acrolein 25-33 serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 Mus musculus 150-162 19729010-5 2009 Acrolein, even at low dose, impaired the anticoagulant function of purified antithrombin by affecting its heparin affinity. Acrolein 0-8 serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 Mus musculus 76-88 19729010-6 2009 However, higher concentrations of acrolein and long incubations are required to cause mild functional effects on plasma antithrombin and mice. Acrolein 34-42 serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 Mus musculus 120-132 19633057-8 2009 Pre-treatment of Nrf2(+/+) MEFs, but not Nrf2(-/-) MEFs, with 15 microM CETP for 24 h conferred 2.4-fold resistance against subsequent exposure to the alpha,beta-unsaturated aldehyde acrolein, indicating that the phytochemical exerts chemopreventive properties against genotoxic xenobiotics. Acrolein 183-191 nuclear factor, erythroid derived 2, like 2 Mus musculus 17-21 19608619-5 2009 Activation of NRF2, by KEAP1 knockdown, caused a 75% increase in the amount of glutathione in HaCaT cells and a 1.4- to 1.6-fold increase in their resistance to the electrophiles acrolein, chlorambucil and cumene hydroperoxide (CuOOH), as well as the redox-cycling agent menadione. Acrolein 179-187 kelch like ECH associated protein 1 Homo sapiens 23-28 19608619-6 2009 Inhibition of glutathione synthesis during KEAP1 knockdown, by treatment with buthionine sulfoximine, abrogated resistance to acrolein, chlorambucil and CuOOH, but not to menadione. Acrolein 126-134 kelch like ECH associated protein 1 Homo sapiens 43-48 19345260-4 2009 This study examines the effects of acrolein on (i) IFNalpha-mediated signaling and antiviral gene expression in cultured and primary human hepatocytes and (ii) HCV replication in an HCV-replicon system. Acrolein 35-43 interferon alpha 1 Homo sapiens 51-59 19631294-0 2009 p38 MAPK and MMP-9 cooperatively regulate mucus overproduction in mice exposed to acrolein fog. Acrolein 82-90 mitogen-activated protein kinase 14 Mus musculus 0-8 19631294-0 2009 p38 MAPK and MMP-9 cooperatively regulate mucus overproduction in mice exposed to acrolein fog. Acrolein 82-90 matrix metallopeptidase 9 Mus musculus 13-18 19631294-0 2009 p38 MAPK and MMP-9 cooperatively regulate mucus overproduction in mice exposed to acrolein fog. Acrolein 82-90 zinc finger protein, multitype 1 Mus musculus 91-94 19631294-2 2009 METHODS: Mice were exposed to 4.0 ppm of acrolein for 21 days with daily intraperitoneal injection of SB203580, a specific inhibitor of p38 MAPK. Acrolein 41-49 mitogen-activated protein kinase 14 Mus musculus 136-144 19631294-8 2009 Acrolein-increased phosphorylation of p38 MAPK was significantly reduced by SB203580. Acrolein 0-8 mitogen-activated protein kinase 14 Mus musculus 38-46 19631294-10 2009 Moreover, SB203580 treatment decreased the acrolein-induced increase of Muc5ac and MMP-9 expression and MMP-9 activity in airway epithelium. Acrolein 43-51 mucin 5, subtypes A and C, tracheobronchial/gastric Mus musculus 72-78 19631294-10 2009 Moreover, SB203580 treatment decreased the acrolein-induced increase of Muc5ac and MMP-9 expression and MMP-9 activity in airway epithelium. Acrolein 43-51 matrix metallopeptidase 9 Mus musculus 83-88 19631294-10 2009 Moreover, SB203580 treatment decreased the acrolein-induced increase of Muc5ac and MMP-9 expression and MMP-9 activity in airway epithelium. Acrolein 43-51 matrix metallopeptidase 9 Mus musculus 104-109 19490921-9 2009 We have further validated two differentially expressed proteins namely annexin II (ANXII) and prohibitin (PHB) in lung epithelial cells treated with acrolein. Acrolein 149-157 prohibitin 1 Rattus norvegicus 94-104 19490921-9 2009 We have further validated two differentially expressed proteins namely annexin II (ANXII) and prohibitin (PHB) in lung epithelial cells treated with acrolein. Acrolein 149-157 prohibitin 1 Rattus norvegicus 106-109 19345260-7 2009 Importantly, acrolein abolished the IFNalpha-mediated down-regulation of HCV viral expression in the HCV-replicon system. Acrolein 13-21 interferon alpha 1 Homo sapiens 36-44 18563599-2 2009 The toxicity of so formed acrolein involves oxidative stress, as (1) strains deficient in antioxidant defense are hypersensitive to allyl alcohol, (2) exposure to allyl alcohol increases the level of thiobarbituric-acid-reactive substances and decreases glutathione level in the cells, (3) hypoxic and anoxic atmosphere and antioxidants protect against allyl alcohol toxicity, and (4) allyl alcohol causes activation of Yap1p. Acrolein 26-34 DNA-binding transcription factor YAP1 Saccharomyces cerevisiae S288C 420-425 19345260-5 2009 Our data demonstrate that nontoxic concentrations of acrolein significantly inhibited IFNalpha-induced tyrosine phosphorylation of both cytoplasmic and nuclear STAT1 and STAT2, without altering the total levels. Acrolein 53-61 interferon alpha 1 Homo sapiens 86-94 19345260-5 2009 Our data demonstrate that nontoxic concentrations of acrolein significantly inhibited IFNalpha-induced tyrosine phosphorylation of both cytoplasmic and nuclear STAT1 and STAT2, without altering the total levels. Acrolein 53-61 signal transducer and activator of transcription 1 Homo sapiens 160-165 19345260-5 2009 Our data demonstrate that nontoxic concentrations of acrolein significantly inhibited IFNalpha-induced tyrosine phosphorylation of both cytoplasmic and nuclear STAT1 and STAT2, without altering the total levels. Acrolein 53-61 signal transducer and activator of transcription 2 Homo sapiens 170-175 19464576-0 2009 Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats. Acrolein 86-94 peroxisome proliferator-activated receptor gamma Rattus norvegicus 17-65 19530727-1 2009 Acrolein reacts with dG to form hydroxylated 1,N(2)-propanodeoxyguanosine (OH-PdG) adducts. Acrolein 0-8 phosphoglycerate dehydrogenase Homo sapiens 78-81 19464576-6 2009 RESULTS: Acrolein exposure significantly induced goblet cell hyperplasia in bronchial epithelium and Muc5ac mRNA and protein expressions in rat lungs, as well as the associated airway inflammation evidenced by the increased numbers of inflammatory cells and levels of inflammatory cytokines in BALF, which were attenuated with rosiglitazone treatment in a dose-dependent manner (P<0.05). Acrolein 9-17 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 101-107 19464576-8 2009 CONCLUSIONS: These findings suggest that PPAR-gamma activation by its ligands can attenuate acrolein-induced airway mucus hypersecretion in rats, which may be involved in inhibition of NF-kappaB pathway. Acrolein 92-100 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-51 19303893-9 2009 Thus Nrf2-dependent up-regulation of GSH is the principal mechanism by which sulforaphane pre-treatment induced resistance to acrolein, CuOOH and chlorambucil, but not menadione. Acrolein 126-134 nuclear factor, erythroid derived 2, like 2 Mus musculus 5-9 19341237-12 2009 The reduced Acr-dG formation is attributed to the reaction of BSA with acrolein as indicated by increased levels of total protein carbonyls. Acrolein 71-79 acrosin Homo sapiens 12-15 19286926-3 2009 By examining a panel of 19 cytokines and chemokines, we found that IL-8 release was elevated by CSE as well as by acrolein, whereas other inflammatory mediators were mostly unaffected. Acrolein 114-122 C-X-C motif chemokine ligand 8 Homo sapiens 67-71 19286926-4 2009 CSE-evoked IL-8 release was mimicked by acrolein and crotonaldehyde at concentrations (3-60 microM each) found in CSE and fully prevented by 1 mM alpha,beta-unsaturated aldehydes scavengers N-acetylcysteine (NAC) or sodium 2-mercaptoethanesulfonate. Acrolein 40-48 C-X-C motif chemokine ligand 8 Homo sapiens 11-15 19286926-8 2009 CSE-evoked p38 and ERK1/2 phosphorylation was mimicked by acrolein and inhibited by NAC. Acrolein 58-66 mitogen-activated protein kinase 1 Homo sapiens 11-14 19286926-8 2009 CSE-evoked p38 and ERK1/2 phosphorylation was mimicked by acrolein and inhibited by NAC. Acrolein 58-66 mitogen-activated protein kinase 3 Homo sapiens 19-25 19341237-13 2009 Similar correlations between Acr-dG formation and apoptosis were observed in HT-29 cells directly incubated with 0-200 microM acrolein. Acrolein 126-134 acrosin Homo sapiens 29-32 19223332-0 2009 Solution structure of DNA containing alpha-OH-PdG: the mutagenic adduct produced by acrolein. Acrolein 84-92 phosphoglycerate dehydrogenase Homo sapiens 46-49 19371603-4 2009 Our studies show that exposure to acrolein resulted in the secretion of MMP-9 from differentiated THP-1 macrophages. Acrolein 34-42 matrix metallopeptidase 9 Mus musculus 72-77 19371603-5 2009 Acrolein-treatment of macrophages also led to an increase in reactive oxygen species (ROS), free intracellular calcium ([Ca2+](i)), and xanthine oxidase (XO) activity. Acrolein 0-8 xanthine dehydrogenase Mus musculus 136-152 19371603-9 2009 These observations suggest that acrolein exposure results in MMP secretion from macrophages via a mechanism that involves an increase in [Ca2+](I), leading to xanthine oxidase activation and an increase in ROS production. Acrolein 32-40 matrix metallopeptidase 9 Mus musculus 61-64 19371603-9 2009 These observations suggest that acrolein exposure results in MMP secretion from macrophages via a mechanism that involves an increase in [Ca2+](I), leading to xanthine oxidase activation and an increase in ROS production. Acrolein 32-40 xanthine dehydrogenase Mus musculus 159-175 19651797-5 2009 Two electrophiles, 4-hydroxynonenal (HNE) and acrolein, induced the expression of phase II genes (GCLC, GCLM, NQO1, NQO2, HO-1, and GSTM-1). Acrolein 46-54 glutamate-cysteine ligase catalytic subunit Homo sapiens 98-102 19651797-5 2009 Two electrophiles, 4-hydroxynonenal (HNE) and acrolein, induced the expression of phase II genes (GCLC, GCLM, NQO1, NQO2, HO-1, and GSTM-1). Acrolein 46-54 glutamate-cysteine ligase modifier subunit Homo sapiens 104-108 19651797-5 2009 Two electrophiles, 4-hydroxynonenal (HNE) and acrolein, induced the expression of phase II genes (GCLC, GCLM, NQO1, NQO2, HO-1, and GSTM-1). Acrolein 46-54 NAD(P)H quinone dehydrogenase 1 Homo sapiens 110-114 19651797-5 2009 Two electrophiles, 4-hydroxynonenal (HNE) and acrolein, induced the expression of phase II genes (GCLC, GCLM, NQO1, NQO2, HO-1, and GSTM-1). Acrolein 46-54 N-ribosyldihydronicotinamide:quinone reductase 2 Homo sapiens 116-120 19651797-5 2009 Two electrophiles, 4-hydroxynonenal (HNE) and acrolein, induced the expression of phase II genes (GCLC, GCLM, NQO1, NQO2, HO-1, and GSTM-1). Acrolein 46-54 heme oxygenase 1 Homo sapiens 122-126 19651797-5 2009 Two electrophiles, 4-hydroxynonenal (HNE) and acrolein, induced the expression of phase II genes (GCLC, GCLM, NQO1, NQO2, HO-1, and GSTM-1). Acrolein 46-54 glutathione S-transferase mu 1 Homo sapiens 132-138 19371406-6 2009 RESULTS: Morphine induced release of calcitonin gene-related peptide and sensitized the release evoked by heat or the TRPA1 agonist acrolein. Acrolein 132-140 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 118-123 18814910-2 2009 TRPA1 is activated by either covalent or reversible binding of various chemical compounds, including allylisothiocyanate or acrolein, and is further sensitised by increases in the intracellular Ca(2+) concentration. Acrolein 124-132 transient receptor potential cation channel subfamily A member 1 Homo sapiens 0-5 19418724-0 2009 [Changes in nitric oxide, prostaglandins and myeloperoxidase activity in acrolein-induced cystitis in rats]. Acrolein 73-81 myeloperoxidase Rattus norvegicus 45-60 19576043-11 2009 The protein expressions of MUC5AC in the bronchial epithelium examined by immunohistochemistry were 4339 +/- 453, 1636 +/- 282, 3996 +/- 346, 3048 +/- 331, 2376 +/- 343 respectively in the acrolein group, the saline control group, the low dose rosiglitazone intervention group, the moderate dose rosiglitazone intervention group, and the high dose rosiglitazone intervention group, the difference being significant among groups (F = 67.74, P < 0.01). Acrolein 189-197 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 27-33 19576043-12 2009 The protein expressions of PPAR-gamma were 1159 +/- 184, 838 +/- 151, 1272 +/- 189, 1568 +/- 282, 1872 +/- 270 respectively in the acrolein group, the saline control group, the low dose rosiglitazone intervention group, the moderate dose rosiglitazone intervention group, and the high dose rosiglitazone intervention group, the difference being significant among groups (F = 21.53, P < 0.01). Acrolein 131-139 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-37 19576043-13 2009 The mRNA expressions of MUC5AC (the relative copies) were 35.3 +/- 10.0, 2.2 +/- 0.7, 30.5 +/- 10.2, 18.6 +/- 5.3, 10.8 +/- 2.6 respectively in the acrolein group, the saline control group, the low dose rosiglitazone intervention group, the moderate dose rosiglitazone intervention group, and the high dose rosiglitazone intervention group, the difference being significant among groups (F = 29.67, P < 0.01). Acrolein 148-156 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 24-30 19576043-14 2009 The mRNA expressions of PPAR-gamma (the relative copies) were 7.8 +/- 1.9, 2.0 +/- 0.6, 9.8 +/- 2.8, 18.6 +/- 5.3, 31.6 +/- 8.9 in the acrolein group, the saline control group, the low dose rosiglitazone intervention group, the moderate dose rosiglitazone intervention group, and the high dose rosiglitazone intervention group, the difference being significant among groups (F = 39.47, P < 0.01). Acrolein 135-143 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-34 19576043-15 2009 The expression of MUC5AC mRNA was negatively correlated with the protein expression of PPAR-gamma in the acrolein group (r = -0.880, P < 0.01). Acrolein 105-113 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 18-24 19576043-15 2009 The expression of MUC5AC mRNA was negatively correlated with the protein expression of PPAR-gamma in the acrolein group (r = -0.880, P < 0.01). Acrolein 105-113 peroxisome proliferator-activated receptor gamma Rattus norvegicus 87-97 19576043-16 2009 CONCLUSIONS: PPAR-gamma was involved in airway mucus hypersecretion induced by acrolein. Acrolein 79-87 peroxisome proliferator-activated receptor gamma Rattus norvegicus 13-23 19576043-17 2009 PPAR-gamma and its ligand rosiglitazone inhibited acrolein-induced airway mucus hypersecretion, possibly through downregulation of MUC5AC. Acrolein 50-58 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 19576043-17 2009 PPAR-gamma and its ligand rosiglitazone inhibited acrolein-induced airway mucus hypersecretion, possibly through downregulation of MUC5AC. Acrolein 50-58 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 131-137 19548361-4 2008 A dose-dependent decrease in the formation of 5-LO products was observed in GM-CSF/fMLP-stimulated neutrophils when acrolein (0-50 microM) was present with almost complete inhibition at > or = 25 microM acrolein. Acrolein 116-124 colony stimulating factor 2 Homo sapiens 76-82 19073213-3 2009 In this study, we have investigated the induction of glutathione (GSH), GSH S-transferase (GST), and aldose reductase (AR) by the unique nutraceutical compound 3H-1,2-dithiole-3-thione (D3T); and the protective effects of the D3T-mediated cellular defenses on acrolein-mediated toxicity in human neuroblastoma SH-SY5Y cells. Acrolein 260-268 aldo-keto reductase family 1 member B Homo sapiens 119-121 18951912-4 2009 Treatment of human umbilical vein endothelial cells (HUVECs) with 2 to 10 microM acrolein led to an increase in the phosphorylation of eIF-2alpha within 10 to 30 min of exposure. Acrolein 81-89 eukaryotic translation initiation factor 2A Homo sapiens 135-145 18951912-7 2009 Acrolein-induced increase in ATF3 was prevented by treating the cells with the chemical chaperone - phenylbutyric acid (PBA). Acrolein 0-8 activating transcription factor 3 Homo sapiens 29-33 18951912-8 2009 Treatment with acrolein increased phosphorylation of ERK1/2, p38, and JNK. Acrolein 15-23 mitogen-activated protein kinase 3 Homo sapiens 53-59 18951912-8 2009 Treatment with acrolein increased phosphorylation of ERK1/2, p38, and JNK. Acrolein 15-23 mitogen-activated protein kinase 1 Homo sapiens 61-64 18951912-8 2009 Treatment with acrolein increased phosphorylation of ERK1/2, p38, and JNK. Acrolein 15-23 mitogen-activated protein kinase 8 Homo sapiens 70-73 18951912-10 2009 Acrolein treatment led to activation and nuclear translocation of the transcription factor NF-kappaB and an increase in TNF-alpha, IL-6 and IL-8, but not MCP-1, mRNA. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 91-100 18951912-10 2009 Acrolein treatment led to activation and nuclear translocation of the transcription factor NF-kappaB and an increase in TNF-alpha, IL-6 and IL-8, but not MCP-1, mRNA. Acrolein 0-8 tumor necrosis factor Homo sapiens 120-129 18951912-10 2009 Acrolein treatment led to activation and nuclear translocation of the transcription factor NF-kappaB and an increase in TNF-alpha, IL-6 and IL-8, but not MCP-1, mRNA. Acrolein 0-8 interleukin 6 Homo sapiens 131-135 18951912-10 2009 Acrolein treatment led to activation and nuclear translocation of the transcription factor NF-kappaB and an increase in TNF-alpha, IL-6 and IL-8, but not MCP-1, mRNA. Acrolein 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 140-144 18951912-10 2009 Acrolein treatment led to activation and nuclear translocation of the transcription factor NF-kappaB and an increase in TNF-alpha, IL-6 and IL-8, but not MCP-1, mRNA. Acrolein 0-8 C-C motif chemokine ligand 2 Homo sapiens 154-159 18951912-12 2009 These findings suggest that exposure to acrolein induces ER stress and triggers the unfolded protein response and that NF-kappaB activation and stimulation of cytokine production by acrolein could be attributed, in part, to ER stress. Acrolein 182-190 nuclear factor kappa B subunit 1 Homo sapiens 119-128 19548361-4 2008 A dose-dependent decrease in the formation of 5-LO products was observed in GM-CSF/fMLP-stimulated neutrophils when acrolein (0-50 microM) was present with almost complete inhibition at > or = 25 microM acrolein. Acrolein 116-124 formyl peptide receptor 1 Homo sapiens 83-87 19548361-4 2008 A dose-dependent decrease in the formation of 5-LO products was observed in GM-CSF/fMLP-stimulated neutrophils when acrolein (0-50 microM) was present with almost complete inhibition at > or = 25 microM acrolein. Acrolein 206-214 colony stimulating factor 2 Homo sapiens 76-82 19548361-4 2008 A dose-dependent decrease in the formation of 5-LO products was observed in GM-CSF/fMLP-stimulated neutrophils when acrolein (0-50 microM) was present with almost complete inhibition at > or = 25 microM acrolein. Acrolein 206-214 formyl peptide receptor 1 Homo sapiens 83-87 19548361-8 2008 Some of these factors were affected by acrolein but did not completely explain the almost complete inhibition of 5-LO product formation in GM-CSF/fMLP-treated cells with acrolein. Acrolein 170-178 colony stimulating factor 2 Homo sapiens 139-145 19548361-8 2008 Some of these factors were affected by acrolein but did not completely explain the almost complete inhibition of 5-LO product formation in GM-CSF/fMLP-treated cells with acrolein. Acrolein 170-178 formyl peptide receptor 1 Homo sapiens 146-150 19080078-1 2008 OBJECTIVE: To examine the effects of YM976, a phosphodiesterase (PDE)4 inhibitor, on mucin hypersecretion of airway stimulated with acrolein. Acrolein 132-140 solute carrier family 13 member 2 Rattus norvegicus 85-90 18266977-7 2008 Acrolein treatment modulated expression of thrombospondin-1 (TSP-1), an endogenous inhibitor of angiogenesis known to be linked to antiangiogenic effects of metronomic CPA therapy. Acrolein 0-8 thrombospondin 1 Mus musculus 43-59 18266977-7 2008 Acrolein treatment modulated expression of thrombospondin-1 (TSP-1), an endogenous inhibitor of angiogenesis known to be linked to antiangiogenic effects of metronomic CPA therapy. Acrolein 0-8 thrombospondin 1 Mus musculus 61-66 19080078-15 2008 CONCLUSION: YM976 inhibits airway inflammatory response and airway mucin hypersecretion induced by acrolein. Acrolein 99-107 solute carrier family 13 member 2 Rattus norvegicus 67-72 19031314-0 2008 Down-regulation of aldose reductase renders J774A.1 cells more susceptible to acrolein- or hydrogen peroxide-induced cell death. Acrolein 78-86 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 19-35 19031314-3 2008 This study investigated the role of AR in acrolein- or hydrogen peroxide-induced apoptosis using the J774.A.1 macrophage cell line. Acrolein 42-50 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 36-38 18972840-0 2008 Inhibition of acrolein-stimulated MUC5AC production by fucoidan in human bronchial epithelial cells. Acrolein 14-22 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 34-40 18972840-3 2008 Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that fucoidan inhibited MUC5AC expression and protein secretion in cells stimulated with acrolein, a toxic aldehyde present in tobacco smoke. Acrolein 162-170 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 97-103 18823586-0 2008 Acrolein, the toxic endogenous aldehyde, induces neurofilament-L aggregation. Acrolein 0-8 neurofilament light chain Homo sapiens 49-64 18823586-2 2008 In the present study, we examined the pattern of neurofilament-L (NF-L) modification elicited by acrolein. Acrolein 97-105 neurofilament light chain Homo sapiens 49-64 18823586-2 2008 In the present study, we examined the pattern of neurofilament-L (NF-L) modification elicited by acrolein. Acrolein 97-105 neurofilament light chain Homo sapiens 66-70 18823586-3 2008 When NF-L was incubated with acrolein, protein aggregation occurred in a acrolein concentration-dependent manner. Acrolein 29-37 neurofilament light chain Homo sapiens 5-9 18823586-3 2008 When NF-L was incubated with acrolein, protein aggregation occurred in a acrolein concentration-dependent manner. Acrolein 73-81 neurofilament light chain Homo sapiens 5-9 18823586-4 2008 Exposure of NF-L to acrolein also led to the generation of protein carbonyl compounds. Acrolein 20-28 neurofilament light chain Homo sapiens 12-16 18823586-5 2008 Through the addition of free radical scavengers we observed a significant decrease in acrolein-mediated NF-L aggregation. Acrolein 86-94 neurofilament light chain Homo sapiens 104-108 18823586-6 2008 These results indicate that free radicals may be involved in the modification of NF-L by acrolein. Acrolein 89-97 neurofilament light chain Homo sapiens 81-85 18823586-7 2008 In addition, dityrosine crosslink formation was observed in acrolein-mediated NF-L aggregates and these aggregates displayed thioflavin T reactivity, reminiscent of amyloid. Acrolein 60-68 neurofilament light chain Homo sapiens 78-82 18823586-8 2008 This study suggests that acrolein-mediated NF-L aggregation might be closely related to oxidative reactions, thus these reactions may play a critical role in neurodegenerative diseases. Acrolein 25-33 neurofilament light chain Homo sapiens 43-47 18448607-8 2008 Systemic treatment with NGF-neutralizing antiserum before instillation of acrolein suppressed subsequent mechanical referred hyperalgesia. Acrolein 74-82 nerve growth factor Rattus norvegicus 24-27 18378108-0 2008 Acrolein sequestering ability of the endogenous tripeptide glycyl-histidyl-lysine (GHK): characterization of conjugation products by ESI-MSn and theoretical calculations. Acrolein 0-8 moesin Homo sapiens 137-140 18448607-10 2008 These results suggest that the bladder-derived NGF acting via trk receptors at least partially mediates peripheral sensitization to mechanical stimuli associated with acute and subacute acrolein-induced cystitis. Acrolein 186-194 nerve growth factor Rattus norvegicus 47-50 18448607-10 2008 These results suggest that the bladder-derived NGF acting via trk receptors at least partially mediates peripheral sensitization to mechanical stimuli associated with acute and subacute acrolein-induced cystitis. Acrolein 186-194 neurotrophic receptor tyrosine kinase 1 Rattus norvegicus 62-65 18568077-2 2008 We hypothesized that 2 alpha,beta-unsaturated aldehydes present in CS, crotonaldehyde and acrolein, induce neurogenic inflammation by stimulating TRPA1, an excitatory ion channel coexpressed with TRPV1 on capsaicin-sensitive nociceptors. Acrolein 90-98 transient receptor potential cation channel subfamily A member 1 Cavia porcellus 146-151 18566440-5 2008 However, exposure to acrolein after LPS instillation markedly diminished the LPS-induced production of several inflammatory cytokines, specifically TNF-alpha, IL-12, and the Th1 cytokine IFN-gamma, which was associated with reduction in NF-kappaB activation. Acrolein 21-29 tumor necrosis factor Mus musculus 148-157 18566440-5 2008 However, exposure to acrolein after LPS instillation markedly diminished the LPS-induced production of several inflammatory cytokines, specifically TNF-alpha, IL-12, and the Th1 cytokine IFN-gamma, which was associated with reduction in NF-kappaB activation. Acrolein 21-29 negative elongation factor complex member C/D, Th1l Mus musculus 174-177 18566440-5 2008 However, exposure to acrolein after LPS instillation markedly diminished the LPS-induced production of several inflammatory cytokines, specifically TNF-alpha, IL-12, and the Th1 cytokine IFN-gamma, which was associated with reduction in NF-kappaB activation. Acrolein 21-29 interferon gamma Mus musculus 187-196 18566440-6 2008 Our data demonstrate that acrolein exposure suppresses LPS-induced Th1 cytokine responses without affecting acute neutrophilia. Acrolein 26-34 negative elongation factor complex member C/D, Th1l Mus musculus 67-70 18769139-2 2008 Activation of TRPA1 by environmental irritants such as mustard oil, allicin and acrolein causes acute pain. Acrolein 80-88 transient receptor potential cation channel subfamily A member 1 Homo sapiens 14-19 18568077-2 2008 We hypothesized that 2 alpha,beta-unsaturated aldehydes present in CS, crotonaldehyde and acrolein, induce neurogenic inflammation by stimulating TRPA1, an excitatory ion channel coexpressed with TRPV1 on capsaicin-sensitive nociceptors. Acrolein 90-98 transient receptor potential cation channel subfamily V member 1 Cavia porcellus 196-201 18568080-5 2008 The identification of TRPA1 activation by toxicants from cigarette smoke and polluted air, such as crotonaldehyde, acrolein, and oxidizing agents such as hydrogen peroxide, is an important finding. Acrolein 115-123 transient receptor potential cation channel subfamily A member 1 Homo sapiens 22-27 18468618-0 2008 Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. Acrolein 0-8 protein kinase C epsilon Homo sapiens 92-102 18798499-12 2008 CONCLUSION: Acrolein inhalation could upregulate the expression of Ang II and NF-kappa B and also increase nuclear translocation ratio of NF-kappa B. Acrolein 12-20 angiotensinogen Rattus norvegicus 67-73 18468618-9 2008 Acrolein-protein adducts were formed in a dose-dependent manner in isolated cardiac mitochondria in vitro and specific acrolein-PKCepsilon adducts were present in cardiac mitochondrial fractions following acrolein exposure in vivo, demonstrating that mitochondria are major targets of aldehyde toxicity. Acrolein 119-127 protein kinase C epsilon Homo sapiens 128-138 18468618-11 2008 Both of these responses were blocked by acrolein pretreatment, providing evidence that aldehydes disrupt cardioprotective signaling events involving PKCepsilon. Acrolein 40-48 protein kinase C epsilon Homo sapiens 149-159 18463259-2 2008 Through covalent modification of cysteine and lysine residues, TRPA1 can be activated by electrophilic compounds, including active ingredients of pungent natural products (e.g., allyl isothiocyanate), environmental irritants (e.g., acrolein), and endogenous ligands (4-hydroxynonenal). Acrolein 232-240 transient receptor potential cation channel subfamily A member 1 Homo sapiens 63-68 18282682-8 2008 In contrast, cytochrome c release was maximal in cells exposed to acrolein in serum-containing F12, conditions which inhibited protein modification and overt cell death. Acrolein 66-74 cytochrome c, somatic Homo sapiens 13-25 18006877-2 2008 Acrolein, a constituent of cigarette smoke and an endogenous mediator of oxidative stress, increases airway mucin 5, subtypes A and C (MUC5AC) production; however, the mechanism remains unclear. Acrolein 0-8 mucin 5, subtypes A and C, tracheobronchial/gastric Mus musculus 108-133 18414004-0 2008 Acrolein with an alpha, beta-unsaturated carbonyl group inhibits LPS-induced homodimerization of toll-like receptor 4. Acrolein 0-8 toll like receptor 4 Homo sapiens 97-117 18414004-7 2008 Acrolein inhibited NF-kappaB and IRF3 activation by LPS, but it did not inhibit NF-kappaB or IRF3 activation by MyD88, inhibitor kappaB kinase (IKK)beta, TRIF, or TNF-receptor-associated factor family member-associated NF-kappaB activator (TANK)-binding kinase 1 (TBK1). Acrolein 0-8 interferon regulatory factor 3 Homo sapiens 33-37 18414004-8 2008 Acrolein inhibited LPS-induced dimerization of TLR4, which resulted in the down-regulation of NF-kappaB and IRF3 activation. Acrolein 0-8 toll like receptor 4 Homo sapiens 47-51 18414004-8 2008 Acrolein inhibited LPS-induced dimerization of TLR4, which resulted in the down-regulation of NF-kappaB and IRF3 activation. Acrolein 0-8 interferon regulatory factor 3 Homo sapiens 108-112 18048804-9 2008 Furthermore, Nrf2 silencing significantly attenuated the HO-1 induction by acrolein. Acrolein 75-83 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 18048804-9 2008 Furthermore, Nrf2 silencing significantly attenuated the HO-1 induction by acrolein. Acrolein 75-83 heme oxygenase 1 Homo sapiens 57-61 18048804-10 2008 Inhibition of PKC-delta significantly decreased acrolein-mediated Nrf2 nuclear translocation, though inhibition of PI3K had no effect. Acrolein 48-56 protein kinase C delta Homo sapiens 14-23 18048804-10 2008 Inhibition of PKC-delta significantly decreased acrolein-mediated Nrf2 nuclear translocation, though inhibition of PI3K had no effect. Acrolein 48-56 NFE2 like bZIP transcription factor 2 Homo sapiens 66-70 18006877-2 2008 Acrolein, a constituent of cigarette smoke and an endogenous mediator of oxidative stress, increases airway mucin 5, subtypes A and C (MUC5AC) production; however, the mechanism remains unclear. Acrolein 0-8 mucin 5, subtypes A and C, tracheobronchial/gastric Mus musculus 135-141 18048804-11 2008 Taken together, our results indicate that acrolein up-regulates HO-1 expression through both PKC-delta and PI3K pathways in HBE1 cells; PKC-delta appears to regulate HO-1 induction via modulating Nrf2 nuclear translocation, while PI3K may work through targeting on downstream signaling molecules other than Nrf2. Acrolein 42-50 heme oxygenase 1 Homo sapiens 64-68 18048804-11 2008 Taken together, our results indicate that acrolein up-regulates HO-1 expression through both PKC-delta and PI3K pathways in HBE1 cells; PKC-delta appears to regulate HO-1 induction via modulating Nrf2 nuclear translocation, while PI3K may work through targeting on downstream signaling molecules other than Nrf2. Acrolein 42-50 protein kinase C delta Homo sapiens 93-102 18006877-5 2008 Acrolein also decreased mTissue inhibitor of metalloproteinase protein 3 (an MMP9 inhibitor) transcript levels. Acrolein 0-8 matrix metallopeptidase 9 Mus musculus 77-81 18048804-11 2008 Taken together, our results indicate that acrolein up-regulates HO-1 expression through both PKC-delta and PI3K pathways in HBE1 cells; PKC-delta appears to regulate HO-1 induction via modulating Nrf2 nuclear translocation, while PI3K may work through targeting on downstream signaling molecules other than Nrf2. Acrolein 42-50 NFE2 like bZIP transcription factor 2 Homo sapiens 196-200 18048804-11 2008 Taken together, our results indicate that acrolein up-regulates HO-1 expression through both PKC-delta and PI3K pathways in HBE1 cells; PKC-delta appears to regulate HO-1 induction via modulating Nrf2 nuclear translocation, while PI3K may work through targeting on downstream signaling molecules other than Nrf2. Acrolein 42-50 NFE2 like bZIP transcription factor 2 Homo sapiens 307-311 18006877-6 2008 In a cell-free system, acrolein increased pro-hMMP9 cleavage and activity in concentrations (100-300 nM) found in sputum from subjects with COPD. Acrolein 23-31 matrix metallopeptidase 9 Homo sapiens 46-51 18006877-7 2008 Acrolein increased hMMP9 transcripts in human airway cells, which was inhibited by an MMP inhibitor, EGFR-neutralizing antibody, or a mitogen-activated protein kinase (MAPK) 3/2 inhibitor. Acrolein 0-8 matrix metallopeptidase 9 Homo sapiens 19-24 18006877-7 2008 Acrolein increased hMMP9 transcripts in human airway cells, which was inhibited by an MMP inhibitor, EGFR-neutralizing antibody, or a mitogen-activated protein kinase (MAPK) 3/2 inhibitor. Acrolein 0-8 epidermal growth factor receptor Homo sapiens 101-105 18048804-0 2008 Acrolein induces heme oxygenase-1 through PKC-delta and PI3K in human bronchial epithelial cells. Acrolein 0-8 heme oxygenase 1 Homo sapiens 17-33 18048804-0 2008 Acrolein induces heme oxygenase-1 through PKC-delta and PI3K in human bronchial epithelial cells. Acrolein 0-8 protein kinase C delta Homo sapiens 42-51 18048804-4 2008 In this investigation we studied HO-1 induction in response to acrolein and determined the signaling pathways involved in human bronchial epithelial cells (HBE1 cells). Acrolein 63-71 heme oxygenase 1 Homo sapiens 33-37 18048804-6 2008 Acrolein-mediated HO-1 induction was significantly attenuated by pan-protein kinase C (PKC) inhibitors RO318220, staurosporine, and PKC-delta selective inhibitor rottlerin and PKC-delta small interfering RNA. Acrolein 0-8 heme oxygenase 1 Homo sapiens 18-22 18048804-6 2008 Acrolein-mediated HO-1 induction was significantly attenuated by pan-protein kinase C (PKC) inhibitors RO318220, staurosporine, and PKC-delta selective inhibitor rottlerin and PKC-delta small interfering RNA. Acrolein 0-8 protein kinase C delta Homo sapiens 87-90 18048804-6 2008 Acrolein-mediated HO-1 induction was significantly attenuated by pan-protein kinase C (PKC) inhibitors RO318220, staurosporine, and PKC-delta selective inhibitor rottlerin and PKC-delta small interfering RNA. Acrolein 0-8 protein kinase C delta Homo sapiens 132-141 18048804-6 2008 Acrolein-mediated HO-1 induction was significantly attenuated by pan-protein kinase C (PKC) inhibitors RO318220, staurosporine, and PKC-delta selective inhibitor rottlerin and PKC-delta small interfering RNA. Acrolein 0-8 protein kinase C delta Homo sapiens 176-185 18504971-1 2008 The absolute rate coefficients for the gas-phase reaction of the NO3 radical with acrolein and crotonaldehyde have been measured overthe temperature range 249-330 K, using a discharge flow system and monitoring the NO3 radical by laser induced fluorescence (LIF). Acrolein 82-90 NBL1, DAN family BMP antagonist Homo sapiens 65-68 18234483-0 2008 Induction of COX-2 expression by acrolein in the rat model of hemorrhagic cystitis. Acrolein 33-41 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 13-18 18504971-6 2008 On the basis of the rate constant measured, the activation energy calculated, and the identified products, abstraction of the aldehydic H seems to be the main degradation pathway at room temperature for the reaction of acrolein with NO3. Acrolein 219-227 NBL1, DAN family BMP antagonist Homo sapiens 233-236 18096571-8 2008 Acrolein potentiated the effect of BP on p53 stabilization and chromatin binding. Acrolein 0-8 tumor protein p53 Homo sapiens 41-44 18367636-9 2008 As compared with wild-type cells, Nrf2(- /-) macrophages were much more susceptible to cell injury induced by reactive oxygen/nitrogen species, as well as two known macrophage toxins, acrolein and cadmium. Acrolein 184-192 nuclear factor, erythroid derived 2, like 2 Mus musculus 34-38 18322093-1 2008 Transient receptor potential A1 (TRPA1) is expressed in a subset of nociceptive sensory neurons where it acts as a sensor for environmental irritants, including acrolein, and some pungent plant ingredients such as allyl isothiocyanate and cinnamaldehyde. Acrolein 161-169 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 33-38 18630690-12 2008 CONCLUSION: Acrolein increases the expression of MUC5AC through activating EGFR, which indicates that EGFR-TKI such as gefitinib can be useful in the treatment of mucus hypersecretion by regulating the signal transduction pathways of EGFR. Acrolein 12-20 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 49-55 18307678-6 2008 Involvement of the TRP cation channel, subfamily A, member 1 (TRPA1) has also been reported in models of neurogenic inflammation and nociception promoted by the cyclophosphamide metabolite, acrolein. Acrolein 190-198 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 62-67 18206177-0 2008 Antithrombin activity is inhibited by acrolein and homocysteine thiolactone: Protection by cysteine. Acrolein 38-46 serpin family C member 1 Homo sapiens 0-12 18206177-3 2008 Antithrombin is one of the most important inhibitors of blood coagulation Since its activation by heparin binding requires critical interactions involving 3 Lys residues; we hypothesized that acrolein or homocysteine thiolactone impair antithrombin activity. Acrolein 192-200 serpin family C member 1 Homo sapiens 0-12 18206177-3 2008 Antithrombin is one of the most important inhibitors of blood coagulation Since its activation by heparin binding requires critical interactions involving 3 Lys residues; we hypothesized that acrolein or homocysteine thiolactone impair antithrombin activity. Acrolein 192-200 serpin family C member 1 Homo sapiens 236-248 18206177-4 2008 When we incubated human antithrombin with increasing concentrations of acrolein (0-2 mmol/L) over a short period of time (0-4 h), a time and concentration dependent loss of activity was apparent (IC(50)=0.25 mmol/L). Acrolein 71-79 serpin family C member 1 Homo sapiens 24-36 18206177-7 2008 When antithrombin was co-incubated with acrolein and cysteine, only less than 10% of antithrombin activity was lost. Acrolein 40-48 serpin family C member 1 Homo sapiens 5-17 18206177-7 2008 When antithrombin was co-incubated with acrolein and cysteine, only less than 10% of antithrombin activity was lost. Acrolein 40-48 serpin family C member 1 Homo sapiens 85-97 18630690-9 2008 RESULTS: Overexpression of MUC5AC, EGFR and increased goblet cells in the lungs of the rats were found in the rats exposed to acrolein inhalations. Acrolein 126-134 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 27-33 18630690-9 2008 RESULTS: Overexpression of MUC5AC, EGFR and increased goblet cells in the lungs of the rats were found in the rats exposed to acrolein inhalations. Acrolein 126-134 epidermal growth factor receptor Rattus norvegicus 35-39 18630690-12 2008 CONCLUSION: Acrolein increases the expression of MUC5AC through activating EGFR, which indicates that EGFR-TKI such as gefitinib can be useful in the treatment of mucus hypersecretion by regulating the signal transduction pathways of EGFR. Acrolein 12-20 epidermal growth factor receptor Rattus norvegicus 75-79 18630690-12 2008 CONCLUSION: Acrolein increases the expression of MUC5AC through activating EGFR, which indicates that EGFR-TKI such as gefitinib can be useful in the treatment of mucus hypersecretion by regulating the signal transduction pathways of EGFR. Acrolein 12-20 epidermal growth factor receptor Rattus norvegicus 102-106 18630690-12 2008 CONCLUSION: Acrolein increases the expression of MUC5AC through activating EGFR, which indicates that EGFR-TKI such as gefitinib can be useful in the treatment of mucus hypersecretion by regulating the signal transduction pathways of EGFR. Acrolein 12-20 epidermal growth factor receptor Rattus norvegicus 102-106 17597105-8 2007 AKR1B10 downregulation enhanced the susceptibility of HCT-8 cells to acrolein (25 microM) and crotonaldehyde (50 microM), resulting in rapid oncotic cell death characterized with lactate dehydrogenase efflux and annexin-V staining. Acrolein 69-77 aldo-keto reductase family 1 member B10 Homo sapiens 0-7 18028974-10 2008 Priming of nrf2(+/+) MEFs, but not nrf2(-/-) MEFs, with C+K conferred 2-fold resistance towards acrolein. Acrolein 96-104 nuclear factor, erythroid derived 2, like 2 Mus musculus 11-15 18023956-0 2008 Acrolein oxidizes the cytosolic and mitochondrial thioredoxins in human endothelial cells. Acrolein 0-8 thioredoxin 2 Homo sapiens 22-62 18023956-4 2008 In human microvascular endothelial cells, Trx1 was more sensitive than Trx2 to oxidation by acrolein. Acrolein 92-100 thioredoxin Homo sapiens 42-46 18023956-4 2008 In human microvascular endothelial cells, Trx1 was more sensitive than Trx2 to oxidation by acrolein. Acrolein 92-100 thioredoxin 2 Homo sapiens 71-75 18023956-5 2008 A 30-min exposure to 2.5 microM acrolein caused partial oxidation of Trx1 but not Trx2. Acrolein 32-40 thioredoxin Homo sapiens 69-73 18023956-6 2008 The active site dithiol of Trx1 was essentially completely oxidized by 5 microM acrolein whereas 12.5 microM was required for complete oxidation of Trx2. Acrolein 80-88 thioredoxin Homo sapiens 27-31 18023956-8 2008 For cells treated with 2.5 or 5 microM acrolein the recovery did not require protein synthesis, whereas protein synthesis was required for the return of reduced Trx1 in cells treated with 12.5 microM acrolein. Acrolein 200-208 thioredoxin Homo sapiens 161-165 18023956-9 2008 Pretreatment of cells with N-acetylcysteine (NAC) resulted in partial protection of Trx1 from oxidation by acrolein. Acrolein 107-115 thioredoxin Homo sapiens 84-88 18205121-6 2008 The adducts dT2-dT5 were formed in reaction of dT1 with acrolein. Acrolein 56-64 anon-63BC-T2 Drosophila melanogaster 12-15 18205121-6 2008 The adducts dT2-dT5 were formed in reaction of dT1 with acrolein. Acrolein 56-64 achaete Drosophila melanogaster 16-19 18205121-6 2008 The adducts dT2-dT5 were formed in reaction of dT1 with acrolein. Acrolein 56-64 anon-68Ea Drosophila melanogaster 47-50 18203133-5 2008 The main endogenous sources of acrolein are myeloperoxidase-mediated degradation of threonine and amine oxidase-mediated degradation of spermine and spermidine, which may constitute a significant source of acrolein in situations of oxidative stress and inflammation. Acrolein 31-39 myeloperoxidase Homo sapiens 44-59 18203133-5 2008 The main endogenous sources of acrolein are myeloperoxidase-mediated degradation of threonine and amine oxidase-mediated degradation of spermine and spermidine, which may constitute a significant source of acrolein in situations of oxidative stress and inflammation. Acrolein 206-214 myeloperoxidase Homo sapiens 44-59 18056434-7 2007 In addition, FANCD2-deficient DT40 cells are hypersensitive to acetaldehyde, but not to acrolein, crotonaldehyde, glyoxal, and methylglyoxal. Acrolein 88-96 Fanconi anemia complementation group D2 Gallus gallus 13-19 17597105-7 2007 Recombinant AKR1B10 protein showed strong enzymatic activity to acrolein and crotonaldehyde, with K(m) = 110.1 +/- 12.2 microM and V(max) = 3,122.0 +/- 64.7 nmol/mg protein/min for acrolein and K(m) = 86.7 +/- 14.3 microM and V(max) = 2,647.5 +/- 132.2 nmol/mg protein/min for crotonaldehyde. Acrolein 64-72 aldo-keto reductase family 1 member B10 Homo sapiens 12-19 18201443-7 2007 RESULTS: In primary HSNEC, IL-8 mRNA levels decreased dose dependently in the range of 10-50 microM of AC with an eightfold decrease at 50 microM. Acrolein 103-105 C-X-C motif chemokine ligand 8 Homo sapiens 27-31 17982132-2 2007 Acrolein and 4-hydroxynonenal (HNE) are reactive aldehydes generated during active inflammation as a consequence of lipid peroxidation; both react with protein thiols, including thioredoxin-1 (Trx1), a protein recently found to regulate antioxidant function in endothelial cells. Acrolein 0-8 thioredoxin Homo sapiens 178-191 17982132-2 2007 Acrolein and 4-hydroxynonenal (HNE) are reactive aldehydes generated during active inflammation as a consequence of lipid peroxidation; both react with protein thiols, including thioredoxin-1 (Trx1), a protein recently found to regulate antioxidant function in endothelial cells. Acrolein 0-8 thioredoxin Homo sapiens 193-197 17600310-5 2007 By gas chromatography/mass spectrometry (GC/MS) we show that acrolein and crotonaldehyde, two alpha,beta-unsaturated aldehydes, are contained in aqueous cigarette smoke extract (CSE) at micromolar concentrations and mimic CSE in evoking the release of the neutrophil chemoattractant IL-8 and of the pleiotropic inflammatory cytokine TNF-alpha from the human macrophagic cell line U937. Acrolein 61-69 C-X-C motif chemokine ligand 8 Homo sapiens 283-287 17600310-5 2007 By gas chromatography/mass spectrometry (GC/MS) we show that acrolein and crotonaldehyde, two alpha,beta-unsaturated aldehydes, are contained in aqueous cigarette smoke extract (CSE) at micromolar concentrations and mimic CSE in evoking the release of the neutrophil chemoattractant IL-8 and of the pleiotropic inflammatory cytokine TNF-alpha from the human macrophagic cell line U937. Acrolein 61-69 tumor necrosis factor Homo sapiens 333-342 17600310-6 2007 In addition, acrolein (10-30 microM) released IL-8 also from cultured human alveolar macrophages and THP-1 macrophagic cells. Acrolein 13-21 C-X-C motif chemokine ligand 8 Homo sapiens 46-50 18201443-9 2007 HBD-2 mRNA decreased twofold and HBD-2 protein decreased fourfold at 50 microM of AC in primary HSNEC. Acrolein 82-84 defensin beta 4A Homo sapiens 0-5 18201443-9 2007 HBD-2 mRNA decreased twofold and HBD-2 protein decreased fourfold at 50 microM of AC in primary HSNEC. Acrolein 82-84 defensin beta 4A Homo sapiens 33-38 18201443-10 2007 However, differentiated HSNEC showed a marginal decrease in a dose-dependent manner for both IL-8 and HBD-2 within the range of 10-50 microM of AC. Acrolein 144-146 C-X-C motif chemokine ligand 8 Homo sapiens 93-97 18201443-10 2007 However, differentiated HSNEC showed a marginal decrease in a dose-dependent manner for both IL-8 and HBD-2 within the range of 10-50 microM of AC. Acrolein 144-146 defensin beta 4A Homo sapiens 102-107 17907782-6 2007 The formation of cross-linked Hsp90 coincided with a rapid loss of carbonyl adducts within cells that had been subjected to a brief "pulse" exposure to a subtoxic concentration of acrolein, suggesting Michael adducts are short-lived within cells due in part to consumption during reactions with protein nucleophiles. Acrolein 180-188 heat shock protein 90 alpha family class A member 1 Homo sapiens 30-35 17907782-9 2007 As previously shown for hydralazine, mass spectrometry studies using a model peptide indicated that bisulfite traps carbonyl groups possessed by Michael addition adducts, and such adduct-trapping reactivity appeared to contribute to the blockade of Hsp90 cross-linking in acrolein-preloaded cells. Acrolein 272-280 heat shock protein 90 alpha family class A member 1 Homo sapiens 249-254 17935603-7 2007 Mice over-expressing GDNF also showed less staining for acrolein, nitrotyrosine, and 8-hydroxydeoxyguanosine, indicating less oxidative damage to lipids, proteins, and DNA. Acrolein 56-64 glial cell line derived neurotrophic factor Mus musculus 21-25 17485251-3 2007 In vitro evidence suggests that MGMT may protect against the urotoxic oxazaphosphorine metabolite, acrolein. Acrolein 99-107 methylated-DNA--protein-cysteine methyltransferase Cricetulus griseus 32-36 17632094-0 2007 Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Acrolein 0-8 paraoxonase 1 Homo sapiens 21-34 17632094-0 2007 Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Acrolein 0-8 paraoxonase 1 Homo sapiens 115-128 17632094-0 2007 Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Acrolein 52-60 paraoxonase 1 Homo sapiens 21-34 17632094-0 2007 Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Acrolein 52-60 paraoxonase 1 Homo sapiens 115-128 17632094-3 2007 We hypothesized that acrolein could also have deleterious effects on paraoxonase 1 (PON-1) activity. Acrolein 21-29 paraoxonase 1 Homo sapiens 69-82 17632094-3 2007 We hypothesized that acrolein could also have deleterious effects on paraoxonase 1 (PON-1) activity. Acrolein 21-29 paraoxonase 1 Homo sapiens 84-89 17632094-7 2007 RESULTS: We found that acrolein inhibits PON-1 activity in HDL in a time and concentration dependent fashion. Acrolein 23-31 paraoxonase 1 Homo sapiens 41-46 17632094-10 2007 Decrease in acrolein levels after dialysis correlate with increases in PON-1 activity (r=0.32, p 0.01). Acrolein 12-20 paraoxonase 1 Homo sapiens 71-76 17632094-11 2007 CONCLUSION: Acrolein inactivates paraoxonase 1 in HDL, a process that is inhibited by N-acetylcysteine. Acrolein 12-20 paraoxonase 1 Homo sapiens 33-46 17632094-13 2007 Decrease in acrolein levels after dialysis correlates with increase in PON-1 activity. Acrolein 12-20 paraoxonase 1 Homo sapiens 71-76 17485251-6 2007 CHO cells expressing a mutant form of MGMT (MGMT(R128A)), known to have >1000-fold less repair activity towards alkylated DNA while maintaining full active site transferase activity towards low molecular weight substrates, exhibited equivalent CAA- and acrolein-induced cytotoxicity to that of CHO cells transfected with plasmid control. Acrolein 256-264 methylated-DNA--protein-cysteine methyltransferase Cricetulus griseus 38-42 17485251-7 2007 These results imply that direct reaction of acrolein or CAA with the active site cysteine residue of MGMT, i.e. scavenging, is unlikely a mechanism to explain MGMT protection from CAA and acrolein-induced toxicity. Acrolein 188-196 methylated-DNA--protein-cysteine methyltransferase Cricetulus griseus 101-105 17655273-3 2007 Protein tyrosine phosphatases (PTPs) are an important class of cysteine-dependent enzymes whose reactivity with acrolein previously has not been well-characterized. Acrolein 112-120 6-pyruvoyltetrahydropterin synthase Homo sapiens 0-29 17655273-3 2007 Protein tyrosine phosphatases (PTPs) are an important class of cysteine-dependent enzymes whose reactivity with acrolein previously has not been well-characterized. Acrolein 112-120 6-pyruvoyltetrahydropterin synthase Homo sapiens 31-35 17655273-6 2007 We find that acrolein is a potent time-dependent inactivator of the enzyme PTP1B ( k inact = 0.02 +/- 0.005 s (-1) and K I = 2.3 +/- 0.6 x 10 (-4) M). Acrolein 13-21 protein tyrosine phosphatase non-receptor type 1 Homo sapiens 75-80 17655273-7 2007 The enzyme activity does not return upon gel filtration of the inactivated enzyme, and addition of the competitive phosphatase inhibitor vanadate slows inactivation of PTP1B by acrolein. Acrolein 177-185 protein tyrosine phosphatase non-receptor type 1 Homo sapiens 168-173 17655273-8 2007 Together, these observations suggest that acrolein covalently modifies the active site of PTP1B. Acrolein 42-50 protein tyrosine phosphatase non-receptor type 1 Homo sapiens 90-95 17684094-2 2007 Environmental irritants such as mustard oil, allicin, and acrolein activate TRPA1, causing acute pain, neuropeptide release, and neurogenic inflammation. Acrolein 58-66 transient receptor potential cation channel subfamily A member 1 Homo sapiens 76-81 17318410-0 2007 Induction of COX-2 by acrolein in rat lung epithelial cells. Acrolein 22-30 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 13-18 17580963-0 2007 Modification by acrolein, a component of tobacco smoke and age-related oxidative stress, mediates functional impairment of human apolipoprotein E. Acrolein 16-24 apolipoprotein E Homo sapiens 129-145 17491020-4 2007 Acrolein inhibited induction of NF-kappaB DNA binding activity after mitogenic stimulation of T cells but had no effect on induction of NFAT or AP-1. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 32-41 17491020-5 2007 Acrolein inhibited NF-kappaB1 (p50) binding to the IL-2 promoter in a chromatin immunoprecipitation assay by >99%. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 31-34 17491020-5 2007 Acrolein inhibited NF-kappaB1 (p50) binding to the IL-2 promoter in a chromatin immunoprecipitation assay by >99%. Acrolein 0-8 interleukin 2 Homo sapiens 51-55 17491020-6 2007 Using purified recombinant p50 in an electrophoretic mobility shift assay, we demonstrated that acrolein was 2000-fold more potent than crotonaldehyde in blocking DNA binding to an NF-kappaB consensus sequence. Acrolein 96-104 nuclear factor kappa B subunit 1 Homo sapiens 27-30 17491020-6 2007 Using purified recombinant p50 in an electrophoretic mobility shift assay, we demonstrated that acrolein was 2000-fold more potent than crotonaldehyde in blocking DNA binding to an NF-kappaB consensus sequence. Acrolein 96-104 nuclear factor kappa B subunit 1 Homo sapiens 181-190 17580963-5 2007 We investigated the effect of acrolein, an aldehydic product of endogenous lipid peroxidation and a tobacco smoke component, on the conformation and function of recombinant human apoE3-NT. Acrolein 30-38 apolipoprotein E Homo sapiens 179-184 17580963-6 2007 Acrolein caused oxidative modification of apoE3-NT as detected by Western blot with acrolein-lysine-specific antibodies, and tertiary conformational alterations. Acrolein 0-8 apolipoprotein E Homo sapiens 42-47 17580963-7 2007 Acrolein modification impairs the ability of apoE3-NT to interact with heparin and the LDL receptor. Acrolein 0-8 apolipoprotein E Homo sapiens 45-50 17580963-7 2007 Acrolein modification impairs the ability of apoE3-NT to interact with heparin and the LDL receptor. Acrolein 0-8 low density lipoprotein receptor Homo sapiens 87-99 17491020-2 2007 The alpha,beta-unsaturated aldehydes in cigarette smoke (acrolein and crotonaldehyde) inhibited production of interleukin-2 (IL-2), IL-10, granulocyte-macrophage colony-stimulating factor, interferon-gamma, and tumor necrosis factor-alpha by human T cells but did not inhibit production of IL-8. Acrolein 57-65 interleukin 2 Homo sapiens 110-123 17491020-2 2007 The alpha,beta-unsaturated aldehydes in cigarette smoke (acrolein and crotonaldehyde) inhibited production of interleukin-2 (IL-2), IL-10, granulocyte-macrophage colony-stimulating factor, interferon-gamma, and tumor necrosis factor-alpha by human T cells but did not inhibit production of IL-8. Acrolein 57-65 interleukin 2 Homo sapiens 125-129 17491020-2 2007 The alpha,beta-unsaturated aldehydes in cigarette smoke (acrolein and crotonaldehyde) inhibited production of interleukin-2 (IL-2), IL-10, granulocyte-macrophage colony-stimulating factor, interferon-gamma, and tumor necrosis factor-alpha by human T cells but did not inhibit production of IL-8. Acrolein 57-65 interleukin 10 Homo sapiens 132-137 17491020-2 2007 The alpha,beta-unsaturated aldehydes in cigarette smoke (acrolein and crotonaldehyde) inhibited production of interleukin-2 (IL-2), IL-10, granulocyte-macrophage colony-stimulating factor, interferon-gamma, and tumor necrosis factor-alpha by human T cells but did not inhibit production of IL-8. Acrolein 57-65 tumor necrosis factor Homo sapiens 139-238 17491020-2 2007 The alpha,beta-unsaturated aldehydes in cigarette smoke (acrolein and crotonaldehyde) inhibited production of interleukin-2 (IL-2), IL-10, granulocyte-macrophage colony-stimulating factor, interferon-gamma, and tumor necrosis factor-alpha by human T cells but did not inhibit production of IL-8. Acrolein 57-65 C-X-C motif chemokine ligand 8 Homo sapiens 290-294 17318410-5 2007 In this study, we investigated the induction of COX-2 by acrolein in rat lung epithelial cells and its related signaling cascade. Acrolein 57-65 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 48-53 17318410-6 2007 Induction of COX-2 by acrolein was significant at 6 h post-treatment and was dependent upon NFkappaB activation. Acrolein 22-30 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 13-18 17318410-7 2007 The activation of NFkappaB by acrolein was induced as a result of degradation of IkappaBalpha over the time of treatment. Acrolein 30-38 NFKB inhibitor alpha Rattus norvegicus 81-93 17318410-9 2007 The results of these studies offer an explanation for the mechanism of COX-2 induction by acrolein in rat lung epithelial cells. Acrolein 90-98 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 71-76 17196791-12 2007 Finally, acrolein induced phosphorylation of the pro-apoptotic factor p53 which is responsible for transcription of pro-apoptotic factors such as Bax and Fas ligand. Acrolein 9-17 cellular tumor antigen p53 Cricetulus griseus 70-73 17363696-0 2007 Acrolein induces cyclooxygenase-2 and prostaglandin production in human umbilical vein endothelial cells: roles of p38 MAP kinase. Acrolein 0-8 prostaglandin-endoperoxide synthase 2 Homo sapiens 17-33 17363696-0 2007 Acrolein induces cyclooxygenase-2 and prostaglandin production in human umbilical vein endothelial cells: roles of p38 MAP kinase. Acrolein 0-8 mitogen-activated protein kinase 1 Homo sapiens 115-118 17329238-3 2007 Using purified ARL-1 protein, we determined its enzymatic activity in response to acrolein and defined its steady-state kinetics with K(m) and V(max) at 0.110 +/- 0.012 mM and 3122.0 +/- 64.7 nmol/mg protein/min, respectively. Acrolein 82-90 aldo-keto reductase family 1 member B10 Homo sapiens 15-20 17329238-5 2007 More significantly, at a low dose of 5 microM acrolein, EGFP/ARL-1 expression enhanced both plating efficiency and focus formation by more than threefold, and the foci (in soft agar) of 293T cells expressing EGFP/ARL-1 were significantly larger than those of the vector control cells. Acrolein 46-54 aldo-keto reductase family 1 member B10 Homo sapiens 61-66 17329238-5 2007 More significantly, at a low dose of 5 microM acrolein, EGFP/ARL-1 expression enhanced both plating efficiency and focus formation by more than threefold, and the foci (in soft agar) of 293T cells expressing EGFP/ARL-1 were significantly larger than those of the vector control cells. Acrolein 46-54 aldo-keto reductase family 1 member B10 Homo sapiens 213-218 17329238-6 2007 At high concentrations of acrolein (25 and 50 microM), EGFP/ARL-1 protein prevented oncotic death of 293T cells induced by acrolein. Acrolein 26-34 aldo-keto reductase family 1 member B10 Homo sapiens 60-65 17329238-6 2007 At high concentrations of acrolein (25 and 50 microM), EGFP/ARL-1 protein prevented oncotic death of 293T cells induced by acrolein. Acrolein 123-131 aldo-keto reductase family 1 member B10 Homo sapiens 60-65 17329238-7 2007 In summary, our data demonstrated for the first time that the ARL-1 protein protects 293T cells from acrolein toxicity. Acrolein 101-109 aldo-keto reductase family 1 member B10 Homo sapiens 62-67 17456575-6 2007 RESULTS: With acrolein in tissue fixative, nuclear ER-beta immunoreactivity was observed in 10.8-28.0% of GnRH neurons of the four different individuals. Acrolein 14-22 estrogen receptor 2 Homo sapiens 51-58 17363696-2 2007 This study examined the effect of acrolein on expression of cyclooxygenase-2 (COX-2) and prostaglandin (PG) production in endothelial cells. Acrolein 34-42 prostaglandin-endoperoxide synthase 2 Homo sapiens 60-76 17363696-2 2007 This study examined the effect of acrolein on expression of cyclooxygenase-2 (COX-2) and prostaglandin (PG) production in endothelial cells. Acrolein 34-42 prostaglandin-endoperoxide synthase 2 Homo sapiens 78-83 17363696-5 2007 Here we report that the levels of COX-2 mRNA and protein are increased in human umbilical vein endothelial cells (HUVECs) after acrolein exposure. Acrolein 128-136 prostaglandin-endoperoxide synthase 2 Homo sapiens 34-39 17363696-7 2007 Inhibition of p38 MAPK activity abolished the induction of COX-2 protein and PGE2 accumulation by acrolein, while suppression of extracellular signal-regulated kinase (ERK) and JNK activity had no effect on the induction of COX-2 expression in experiments using inhibitors and siRNA. Acrolein 98-106 mitogen-activated protein kinase 1 Homo sapiens 14-17 17363696-7 2007 Inhibition of p38 MAPK activity abolished the induction of COX-2 protein and PGE2 accumulation by acrolein, while suppression of extracellular signal-regulated kinase (ERK) and JNK activity had no effect on the induction of COX-2 expression in experiments using inhibitors and siRNA. Acrolein 98-106 mitogen-activated protein kinase 1 Homo sapiens 18-22 17363696-7 2007 Inhibition of p38 MAPK activity abolished the induction of COX-2 protein and PGE2 accumulation by acrolein, while suppression of extracellular signal-regulated kinase (ERK) and JNK activity had no effect on the induction of COX-2 expression in experiments using inhibitors and siRNA. Acrolein 98-106 prostaglandin-endoperoxide synthase 2 Homo sapiens 59-64 17363696-9 2007 CONCLUSION: These results provide that acrolein may play a role in progression of atherosclerosis and new information on the signaling pathways involved in COX-2 upregulation in response to acrolein and provide evidence that PKCdelta and p38 MAPK are required for transcriptional activation of COX-2. Acrolein 190-198 prostaglandin-endoperoxide synthase 2 Homo sapiens 156-161 17363696-9 2007 CONCLUSION: These results provide that acrolein may play a role in progression of atherosclerosis and new information on the signaling pathways involved in COX-2 upregulation in response to acrolein and provide evidence that PKCdelta and p38 MAPK are required for transcriptional activation of COX-2. Acrolein 190-198 mitogen-activated protein kinase 1 Homo sapiens 238-241 17363696-9 2007 CONCLUSION: These results provide that acrolein may play a role in progression of atherosclerosis and new information on the signaling pathways involved in COX-2 upregulation in response to acrolein and provide evidence that PKCdelta and p38 MAPK are required for transcriptional activation of COX-2. Acrolein 190-198 prostaglandin-endoperoxide synthase 2 Homo sapiens 294-299 17329238-2 2007 In this study, we report aldose reductase-like-1 (ARL-1) as a novel enzyme that catalyzes the reduction of acrolein and protects cells from their toxicity. Acrolein 107-115 aldo-keto reductase family 1 member B10 Homo sapiens 25-48 17329238-2 2007 In this study, we report aldose reductase-like-1 (ARL-1) as a novel enzyme that catalyzes the reduction of acrolein and protects cells from their toxicity. Acrolein 107-115 aldo-keto reductase family 1 member B10 Homo sapiens 50-55 17196791-12 2007 Finally, acrolein induced phosphorylation of the pro-apoptotic factor p53 which is responsible for transcription of pro-apoptotic factors such as Bax and Fas ligand. Acrolein 9-17 apoptosis regulator BAX Cricetulus griseus 146-149 17196791-12 2007 Finally, acrolein induced phosphorylation of the pro-apoptotic factor p53 which is responsible for transcription of pro-apoptotic factors such as Bax and Fas ligand. Acrolein 9-17 tumor necrosis factor ligand superfamily member 6 Cricetulus griseus 154-164 16860297-7 2007 Exposure to the photochemically generated products of BD (primarily acrolein, acetaldehyde, formaldehyde, furan and ozone) induced significant increases in cytotoxicity, IL-8, and IL-6 gene expression compared to a synthetic mixture of primary products that was created by injecting the correct concentrations of the detected products from the irradiation experiments. Acrolein 68-76 C-X-C motif chemokine ligand 8 Homo sapiens 170-174 16860297-7 2007 Exposure to the photochemically generated products of BD (primarily acrolein, acetaldehyde, formaldehyde, furan and ozone) induced significant increases in cytotoxicity, IL-8, and IL-6 gene expression compared to a synthetic mixture of primary products that was created by injecting the correct concentrations of the detected products from the irradiation experiments. Acrolein 68-76 interleukin 6 Homo sapiens 180-184 17249797-1 2007 [reaction: see text] The alcohol-catalyzed Diels-Alder reactions of acrolein and benzaldehyde with Rawal"s diene were evaluated with density functional theory (B3LYP/6-31G(d)). Acrolein 68-76 protein tyrosine phosphatase non-receptor type 22 Homo sapiens 162-165 17320762-5 2007 Exposure of Chinese hamster ovary cells to acrolein caused translocation of adaptor protein Fas associated with death domain to the cytoplasmic membrane and caspase-8 activation. Acrolein 43-51 caspase-8 Cricetulus griseus 157-166 17320762-9 2007 Activation of the mitochondrial pathway by acrolein was confirmed by caspase-9 activation. Acrolein 43-51 caspase-9 Cricetulus griseus 69-78 17222828-3 2007 In contrast to BSO, acrolein caused a loss of caspase-8 cysteine content in association with direct alkylation of caspase-8. Acrolein 20-28 caspase 8 Homo sapiens 46-55 17222828-3 2007 In contrast to BSO, acrolein caused a loss of caspase-8 cysteine content in association with direct alkylation of caspase-8. Acrolein 20-28 caspase 8 Homo sapiens 114-123 17222828-4 2007 Our findings indicate that inhibition of caspase-8 by thiol-reactive agents such as acrolein is not due to GSH depletion but caused by direct protein thiol modifications. Acrolein 84-92 caspase 8 Homo sapiens 41-50 17690948-7 2007 Modification of recombinant alphaSYN by ACR enhanced its oligomerization, and at higher ACR concentrations alphaSYN was fragmented and polymerized forming a smear pattern in SDS-PAGE. Acrolein 40-43 synuclein alpha Homo sapiens 28-36 17690948-0 2007 In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. Acrolein 65-73 synuclein alpha Homo sapiens 34-49 16820484-6 2006 Most strikingly, a mutant lacking an old yellow enzyme (OYE2) was identified as being acrolein sensitive. Acrolein 86-94 NADPH dehydrogenase Saccharomyces cerevisiae S288C 56-60 17690948-4 2007 This paper reports that in the dopamine neurons of the substantia nigra containing neuromelanin from PD patients, alphaSYN was modified with acrolein (ACR), an aldehyde product of lipid peroxidation. Acrolein 141-149 synuclein alpha Homo sapiens 114-122 17690948-4 2007 This paper reports that in the dopamine neurons of the substantia nigra containing neuromelanin from PD patients, alphaSYN was modified with acrolein (ACR), an aldehyde product of lipid peroxidation. Acrolein 151-154 synuclein alpha Homo sapiens 114-122 17023561-7 2007 Acrolein and other alpha,beta-unsaturated carbonyls are bifunctional (electrophilic reactivity at the C-1 and C-3 positions) and could produce in vitro neurotoxicity by forming protein cross-links rather than thiol monoadducts. Acrolein 0-8 complement C3 Rattus norvegicus 102-113 17030796-0 2006 Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. Acrolein 0-8 tumor protein p53 Homo sapiens 81-84 16543915-1 2006 Cytochrome P450 (CYP) enzyme 2B1 metabolizes the anticancer prodrug cyclophosphamide (CPA) to 4-hydroxy-CPA, which decomposes to the cytotoxic metabolites acrolein and phosphoramide mustard. Acrolein 155-163 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 11-15 17197552-4 2007 RESULTS: Acute acrolein exposure exceeding 50 microM (24 hours) in ARPR19 cells caused toxicity, including decreases in cell viability, mitochondrial potential, GSH, antioxidant capacity, Nrf2 expression, enzyme activity (mitochondrial complexes I, II, III; superoxide dismutase; and glutathione peroxidase). Acrolein 15-23 NFE2 like bZIP transcription factor 2 Homo sapiens 188-192 17582205-11 2007 Moreover, associated with the increased renal expression of Txnip, diabetic conditions increased oxidative stress as determined by urinary excretion of 8-hydroxy-2"-deoxyguanosine and acrolein adduct, which are oxidative stress markers. Acrolein 184-192 thioredoxin interacting protein Mus musculus 60-65 17026969-3 2006 Both aminoaldehydes and acrolein are generated from the metabolism of polyamines to putrescine by polyamine oxidase. Acrolein 24-32 polyamine oxidase Homo sapiens 98-115 16554974-4 2006 As acrolein was a major toxic compound produced from spermine by polyamine oxidase, the levels of free and protein-conjugated acrolein in plasma were also measured. Acrolein 3-11 polyamine oxidase Homo sapiens 65-82 16554974-7 2006 It was found that acrolein is mainly produced by spermine oxidase in plasma. Acrolein 18-26 spermine oxidase Homo sapiens 49-65 16480751-0 2006 Upregulation of endothelial heme oxygenase-1 expression through the activation of the JNK pathway by sublethal concentrations of acrolein. Acrolein 129-137 heme oxygenase 1 Homo sapiens 28-44 16480751-0 2006 Upregulation of endothelial heme oxygenase-1 expression through the activation of the JNK pathway by sublethal concentrations of acrolein. Acrolein 129-137 mitogen-activated protein kinase 8 Homo sapiens 86-89 16480751-3 2006 In this study, the regulatory effects of acrolein upon the expression of HO-1 were investigated in endothelial cells (ECs). Acrolein 41-49 heme oxygenase 1 Homo sapiens 73-77 16480751-4 2006 We demonstrate that acrolein induces the elevation of HO-1 protein levels, and subsequent enzyme activity, at non-cytotoxic concentrations. Acrolein 20-28 heme oxygenase 1 Homo sapiens 54-58 16480751-8 2006 We show that acrolein induces Nrf2 translocation and ARE-luciferase reporter activity. Acrolein 13-21 NFE2 like bZIP transcription factor 2 Homo sapiens 30-34 16480751-15 2006 In addition, only the JNK inhibitor SP600125 and tyrosine kinase inhibitor genistein had any significant inhibitory impact upon the upregulation of HO-1 by acrolein. Acrolein 156-164 mitogen-activated protein kinase 8 Homo sapiens 22-25 16480751-15 2006 In addition, only the JNK inhibitor SP600125 and tyrosine kinase inhibitor genistein had any significant inhibitory impact upon the upregulation of HO-1 by acrolein. Acrolein 156-164 heme oxygenase 1 Homo sapiens 148-152 16480751-17 2006 Hence, we show in our current experiments that a sublethal concentration of acrolein is in fact a novel HO-1 inducer, and we further identify the principal underlying mechanisms involved in this process. Acrolein 76-84 heme oxygenase 1 Homo sapiens 104-108 16820484-8 2006 We show that mutants lacking OYE2, but not OYE3, are sensitive to acrolein, and overexpression of both isoenzymes increases acrolein tolerance. Acrolein 66-74 NADPH dehydrogenase Saccharomyces cerevisiae S288C 29-33 16820484-8 2006 We show that mutants lacking OYE2, but not OYE3, are sensitive to acrolein, and overexpression of both isoenzymes increases acrolein tolerance. Acrolein 124-132 NADPH dehydrogenase Saccharomyces cerevisiae S288C 29-33 16820484-9 2006 Our data indicate that OYE2 is required for basal levels of tolerance, whereas OYE3 expression is particularly induced following acrolein stress. Acrolein 129-137 NADPH dehydrogenase Saccharomyces cerevisiae S288C 79-83 16619238-12 2006 Caspase 3 activity and DNA fragmentation assays were performed and supported the notion that 100 microM acrolein induced PC12 cell death by the mechanism of necrosis, not apoptosis. Acrolein 104-112 caspase 3 Rattus norvegicus 0-9 16849425-8 2006 The staining for acrolein in remaining cones at P35 was eliminated in antioxidant-treated rd1 mice, confirming that the treatment markedly reduced oxidative damage in cones; this was accompanied by a 2-fold increase in cone cell density and a 50% increase in medium-wavelength cone opsin mRNA. Acrolein 17-25 interleukin 12a Mus musculus 48-51 16849425-8 2006 The staining for acrolein in remaining cones at P35 was eliminated in antioxidant-treated rd1 mice, confirming that the treatment markedly reduced oxidative damage in cones; this was accompanied by a 2-fold increase in cone cell density and a 50% increase in medium-wavelength cone opsin mRNA. Acrolein 17-25 phosphodiesterase 6B, cGMP, rod receptor, beta polypeptide Mus musculus 90-93 16725382-5 2006 Acrolein incubation (10-1000 microM, or 0.02-2 micromol/mg protein) with mitochondria caused dose-dependent inhibition of NADH- and succinate-linked mitochondrial respiration chain, change of mitochondrial permeability transition, increase in protein carbonyls, and selective enzyme inhibition of mitochondrial complex I, II, pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, but no effects on mitochondrial complex III, IV, V and malate dehydrogenase. Acrolein 0-8 oxoglutarate dehydrogenase Rattus norvegicus 350-383 16819267-5 2006 Finally, the correlation between acrolein produced from polyamines by polyamine oxidase and chronic renal failure and brain stroke is summarized. Acrolein 33-41 polyamine oxidase Homo sapiens 70-87 16608169-4 2006 The reaction of 2"-deoxyadenosine with acrolein resulted in the formation of four structurally different adducts (dAI, dAII, dAIII, dAIV). Acrolein 39-47 Arrestin 1 Drosophila melanogaster 114-117 16608169-4 2006 The reaction of 2"-deoxyadenosine with acrolein resulted in the formation of four structurally different adducts (dAI, dAII, dAIII, dAIV). Acrolein 39-47 Arrestin 2 Drosophila melanogaster 119-123 16608169-6 2006 The adduct dAIII was found to arise via a Dimroth rearrangement of adduct dAI, while the adduct dAIV was shown to be formed upon further reaction of acrolein with dAIII. Acrolein 149-157 Arrestin 1 Drosophila melanogaster 11-14 16564016-4 2006 TRPA1 is also targeted by environmental irritants, such as acrolein, that account for toxic and inflammatory actions of tear gas, vehicle exhaust, and metabolic byproducts of chemotherapeutic agents. Acrolein 59-67 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 0-5 16354708-4 2006 Previously, we have shown that proficient and error-free replication through the gamma-HOPdG (gamma-hydroxy-1,N2-propano-2"-deoxyguanosine) adduct, which is formed from the reaction of acrolein with the N2 of guanine, is mediated by the sequential action of human Poliota and Polkappa, in which Poliota incorporates the nucleotide opposite the lesion site and Polkappa carries out the subsequent extension reaction. Acrolein 185-193 DNA polymerase mu Homo sapiens 264-271 16337876-0 2006 Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Acrolein 45-53 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 27-32 16337876-0 2006 Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Acrolein 45-53 cAMP responsive element binding protein 1 Homo sapiens 37-41 16337876-3 2006 Acrolein and 4HNE increased the levels of active phosphorylated forms of c-jun and CREB, the transcription factors that promote apoptosis and cell survival, respectively. Acrolein 0-8 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 73-78 16337876-3 2006 Acrolein and 4HNE increased the levels of active phosphorylated forms of c-jun and CREB, the transcription factors that promote apoptosis and cell survival, respectively. Acrolein 0-8 cAMP responsive element binding protein 1 Homo sapiens 83-87 16337876-7 2006 Finally, adenoviral transduction of hippocampal neurons with VP 16-CREB resulted in significant reduction in caspase-3 activation by acrolein and 4HNE. Acrolein 133-141 host cell factor C1 Homo sapiens 61-66 16337876-7 2006 Finally, adenoviral transduction of hippocampal neurons with VP 16-CREB resulted in significant reduction in caspase-3 activation by acrolein and 4HNE. Acrolein 133-141 cAMP responsive element binding protein 1 Homo sapiens 67-71 16337876-7 2006 Finally, adenoviral transduction of hippocampal neurons with VP 16-CREB resulted in significant reduction in caspase-3 activation by acrolein and 4HNE. Acrolein 133-141 caspase 3 Homo sapiens 109-118 16678976-6 2006 The redox and surfactant properties of Abeta allow it to catalyze the polymerization of acrolein. Acrolein 88-96 amyloid beta precursor protein Homo sapiens 39-44 16354708-4 2006 Previously, we have shown that proficient and error-free replication through the gamma-HOPdG (gamma-hydroxy-1,N2-propano-2"-deoxyguanosine) adduct, which is formed from the reaction of acrolein with the N2 of guanine, is mediated by the sequential action of human Poliota and Polkappa, in which Poliota incorporates the nucleotide opposite the lesion site and Polkappa carries out the subsequent extension reaction. Acrolein 185-193 DNA polymerase lambda Homo sapiens 276-284 16354708-4 2006 Previously, we have shown that proficient and error-free replication through the gamma-HOPdG (gamma-hydroxy-1,N2-propano-2"-deoxyguanosine) adduct, which is formed from the reaction of acrolein with the N2 of guanine, is mediated by the sequential action of human Poliota and Polkappa, in which Poliota incorporates the nucleotide opposite the lesion site and Polkappa carries out the subsequent extension reaction. Acrolein 185-193 DNA polymerase mu Homo sapiens 295-302 16354708-4 2006 Previously, we have shown that proficient and error-free replication through the gamma-HOPdG (gamma-hydroxy-1,N2-propano-2"-deoxyguanosine) adduct, which is formed from the reaction of acrolein with the N2 of guanine, is mediated by the sequential action of human Poliota and Polkappa, in which Poliota incorporates the nucleotide opposite the lesion site and Polkappa carries out the subsequent extension reaction. Acrolein 185-193 DNA polymerase lambda Homo sapiens 360-368 16300370-5 2005 Both acrolein and methyl vinyl ketone displayed comparable protein carbonylating activity during in vitro studies with the model protein bovine serum albumin, confirming the alpha,beta,-unsaturated bond of both compounds is an efficient Michael acceptor for protein nucleophiles. Acrolein 5-13 albumin Mus musculus 144-157 16204758-10 2005 Acrolein increased the generation of lipid hydroperoxide in plasma and aortic tissue by 21% and 124% respectively, increased glutathione-S-transferase (GST) and glutathione peroxidase (GSH-Px) activities. Acrolein 0-8 hematopoietic prostaglandin D synthase Rattus norvegicus 125-150 16126721-0 2005 Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. Acrolein 0-8 apolipoprotein A1 Homo sapiens 131-149 16126721-4 2005 Tandem mass spectrometric analysis demonstrated that lysine 226, located near the center of helix 10 in apoA-I, was the major site modified by acrolein. Acrolein 143-151 apolipoprotein A1 Homo sapiens 104-110 16126721-6 2005 Indeed, we found that conversion of Lys-226 to N(epsilon)-(3-methylpyridinium)lysine by acrolein associated quantitatively with decreased cholesterol efflux from cells via the ATP-binding cassette transporter A1 pathway. Acrolein 88-96 ATP binding cassette subfamily A member 1 Homo sapiens 176-211 16126721-8 2005 Finally, immunohistochemical studies with a monoclonal antibody revealed co-localization of apoA-I with acrolein adducts in human atherosclerotic lesions. Acrolein 104-112 apolipoprotein A1 Homo sapiens 92-98 16126721-9 2005 Our observations suggest that acrolein might interfere with normal reverse cholesterol transport by HDL by modifying specific sites in apoA-I. Acrolein 30-38 apolipoprotein A1 Homo sapiens 135-141 16195596-2 2005 Acrolein-modified apoE in VLDL was not taken up by human hepatoma cell whereas unmodified apoE in the presence of ascorbate was taken up. Acrolein 0-8 apolipoprotein E Homo sapiens 18-22 16195596-2 2005 Acrolein-modified apoE in VLDL was not taken up by human hepatoma cell whereas unmodified apoE in the presence of ascorbate was taken up. Acrolein 0-8 apolipoprotein E Homo sapiens 90-94 16267254-6 2005 METHODS AND RESULTS: In studies with cell types found in vascular tissue, MPO-oxidation products of glycine (formaldehyde) and threonine (acrolein) were the most cytotoxic. Acrolein 138-146 myeloperoxidase Mus musculus 74-77 16081039-2 2005 Amyloid-beta (Abeta) peptide co-localizes with acrolein presumably due to Abeta-induced lipid peroxidation. Acrolein 47-55 amyloid beta precursor protein Homo sapiens 0-12 16081039-2 2005 Amyloid-beta (Abeta) peptide co-localizes with acrolein presumably due to Abeta-induced lipid peroxidation. Acrolein 47-55 amyloid beta precursor protein Homo sapiens 14-19 16081039-2 2005 Amyloid-beta (Abeta) peptide co-localizes with acrolein presumably due to Abeta-induced lipid peroxidation. Acrolein 47-55 amyloid beta precursor protein Homo sapiens 74-79 16081039-4 2005 Following incubation of Abeta with acrolein (16-750 mM), we observed the formation of thin plastic fragments that were extensively punctuated. Acrolein 35-43 amyloid beta precursor protein Homo sapiens 24-29 16081039-7 2005 The ability of Abeta to catalyze the polymerization of acrolein is likely due to Abeta"s surfactant and redox properties. Acrolein 55-63 amyloid beta precursor protein Homo sapiens 15-20 16081039-7 2005 The ability of Abeta to catalyze the polymerization of acrolein is likely due to Abeta"s surfactant and redox properties. Acrolein 55-63 amyloid beta precursor protein Homo sapiens 81-86 16204758-10 2005 Acrolein increased the generation of lipid hydroperoxide in plasma and aortic tissue by 21% and 124% respectively, increased glutathione-S-transferase (GST) and glutathione peroxidase (GSH-Px) activities. Acrolein 0-8 hematopoietic prostaglandin D synthase Rattus norvegicus 152-155 16036326-0 2005 Acrolein induces Hsp72 via both PKCdelta/JNK and calcium signaling pathways in human umbilical vein endothelial cells. Acrolein 0-8 heat shock protein family A (Hsp70) member 1A Homo sapiens 17-22 16037261-0 2005 Acrolein modifies apolipoprotein A-I in the human artery wall. Acrolein 0-8 apolipoprotein A1 Homo sapiens 18-36 16037261-4 2005 We therefore investigated the possibility that acrolein might react with apolipoprotein A-I (apoA-I), the major protein of high-density lipoprotein (HDL), which plays a critical role in mobilizing cholesterol from artery wall macrophages. Acrolein 47-55 apolipoprotein A1 Homo sapiens 73-91 16037261-4 2005 We therefore investigated the possibility that acrolein might react with apolipoprotein A-I (apoA-I), the major protein of high-density lipoprotein (HDL), which plays a critical role in mobilizing cholesterol from artery wall macrophages. Acrolein 47-55 apolipoprotein A1 Homo sapiens 93-99 16037261-5 2005 Tandem mass spectrometric analysis demonstrated that lysine residues were the only amino acids in apoA-I that were modified by acrolein. Acrolein 127-135 apolipoprotein A1 Homo sapiens 98-104 16037261-6 2005 Immunohistochemical studies with a monoclonal antibody revealed that acrolein adducts colocalized with apoA-I in human atherosclerotic lesions. Acrolein 69-77 apolipoprotein A1 Homo sapiens 103-109 16037261-7 2005 Moreover, the ability of apoA-I to remove cholesterol from cultured cells was impaired after exposure to acrolein, suggesting that the carbonyl might interfere with apoA-I"s normal function of promoting cholesterol efflux from artery wall cells. Acrolein 105-113 apolipoprotein A1 Homo sapiens 25-31 16037261-7 2005 Moreover, the ability of apoA-I to remove cholesterol from cultured cells was impaired after exposure to acrolein, suggesting that the carbonyl might interfere with apoA-I"s normal function of promoting cholesterol efflux from artery wall cells. Acrolein 105-113 apolipoprotein A1 Homo sapiens 165-171 16037261-8 2005 Our observations suggest that acrolein may interfere with normal HDL cholesterol transport by modifying apoA-I. Acrolein 30-38 apolipoprotein A1 Homo sapiens 104-110 15776493-4 2005 Acroleins with alpha-branched alkyl side chains were coupled to give the corresponding syn pinacols, while on the other hand, acroleins with less bulky substituents furnished the anti derivatives. Acrolein 0-9 synemin Homo sapiens 87-90 16036326-0 2005 Acrolein induces Hsp72 via both PKCdelta/JNK and calcium signaling pathways in human umbilical vein endothelial cells. Acrolein 0-8 protein kinase C delta Homo sapiens 32-40 16036326-0 2005 Acrolein induces Hsp72 via both PKCdelta/JNK and calcium signaling pathways in human umbilical vein endothelial cells. Acrolein 0-8 mitogen-activated protein kinase 8 Homo sapiens 41-44 16036326-4 2005 Here, we report that low concentrations of acrolein induce Hsp72 in human umbilical vein endothelial cells (HUVEC) and that both the PKCdelta/JNK pathway and calcium pathway were involved in the induction. Acrolein 43-51 heat shock protein family A (Hsp70) member 1A Homo sapiens 59-64 16036326-4 2005 Here, we report that low concentrations of acrolein induce Hsp72 in human umbilical vein endothelial cells (HUVEC) and that both the PKCdelta/JNK pathway and calcium pathway were involved in the induction. Acrolein 43-51 protein kinase C delta Homo sapiens 133-141 16036326-4 2005 Here, we report that low concentrations of acrolein induce Hsp72 in human umbilical vein endothelial cells (HUVEC) and that both the PKCdelta/JNK pathway and calcium pathway were involved in the induction. Acrolein 43-51 mitogen-activated protein kinase 8 Homo sapiens 142-145 15650393-0 2005 Inhibition of NFkappaB activation and IL-8 expression in human bronchial epithelial cells by acrolein. Acrolein 93-101 nuclear factor kappa B subunit 1 Homo sapiens 14-22 15531749-2 2005 Acrolein, a component of cigarette smoke, increases mucin 5AC (MUC5AC), a prevalent airway mucin in NCI-H292 cells by transcriptional activation, but the signal transduction pathways involved in acrolein-induced MUC5AC expression are unknown. Acrolein 0-8 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 52-61 15531749-2 2005 Acrolein, a component of cigarette smoke, increases mucin 5AC (MUC5AC), a prevalent airway mucin in NCI-H292 cells by transcriptional activation, but the signal transduction pathways involved in acrolein-induced MUC5AC expression are unknown. Acrolein 0-8 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 63-69 15531749-2 2005 Acrolein, a component of cigarette smoke, increases mucin 5AC (MUC5AC), a prevalent airway mucin in NCI-H292 cells by transcriptional activation, but the signal transduction pathways involved in acrolein-induced MUC5AC expression are unknown. Acrolein 0-8 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 212-218 15531749-2 2005 Acrolein, a component of cigarette smoke, increases mucin 5AC (MUC5AC), a prevalent airway mucin in NCI-H292 cells by transcriptional activation, but the signal transduction pathways involved in acrolein-induced MUC5AC expression are unknown. Acrolein 195-203 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 212-218 15531749-3 2005 Acrolein depleted cellular glutathione at doses of 10 muM or greater, higher than those sufficient (0.03 muM) to increase MUC5AC mRNA, suggesting that MUC5AC expression was independent of oxidative stress. Acrolein 0-8 latexin Homo sapiens 54-57 15531749-3 2005 Acrolein depleted cellular glutathione at doses of 10 muM or greater, higher than those sufficient (0.03 muM) to increase MUC5AC mRNA, suggesting that MUC5AC expression was independent of oxidative stress. Acrolein 0-8 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 122-128 15531749-7 2005 Acrolein increased the release and subsequent activation of pro-MMP9. Acrolein 0-8 matrix metallopeptidase 9 Homo sapiens 64-68 15531749-8 2005 Acrolein increased MMP9 and decreased tissue inhibitor of metalloproteinase 3 (TIMP3), an endogenous inhibitor of ADAM17, transcripts. Acrolein 0-8 matrix metallopeptidase 9 Homo sapiens 19-23 15531749-8 2005 Acrolein increased MMP9 and decreased tissue inhibitor of metalloproteinase 3 (TIMP3), an endogenous inhibitor of ADAM17, transcripts. Acrolein 0-8 TIMP metallopeptidase inhibitor 3 Homo sapiens 38-77 15531749-8 2005 Acrolein increased MMP9 and decreased tissue inhibitor of metalloproteinase 3 (TIMP3), an endogenous inhibitor of ADAM17, transcripts. Acrolein 0-8 TIMP metallopeptidase inhibitor 3 Homo sapiens 79-84 15531749-8 2005 Acrolein increased MMP9 and decreased tissue inhibitor of metalloproteinase 3 (TIMP3), an endogenous inhibitor of ADAM17, transcripts. Acrolein 0-8 ADAM metallopeptidase domain 17 Homo sapiens 114-120 15531749-9 2005 Together, these data suggest that acrolein induces MUC5AC expression via an initial ligand-dependent activation of EGFR mediated by ADAM17 and MMP9. Acrolein 34-42 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 51-57 15531749-9 2005 Together, these data suggest that acrolein induces MUC5AC expression via an initial ligand-dependent activation of EGFR mediated by ADAM17 and MMP9. Acrolein 34-42 epidermal growth factor receptor Homo sapiens 115-119 15531749-9 2005 Together, these data suggest that acrolein induces MUC5AC expression via an initial ligand-dependent activation of EGFR mediated by ADAM17 and MMP9. Acrolein 34-42 ADAM metallopeptidase domain 17 Homo sapiens 132-138 15531749-9 2005 Together, these data suggest that acrolein induces MUC5AC expression via an initial ligand-dependent activation of EGFR mediated by ADAM17 and MMP9. Acrolein 34-42 matrix metallopeptidase 9 Homo sapiens 143-147 15531749-10 2005 In addition, a prolonged effect of acrolein may be mediated by altering MMP9 and TIMP3 transcription. Acrolein 35-43 matrix metallopeptidase 9 Homo sapiens 72-76 15531749-10 2005 In addition, a prolonged effect of acrolein may be mediated by altering MMP9 and TIMP3 transcription. Acrolein 35-43 TIMP metallopeptidase inhibitor 3 Homo sapiens 81-86 15843039-6 2005 Acrolein induced apoptosis through a decrease in mitochondrial membrane potential, the liberation of cytochrome c, the activation of initiator caspase-9, and the activation of the effector caspase-7. Acrolein 0-8 cytochrome c, somatic Homo sapiens 101-113 15843039-6 2005 Acrolein induced apoptosis through a decrease in mitochondrial membrane potential, the liberation of cytochrome c, the activation of initiator caspase-9, and the activation of the effector caspase-7. Acrolein 0-8 caspase 9 Homo sapiens 143-152 15843039-6 2005 Acrolein induced apoptosis through a decrease in mitochondrial membrane potential, the liberation of cytochrome c, the activation of initiator caspase-9, and the activation of the effector caspase-7. Acrolein 0-8 caspase 7 Homo sapiens 189-198 15843039-7 2005 However, acrolein inhibited enzymatic activity of the effector caspase-3, although a cleavage of pro-caspase-3 occurred. Acrolein 9-17 caspase 3 Homo sapiens 63-72 15843039-10 2005 The induction of apoptosis by acrolein was confirmed morphologically by the condensation of nuclear chromatin and by the cleavage of the inhibitor of caspase activated DNase (ICAD), which leads to the liberation of CAD that causes DNA fragmentation. Acrolein 30-38 DNA fragmentation factor subunit beta Homo sapiens 150-173 15843039-10 2005 The induction of apoptosis by acrolein was confirmed morphologically by the condensation of nuclear chromatin and by the cleavage of the inhibitor of caspase activated DNase (ICAD), which leads to the liberation of CAD that causes DNA fragmentation. Acrolein 30-38 DNA fragmentation factor subunit alpha Homo sapiens 175-179 15652504-4 2005 The findings reported here show that low concentrations of acrolein rapidly inactivate TR, both in vitro and in vivo. Acrolein 59-67 peroxiredoxin 5 Homo sapiens 87-89 15652504-7 2005 The results of the present study suggest that HUVEC may have a protective system against cell damage by acrolein via the upregulation of TR, which is an adaptive response to oxidative stress. Acrolein 104-112 peroxiredoxin 5 Homo sapiens 137-139 15746054-2 2005 Cytochrome P450 enzymes are primarily expressed in the liver and convert the prodrug cyclophosphamide to an active phosphoramide mustard and acrolein. Acrolein 141-149 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-15 16839111-0 2005 Spin-coupled study of the electronic mechanism of the hetero-Diels-Alder reaction of acrolein and ethene. Acrolein 85-93 spindlin 1 Homo sapiens 0-4 15650393-0 2005 Inhibition of NFkappaB activation and IL-8 expression in human bronchial epithelial cells by acrolein. Acrolein 93-101 C-X-C motif chemokine ligand 8 Homo sapiens 38-42 15650393-4 2005 Cell exposure to acrolein dose-dependently suppressed IL-8 mRNA levels in HBE1 cells (26, 40, and 79% at 5, 10, and 25 microM acrolein concentrations, respectively) and resulted in corresponding decreases in IL-8 production. Acrolein 17-25 C-X-C motif chemokine ligand 8 Homo sapiens 54-58 15650393-4 2005 Cell exposure to acrolein dose-dependently suppressed IL-8 mRNA levels in HBE1 cells (26, 40, and 79% at 5, 10, and 25 microM acrolein concentrations, respectively) and resulted in corresponding decreases in IL-8 production. Acrolein 17-25 hemoglobin subunit epsilon 1 Homo sapiens 74-78 15650393-4 2005 Cell exposure to acrolein dose-dependently suppressed IL-8 mRNA levels in HBE1 cells (26, 40, and 79% at 5, 10, and 25 microM acrolein concentrations, respectively) and resulted in corresponding decreases in IL-8 production. Acrolein 17-25 C-X-C motif chemokine ligand 8 Homo sapiens 208-212 15650393-4 2005 Cell exposure to acrolein dose-dependently suppressed IL-8 mRNA levels in HBE1 cells (26, 40, and 79% at 5, 10, and 25 microM acrolein concentrations, respectively) and resulted in corresponding decreases in IL-8 production. Acrolein 126-134 hemoglobin subunit epsilon 1 Homo sapiens 74-78 15650393-7 2005 In summary, our results demonstrate that acrolein can suppress inflammatory processes in the airways by inhibiting epithelial IL-8 production through direct or indirect inhibitory effects on NFkappaB activation. Acrolein 41-49 C-X-C motif chemokine ligand 8 Homo sapiens 126-130 15650393-7 2005 In summary, our results demonstrate that acrolein can suppress inflammatory processes in the airways by inhibiting epithelial IL-8 production through direct or indirect inhibitory effects on NFkappaB activation. Acrolein 41-49 nuclear factor kappa B subunit 1 Homo sapiens 191-199 15388247-0 2004 Effect of acrolein and glutathione depleting agents on thioredoxin. Acrolein 10-18 thioredoxin Cricetulus griseus 55-66 15388247-3 2004 In the present study, A549 cells treated with 5-25 microM acrolein for 30 min lost cellular Trx activity in a dose-dependent fashion. Acrolein 58-66 thioredoxin Cricetulus griseus 92-95 15388247-6 2004 Both Trx activity and protein levels increased 4h after the acrolein treatment. Acrolein 60-68 thioredoxin Cricetulus griseus 5-8 14676331-7 2004 Furthermore, glutathione depletion sensitizes the cells to the acrolein-induced toxicity, but not the glycolaldehyde-induced toxicity, while AR inhibition sensitizes the cells to both acrolein- and glycolaldehyde-induced. Acrolein 184-192 aldo-keto reductase family 1 member B Homo sapiens 141-143 15207723-2 2004 Acrolein (H2C=HC-CH=O), which can be produced by the oxidative properties of amyloid-beta (Abeta) peptide, localizes to areas immediately surrounding early Abeta aggregates. Acrolein 0-8 amyloid beta precursor protein Homo sapiens 77-89 15207723-2 2004 Acrolein (H2C=HC-CH=O), which can be produced by the oxidative properties of amyloid-beta (Abeta) peptide, localizes to areas immediately surrounding early Abeta aggregates. Acrolein 0-8 amyloid beta precursor protein Homo sapiens 91-96 15207723-2 2004 Acrolein (H2C=HC-CH=O), which can be produced by the oxidative properties of amyloid-beta (Abeta) peptide, localizes to areas immediately surrounding early Abeta aggregates. Acrolein 0-8 amyloid beta precursor protein Homo sapiens 156-161 15199127-5 2004 To check the validity of this idea, we examined whether Poliota could incorporate nucleotides opposite the gamma-HOPdG adduct, which is formed from an initial reaction of acrolein with the N(2) of guanine. Acrolein 171-179 DNA polymerase mu Homo sapiens 56-63 15033435-6 2004 We have investigated the inactivation of the transmembrane enzyme aminophospholipid-translocase (or flippase) by HNE and acrolein. Acrolein 121-129 ATPase phospholipid transporting 8A1 Homo sapiens 66-95 15019089-9 2004 Cells expressing AKR7A1 were also found to be less susceptible to DNA damage, showing a decrease in mutation rate in the presence of acrolein as measured by hypoxanthine guanine phosphoribosyl transferase (HGPRT) mutagenicity assays. Acrolein 133-141 hypoxanthine-guanine phosphoribosyltransferase Cricetulus griseus 157-204 15019089-9 2004 Cells expressing AKR7A1 were also found to be less susceptible to DNA damage, showing a decrease in mutation rate in the presence of acrolein as measured by hypoxanthine guanine phosphoribosyl transferase (HGPRT) mutagenicity assays. Acrolein 133-141 hypoxanthine-guanine phosphoribosyltransferase Cricetulus griseus 206-211 14978244-6 2004 We report that hydralazine abolished the immunoreactivity of an acrolein-modified model protein (bovine serum albumin), but only if the drug was added to the protein within 30 min of commencing modification by acrolein. Acrolein 64-72 albumin Homo sapiens 104-117 14504272-5 2003 This technique identified nine peptides, which contained the acrolein adducts at Lys-29 and the N terminus, and revealed that the reaction of the insulin B chain with acrolein gave multiple adducts, including an unknown adduct containing two molecules of acrolein per lysine. Acrolein 167-175 insulin Homo sapiens 146-153 14522963-1 2003 Acrolein is a representative carcinogenic aldehyde found ubiquitously in the environment and formed endogenously through oxidation reactions, such as lipid peroxidation and myeloperoxidase-catalyzed amino acid oxidation. Acrolein 0-8 myeloperoxidase Rattus norvegicus 173-188 14504272-5 2003 This technique identified nine peptides, which contained the acrolein adducts at Lys-29 and the N terminus, and revealed that the reaction of the insulin B chain with acrolein gave multiple adducts, including an unknown adduct containing two molecules of acrolein per lysine. Acrolein 167-175 insulin Homo sapiens 146-153 14504272-2 2003 In this study, to gain a better understanding of the molecular basis of acrolein modification of protein, we characterized the acrolein modification of a model peptide (the oxidized B chain of insulin) by electrospray ionization-liquid chromatography/mass spectrometry method and established a novel acrolein-lysine condensation reaction. Acrolein 127-135 insulin Homo sapiens 193-200 14504272-2 2003 In this study, to gain a better understanding of the molecular basis of acrolein modification of protein, we characterized the acrolein modification of a model peptide (the oxidized B chain of insulin) by electrospray ionization-liquid chromatography/mass spectrometry method and established a novel acrolein-lysine condensation reaction. Acrolein 127-135 insulin Homo sapiens 193-200 12694595-3 2003 Small alpha,beta-unsaturated carbonyl compounds (e.g. acrolein and methyl vinyl ketone) were highly active and proved to be potent stimulators of expression of the pathogenesis-related gene HEL (PR4). Acrolein 54-62 pathogenesis-related 4 Arabidopsis thaliana 190-193 14504272-4 2003 To identify the modification site and structures of adducts generated in the acrolein-modified insulin B chain, both the acrolein-pretreated and untreated peptides were digested with V8 protease and the resulting peptides were subjected to electrospray ionization-liquid chromatography/mass spectrometry. Acrolein 77-85 insulin Homo sapiens 95-102 12921788-1 2003 Activated phagocytes employ myeloperoxidase to generate glycolaldehyde, 2-hydroxypropanal, and acrolein. Acrolein 95-103 myeloperoxidase Homo sapiens 28-43 12807757-3 2003 The current study examines the ability of acrolein to modulate the effect of benzo[a]pyrene (B[a]P), a major carcinogen found in smoke, on p53. Acrolein 42-50 tumor protein p53 Homo sapiens 139-142 12807757-7 2003 However, acrolein treatments profoundly inhibited the DNA binding of p53 under both basal and B[a]P-induced conditions. Acrolein 9-17 tumor protein p53 Homo sapiens 69-72 12807757-8 2003 Depleting glutathione with buthionine sulfoximine in B[a]P-treated cells to levels similar to those obtained with acrolein decreased p53 DNA binding substantially less than with acrolein. Acrolein 114-122 tumor protein p53 Homo sapiens 133-136 12807757-9 2003 Using a p53 dual luciferase reporter assay, acrolein caused an 83% decrease in the p53 activity induced by B[a]P (1 mM for 24 h post-transfection). Acrolein 44-52 tumor protein p53 Homo sapiens 8-11 12807757-9 2003 Using a p53 dual luciferase reporter assay, acrolein caused an 83% decrease in the p53 activity induced by B[a]P (1 mM for 24 h post-transfection). Acrolein 44-52 tumor protein p53 Homo sapiens 83-86 12807757-10 2003 The p53 protein that was immunoprecipitated after acrolein treatment was reactive with an anti-acrolein antibody indicating covalent modification. Acrolein 50-58 tumor protein p53 Homo sapiens 4-7 12807757-11 2003 Results from this study suggest that acrolein can inhibit p53 DNA binding and activity by direct covalent modification as well as alteration of intracellular redox status. Acrolein 37-45 tumor protein p53 Homo sapiens 58-61 12763045-7 2003 The ARE from the mouse GST A1 promoter was activated about 9-fold by spermine and 5-fold by spermidine treatment, but could be inhibited by the amine oxidase inhibitor, aminoguanidine, suggesting that acrolein or hydrogen peroxide generated from polyamines by serum amine oxidase may be mediators for phase 2 enzyme induction. Acrolein 201-209 glutathione S-transferase, alpha 1 (Ya) Mus musculus 23-29 12763045-9 2003 Direct addition of acrolein to PE cells induced multiple phase 2 genes and elevated nuclear levels of Nrf2, a transcription factor that binds to the ARE. Acrolein 19-27 nuclear factor, erythroid derived 2, like 2 Mus musculus 102-106 12763045-10 2003 Expression of mutant Nrf2 repressed the activation of the ARE-luciferase reporter by polyamines and acrolein. Acrolein 100-108 nuclear factor, erythroid derived 2, like 2 Mus musculus 21-25 12763045-11 2003 These results indicate that spermidine and spermine increase the expression of phase 2 genes in cells grown in culture through activation of the Nrf2-ARE pathway by generating the sulfhydryl reactive aldehyde, acrolein. Acrolein 210-218 nuclear factor, erythroid derived 2, like 2 Mus musculus 145-149 12732208-6 2003 It was found that acrolein is mainly produced by polyamine oxidase in plasma. Acrolein 18-26 polyamine oxidase Homo sapiens 49-66 12694595-3 2003 Small alpha,beta-unsaturated carbonyl compounds (e.g. acrolein and methyl vinyl ketone) were highly active and proved to be potent stimulators of expression of the pathogenesis-related gene HEL (PR4). Acrolein 54-62 pathogenesis-related 4 Arabidopsis thaliana 195-198 12527414-6 2003 Acrolein potently inhibited SSADH activity (IC(50)=15 microM) in rat brain mitochondrial preparations. Acrolein 0-8 aldehyde dehydrogenase 5 family, member A1 Rattus norvegicus 28-33 12605413-4 2003 We have found that acrolein, a peroxidation product from arachidonic acid, increases the phosphorylation of tau at the site recognized by PHF-1 both in human neuroblastoma cells and in primary cultures of mouse embryo cortical neurons. Acrolein 19-27 PHD finger protein 1 Homo sapiens 138-143 12604195-6 2003 Although acrolein-induced cytotoxicity was only delayed by antioxidants or glycolytic substrates (e.g. fructose), it was prevented by NADH generators (e.g. xylitol and sorbitol) due to increased metabolism by ADH1. Acrolein 9-17 alcohol dehydrogenase 1C (class I), gamma polypeptide Rattus norvegicus 209-213 12604195-12 2003 There was also marked cytotoxic synergism between acrolein and decadienal presumably because of ALDH inactivation by acrolein. Acrolein 50-58 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 96-100 12604195-12 2003 There was also marked cytotoxic synergism between acrolein and decadienal presumably because of ALDH inactivation by acrolein. Acrolein 117-125 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 96-100 12487375-6 2002 Furthermore, exposure to acrolein results in activation of members of the mitogen-activated protein kinase (MAPK) family and protein tyrosine kinases. Acrolein 25-33 mitogen activated protein kinase 3 Rattus norvegicus 108-112 14715435-4 2003 In this study, we examined the effects of nanomolar levels of acrolein on the activities of pyruvate dehydrogenase (PDH) and Alpha-ketoglutarate dehydrogenase (KGDH), both reduced nicotinamide adenine dinucleotide (NADH)-linked mitochondrial enzymes. Acrolein 62-70 pyruvate dehydrogenase phosphatase catalytic subunit 1 Homo sapiens 92-114 14715435-4 2003 In this study, we examined the effects of nanomolar levels of acrolein on the activities of pyruvate dehydrogenase (PDH) and Alpha-ketoglutarate dehydrogenase (KGDH), both reduced nicotinamide adenine dinucleotide (NADH)-linked mitochondrial enzymes. Acrolein 62-70 pyruvate dehydrogenase phosphatase catalytic subunit 1 Homo sapiens 116-119 14715435-5 2003 Acrolein decreased PDH and KGDH activities significantly in a dose-dependent manner. Acrolein 0-8 pyruvate dehydrogenase phosphatase catalytic subunit 1 Homo sapiens 19-22 14715435-6 2003 Using high performance liquid chromatography coupled to mass spectrometry (HPLC-MS), acrolein was found to bind lipoic acid, a component in both the PDH and KGDH complexes, most likely explaining the loss of enzyme activity. Acrolein 85-93 pyruvate dehydrogenase phosphatase catalytic subunit 1 Homo sapiens 149-152 14715435-8 2003 Acrolein, which is increased in AD brain, may be partially responsible for the dysfunction of mitochondria and loss of energy found in AD brain by inhibition of PDH and KGDH activities, potentially contributing to the neurodegeneration in this disorder. Acrolein 0-8 pyruvate dehydrogenase phosphatase catalytic subunit 1 Homo sapiens 161-164 12487375-7 2002 The extracellular signal-regulated kinases 1 and 2 (ERK1/2), stress-activated protein kinases/c-jun NH2-terminal kinases (SAPK/JNK) and p38MAPK are effectively and transiently activated by acrolein in a concentration and time-dependent fashion. Acrolein 189-197 mitogen activated protein kinase 3 Rattus norvegicus 4-50 12487375-7 2002 The extracellular signal-regulated kinases 1 and 2 (ERK1/2), stress-activated protein kinases/c-jun NH2-terminal kinases (SAPK/JNK) and p38MAPK are effectively and transiently activated by acrolein in a concentration and time-dependent fashion. Acrolein 189-197 mitogen activated protein kinase 3 Rattus norvegicus 52-58 12487375-8 2002 While all three MAPKs exhibit significant activation within 5 min of exposure to acrolein, maximum activation (ERK1/2 and p38MAPK) or close to maximum activation (SAPK/JNK) occurs on exposure to 5 microg/ml acrolein for 2 h. Acrolein-induced activation of MAPKs is further substantiated by the activation of transcription factors, c-jun and activator transcription factor-2 (ATF-2), by acrolein-activated SAPK/JNK and p38MAPK, respectively. Acrolein 81-89 activating transcription factor 2 Rattus norvegicus 341-373 12487375-8 2002 While all three MAPKs exhibit significant activation within 5 min of exposure to acrolein, maximum activation (ERK1/2 and p38MAPK) or close to maximum activation (SAPK/JNK) occurs on exposure to 5 microg/ml acrolein for 2 h. Acrolein-induced activation of MAPKs is further substantiated by the activation of transcription factors, c-jun and activator transcription factor-2 (ATF-2), by acrolein-activated SAPK/JNK and p38MAPK, respectively. Acrolein 81-89 activating transcription factor 2 Rattus norvegicus 375-380 12487375-8 2002 While all three MAPKs exhibit significant activation within 5 min of exposure to acrolein, maximum activation (ERK1/2 and p38MAPK) or close to maximum activation (SAPK/JNK) occurs on exposure to 5 microg/ml acrolein for 2 h. Acrolein-induced activation of MAPKs is further substantiated by the activation of transcription factors, c-jun and activator transcription factor-2 (ATF-2), by acrolein-activated SAPK/JNK and p38MAPK, respectively. Acrolein 207-215 mitogen activated protein kinase 3 Rattus norvegicus 111-117 12487375-8 2002 While all three MAPKs exhibit significant activation within 5 min of exposure to acrolein, maximum activation (ERK1/2 and p38MAPK) or close to maximum activation (SAPK/JNK) occurs on exposure to 5 microg/ml acrolein for 2 h. Acrolein-induced activation of MAPKs is further substantiated by the activation of transcription factors, c-jun and activator transcription factor-2 (ATF-2), by acrolein-activated SAPK/JNK and p38MAPK, respectively. Acrolein 207-215 activating transcription factor 2 Rattus norvegicus 341-373 12487375-8 2002 While all three MAPKs exhibit significant activation within 5 min of exposure to acrolein, maximum activation (ERK1/2 and p38MAPK) or close to maximum activation (SAPK/JNK) occurs on exposure to 5 microg/ml acrolein for 2 h. Acrolein-induced activation of MAPKs is further substantiated by the activation of transcription factors, c-jun and activator transcription factor-2 (ATF-2), by acrolein-activated SAPK/JNK and p38MAPK, respectively. Acrolein 207-215 activating transcription factor 2 Rattus norvegicus 375-380 12487375-16 2002 These results provide the first evidence that the activation of both growth-regulated (ERK1/2) and stress-regulated (SAPK/JNK and p38MAPK) MAPKs as well as tyrosine kinases are involved in the mediation of acrolein-induced effects on VSMC, which may play a crucial role in vascular pathogenesis due to environmentally and endogenously produced acrolein. Acrolein 206-214 mitogen activated protein kinase 3 Rattus norvegicus 87-93 12487375-16 2002 These results provide the first evidence that the activation of both growth-regulated (ERK1/2) and stress-regulated (SAPK/JNK and p38MAPK) MAPKs as well as tyrosine kinases are involved in the mediation of acrolein-induced effects on VSMC, which may play a crucial role in vascular pathogenesis due to environmentally and endogenously produced acrolein. Acrolein 344-352 mitogen activated protein kinase 3 Rattus norvegicus 87-93 12032148-6 2002 When a sulfhydryl enzyme, glyceraldehyde-3-phosphate dehydrogenase, was incubated with acrolein-modified bovine serum albumin in sodium phosphate buffer (pH 7.2) at 37 degrees C, a significant loss of sulfhydryl groups, which was accompanied by the loss of enzyme activity and the formation of high molecular mass protein species (>200 kDa), was observed. Acrolein 87-95 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 26-66 12032148-6 2002 When a sulfhydryl enzyme, glyceraldehyde-3-phosphate dehydrogenase, was incubated with acrolein-modified bovine serum albumin in sodium phosphate buffer (pH 7.2) at 37 degrees C, a significant loss of sulfhydryl groups, which was accompanied by the loss of enzyme activity and the formation of high molecular mass protein species (>200 kDa), was observed. Acrolein 87-95 albumin Homo sapiens 112-125 12032148-8 2002 (i) N(alpha)-acetyl-FDP-lysine, prepared from the reaction of N(alpha)-acetyl lysine with acrolein, was covalently bound to glyceraldehyde-3-phosphate dehydrogenase. Acrolein 90-98 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 124-164 12084617-0 2002 Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells. Acrolein 0-8 NFE2 like bZIP transcription factor 2 Homo sapiens 77-81 12084617-4 2002 Exposure of human type II lung epithelial (A549) cells to non-lethal dose of acrolein (150 fmol/cell for 1 h) depletes 80% of intracellular glutathione and increases the transcription of gamma-glutamylcysteine synthetase (gamma-GCS) at 6-12 h post-treatment, which helps in replenishing the glutathione to normal level. Acrolein 77-85 glutamate-cysteine ligase catalytic subunit Homo sapiens 187-220 12084617-4 2002 Exposure of human type II lung epithelial (A549) cells to non-lethal dose of acrolein (150 fmol/cell for 1 h) depletes 80% of intracellular glutathione and increases the transcription of gamma-glutamylcysteine synthetase (gamma-GCS) at 6-12 h post-treatment, which helps in replenishing the glutathione to normal level. Acrolein 77-85 glutamate-cysteine ligase catalytic subunit Homo sapiens 222-231 12084617-5 2002 Acrolein treatment activates transcription of phase II genes in general, as indicated by an increase in mRNA for NAD (P) H:quinone oxidoreductase (NQO1). Acrolein 0-8 crystallin zeta Homo sapiens 123-145 12084617-5 2002 Acrolein treatment activates transcription of phase II genes in general, as indicated by an increase in mRNA for NAD (P) H:quinone oxidoreductase (NQO1). Acrolein 0-8 NAD(P)H quinone dehydrogenase 1 Homo sapiens 147-151 12084617-6 2002 Western blot analysis revealed the increased level of the transcription factor, Nrf2 in the nuclear extract from acrolein treated cells. Acrolein 113-121 NFE2 like bZIP transcription factor 2 Homo sapiens 80-84 12084617-8 2002 The involvement of Nrf2 in ARE mediated transcriptional activation in response to acrolein exposure has been confirmed by human NQO1-ARE reporter assay. Acrolein 82-90 NFE2 like bZIP transcription factor 2 Homo sapiens 19-23 12084617-8 2002 The involvement of Nrf2 in ARE mediated transcriptional activation in response to acrolein exposure has been confirmed by human NQO1-ARE reporter assay. Acrolein 82-90 NAD(P)H quinone dehydrogenase 1 Homo sapiens 128-132 11788155-3 2002 In this study, the mechanisms of acrolein-induced cytotoxicity in human bronchial epithelial cells (HBE1) and the modulating effects of antioxidants were examined. Acrolein 33-41 hemoglobin subunit epsilon 1 Homo sapiens 100-104 12010847-10 2002 Recent studies with acrolein and cigarette smoke have suggested that MUC5AC is inducible (accompanied by epidermal growth factor [EGF] ligand formation and the activation of EGF receptor-dependent pathways), whereas MUC5B is constitutively expressed (increasing through gland enlargement). Acrolein 20-28 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 69-75 11849044-11 2002 Immunoprecipitation of c-jun protein after treating A549 cells with acrolein revealed the presence of a lysine-acrolein adduct. Acrolein 68-76 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 23-28 11600134-7 2001 Unsaturated aldehydes, 4-hydroxynonenal, crotonaldehyde and acrolein, given by the same route induced putatively preneoplastic single cells positive for GST-P. Acrolein 60-68 glutathione S-transferase pi 1 Rattus norvegicus 153-158 11803030-0 2002 Acrolein-induced cell death: a caspase-influenced decision between apoptosis and oncosis/necrosis. Acrolein 0-8 caspase 8 Mus musculus 31-38 11803030-4 2002 Analysis of acrolein-treated cell lysates or recombinant caspase enzymes showed overall dose-dependent decreases in caspase-3, -8 and -9 activities. Acrolein 12-20 caspase 3 Mus musculus 116-136 11803030-6 2002 Acrolein at doses > or =20 microM circumvented etoposide or interleukin-3 withdrawal induced apoptosis. Acrolein 0-8 interleukin 3 Mus musculus 63-76 11223428-9 2001 Moreover, high doses (1.0-10 mM) of acrolein and 4-hydroxynonenal, reactive aldehydic species associated with cigarette smoke, completely inhibited plasma LCAT activity, whereas PAF-AH was resistant to such exposures. Acrolein 36-44 lecithin-cholesterol acyltransferase Homo sapiens 155-159 11543647-7 2001 We propose a two-step model for AA induction of CA vasospasm and resultant myocardial necrosis: (1) metabolism of AA to acrolein by coronary arterial SSAO activity and (2) acrolein induction of CA vasospasm independent of endothelial injury-a novel path. Acrolein 120-128 amine oxidase copper containing 2 Homo sapiens 150-154 11453231-9 2001 CONCLUSIONS: Our experimental findings suggest that volatile fractions of cigarette smoke such as acrolein and acetaldehyde, because their ability to bind and interact with the cytoskeleton, prevent HGF adhesion. Acrolein 98-106 hepatocyte growth factor Homo sapiens 199-202 11368548-7 2001 Given that electrophilic substrates such as 2-propenal have been shown to inhibit GSTs, we also examined the inhibition of GSTM1-1, GSTP1-1 and GSTA1-1 by 2-phenylpropenal. Acrolein 44-54 glutathione S-transferase alpha 1 Homo sapiens 82-86 11504702-3 2001 Exposure of freshly isolated human neutrophils to acrolein markedly inhibited spontaneous neutrophil apoptosis as indicated by loss of membrane asymmetry and DNA fragmentation and induced increased neutrophil production of the chemokine interleukin-8 (IL-8). Acrolein 50-58 C-X-C motif chemokine ligand 8 Homo sapiens 237-250 11504702-3 2001 Exposure of freshly isolated human neutrophils to acrolein markedly inhibited spontaneous neutrophil apoptosis as indicated by loss of membrane asymmetry and DNA fragmentation and induced increased neutrophil production of the chemokine interleukin-8 (IL-8). Acrolein 50-58 C-X-C motif chemokine ligand 8 Homo sapiens 252-256 11504702-4 2001 Acrolein (1--50 microM) was found to induce marked activation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinases (MAPKs), and inhibition of p38 MAPK activation by SB-203580 prevented acrolein-induced IL-8 release. Acrolein 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 238-242 11325063-0 2001 Microtubules and vimentin associated filaments (VIFs) in cultured human gingival fibroblasts (HGFs) after exposure to acrolein and acetaldehyde. Acrolein 118-126 vimentin Homo sapiens 17-25 11223428-9 2001 Moreover, high doses (1.0-10 mM) of acrolein and 4-hydroxynonenal, reactive aldehydic species associated with cigarette smoke, completely inhibited plasma LCAT activity, whereas PAF-AH was resistant to such exposures. Acrolein 36-44 phospholipase A2 group VII Homo sapiens 178-184 11329622-0 2001 Acrolein induces activation of the epidermal growth factor receptor of human keratinocytes for cell death. Acrolein 0-8 epidermal growth factor receptor Homo sapiens 35-67 11160078-2 2001 To examine the mechanisms involved, we studied the effect of acrolein on ACh- and caffeine-induced membrane currents (patch-clamp) in myocytes freshly isolated from rat trachea. Acrolein 61-69 acyl-CoA thioesterase 12 Rattus norvegicus 73-76 11160078-4 2001 Exposure to acrolein (0.2 microM) for 10 min significantly enhanced the amplitude of the low-ACh (0.1 microM) concentration-induced initial peak of current (318.8 +/- 28.3 vs. 251.2 +/- 40.3 pA; n = 25, P < 0.05). Acrolein 12-20 acyl-CoA thioesterase 12 Rattus norvegicus 93-96 11160078-8 2001 It is concluded that acrolein alters ACh-induced current as a consequence of its effect on the cytosolic Ca(2+) concentration response and that the protective role of inhibitors of Cl(-) channels in air pollutant-induced airway hyperresponsiveness should be examined. Acrolein 21-29 acyl-CoA thioesterase 12 Rattus norvegicus 37-40 12718659-2 2001 However, the species of glutathione S-transferases (GSTP1-1) linked to neoplasia of rat and human were recently shown to be selective for hydrophilic carcinogens such as acrolein and hydroxyalkenals (Satoh, 1998; Satoh et al., 1999) in accord with the finding of a water-network in the active site of the human GSTP1-1 by X-ray analysis (Hu et al. Acrolein 170-178 glutathione S-transferase pi 1 Rattus norvegicus 52-59 12718659-2 2001 However, the species of glutathione S-transferases (GSTP1-1) linked to neoplasia of rat and human were recently shown to be selective for hydrophilic carcinogens such as acrolein and hydroxyalkenals (Satoh, 1998; Satoh et al., 1999) in accord with the finding of a water-network in the active site of the human GSTP1-1 by X-ray analysis (Hu et al. Acrolein 170-178 glutathione S-transferase pi 1 Homo sapiens 311-318 11329622-3 2001 Incubation of human keratinocytes with a relatively low concentration (50 microM) of acrolein caused a prompt and selective induction of tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as a 180-kDa molecule during the period from 5-30 min after the start of incubation. Acrolein 85-93 epidermal growth factor receptor Homo sapiens 169-201 11329622-3 2001 Incubation of human keratinocytes with a relatively low concentration (50 microM) of acrolein caused a prompt and selective induction of tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as a 180-kDa molecule during the period from 5-30 min after the start of incubation. Acrolein 85-93 epidermal growth factor receptor Homo sapiens 203-207 11329622-7 2001 Selective prompt phosphorylation/activation of EGFR followed by phosphorylation of MAP family kinases and c-Jun and their blockade by a specific EGFR inhibitor, AG1478, suggested that activation of EGFR is the major, and possibly single, cell surface element for intracellular signal transduction in acrolein-treated cells. Acrolein 300-308 epidermal growth factor receptor Homo sapiens 47-51 11329622-7 2001 Selective prompt phosphorylation/activation of EGFR followed by phosphorylation of MAP family kinases and c-Jun and their blockade by a specific EGFR inhibitor, AG1478, suggested that activation of EGFR is the major, and possibly single, cell surface element for intracellular signal transduction in acrolein-treated cells. Acrolein 300-308 epidermal growth factor receptor Homo sapiens 145-149 11329622-7 2001 Selective prompt phosphorylation/activation of EGFR followed by phosphorylation of MAP family kinases and c-Jun and their blockade by a specific EGFR inhibitor, AG1478, suggested that activation of EGFR is the major, and possibly single, cell surface element for intracellular signal transduction in acrolein-treated cells. Acrolein 300-308 epidermal growth factor receptor Homo sapiens 145-149 11111937-2 2000 Liquid 3-MTP may contain trace amounts of acrolein (up to 0.1%), and therefore acrolein vapor may also be present. Acrolein 42-50 microsomal triglyceride transfer protein Rattus norvegicus 9-12 11111937-8 2000 These findings indicate that the toxicity associated with acute static exposures to 3-MTP vapor was due to accumulated acrolein vapor, and that 3-MTP per se has a low order of acute vapor inhalation toxicity. Acrolein 119-127 microsomal triglyceride transfer protein Rattus norvegicus 86-89 10966506-7 2000 It is apparent that the activation of the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein 1 (AP-1) can be inhibited by acrolein. Acrolein 151-159 nuclear factor kappa B subunit 1 Homo sapiens 64-86 11035637-5 2000 The results show that acrolein and acetaldehyde produced dose dependent inhibition of HGF viability and alteration of cytoplasmic organelles. Acrolein 22-30 hepatocyte growth factor Homo sapiens 86-89 11035637-6 2000 The main ultrastructural finding for the HGF cytoplasm was the presence of vacuoles and lysosomal structures which became prominent with increasing concentration of acrolein and acetaldehyde. Acrolein 165-173 hepatocyte growth factor Homo sapiens 41-44 10966506-7 2000 It is apparent that the activation of the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein 1 (AP-1) can be inhibited by acrolein. Acrolein 151-159 nuclear factor kappa B subunit 1 Homo sapiens 88-98 10966506-7 2000 It is apparent that the activation of the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein 1 (AP-1) can be inhibited by acrolein. Acrolein 151-159 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 104-123 10966506-7 2000 It is apparent that the activation of the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein 1 (AP-1) can be inhibited by acrolein. Acrolein 151-159 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 125-129 10764631-4 2000 In freshly isolated rat tracheal smooth muscle cells, preexposure to acrolein increased the [Ca(2+)](i) oscillation frequency in response to endothelin 1 (ET-1, 0.1 microM), a contractile agonist that acts via the activation of a receptor different from the muscarinic cholinoceptor. Acrolein 69-77 endothelin 1 Rattus norvegicus 141-153 10799737-1 2000 The catalytic efficiencies of the allelic variants of human glutathione (GSH) S-transferase Pi (hGSTP1-1), which differ in their primary structures by the amino acids in positions 104 (isoleucine or valine) and/or 113 (alanine or valine), in the GSH conjugation (detoxification) of acrolein and crotonaldehyde have been determined. Acrolein 282-290 glutathione S-transferase pi 1 Homo sapiens 96-104 10799737-2 2000 The k(cat)/K(m) values for hGSTP1-1 isoforms I104,A113 (IA), I104, V113 (IV), V104,A113 (VA) and V104,V113 (VV) toward acrolein were 129+/-3, 116+/-3, 128+/-4 and 92+/-3 mM(-1) s(-1), respectively. Acrolein 119-127 glutathione S-transferase pi 1 Homo sapiens 27-35 10799737-3 2000 The catalytic efficiencies of the hGSTP1-1 variants IA, IV, and VA in the GSH conjugation of acrolein were statistically significantly higher (at P=0.05) compared with the VV isoform. Acrolein 93-101 glutathione S-transferase pi 1 Homo sapiens 34-42 10799737-5 2000 Our results suggest that hGSTP1-1 polymorphism may be an important factor in differential susceptibility of individuals to the toxic effects of acrolein, which is a widely spread environmental pollutant and generated endogenously during metabolic activation of anticancer drug cyclophosphamide. Acrolein 144-152 glutathione S-transferase pi 1 Homo sapiens 25-33 10905545-6 2000 Each compound attenuated carbonylation of a model protein, bovine serum albumin, during reactions with acrolein at neutral pH and 37 degrees C. However, the most efficient agent was hydralazine, which strongly suppressed carbonylation under these conditions. Acrolein 103-111 albumin Mus musculus 66-79 10776930-7 2000 RESULTS: The results show that acrolein and acetaldehyde produced dose-dependent inhibition of HGF attachment and proliferation. Acrolein 31-39 hepatocyte growth factor Homo sapiens 95-98 10776930-9 2000 The main ultrastructural finding for the HGF cytoplasm was the presence of vacuoles and lysosomal structures that became prominent with increasing concentration of acrolein and acetaldehyde. Acrolein 164-172 hepatocyte growth factor Homo sapiens 41-44 10776930-10 2000 CONCLUSIONS: Our experimental data suggest that acrolein and acetaldehyde, volatile components of tobacco smoke, are detrimental to HGF survival and consequently to the oral connective tissue. Acrolein 48-56 hepatocyte growth factor Homo sapiens 132-135 10397244-8 1999 At 30 microM acrolein, the cell survival for CHO(AGT) was 30% compared with 18.7% for CHOpcDNA3. Acrolein 13-21 angiotensinogen Cricetulus griseus 45-53 10892891-2 1999 Some previous studies on cultured endothelial cells indicate that cytotoxic metabolites (e.g. hydrogen peroxide, formaldehyde, acrolein) formed by serum SSAO may cause endothelial injury and subsequently induce atherosclerosis. Acrolein 127-135 amine oxidase copper containing 2 Homo sapiens 153-157 10484460-1 1999 Increased phospholipase A2 (PLA2) activity was measured in cytosolic fractions of lungs from sheep exposed to smoke from burning cotton or to synthetic smoke consisting of carbon and acrolein, a cotton smoke toxin. Acrolein 183-191 phospholipase A2 Ovis aries 28-32 10406932-5 1999 Our previous studies suggest that the isozyme rGST8-8 is a principal defense against electrophilic stress exerted by alpha,beta-unsaturated carbonyls such as AC. Acrolein 158-160 glutathione S-transferase alpha 4 Rattus norvegicus 46-53 10484456-0 1999 Monocyte inflammation augments acrolein-induced Muc5ac expression in mouse lung. Acrolein 31-39 mucin 5, subtypes A and C, tracheobronchial/gastric Mus musculus 48-54 10484460-1 1999 Increased phospholipase A2 (PLA2) activity was measured in cytosolic fractions of lungs from sheep exposed to smoke from burning cotton or to synthetic smoke consisting of carbon and acrolein, a cotton smoke toxin. Acrolein 183-191 phospholipase A2 Ovis aries 10-26 10397244-11 1999 The present study demonstrates that AGT plays an important role in protecting against the toxic and mutagenic effect of cyclophosphamide and suggests that acrolein, not PM, is responsible for generating the toxic and mutagenic lesion(s) protected by the AGT protein. Acrolein 155-163 angiotensinogen Cricetulus griseus 36-39 10397244-11 1999 The present study demonstrates that AGT plays an important role in protecting against the toxic and mutagenic effect of cyclophosphamide and suggests that acrolein, not PM, is responsible for generating the toxic and mutagenic lesion(s) protected by the AGT protein. Acrolein 155-163 angiotensinogen Cricetulus griseus 254-257 10320558-5 1999 In contrast, following fixation either with acrolein (with or without paraformaldehyde) or with a mixture of paraformaldehyde and glutaraldehyde there was extensive ERalpha-IR throughout layers II to VI; this was absent when the antibodies were preincubated with the peptide fragment used in their production. Acrolein 44-52 estrogen receptor 1 Rattus norvegicus 165-172 10092592-0 1999 Acrolein causes inhibitor kappaB-independent decreases in nuclear factor kappaB activation in human lung adenocarcinoma (A549) cells. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 26-32 10378479-10 1999 A bell-shaped dose response curve was observed with a maximum for 5 microM acrolein for GST and GRED activities. Acrolein 75-83 hematopoietic prostaglandin D synthase Rattus norvegicus 88-91 10378479-10 1999 A bell-shaped dose response curve was observed with a maximum for 5 microM acrolein for GST and GRED activities. Acrolein 75-83 glutathione-disulfide reductase Rattus norvegicus 96-100 10092592-0 1999 Acrolein causes inhibitor kappaB-independent decreases in nuclear factor kappaB activation in human lung adenocarcinoma (A549) cells. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 73-79 10092592-2 1999 In the present study, the effects of sublethal doses of acrolein on nuclear factor kappaB (NF-kappaB) activation in A549 human lung adenocarcinoma cells were investigated. Acrolein 56-64 nuclear factor kappa B subunit 1 Homo sapiens 83-89 10092592-2 1999 In the present study, the effects of sublethal doses of acrolein on nuclear factor kappaB (NF-kappaB) activation in A549 human lung adenocarcinoma cells were investigated. Acrolein 56-64 nuclear factor kappa B subunit 1 Homo sapiens 91-100 10092592-5 1999 Pretreatment with acrolein completely blocked 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced activation of NF-kappaB. Acrolein 18-26 nuclear factor kappa B subunit 1 Homo sapiens 111-120 10092592-10 1999 Furthermore, acrolein decreased NF-kappaB activation in cells depleted of IkappaB-alpha by TPA stimulation in the presence of cycloheximide, demonstrating that the decrease in NF-kappaB activation was not the result of increased binding by the inhibitory protein. Acrolein 13-21 nuclear factor kappa B subunit 1 Homo sapiens 32-41 10092592-10 1999 Furthermore, acrolein decreased NF-kappaB activation in cells depleted of IkappaB-alpha by TPA stimulation in the presence of cycloheximide, demonstrating that the decrease in NF-kappaB activation was not the result of increased binding by the inhibitory protein. Acrolein 13-21 NFKB inhibitor alpha Homo sapiens 74-87 10092592-10 1999 Furthermore, acrolein decreased NF-kappaB activation in cells depleted of IkappaB-alpha by TPA stimulation in the presence of cycloheximide, demonstrating that the decrease in NF-kappaB activation was not the result of increased binding by the inhibitory protein. Acrolein 13-21 nuclear factor kappa B subunit 1 Homo sapiens 176-185 10092592-11 1999 This conclusion was further supported by the finding that acrolein modified NF-kappaB in the cytosol prior to chemical dissociation from IkappaB with detergent. Acrolein 58-66 nuclear factor kappa B subunit 1 Homo sapiens 76-85 10198352-3 1999 MUC5AC mRNA levels increased after >/=0.01 nM acrolein, 10 microM prostaglandin E2 or 15-hydroxyeicosatetraenoic acid, 1.0 nM tumor necrosis factor-alpha (TNF-alpha), or 10 nM phorbol 12-myristate 13-acetate (a protein kinase C activator). Acrolein 49-57 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 0-6 10198352-6 1999 Together, these findings imply that irritants like acrolein can directly and indirectly (via inflammatory mediators) increase airway mucin transcripts in epithelial cells. Acrolein 51-59 LOC100508689 Homo sapiens 133-138 9884322-0 1999 Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein. Acrolein 98-106 aldehyde dehydrogenase 1 family member A1 Homo sapiens 20-44 9882456-6 1999 In contrast to the Alpha and Mu classes being selective for strongly electrophilic compounds, the neoplastic P1-1 species was indicated to be selective for weakly electrophilic and water-soluble carcinogens such as acrolein and hydroxyalkenals. Acrolein 215-223 S100 calcium binding protein A10 Homo sapiens 109-113 9884322-8 1999 The percentage of inhibition of ALDH1 activity in vivo by acrolein in patients receiving CY was calculated based on the in vitro Ki of acrolein, the in vitro Km of HCY, and the in vivo peak blood concentrations of HCY and acrolein. Acrolein 135-143 aldehyde dehydrogenase 1 family member A1 Homo sapiens 32-37 9884322-4 1999 In human liver cytosol incubations, HCY inhibited ALDH activity mainly through its degradation product acrolein, whereas carboxyethylphosphoramide mustard inhibited ALDH activity only at supraclinical concentrations. Acrolein 103-111 aldehyde dehydrogenase 1 family member A1 Homo sapiens 50-54 9884322-6 1999 The inhibition of ALDH1 activity by acrolein in incubations with human erythrocyte ALDH1 was competitive with a Ki of 0.646 microM. Acrolein 36-44 aldehyde dehydrogenase 1 family member A1 Homo sapiens 18-23 9884322-6 1999 The inhibition of ALDH1 activity by acrolein in incubations with human erythrocyte ALDH1 was competitive with a Ki of 0.646 microM. Acrolein 36-44 aldehyde dehydrogenase 1 family member A1 Homo sapiens 83-88 9884322-8 1999 The percentage of inhibition of ALDH1 activity in vivo by acrolein in patients receiving CY was calculated based on the in vitro Ki of acrolein, the in vitro Km of HCY, and the in vivo peak blood concentrations of HCY and acrolein. Acrolein 58-66 aldehyde dehydrogenase 1 family member A1 Homo sapiens 32-37 9884322-8 1999 The percentage of inhibition of ALDH1 activity in vivo by acrolein in patients receiving CY was calculated based on the in vitro Ki of acrolein, the in vitro Km of HCY, and the in vivo peak blood concentrations of HCY and acrolein. Acrolein 135-143 aldehyde dehydrogenase 1 family member A1 Homo sapiens 32-37 9022075-0 1997 Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. Acrolein 154-162 myeloperoxidase Homo sapiens 29-44 9698086-5 1998 We found that both ALDH isozymes were inhibited by acrolein, with IC50 values of 35 and 144 microM for ALDH-1 or ALDH-3, respectively. Acrolein 51-59 aldehyde dehydrogenase 1 family member A1 Homo sapiens 103-109 9698086-5 1998 We found that both ALDH isozymes were inhibited by acrolein, with IC50 values of 35 and 144 microM for ALDH-1 or ALDH-3, respectively. Acrolein 51-59 aldehyde dehydrogenase 3 family member A1 Homo sapiens 113-119 9698086-7 1998 In contrast, thiol conjugates of acrolein did not inhibit ALDH-3 activity, but were substrates only for ALDH-1. Acrolein 33-41 aldehyde dehydrogenase 1 family member A1 Homo sapiens 104-110 9698086-8 1998 Further, acrolein was shown to be oxidized by ALDH-3, but not by ALDH-1. Acrolein 9-17 aldehyde dehydrogenase 3 family member A1 Homo sapiens 46-52 9266806-5 1997 In addition, at lower doses, acrolein caused induction of heme oxygenase 1 protein; however, stress protein 72 (SP72) was not induced. Acrolein 29-37 heme oxygenase 1 Homo sapiens 58-74 9266806-8 1997 Acrolein caused a dose-dependent inhibition of release of IL-1beta, TNF-alpha, and IL-12. Acrolein 0-8 interleukin 1 beta Homo sapiens 58-66 9266806-8 1997 Acrolein caused a dose-dependent inhibition of release of IL-1beta, TNF-alpha, and IL-12. Acrolein 0-8 tumor necrosis factor Homo sapiens 68-77 9154890-6 1997 Two major volatile factors in cigarette smoke, acrolein and acetaldehyde, augmented IL-8 release. Acrolein 47-55 C-X-C motif chemokine ligand 8 Homo sapiens 84-88 9575876-0 1998 Acrolein-induced MUC5ac expression in rat airways. Acrolein 0-8 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 17-23 9575876-9 1998 These findings indicate that acrolein-induced mucus hypersecretion is due, in part, to increases in MUC5ac rather than to MUC2 gene expression. Acrolein 29-37 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 100-106 9575876-9 1998 These findings indicate that acrolein-induced mucus hypersecretion is due, in part, to increases in MUC5ac rather than to MUC2 gene expression. Acrolein 29-37 mucin 2, oligomeric mucus/gel-forming Rattus norvegicus 122-126 9575042-8 1998 We demonstrate that detection of Fos in monkey brain tissue perfused with 4% paraformaldehyde can be improved by postfixation in a dilute acrolein solution. Acrolein 138-146 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 33-36 9463521-2 1997 When GSTP1-1 was incubated with a 50-fold molar excess of the aldehydes acrolein (ACR) and 4-hydroxy-2-nonenal (HNE) and the ketones curcumin (CUR) and ethacrynic acid (EA) at 22 degrees C, all of them inactivated GSTP1-1. Acrolein 82-85 glutathione S-transferase pi 1 Homo sapiens 5-12 9174132-10 1997 Moreover, addition of IL-2 to cells preincubated with acrolein increased GSH levels and proliferation with respect to acrolein alone. Acrolein 54-62 interleukin 2 Mus musculus 22-26 9174132-10 1997 Moreover, addition of IL-2 to cells preincubated with acrolein increased GSH levels and proliferation with respect to acrolein alone. Acrolein 118-126 interleukin 2 Mus musculus 22-26 9175718-4 1997 alpha,beta-Unsaturated aldehydes such as acrolein, crotonaldehyde, and cinnamaldehyde also inactivated glutathione reductase, although rates varied widely. Acrolein 41-49 glutathione-disulfide reductase Homo sapiens 103-124 9816303-0 1996 Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). Acrolein 14-22 ATP binding cassette subfamily C member 3 Homo sapiens 86-125 9157850-1 1997 Proteolysis of recombinant human proinsulin by the native trypsin, by trypsin modified with a copolymer of vinylpyrrolidone and acrolein, and by the same modified trypsin immobilized on Silochrom 1.5 was studied by RP HPLC and mass spectrometry. Acrolein 128-136 insulin Homo sapiens 33-43 9816303-0 1996 Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). Acrolein 14-22 ATP binding cassette subfamily C member 3 Homo sapiens 127-130 9816303-4 1996 To determine whether AC and CHA can modulate the function of MRP by inducing GSH depletion, we used two human lung cancer cell lines overexpressing MRP: the large cell carcinoma cell line COR-L23/R and the adenocarcinoma cell line MOR/R0.4, along with their respective sensitive parental lines, COR-L23/P and MOR/P. Acrolein 21-23 ATP binding cassette subfamily C member 3 Homo sapiens 61-64 9816303-6 1996 In addition, concentrations of 50 micrometer AC and 5 mm CHA could completely reverse the daunorubicin (DNR) and vinblastine accumulation deficit present in COR-L23/R and partially reverse the DNR accumulation deficit in MOR/R0.4. Acrolein 45-47 opioid receptor mu 1 Homo sapiens 221-224 9816303-12 1996 In conclusion, treatment with AC or CHA can reverse the drug accumulation deficit of MRP-overexpressing cells, and this effect appears to be mediated by GSH depletion. Acrolein 30-32 ATP binding cassette subfamily C member 3 Homo sapiens 85-88 7583533-6 1995 The short-chain (acrolein) and long-chain (HNE) alpha,beta-unsaturated aldehydes were the most effective LCAT inhibitors. Acrolein 17-25 lecithin-cholesterol acyltransferase Homo sapiens 105-109 8742318-10 1996 Activities of glutathione S-transferase and glutathione reductase after 3 days of exposure to acrolein, alone or in combination with formaldehyde and acetaldehyde, were depressed whereas the glutathione peroxidase activity was elevated. Acrolein 94-102 hematopoietic prostaglandin D synthase Rattus norvegicus 14-39 8742318-10 1996 Activities of glutathione S-transferase and glutathione reductase after 3 days of exposure to acrolein, alone or in combination with formaldehyde and acetaldehyde, were depressed whereas the glutathione peroxidase activity was elevated. Acrolein 94-102 glutathione-disulfide reductase Rattus norvegicus 44-65 7577467-4 1995 These amines are oxidised by polyamine oxidase (PAO) and diamine oxidase (DAO) to generate oxygen radicals and hydrogen peroxide, reactive aldehydes and acrolein, which are likely to exert local mutagenic, cytotoxic and immunosuppressive effects in vivo. Acrolein 153-161 polyamine oxidase Homo sapiens 29-46 7577467-4 1995 These amines are oxidised by polyamine oxidase (PAO) and diamine oxidase (DAO) to generate oxygen radicals and hydrogen peroxide, reactive aldehydes and acrolein, which are likely to exert local mutagenic, cytotoxic and immunosuppressive effects in vivo. Acrolein 153-161 polyamine oxidase Homo sapiens 48-51 7577467-4 1995 These amines are oxidised by polyamine oxidase (PAO) and diamine oxidase (DAO) to generate oxygen radicals and hydrogen peroxide, reactive aldehydes and acrolein, which are likely to exert local mutagenic, cytotoxic and immunosuppressive effects in vivo. Acrolein 153-161 amine oxidase copper containing 1 Homo sapiens 57-72 7577467-4 1995 These amines are oxidised by polyamine oxidase (PAO) and diamine oxidase (DAO) to generate oxygen radicals and hydrogen peroxide, reactive aldehydes and acrolein, which are likely to exert local mutagenic, cytotoxic and immunosuppressive effects in vivo. Acrolein 153-161 amine oxidase copper containing 1 Homo sapiens 74-77 7583533-11 1995 The alpha,beta-unsaturated aldehydes acrolein and HNE were fourfold to eightfold more effective cross-linkers of apolipoproteins A-I and A-II than the other aldehydes studied. Acrolein 37-45 apolipoprotein A1 Homo sapiens 113-141 7473602-10 1995 When plasma was incubated with 1 mM acrolein in the presence of 2.5 mM glutathione or dihydrolipoic acid, 100 and 57% of LCAT activity, respectively, remained after incubation. Acrolein 36-44 lecithin-cholesterol acyltransferase Homo sapiens 121-125 7597707-6 1995 A significant increase in gamma-glutamylcysteine synthetase activity and GST activity toward 4-hydroxynonenal and acrolein, which are preferred substrates of GST8-8, was seen as early as 3 days following AA treatment. Acrolein 114-122 glutathione S-transferase alpha 4 Rattus norvegicus 158-164 7473602-7 1995 Among five aldehydes tested, acrolein was the strongest inhibitor of LCAT, with complete enzyme inhibition occurring at 1 mM. Acrolein 29-37 lecithin-cholesterol acyltransferase Homo sapiens 69-73 7728738-3 1994 Acrolein and phosphoramide mustard are the metabolites of cyclophosphamide which are among the causative agents which reduce the activity of superoxide dismultase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase in erythrocytes of CMF treated breast cancer patients. Acrolein 0-8 glutathione S-transferase kappa 1 Homo sapiens 221-246 7762674-7 1995 Acrolein reduced BBEC migration to fibronectin but had no effect on attachment. Acrolein 0-8 fibronectin 1 Bos taurus 35-46 8584666-5 1995 Indeed, SSAO has been implicated in experimental models of cardiovascular toxicity involving conversion of the industrial aliphatic amine allylamine to acrolein. Acrolein 152-160 amine oxidase copper containing 2 Homo sapiens 8-12 8584667-5 1995 The possibility that SSAO enzymes can convert amine substrates to highly toxic metabolites is illustrated by the production of acrolein from the xenobiotic amine, allylamine and formaldehyde and methylglyoxal from methylamine and aminoacetone, respectively. Acrolein 127-135 amine oxidase copper containing 2 Homo sapiens 21-25 7728738-3 1994 Acrolein and phosphoramide mustard are the metabolites of cyclophosphamide which are among the causative agents which reduce the activity of superoxide dismultase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase in erythrocytes of CMF treated breast cancer patients. Acrolein 0-8 catalase Homo sapiens 164-172 7728738-3 1994 Acrolein and phosphoramide mustard are the metabolites of cyclophosphamide which are among the causative agents which reduce the activity of superoxide dismultase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase in erythrocytes of CMF treated breast cancer patients. Acrolein 0-8 glucose-6-phosphate dehydrogenase Homo sapiens 251-284 7728738-3 1994 Acrolein and phosphoramide mustard are the metabolites of cyclophosphamide which are among the causative agents which reduce the activity of superoxide dismultase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase in erythrocytes of CMF treated breast cancer patients. Acrolein 0-8 glutathione-disulfide reductase Homo sapiens 198-219 8200104-1 1994 A 32P-postlabeling method is described that specifically detects and quantifies the 1,N2-propanodeoxyguanosine adducts derived from acrolein (AdG) and crotonaldehyde (CdG) and 1,N2-ethenodeoxyguanosine (EdG) in DNA. Acrolein 132-140 ADG Bos taurus 142-145 8071856-9 1994 The rates of acrolein formation from CP and IF in human hepatic microsomes (0.76 +/- 0.23 and 0.19 +/- 0.07 nmol min-1 mg-1 of protein, respectively) were only 18% and 10% of the rates estimated in fractions from untreated rat liver (4.20 +/- 0.04 and 1.96 +/- 0.12 nmol min-1 mg-1 of protein, respectively). Acrolein 13-21 CD59 molecule (CD59 blood group) Homo sapiens 113-123 8071856-9 1994 The rates of acrolein formation from CP and IF in human hepatic microsomes (0.76 +/- 0.23 and 0.19 +/- 0.07 nmol min-1 mg-1 of protein, respectively) were only 18% and 10% of the rates estimated in fractions from untreated rat liver (4.20 +/- 0.04 and 1.96 +/- 0.12 nmol min-1 mg-1 of protein, respectively). Acrolein 13-21 CD59 molecule (CD59 blood group) Homo sapiens 271-281 8075374-5 1994 In addition, 2-propyn-1-ol-derived 2-propyn-1-al inhibited the peroxidatic and catalytic activities of catalase, whereas 2-propen-1-ol-derived 2-propen-1-al had no effect on these activities of catalase. Acrolein 143-156 catalase Bos taurus 103-111 8032584-17 1994 The effect of acrolein in vitro was significantly reduced by pretreatment of the bladder with a combination of tachykinin NK1 and NK2 receptor antagonists, RP 67,580 (3 microM) and SR 48,968 (1 microM). Acrolein 14-22 tachykinin receptor 2 Rattus norvegicus 130-142 8108434-2 1994 Human glutathione transferases (GSTs; RX:glutathione R-transferase, EC 2.5.1.18) of classes Alpha, Mu, and Pi were shown to promote the conjugation of glutathione with base propenals and related alkenes. Acrolein 173-182 glutathione S-transferase alpha 1 Homo sapiens 32-36 8183257-2 1994 Aldose reductase (EC 1.1.1.21), a member of the aldo-keto reductase superfamily, catalyzes the NADPH-dependent reduction of acrolein to allyl alcohol (Km = 80 microM, kcat = 87 min-1). Acrolein 124-132 aldo-keto reductase family 1 member B Homo sapiens 0-16 8183257-5 1994 In addition to being a substrate, acrolein also produces a time-dependent 7-20-fold increase in the activity of aldose reductase toward a variety of substrates. Acrolein 34-42 aldo-keto reductase family 1 member B Homo sapiens 112-128 8108434-3 1994 GST P1-1 was particularly active in catalyzing the reactions with the propenal derivatives, and adenine propenal was the substrate giving the highest activity. Acrolein 70-78 glutathione S-transferase pi 1 Homo sapiens 0-8 8108434-10 1994 GST P1-1 introduced into Hep G2 cells by electroporation was similarly found to increase their resistance to acrolein. Acrolein 109-117 glutathione S-transferase pi 1 Homo sapiens 0-8 7931255-4 1994 Also the xenobiotic aliphatic amine allylamine produces cardiovascular damage in experimental animals by a mechanism which involves its deamination by SSAO to acrolein. Acrolein 159-167 amine oxidase copper containing 2 Homo sapiens 151-155 8306034-5 1994 Although in vitro exposure of the human bronchus to 0.3 microM acrolein did not alter responses to KCl, it did increase the efficacy of carbachol and NKA without altering their potency. Acrolein 63-71 tachykinin precursor 1 Homo sapiens 150-153 8306034-7 1994 Pretreatment with phosphoramidon abolished the differential effect of acrolein on airway response to NKA. Acrolein 70-78 tachykinin precursor 1 Homo sapiens 101-104 8212054-0 1993 In vitro inactivation of glucose-6-phosphate dehydrogenase from human red blood cells by acrolein: a possible biomarker of exposure. Acrolein 89-97 glucose-6-phosphate dehydrogenase Homo sapiens 25-58 8212054-1 1993 We have investigated the possibility of utilizing glucose-6-phosphate dehydrogenase (G6PD) as a macromolecular (biological) marker of acrolein exposure. Acrolein 134-142 glucose-6-phosphate dehydrogenase Homo sapiens 50-83 8212054-1 1993 We have investigated the possibility of utilizing glucose-6-phosphate dehydrogenase (G6PD) as a macromolecular (biological) marker of acrolein exposure. Acrolein 134-142 glucose-6-phosphate dehydrogenase Homo sapiens 85-89 8423767-10 1993 Acrolein inhibited thrombin- and phorbol ester-induced phosphorylation of a 40-kDa polypeptide and other substrates, indicating a cellular defect in protein kinase C signaling. Acrolein 0-8 coagulation factor II, thrombin Homo sapiens 19-27 8495410-0 1993 Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Acrolein 155-163 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 39-59 8430435-2 1993 Previous studies showed that allylamine-induced chronic lesions are markedly reduced by semicarbazide, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and that allylamine is metabolized to the aldehyde, acrolein, by SSAO. Acrolein 217-225 amine oxidase, copper containing 3 Rattus norvegicus 158-162 2118418-10 1990 In vitro experiments revealed that P-450j was severalfold more susceptible to inactivation by the cyclophosphamide metabolite acrolein as compared with P-450 3. Acrolein 126-134 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 35-41 1348271-3 1992 Using a dual-labeling, immunoperoxidase and immunogold-silver method, we localized antisera directed against leu5-enkephalin (ENK) and the catecholamine-synthesizing enzyme tyrosine hydroxylase (TH) in acrolein-fixed sections through the VTA. Acrolein 202-210 proenkephalin Rattus norvegicus 126-129 1348271-3 1992 Using a dual-labeling, immunoperoxidase and immunogold-silver method, we localized antisera directed against leu5-enkephalin (ENK) and the catecholamine-synthesizing enzyme tyrosine hydroxylase (TH) in acrolein-fixed sections through the VTA. Acrolein 202-210 tyrosine hydroxylase Rattus norvegicus 173-193 1380696-6 1992 In addition, studies using poly([4"-2H]dA) poly(rU) and poly([1"-2H]dA) poly(rU) unambiguously establish that the altered base to base propenal ratio is not the result of C-1" chemistry, but a direct consequence of C-4" chemistry. Acrolein 135-143 heterogeneous nuclear ribonucleoprotein C Homo sapiens 171-174 1380696-6 1992 In addition, studies using poly([4"-2H]dA) poly(rU) and poly([1"-2H]dA) poly(rU) unambiguously establish that the altered base to base propenal ratio is not the result of C-1" chemistry, but a direct consequence of C-4" chemistry. Acrolein 135-143 complement C4A (Rodgers blood group) Homo sapiens 215-218 1577225-7 1992 The decrease of cellular GSH-Px activity with acrolein treatment was not mitigated by co-treatment with alpha-tocopherol. Acrolein 46-54 glutathione peroxidase 1 Rattus norvegicus 25-31 2061556-0 1991 Gene mutation assay of acrolein in the CHO/HGPRT test system. Acrolein 23-31 hypoxanthine phosphoribosyltransferase 1 Rattus norvegicus 43-48 2061556-3 1991 This study was undertaken to assess the mutagenic potential of acrolein using the CHO/HGPRT assay, both with and without metabolic activation. Acrolein 63-71 hypoxanthine phosphoribosyltransferase 1 Rattus norvegicus 86-91 2118418-11 1990 These observations suggest that P-450j protein is induced by cyclophosphamide treatment but that the protein is inactivated by the cyclophosphamide metabolite acrolein. Acrolein 159-167 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 32-38 1696540-0 1990 Acrolein depletes the neuropeptides CGRP and substance P in sensory nerves in rat respiratory tract. Acrolein 0-8 calcitonin-related polypeptide alpha Rattus norvegicus 36-40 1696540-10 1990 The acrolein-treated animals had a dose-related decrease in tracheal substance P- and CGRP-immunoreactive nerve fibers compared with controls. Acrolein 4-12 calcitonin-related polypeptide alpha Rattus norvegicus 86-90 2104785-3 1990 Oxidative deamination of allylamine to a highly toxic aldehyde, acrolein, was blocked through enzyme inhibition by semicarbazide-sensitive amine oxidase suggests that this vascular enzyme"s physiological role may include metabolism of exogenous amines. Acrolein 64-72 amine oxidase copper containing 2 Homo sapiens 115-152 2118426-1 1990 Acrolein, a component of tobacco smoke, potentiated platelet aggregation and increased thromboxane A2 (TXA2) formation caused by thrombin and arachidonic acid (AA). Acrolein 0-8 coagulation factor II, thrombin Homo sapiens 129-137 34538315-4 2021 After CYFRA 21-1 bound to cAb, the amino groups of them were blocked with acrolein. Acrolein 74-82 neural proliferation, differentiation and control 1 Homo sapiens 26-29 2118426-4 1990 Acrolein increased the mobilization of [3H]arachidonic acid from prelabelled platelets in response to thrombin and arachidonic acid. Acrolein 0-8 coagulation factor II, thrombin Homo sapiens 102-110 19135121-5 2009 The effects of acrolein on TrxR, Trx and Prx in human bronchial epithelial (BEAS-2B) cells were determined. Acrolein 15-23 thioredoxin Homo sapiens 27-30 19135121-6 2009 A 30-min exposure to 5 microM acrolein oxidized both Trx1 and Trx2, although significant effects were noted for Trx1 at even lower acrolein concentrations. Acrolein 30-38 thioredoxin Homo sapiens 53-57 19135121-6 2009 A 30-min exposure to 5 microM acrolein oxidized both Trx1 and Trx2, although significant effects were noted for Trx1 at even lower acrolein concentrations. Acrolein 30-38 thioredoxin 2 Homo sapiens 62-66 19135121-6 2009 A 30-min exposure to 5 microM acrolein oxidized both Trx1 and Trx2, although significant effects were noted for Trx1 at even lower acrolein concentrations. Acrolein 30-38 thioredoxin Homo sapiens 112-116 19135121-8 2009 TrxR activity was inhibited 60% and >85% by 2.5 and 5 microM acrolein, respectively. Acrolein 64-72 peroxiredoxin 5 Homo sapiens 0-4 19135121-11 2009 While there was a strong correlation between TrxR inhibition and Trx1 oxidation, the irreversible effects on Trx1 suggest direct effects of acrolein rather than loss of reducing equivalents from TrxR. Acrolein 140-148 thioredoxin Homo sapiens 109-113 19135121-15 2009 The effects of acrolein on the thioredoxin system and peroxiredoxins could have important implications for cell survival, redox-sensitive cell signaling, and tolerance to other oxidant insults. Acrolein 15-23 thioredoxin Homo sapiens 31-42 34813903-4 2022 Here, 25 muM acrolein-induced ferroptosis is observed in mouse pancreatic beta-cell MIN6 cells as indicated by ferroptosis-related indicators, including GPX4 exhaustion, lipid peroxides accumulation, and insulin secretion impairment. Acrolein 13-21 glutathione peroxidase 4 Mus musculus 153-157 34813903-8 2022 Moreover, resveratrol, an antioxidant natural product, may relieve ER stress and upregulate PPARgamma expression, thereby inhibiting acrolein-induced ferroptosis. Acrolein 133-141 peroxisome proliferator activated receptor gamma Mus musculus 92-101 34371361-7 2022 We found urinary CEMA+3-HPMA ( acrolein) was significantly associated with higher levels of serum triglycerides (TG), hs-CRP, and lower levels of high-density lipoprotein cholesterol (HDL-C). Acrolein 31-39 C-reactive protein Homo sapiens 121-124 34371361-11 2022 In conclusion, acrolein exposure is associated with the levels of serum TG, HDL-C, and hs-CRP. Acrolein 15-23 C-reactive protein Homo sapiens 90-93 34371361-12 2022 Hs-CRP may mediate acrolein-associated alterations of blood lipids. Acrolein 19-27 C-reactive protein Homo sapiens 3-6 34237580-6 2021 The concentration of acrolein in carbonated water was up to 3.8 times greater than that measured in non-carbonated water (0.07-0.44 +- 0.01 ng mL-1). Acrolein 21-29 L1 cell adhesion molecule Mus musculus 143-147 34908224-8 2022 Moreover, acrolein induced G0/G1phase arrest, promoted the expression of gamma-H2AX, activated the DDR signaling pathway (Ataxia-Telangiectasia-Mutated (ATM) and Rad-3-related/Chk1 and ATM/Chk2), and triggered the consequent cell cycle checkpoints. Acrolein 10-18 ATM serine/threonine kinase Homo sapiens 122-151 34908224-8 2022 Moreover, acrolein induced G0/G1phase arrest, promoted the expression of gamma-H2AX, activated the DDR signaling pathway (Ataxia-Telangiectasia-Mutated (ATM) and Rad-3-related/Chk1 and ATM/Chk2), and triggered the consequent cell cycle checkpoints. Acrolein 10-18 ATM serine/threonine kinase Homo sapiens 153-156 34908224-8 2022 Moreover, acrolein induced G0/G1phase arrest, promoted the expression of gamma-H2AX, activated the DDR signaling pathway (Ataxia-Telangiectasia-Mutated (ATM) and Rad-3-related/Chk1 and ATM/Chk2), and triggered the consequent cell cycle checkpoints. Acrolein 10-18 checkpoint kinase 1 Homo sapiens 176-180 34908224-8 2022 Moreover, acrolein induced G0/G1phase arrest, promoted the expression of gamma-H2AX, activated the DDR signaling pathway (Ataxia-Telangiectasia-Mutated (ATM) and Rad-3-related/Chk1 and ATM/Chk2), and triggered the consequent cell cycle checkpoints. Acrolein 10-18 ATM serine/threonine kinase Homo sapiens 185-188 34908224-8 2022 Moreover, acrolein induced G0/G1phase arrest, promoted the expression of gamma-H2AX, activated the DDR signaling pathway (Ataxia-Telangiectasia-Mutated (ATM) and Rad-3-related/Chk1 and ATM/Chk2), and triggered the consequent cell cycle checkpoints. Acrolein 10-18 checkpoint kinase 2 Homo sapiens 189-193 34587326-5 2021 Similarly, higher levels of acrolein, benzaldehyde, crotonaldehyde, propionaldehyde, trans-2-hexenal and acetaldehyde were accumulated in aao3 mutants upon UV-C irradiation. Acrolein 28-36 abscisic aldehyde oxidase 3 Arabidopsis thaliana 138-142 34587326-6 2021 Aldehydes application to plants hastened profuse senescence symptoms and higher accumulation of aldehydes, such as acrolein, benzaldehyde and 4-hydroxy-2-nonenal, in aao3 mutant leaves as compared to WT. Acrolein 115-123 abscisic aldehyde oxidase 3 Arabidopsis thaliana 166-170 34714663-3 2021 We investigated the capacity of cyanidin-3-O-glucoside (C3G) and its degradants/metabolites to capture ACR during thermal processing or in vivo. Acrolein 103-106 Rap guanine nucleotide exchange factor 1 Homo sapiens 56-59 34714663-4 2021 Our results indicated that both C3G and its degradants, including phloroglucinaldehyde (PGA) and protocatechuic acid (PCA), could efficiently trap ACR to form adducts, such as C3G-ACR, C3G-2ACR, PGA-ACR, PGA-2ACR, PCA-ACR, and PCA-2ACR. Acrolein 147-150 Rap guanine nucleotide exchange factor 1 Homo sapiens 32-35 34714663-6 2021 The adducts of C3G and its metabolites conjugated with ACR, such as C3G-ACR, C3G-2ACR, PGA-ACR, and 4-hydroxybenzoic-acid-ACR (4-HBA-ACR), were also detected in mice feces treated with C3G by oral gavage, where the adduct level was dose-dependent. Acrolein 55-58 Rap guanine nucleotide exchange factor (GEF) 1 Mus musculus 15-18 34714663-6 2021 The adducts of C3G and its metabolites conjugated with ACR, such as C3G-ACR, C3G-2ACR, PGA-ACR, and 4-hydroxybenzoic-acid-ACR (4-HBA-ACR), were also detected in mice feces treated with C3G by oral gavage, where the adduct level was dose-dependent. Acrolein 55-58 Rap guanine nucleotide exchange factor (GEF) 1 Mus musculus 185-188 34238121-4 2021 Additionally, acrolein induces EAhy926 cells inflammatory response and pyroptosis by activating NOD-like receptor protein 3 (NLRP3) inflammasome. Acrolein 14-22 NLR family pyrin domain containing 3 Homo sapiens 96-123 34238121-4 2021 Additionally, acrolein induces EAhy926 cells inflammatory response and pyroptosis by activating NOD-like receptor protein 3 (NLRP3) inflammasome. Acrolein 14-22 NLR family pyrin domain containing 3 Homo sapiens 125-130 34238121-7 2021 Notably, the present study also indicates that autophagy inhibited by inhibitor 3-methyladenine (3MA) and siAtg7 exacerbate acrolein-induced NLRP3 inflammasome activation and pyroptosis. Acrolein 124-132 NLR family pyrin domain containing 3 Homo sapiens 141-146 34238121-8 2021 In summary, acrolein induced cytotoxicity by ROS-mediated NLRP3 inflammasome activation, and ROS upregulates the level of autophagy to inhibit the NLRP3 inflammasome excessive activation, indicating the bidirectional role of ROS in acrolein-induced cellular inflammation. Acrolein 12-20 NLR family pyrin domain containing 3 Homo sapiens 58-63 34238121-8 2021 In summary, acrolein induced cytotoxicity by ROS-mediated NLRP3 inflammasome activation, and ROS upregulates the level of autophagy to inhibit the NLRP3 inflammasome excessive activation, indicating the bidirectional role of ROS in acrolein-induced cellular inflammation. Acrolein 232-240 NLR family pyrin domain containing 3 Homo sapiens 147-152 34607437-3 2021 In this article, we attempted to discover a new attribute of cyanidin-3-O-glucoside (C3G), including its ACR-scavenging capacity, reaction pathway, and possible application. Acrolein 105-108 Rap guanine nucleotide exchange factor 1 Homo sapiens 85-88 34607437-7 2021 More than 65.9% of ACR was eliminated by C3G-ACR within 5 min via further formation of C3G-2ACR, but there was no obvious effect of C3G on ACR. Acrolein 45-48 Rap guanine nucleotide exchange factor 1 Homo sapiens 41-44 34607437-8 2021 When the incubation time was extended to 120 min, C3G could remove up to 83.2% of ACR. Acrolein 82-85 Rap guanine nucleotide exchange factor 1 Homo sapiens 50-53 34607437-9 2021 Subsequently, we also observed that mynica red (>5% C3G), as a pigmented food additive, could efficiently eliminate ACR generated in the Chinese liquor model and real red bayberry wine products to form C3G-ACR and C3G-2ACR. Acrolein 116-119 Rap guanine nucleotide exchange factor 1 Homo sapiens 52-55 34968849-3 2022 In this research, a novel fluorescent probe named "probe for acrolein detection" (Pr-ACR) was designed and synthesized based on a naphthalimide fluorophore skeleton, and a thiol group (-SH) was introduced into its structure for acrolein recognition. Acrolein 61-69 acrosin Homo sapiens 85-88 34968849-3 2022 In this research, a novel fluorescent probe named "probe for acrolein detection" (Pr-ACR) was designed and synthesized based on a naphthalimide fluorophore skeleton, and a thiol group (-SH) was introduced into its structure for acrolein recognition. Acrolein 228-236 acrosin Homo sapiens 85-88 34968849-7 2022 After methyl esterification, the methyl esterified probe (mPr-ACR) successfully visualised acrolein in Hela cells under a laser scanning confocal microscope. Acrolein 91-99 acrosin Homo sapiens 62-65 34968849-8 2022 This finding proved that Pr-ACR and mPr-ACR are potential tools for the detection and visualisation of acrolein from different sources. Acrolein 103-111 acrosin Homo sapiens 28-31 34968849-8 2022 This finding proved that Pr-ACR and mPr-ACR are potential tools for the detection and visualisation of acrolein from different sources. Acrolein 103-111 acrosin Homo sapiens 40-43 34668566-11 2021 In the overall population, metabolites of acrolein, acrylonitrile, acrylamide, 1,3-butadiene, crotonaldehyde, styrene and xylene were positively associated with alkaline phosphatase (ALP). Acrolein 42-50 alkaline phosphatase, placental Homo sapiens 161-181 34668566-11 2021 In the overall population, metabolites of acrolein, acrylonitrile, acrylamide, 1,3-butadiene, crotonaldehyde, styrene and xylene were positively associated with alkaline phosphatase (ALP). Acrolein 42-50 alkaline phosphatase, placental Homo sapiens 183-186 34587326-4 2021 Aldehyde profiling in leaves of 24-days old plants revealed higher accumulation of acrolein, crotonaldehyde, 3Z-hexenal, hexanal and acetaldehyde in aao3 mutants compared to wild-type leaves. Acrolein 83-91 abscisic aldehyde oxidase 3 Arabidopsis thaliana 149-153 34746455-18 2021 Also, there is a relationship between 3-HPMA levels, CYP2B6 polymorphisms, and the occurrences of hematuria after the administration of cyclophosphamide, which is a type of CYP2B6 polymorph, namely CYP2B6*6, can increase cyclophosphamide hydroxylation so that it can increase the levels of acrolein and 3-HPMA, as its metabolites, and risk of hematuria. Acrolein 290-298 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 53-59 34746455-18 2021 Also, there is a relationship between 3-HPMA levels, CYP2B6 polymorphisms, and the occurrences of hematuria after the administration of cyclophosphamide, which is a type of CYP2B6 polymorph, namely CYP2B6*6, can increase cyclophosphamide hydroxylation so that it can increase the levels of acrolein and 3-HPMA, as its metabolites, and risk of hematuria. Acrolein 290-298 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 173-179 34746455-18 2021 Also, there is a relationship between 3-HPMA levels, CYP2B6 polymorphisms, and the occurrences of hematuria after the administration of cyclophosphamide, which is a type of CYP2B6 polymorph, namely CYP2B6*6, can increase cyclophosphamide hydroxylation so that it can increase the levels of acrolein and 3-HPMA, as its metabolites, and risk of hematuria. Acrolein 290-298 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 198-204 34658764-15 2021 The mRNA expression levels of Nlrp6 and Casp11 were significantly increased in the cystitis rat model and in the acrolein-treated neurons. Acrolein 113-121 NLR family, pyrin domain containing 6 Rattus norvegicus 30-35 34658764-15 2021 The mRNA expression levels of Nlrp6 and Casp11 were significantly increased in the cystitis rat model and in the acrolein-treated neurons. Acrolein 113-121 caspase 4 Rattus norvegicus 40-46 34540868-0 2021 ROCK1 Mediates Retinal Glial Cell Migration Promoted by Acrolein. Acrolein 56-64 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 0-5 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 H3.3 histone B Mus musculus 25-30 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 pro-platelet basic protein Mus musculus 36-62 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 pro-platelet basic protein Mus musculus 64-68 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 pro-platelet basic protein Mus musculus 73-78 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 H3.3 histone B Mus musculus 283-288 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 pro-platelet basic protein Mus musculus 293-297 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 H3.3 histone B Mus musculus 351-356 34605213-11 2021 Further, H3.3 histone B (H3F3B) and pro-platelet basic protein (PPBP aka CXCL7), transcripts increased in acrolein exposed mouse BAL and plasma at 3 h, while H3F3B protein that is associated with neutrophil extracellular traps formation increased at 12 h. These results suggest that H3F3B and PPBP transcripts increase may contribute to extracellular H3F3B and PPBP proteins increase. Acrolein 106-114 pro-platelet basic protein Mus musculus 361-365 34540868-9 2021 In TR-MUL5 cells, the mRNA expression level of Rock1, but not Rock2, was increased following acrolein stimulation. Acrolein 93-101 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 47-52 34540868-10 2021 In line with the PCR data, western blotting showed increase in ROCK1 and cleaved ROCK1 protein in TR-MUL5 cells stimulated with acrolein. Acrolein 128-136 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 63-68 34540868-10 2021 In line with the PCR data, western blotting showed increase in ROCK1 and cleaved ROCK1 protein in TR-MUL5 cells stimulated with acrolein. Acrolein 128-136 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 81-86 34540868-12 2021 Acrolein augmented the phosphorylation of MYPT1 and MLC2 and increased the cell migration rate of TR-MUL5 cells, both of which were abrogated by ripasudil. Acrolein 0-8 protein phosphatase 1, regulatory subunit 12A Rattus norvegicus 42-47 34540868-12 2021 Acrolein augmented the phosphorylation of MYPT1 and MLC2 and increased the cell migration rate of TR-MUL5 cells, both of which were abrogated by ripasudil. Acrolein 0-8 myosin light chain 2 Rattus norvegicus 52-56 34540868-13 2021 Conclusions: Our study demonstrated that ROCK1 mediates the migration of retinal glial cells promoted by the unsaturated aldehyde acrolein. Acrolein 130-138 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 41-46 34456718-0 2021 P2X7 Receptor Blockade Protects Against Acrolein-Induced Bladder Damage: A Potential New Therapeutic Approach for the Treatment of Bladder Inflammatory Diseases. Acrolein 40-48 purinergic receptor P2X 7 Homo sapiens 0-13 34278746-0 2021 Reduced Acrolein Detoxification in akr1a1a Zebrafish Mutants Causes Impaired Insulin Receptor Signaling and Microvascular Alterations. Acrolein 8-16 aldo-keto reductase family 1, member A1a (aldehyde reductase) Danio rerio 35-42 34278746-7 2021 Akr1a1a-/- larvae display impaired glucose homeostasis and angiogenic retina hyaloid vasculature, which are caused by reduced acrolein detoxification ability and increased internal ACR concentration. Acrolein 126-134 aldo-keto reductase family 1, member A1a (aldehyde reductase) Danio rerio 0-7 34278746-7 2021 Akr1a1a-/- larvae display impaired glucose homeostasis and angiogenic retina hyaloid vasculature, which are caused by reduced acrolein detoxification ability and increased internal ACR concentration. Acrolein 181-184 aldo-keto reductase family 1, member A1a (aldehyde reductase) Danio rerio 0-7 34271065-0 2021 Acrolein but not its metabolite, 3-Hydroxypropylmercapturic acid (3HPMA), activates vascular transient receptor potential Ankyrin-1 (TRPA1): Physiological to toxicological implications. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 93-131 34271065-0 2021 Acrolein but not its metabolite, 3-Hydroxypropylmercapturic acid (3HPMA), activates vascular transient receptor potential Ankyrin-1 (TRPA1): Physiological to toxicological implications. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 133-138 34271065-3 2021 The hypothesis of this study is the direct effects of acrolein in isolated murine blood vessels (aorta and superior mesenteric artery, SMA) are transient receptor potential ankyrin-1 (TRPA1) dependent. Acrolein 54-62 immunoglobulin mu binding protein 2 Mus musculus 135-138 34271065-3 2021 The hypothesis of this study is the direct effects of acrolein in isolated murine blood vessels (aorta and superior mesenteric artery, SMA) are transient receptor potential ankyrin-1 (TRPA1) dependent. Acrolein 54-62 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 144-182 34271065-3 2021 The hypothesis of this study is the direct effects of acrolein in isolated murine blood vessels (aorta and superior mesenteric artery, SMA) are transient receptor potential ankyrin-1 (TRPA1) dependent. Acrolein 54-62 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 184-189 34271065-5 2021 Acrolein inhibited phenylephrine (PE)-induced contractions (approximately 90%) in aorta and SMA of male and female mice in a concentration-dependent (0.01-100 muM) manner. Acrolein 0-8 immunoglobulin mu binding protein 2 Mus musculus 92-95 34271065-6 2021 The major metabolite of acrolein, 3-hydroxypropylmercapturic acid (3HPMA), also relaxed PE-precontracted SMA. Acrolein 24-32 immunoglobulin mu binding protein 2 Mus musculus 105-108 34271065-7 2021 As the SMA was 20x more sensitive to acrolein than aorta (SMA EC50 0.8 +- 0.2 muM; aorta EC50 > 29.4 +- 4.4 muM), the mechanisms of acrolein-induced relaxation were studied in SMA. Acrolein 37-45 immunoglobulin mu binding protein 2 Mus musculus 58-61 34271065-8 2021 The potency of acrolein-induced relaxation was inhibited significantly by: 1) mechanically-impaired endothelium; 2) Nomega-Nitro-L-arginine methyl ester hydrochloride (L-NAME); 3) guanylyl cyclase (GC) inhibitor (ODQ); and, 4) a TRPA1 antagonist (A967079). Acrolein 15-23 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 229-234 34271065-10 2021 Compared with other known TRPA1 agonists, including allyl isothiocyanate (AITC), cinnamaldehyde, crotonaldehyde, and formaldehyde, acrolein stimulated a more potent TRPA1-dependent relaxation. Acrolein 131-139 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 26-31 34271065-10 2021 Compared with other known TRPA1 agonists, including allyl isothiocyanate (AITC), cinnamaldehyde, crotonaldehyde, and formaldehyde, acrolein stimulated a more potent TRPA1-dependent relaxation. Acrolein 131-139 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 165-170 34456718-3 2021 The aim of this study was to investigate the role of the P2X7 receptor in acrolein-induced inflammatory damage using the porcine urinary bladder. Acrolein 74-82 purinergic receptor P2X 7 Homo sapiens 57-70 34456718-8 2021 All these acrolein-induced responses were attenuated by pre-treatment with the P2X7 receptor antagonist A804598. Acrolein 10-18 purinergic receptor P2X 7 Homo sapiens 79-92 34456718-10 2021 These findings suggested that the P2X7 receptor is involved in the acrolein-induced damage to the urothelium; therefore, the P2X7 receptor antagonists may be a new therapeutic option for the treatment of bladder inflammation. Acrolein 67-75 purinergic receptor P2X 7 Homo sapiens 34-47 34456718-10 2021 These findings suggested that the P2X7 receptor is involved in the acrolein-induced damage to the urothelium; therefore, the P2X7 receptor antagonists may be a new therapeutic option for the treatment of bladder inflammation. Acrolein 67-75 purinergic receptor P2X 7 Homo sapiens 125-138 34131238-9 2021 Furthermore, acrolein-induced DNA damages (Acr-dG adducts) were higher in CRC tumor tissues than in normal epithelial cells in CRC patients. Acrolein 13-21 acrosin Homo sapiens 43-46 34281282-0 2021 Low-Dose Acrolein, an Endogenous and Exogenous Toxic Molecule, Inhibits Glucose Transport via an Inhibition of Akt-Regulated GLUT4 Signaling in Skeletal Muscle Cells. Acrolein 9-17 AKT serine/threonine kinase 1 Homo sapiens 111-114 34281282-0 2021 Low-Dose Acrolein, an Endogenous and Exogenous Toxic Molecule, Inhibits Glucose Transport via an Inhibition of Akt-Regulated GLUT4 Signaling in Skeletal Muscle Cells. Acrolein 9-17 solute carrier family 2 member 4 Homo sapiens 125-130 34127699-3 2021 Incubation of acrolein consistently increased phosphorylated ERK levels. Acrolein 14-22 mitogen-activated protein kinase 1 Homo sapiens 61-64 34127699-4 2021 Co-treatment of selumetinib blocked acrolein-induced ERK phosphorylation. Acrolein 36-44 mitogen-activated protein kinase 1 Homo sapiens 53-56 34127699-5 2021 Furthermore, selumetinib reduced acrolein-induced increases in heme oxygenase-1 (a redox-regulated chaperone protein) and its transcriptional factor, Nrf-2 as well as FDP-lysine (acrolein-lysine adducts) and alpha-synuclein aggregation (a pathological biomarker of neurodegeneration). Acrolein 33-41 heme oxygenase 1 Homo sapiens 63-79 34298758-0 2021 Cigarette Smoke Containing Acrolein Upregulates EGFR Signaling Contributing to Oral Tumorigenesis In Vitro and In Vivo. Acrolein 27-35 epidermal growth factor receptor Homo sapiens 48-52 34298758-11 2021 Furthermore, by examining tissue sample from patients, we found an increased EGFR copy number was positively associated with acrolein-induced DNA damages in OSCC patients. Acrolein 125-133 epidermal growth factor receptor Homo sapiens 77-81 34298758-12 2021 Taken together, our results indicate that acrolein is important in tumorigenic transformation through amplification of EGFR and activating the downstream signaling pathway, contributing to oral carcinogenesis. Acrolein 42-50 epidermal growth factor receptor Homo sapiens 119-123 34298758-13 2021 This is the first study to provide molecular evidence showing that CS containing acrolein contributes to EGFR amplification in OSCC. Acrolein 81-89 epidermal growth factor receptor Homo sapiens 105-109 34281282-6 2021 The glucose transporter-4 (GLUT4) protein expression was significantly decreased in soleus muscles of acrolein-treated mice. Acrolein 102-110 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 4-25 34281282-6 2021 The glucose transporter-4 (GLUT4) protein expression was significantly decreased in soleus muscles of acrolein-treated mice. Acrolein 102-110 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 27-32 34281282-7 2021 The glucose uptake was significantly decreased in differentiated C2C12 myotubes treated with a non-cytotoxic dose of acrolein (1 muM) for 24 and 72 h. Acrolein (0.5-2 muM) also significantly decreased the GLUT4 expression in myotubes. Acrolein 117-125 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 205-210 34281282-7 2021 The glucose uptake was significantly decreased in differentiated C2C12 myotubes treated with a non-cytotoxic dose of acrolein (1 muM) for 24 and 72 h. Acrolein (0.5-2 muM) also significantly decreased the GLUT4 expression in myotubes. Acrolein 151-159 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 205-210 34281282-8 2021 Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3alpha/beta. Acrolein 0-8 insulin receptor substrate 1 Homo sapiens 69-73 34281282-8 2021 Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3alpha/beta. Acrolein 0-8 AKT serine/threonine kinase 1 Homo sapiens 75-78 34281282-8 2021 Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3alpha/beta. Acrolein 0-8 mechanistic target of rapamycin kinase Homo sapiens 80-84 34281282-8 2021 Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3alpha/beta. Acrolein 0-8 ribosomal protein S6 kinase B1 Homo sapiens 86-92 34281282-8 2021 Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3alpha/beta. Acrolein 0-8 glycogen synthase kinase 3 alpha Homo sapiens 98-112 34281282-9 2021 Over-expression of constitutive activation of Akt reversed the inhibitory effects of acrolein on GLUT4 protein expression and glucose uptake in myotubes. Acrolein 85-93 AKT serine/threonine kinase 1 Homo sapiens 46-49 34281282-9 2021 Over-expression of constitutive activation of Akt reversed the inhibitory effects of acrolein on GLUT4 protein expression and glucose uptake in myotubes. Acrolein 85-93 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 97-102 34095924-0 2021 Kinetics of CH2OO and syn-CH3CHOO reaction with acrolein. Acrolein 48-56 synemin Homo sapiens 22-25 34095924-1 2021 The kinetics for the reactions of CH2OO and syn-CH3CHOO with acrolein, a typical unsaturated aldehyde in the atmosphere, were studied in a flash photolysis flow reactor using the OH laser-induced fluorescence (LIF) method. Acrolein 61-69 synemin Homo sapiens 44-47 34095924-4 2021 Both reactions exhibit negative temperature-dependence, with an activation energy of (-1.70 +- 0.19) and (-1.47 +- 0.24) kcal mol-1 for CH2OO and syn-CH3CHOO reacting with acrolein, derived from the Arrhenius equation. Acrolein 172-180 synemin Homo sapiens 146-149 34127699-5 2021 Furthermore, selumetinib reduced acrolein-induced increases in heme oxygenase-1 (a redox-regulated chaperone protein) and its transcriptional factor, Nrf-2 as well as FDP-lysine (acrolein-lysine adducts) and alpha-synuclein aggregation (a pathological biomarker of neurodegeneration). Acrolein 33-41 NFE2 like bZIP transcription factor 2 Homo sapiens 150-155 34127699-5 2021 Furthermore, selumetinib reduced acrolein-induced increases in heme oxygenase-1 (a redox-regulated chaperone protein) and its transcriptional factor, Nrf-2 as well as FDP-lysine (acrolein-lysine adducts) and alpha-synuclein aggregation (a pathological biomarker of neurodegeneration). Acrolein 33-41 synuclein alpha Homo sapiens 208-223 34127699-7 2021 Moreover, selumetinib prevented acrolein-induced programmed cell death via decreasing active caspase 3 (a hallmark of apoptosis) as well as RIP (receptor-interacting protein) 1 and RIP3 (biomarkers for necroptosis). Acrolein 32-40 caspase 3 Homo sapiens 93-102 34127699-7 2021 Moreover, selumetinib prevented acrolein-induced programmed cell death via decreasing active caspase 3 (a hallmark of apoptosis) as well as RIP (receptor-interacting protein) 1 and RIP3 (biomarkers for necroptosis). Acrolein 32-40 receptor interacting serine/threonine kinase 1 Homo sapiens 140-143 34127699-7 2021 Moreover, selumetinib prevented acrolein-induced programmed cell death via decreasing active caspase 3 (a hallmark of apoptosis) as well as RIP (receptor-interacting protein) 1 and RIP3 (biomarkers for necroptosis). Acrolein 32-40 receptor interacting serine/threonine kinase 1 Homo sapiens 145-176 34127699-7 2021 Moreover, selumetinib prevented acrolein-induced programmed cell death via decreasing active caspase 3 (a hallmark of apoptosis) as well as RIP (receptor-interacting protein) 1 and RIP3 (biomarkers for necroptosis). Acrolein 32-40 receptor interacting serine/threonine kinase 3 Homo sapiens 181-185 34127699-8 2021 In conclusion, our study showed that selumetinib inhibited acrolein-activated Nrf-2-HO-1 pathway, acrolein-induced protein conjugation and aggregation as well as damage in neurite outgrowth and cell death, suggesting that selumetinib, a MEK-ERK inhibitor, may be a potential neuroprotective agent against acrolein-induced neurotoxicity in the CNS neurodegenerative diseases. Acrolein 59-67 NFE2 like bZIP transcription factor 2 Homo sapiens 78-83 34127699-8 2021 In conclusion, our study showed that selumetinib inhibited acrolein-activated Nrf-2-HO-1 pathway, acrolein-induced protein conjugation and aggregation as well as damage in neurite outgrowth and cell death, suggesting that selumetinib, a MEK-ERK inhibitor, may be a potential neuroprotective agent against acrolein-induced neurotoxicity in the CNS neurodegenerative diseases. Acrolein 59-67 heme oxygenase 1 Homo sapiens 84-88 35398259-7 2022 AKR1C1 and AKR1C4 also showed broad substrate specificity for nonsteroidal carbonyl compounds including endogenous 4-oxo-2-nonenal, 4-hydroxy-nonenal, acrolein, isocaproaldehyde, farnesal, isatin and methylglyoxal, of which 4-oxo-2-nonenal was reduced with the lowest Km value of 0.9microM. Acrolein 151-159 aldo-keto reductase family 1 member C1 Homo sapiens 0-6 34334796-1 2021 We report the detection of the oxygen-bearing complex organic molecules propenal (C2H3CHO), vinyl alcohol (C2H3OH), methyl formate (HCOOCH3), and dimethyl ether (CH3OCH3) toward the cyanopolyyne peak of the starless core TMC-1. Acrolein 72-80 transmembrane channel like 1 Homo sapiens 221-226 35398259-7 2022 AKR1C1 and AKR1C4 also showed broad substrate specificity for nonsteroidal carbonyl compounds including endogenous 4-oxo-2-nonenal, 4-hydroxy-nonenal, acrolein, isocaproaldehyde, farnesal, isatin and methylglyoxal, of which 4-oxo-2-nonenal was reduced with the lowest Km value of 0.9microM. Acrolein 151-159 aldo-keto reductase family 1 member C4 Homo sapiens 11-17 35216248-7 2022 Furthermore, SMOX inhibition upregulated antioxidant signaling (indicated by elevated Nrf2 and HO-1 levels) and reduced protein-conjugated acrolein in excitotoxic retinas. Acrolein 139-147 spermine oxidase Mus musculus 13-17 35492615-9 2022 The urothelial barrier function, indicated by TEER values, was also significantly reduced by acrolein, whereas pre-incubation with P2X7R antagonist significantly protected the urothelial cell barrier from acrolein-induced TEER reduction. Acrolein 205-213 purinergic receptor P2X 7 Homo sapiens 131-136 35492615-10 2022 The structure of urothelial cell tight junctions was similarly impacted by acrolein treatment, showing the fragmentation of zona occludens-1 (ZO-1) immunoreactivity. Acrolein 75-83 tight junction protein 1 Homo sapiens 124-140 35492615-10 2022 The structure of urothelial cell tight junctions was similarly impacted by acrolein treatment, showing the fragmentation of zona occludens-1 (ZO-1) immunoreactivity. Acrolein 75-83 tight junction protein 1 Homo sapiens 142-146 35492615-12 2022 The damaging effect of acrolein on urothelial cells integrity could be impaired by inhibition of P2X7R, therefore P2X7R blockade may be a possible therapy in patients with bladder cystitis caused by cyclophosphamide treatment. Acrolein 23-31 purinergic receptor P2X 7 Homo sapiens 97-102 35492615-12 2022 The damaging effect of acrolein on urothelial cells integrity could be impaired by inhibition of P2X7R, therefore P2X7R blockade may be a possible therapy in patients with bladder cystitis caused by cyclophosphamide treatment. Acrolein 23-31 purinergic receptor P2X 7 Homo sapiens 114-119 35432586-0 2022 An Inhibitor of Nuclear Factor-Kappa B Pathway Attenuates the Release of TGF-beta1 and Inhibits the Fibrogenic Progress in a Model of Airway Remodeling Induced by Acrolein. Acrolein 163-171 transforming growth factor, beta 1 Mus musculus 73-82 35432586-10 2022 Furthermore, TGF-beta1 was significantly decreased in the acrolein+CAPE group compared with the acrolein group. Acrolein 58-66 transforming growth factor, beta 1 Mus musculus 13-22 35432586-13 2022 In conclusion, as an inhibitor of the NF-kappaB pathway, CAPE attenuated the release of TGF-beta1, which inhibited the fibrogenic progress induced by acrolein in mice and took no effect on inhibiting airway mucus hypersecretion. Acrolein 150-158 transforming growth factor, beta 1 Mus musculus 88-97 35216248-8 2022 In vitro studies using C8-B4 cells showed changes in cellular morphology and increased reactive oxygen species formation in response to acrolein (a product of SMOX activity) treatment. Acrolein 136-144 spermine oxidase Mus musculus 159-163 2565200-5 1989 The possibility that methoxyflurane increases alcohol dehydrogenase-dependent oxidation of allyl alcohol to acrolein, the proposed toxic metabolite, was evaluated by measuring the rate of acrolein formation in the presence of allyl alcohol and liver cytosol. Acrolein 108-116 aldo-keto reductase family 1 member A1 Rattus norvegicus 46-67 2795457-6 1989 Collectively, these results indicate that the glutathione-acrolein adduct formed after exposure to acrolein, or as a result of allyl alcohol oxidation and cyclophosphamide metabolism, can be oxidized by hepatic ALDH or ADH, respectively. Acrolein 58-66 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 211-215 2795457-6 1989 Collectively, these results indicate that the glutathione-acrolein adduct formed after exposure to acrolein, or as a result of allyl alcohol oxidation and cyclophosphamide metabolism, can be oxidized by hepatic ALDH or ADH, respectively. Acrolein 99-107 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 211-215 35053972-1 2022 This study was designed to explore the beneficial effect and mechanism of Ganoderma atrum (G. atrum) polysaccharide (PSG-1) on acrolein-induced IEC-6 cells. Acrolein 127-135 pregnancy specific beta-1-glycoprotein 1 Homo sapiens 117-122 35053972-2 2022 Our results indicated that PSG-1 significantly reduced the impairment of acrolein on cell viability, decreased oxidative stress, and enabled normal expression of tight junction (TJ) proteins that were inhibited by acrolein in IEC-6 cells. Acrolein 73-81 pregnancy specific beta-1-glycoprotein 1 Homo sapiens 27-32 35053972-2 2022 Our results indicated that PSG-1 significantly reduced the impairment of acrolein on cell viability, decreased oxidative stress, and enabled normal expression of tight junction (TJ) proteins that were inhibited by acrolein in IEC-6 cells. Acrolein 214-222 pregnancy specific beta-1-glycoprotein 1 Homo sapiens 27-32 35053972-3 2022 Furthermore, PSG-1 attenuated the elevation of microtubule-associated proteins light chain 3 (LC3) and Beclin 1-like protein 1 (Beclin 1) and increased the protein levels of phospho-mTOR (p-mTOR) and phospho-akt (p-akt), indicating that PSG-1 activated the mammalian target of rapamycin (mTOR) signaling pathway and alleviated acrolein-induced autophagy in IEC-6 cells. Acrolein 327-335 pregnancy specific beta-1-glycoprotein 1 Homo sapiens 13-18 35053972-3 2022 Furthermore, PSG-1 attenuated the elevation of microtubule-associated proteins light chain 3 (LC3) and Beclin 1-like protein 1 (Beclin 1) and increased the protein levels of phospho-mTOR (p-mTOR) and phospho-akt (p-akt), indicating that PSG-1 activated the mammalian target of rapamycin (mTOR) signaling pathway and alleviated acrolein-induced autophagy in IEC-6 cells. Acrolein 327-335 mechanistic target of rapamycin kinase Homo sapiens 182-186 35053972-4 2022 Moreover, PSG-1 markedly attenuated the acrolein-induced apoptosis, as evidenced by the increase in mitochondrial membrane potential (MMP) and B-cell lymphoma 2 (Bcl-2) expression, and the decrease in cysteine aspartate lyase (caspase)-3 and caspase-9. Acrolein 40-48 pregnancy specific beta-1-glycoprotein 1 Homo sapiens 10-15 35053972-4 2022 Moreover, PSG-1 markedly attenuated the acrolein-induced apoptosis, as evidenced by the increase in mitochondrial membrane potential (MMP) and B-cell lymphoma 2 (Bcl-2) expression, and the decrease in cysteine aspartate lyase (caspase)-3 and caspase-9. Acrolein 40-48 BCL2, apoptosis regulator Rattus norvegicus 162-167 35053972-6 2022 Taken together, the present study proved that PSG-1 could protect IEC-6 cells from acrolein-induced oxidative stress and could repair TJ by inhibiting apoptosis and autophagic flux, where autophagy and apoptosis were mutually regulated. Acrolein 83-91 pregnancy specific beta-1-glycoprotein 1 Homo sapiens 46-51 2501305-0 1989 Chemical modification of carbonic anhydrase II with acrolein. Acrolein 52-60 carbonic anhydrase 2 Homo sapiens 25-46 2501305-1 1989 We have reacted acrolein with human carbonic anhydrase II using conditions reported to result in maximal formylethylation of exposed histidine and lysine residues (Pocker, Y., and Janjic, N. (1988) J. Biol. Acrolein 16-24 carbonic anhydrase 2 Homo sapiens 36-57 2501305-7 1989 The 18O-exchange kinetics catalyzed by the acrolein-modified carbonic anhydrase II was similar to that catalyzed by a mutant human carbonic anhydrase II in which histidine at residue 64 was replaced with alanine. Acrolein 43-51 carbonic anhydrase 2 Homo sapiens 61-82 2501305-7 1989 The 18O-exchange kinetics catalyzed by the acrolein-modified carbonic anhydrase II was similar to that catalyzed by a mutant human carbonic anhydrase II in which histidine at residue 64 was replaced with alanine. Acrolein 43-51 carbonic anhydrase 2 Homo sapiens 131-152 2501305-8 1989 Moreover, modification of this mutant carbonic anhydrase II with acrolein did not alter to a significant extent its 18O-exchange pattern. Acrolein 65-73 carbonic anhydrase 2 Homo sapiens 38-59 2565200-5 1989 The possibility that methoxyflurane increases alcohol dehydrogenase-dependent oxidation of allyl alcohol to acrolein, the proposed toxic metabolite, was evaluated by measuring the rate of acrolein formation in the presence of allyl alcohol and liver cytosol. Acrolein 188-196 aldo-keto reductase family 1 member A1 Rattus norvegicus 46-67 3603576-8 1987 CP and acrolein-stimulated lipid peroxidation with and without O2 exposure was significantly (P less than 0.05) reduced by prior addition of SOD, GSH, DTT, or EDTA to the lung microsomal suspension. Acrolein 7-15 superoxide dismutase 1 Homo sapiens 141-144 3129421-1 1988 Incubation of carbonic anhydrase II with acrolein results in a rapid, time-dependent loss of all but approximately 3-6% of the original catalytic activity toward CO2 hydration and HCO3- dehydration, with the inactivation rate being first-order in both acrolein and the enzyme. Acrolein 41-49 carbonic anhydrase 2 Homo sapiens 14-35 3129421-1 1988 Incubation of carbonic anhydrase II with acrolein results in a rapid, time-dependent loss of all but approximately 3-6% of the original catalytic activity toward CO2 hydration and HCO3- dehydration, with the inactivation rate being first-order in both acrolein and the enzyme. Acrolein 252-260 carbonic anhydrase 2 Homo sapiens 14-35 3129421-3 1988 The amount of residual CO2 hydratase activity is proportional to the molar excess of acrolein over carbonic anhydrase II with 5 histidyl and 3 lysyl residues being subject to alkylation under conditions where [acrolein] to [carbonic anhydrase II] ratio is greater than 100. Acrolein 85-93 complement C2 Homo sapiens 23-26 3129421-3 1988 The amount of residual CO2 hydratase activity is proportional to the molar excess of acrolein over carbonic anhydrase II with 5 histidyl and 3 lysyl residues being subject to alkylation under conditions where [acrolein] to [carbonic anhydrase II] ratio is greater than 100. Acrolein 85-93 carbonic anhydrase 2 Homo sapiens 224-245 3382415-1 1988 The in vitro effect of the toxin and teratogen, acrolein, on the fetal rat liver glutathione S-transferase isoenzyme, YcYfetus, was investigated and compared with acrolein"s effect on some of the adult rat liver glutathione S-transferase isoenzymes. Acrolein 48-56 hematopoietic prostaglandin D synthase Rattus norvegicus 81-106 2894953-2 1988 Previous investigations into the enzymatic process responsible for the detoxification of acrolein implicated rat liver aldehyde dehydrogenase (ALDH) in the oxidation of this aldehyde. Acrolein 89-97 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 119-141 2894953-2 1988 Previous investigations into the enzymatic process responsible for the detoxification of acrolein implicated rat liver aldehyde dehydrogenase (ALDH) in the oxidation of this aldehyde. Acrolein 89-97 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 143-147 2894953-7 1988 The inhibition is rapid with a 91 and 33% reduction in control mitochondrial and cytosolic ALDH activities, respectively, with a 5-sec preincubation of 30 microM acrolein prior to the addition of the aldehyde substrate. Acrolein 162-170 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 91-95 3678446-8 1987 Oxidation of spermidine by polyamine oxidase leads to the production of unstable aldehydes, acrolein, ammonia, O2-, HO, and H2O2. Acrolein 92-100 polyamine oxidase Bos taurus 27-44 3679418-7 1987 In-vitro assays of O6-methylguanine-DNA methyltransferase (MMT) activity indicate that it is markedly inhibited by acrolein, and to a lesser extent by formaldehyde. Acrolein 115-123 O-6-methylguanine-DNA methyltransferase Homo sapiens 19-57 3296321-2 1987 All the model compounds tested in the present study (acrolein, propylene oxide, styrene oxide, ethylene dibromide and ethylene dichloride) showed a dose-dependent inactivation of erythrocyte GST in situ as well as the inhibition of purified erythrocyte GST. Acrolein 53-61 glutathione S-transferase kappa 1 Homo sapiens 191-194 3296321-2 1987 All the model compounds tested in the present study (acrolein, propylene oxide, styrene oxide, ethylene dibromide and ethylene dichloride) showed a dose-dependent inactivation of erythrocyte GST in situ as well as the inhibition of purified erythrocyte GST. Acrolein 53-61 glutathione S-transferase kappa 1 Homo sapiens 253-256 3103627-3 1987 Our laboratory has shown that trans,trans-muconaldehyde (a possible metabolite of benzene) as well as acrolein and crotonaldehyde, when added to hepatic microsomes, decreased cytochrome P-450 (measured spectrophotometrically). Acrolein 102-110 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 175-191 3679418-7 1987 In-vitro assays of O6-methylguanine-DNA methyltransferase (MMT) activity indicate that it is markedly inhibited by acrolein, and to a lesser extent by formaldehyde. Acrolein 115-123 O-6-methylguanine-DNA methyltransferase Homo sapiens 59-62 2933316-5 1985 Thus, these data demonstrate that metabolism of allyl alcohol to acrolein by alcohol dehydrogenase is obligatory for the hepatotoxicity of allyl alcohol. Acrolein 65-73 aldo-keto reductase family 1, member A1 (aldehyde reductase) Mus musculus 77-98 4074386-1 1985 Acrolein, a highly reactive aldehyde found in cigarette smoke, was shown to induce time-dependent inactivation of NAD+-linked 15-hydroxyprostaglandin dehydrogenase from porcine lung. Acrolein 0-8 carbonyl reductase 1 Homo sapiens 126-163 2875140-2 1986 In the first portion of the study, a rabbit antiserum to TH was immunocytochemically localized in coronal sections through the lateral PBR from acrolein-fixed brains using the peroxidase-antiperoxidase method. Acrolein 144-152 tyrosine hydroxylase Rattus norvegicus 57-59 3969686-7 1985 The amount of elastin per unit dry weight was 173% of control values in the animals exposed to 4.0 ppm acrolein. Acrolein 103-111 elastin Rattus norvegicus 14-21 6616456-3 1983 CP is metabolized by the cytochrome P-450 drug-metabolizing enzyme system in the liver to alkylating metabolites, to active antineoplastic agents, and to acrolein, the most toxic and least antineoplastic metabolite. Acrolein 154-162 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 25-41 6148213-1 1984 Addition of acrolein to rat lung or liver microsomal suspensions resulted in total inactivation of NADPH-cytochrome c reductase and partial conversion of cytochrome P-450 to P-420 in a concentration- and time-dependent fashion. Acrolein 12-20 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 154-170 6148213-3 1984 Maxima of about 60% of the total lung cytochrome P-450 and 50% of the liver cytochrome P-450 in acrolein-treated microsomes did not support the N-demethylation of benzphetamine or ethylmorphine or hydroxylation of aniline because of the total loss of NADPH-cytochrome c reductase. Acrolein 96-104 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 76-92 6380709-0 1984 Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450. Acrolein 62-70 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 97-113 7059981-4 1982 Conversion of 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein was first-order with respect to 4-hydroxycyclophosphamide (k = 0.126 min-1 in 0.5 M phosphate buffer, pH 8, 37 degrees) as well as first-order with respect to phosphate serving as a catalyst. Acrolein 69-77 CD59 molecule (CD59 blood group) Homo sapiens 147-152 6806077-1 1982 The distribution of immunoreactive TRH in the rat hypothalamus and pituitary was demonstrated using the peroxidase-antiperoxidase technique after rapid fixation of the rat brain with 5% acrolein. Acrolein 186-194 thyrotropin releasing hormone Rattus norvegicus 35-38 7028044-0 1981 Conversion of 3-nitro-1-propanol (miserotoxin aglycone) to cytotoxic acrolein by alcohol dehydrogenase. Acrolein 69-77 aldo-keto reductase family 1 member A1 Homo sapiens 81-102 7298626-10 1981 Acrolein most likely produces this effect by alkylation of the sulfhydryl group(s) in the active site of cytochrome P-450. Acrolein 0-8 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 105-121 33675918-0 2021 Acrolein-conjugated proteomics in brains of adult C57BL/6 mice chronically exposed to acrolein and aged APP/PS1 transgenic AD mice. Acrolein 0-8 presenilin 1 Mus musculus 108-111 187691-2 1976 At low concentrations, acrolein preserves the activities of the enzymes investigated, including those of glucose-6-phosphatase, which is known as one of the most vulnerable to aldehyde fixation; thus, acrolein is usable in enzyme ultracytochemistry. Acrolein 23-31 glucose-6-phosphatase catalytic subunit 1 Homo sapiens 105-126 187691-2 1976 At low concentrations, acrolein preserves the activities of the enzymes investigated, including those of glucose-6-phosphatase, which is known as one of the most vulnerable to aldehyde fixation; thus, acrolein is usable in enzyme ultracytochemistry. Acrolein 201-209 glucose-6-phosphatase catalytic subunit 1 Homo sapiens 105-126 241172-12 1975 Acrolein and methyl vinyl ketone (k1 = 120 and 32 mol-1 sec-1, resp.) react more rapidly than any other carbonyl to give very stable adducts (half-lives for reverse reaction 4.6 and 60.7 days, resp). Acrolein 0-8 secretory blood group 1, pseudogene Homo sapiens 56-61 33939120-5 2021 Our results showed that acrolein may contribute to an early hypercoagulable state after TBI by regulating VWF secretion. Acrolein 24-32 Von Willebrand factor Mus musculus 106-109 33974424-6 2021 In vivo, oxidation with AAPH and acrolein caused a significant reduction in IgE, IgG, IgG1, mast cell protease 1, and plasma histamine, along with the reduction of mast surface c-Kit+ and FcepsilonRI+ expression. Acrolein 33-41 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 177-182 33939120-0 2021 Acrolein Induces Systemic Coagulopathy via Autophagy-dependent Secretion of von Willebrand Factor in Mice after Traumatic Brain Injury. Acrolein 0-8 Von Willebrand factor Mus musculus 76-97 33373621-9 2021 Oxidative stress assessed by anti-acrolein antibody staining in ischemic tissues and urinary 8-iso-PGF2alpha excretion were significantly increased in ApoE-/- mice compared with those in WT and Bach1-/- mice. Acrolein 34-42 apolipoprotein E Mus musculus 151-155 33939120-4 2021 Using a controlled cortical impact mouse model, we demonstrated that the acrolein scavenger phenelzine prevented TBI-induced coagulopathy and recombinant ADAMTS-13 prevented acrolein-induced coagulopathy by cleaving von Willebrand factor (VWF). Acrolein 174-182 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13 Mus musculus 154-163 33910636-0 2021 Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson"s disease: implication of acrolein and TRPA1. Acrolein 0-8 transient receptor potential cation channel subfamily A member 1 Homo sapiens 125-130 33910636-11 2021 In addition, DP lowered acrolein and protected DA-like cells in vitro. Acrolein 24-32 SRP receptor subunit alpha Homo sapiens 13-15 33910636-12 2021 Acrolein"s ability to upregulate TRPA1 was also verified in vitro using cell lines. Acrolein 0-8 transient receptor potential cation channel subfamily A member 1 Homo sapiens 33-38 32919080-1 2021 We have reported that acrolein-conjugated low-density lipoprotein (Acro-LDL) uptake by scavenger receptor class A type 1 (SR-A1) can mediate macrophage foam cell formation. Acrolein 22-30 steroid receptor RNA activator 1 Homo sapiens 87-120 32919080-1 2021 We have reported that acrolein-conjugated low-density lipoprotein (Acro-LDL) uptake by scavenger receptor class A type 1 (SR-A1) can mediate macrophage foam cell formation. Acrolein 22-30 steroid receptor RNA activator 1 Homo sapiens 122-127 32919080-2 2021 The purpose of this study was to determine which amino acid residues of apoB protein in LDL are conjugated with acrolein. Acrolein 112-120 apolipoprotein B Homo sapiens 72-76 32919080-3 2021 Acro-apoB was prepared by incubation of LDL with acrolein (10 to 60 muM) at 37 C for 7 days. Acrolein 49-57 apolipoprotein B Homo sapiens 5-9 32919080-4 2021 Identification of acrolein-conjugated amino acid residues in apoB was performed using LC-MS/MS. Acrolein 18-26 apolipoprotein B Homo sapiens 61-65 32919080-5 2021 The levels of acrolein-conjugated amino acid residues of apoB as well as crosslinking apoB increased in proportion to acrolein concentration. Acrolein 14-22 apolipoprotein B Homo sapiens 57-61 32919080-5 2021 The levels of acrolein-conjugated amino acid residues of apoB as well as crosslinking apoB increased in proportion to acrolein concentration. Acrolein 118-126 apolipoprotein B Homo sapiens 57-61 32919080-5 2021 The levels of acrolein-conjugated amino acid residues of apoB as well as crosslinking apoB increased in proportion to acrolein concentration. Acrolein 118-126 apolipoprotein B Homo sapiens 86-90 32919080-6 2021 The level of LDL uptake by macrophages was parallel with the acrolein-conjugated monomer apoB. Acrolein 61-69 apolipoprotein B Homo sapiens 89-93 32919080-7 2021 Acrolein-conjugated amino acid residues in apoB were C212, K327, K742, K949, K1087, H1923, K2634, K3237 and K3846. Acrolein 0-8 apolipoprotein B Homo sapiens 43-47 32919080-8 2021 The NH2-teriminal four amino acid residues (C212, K327, K742 and K949) were located at the scavenger receptor SR-A1 recognition site, suggesting that these four acrolein-conjugated amino acids are involved in the rapid uptake of Acro-LDL by macrophages. Acrolein 161-169 steroid receptor RNA activator 1 Homo sapiens 110-115 32919080-9 2021 It is proposed that the rapid uptake of LDL by macrophages is dependent on acrolein conjugation of four amino acids residues at the scavenger receptor recognition site of apoB in LDL. Acrolein 75-83 apolipoprotein B Homo sapiens 171-175 33244022-1 2020 In this study, we investigated how carbonylation of fibrinogen by acrolein modified its indispensable function to enhance fibrinolysis after being converted to fibrin and contributed to generating a fibrinolysis-resistant fibrin clot. Acrolein 66-74 fibrinogen beta chain Homo sapiens 52-62 33127645-7 2020 Interestingly, scission activity of proHPSE produced by immortalized endothelial cells and HEK293 cells transfected with hHPSE1 cDNA were activated by acrolein (ACR) exposure. Acrolein 151-159 heparanase Homo sapiens 121-127 33127645-7 2020 Interestingly, scission activity of proHPSE produced by immortalized endothelial cells and HEK293 cells transfected with hHPSE1 cDNA were activated by acrolein (ACR) exposure. Acrolein 161-164 heparanase Homo sapiens 121-127 33253558-4 2020 Our results indicated that TP, which possesses an -NH moiety at the N-7 position, exhibits the best ACR-trapping capacity in vitro, while CAF has a slight ability to trap ACR due to the substitutions by -CH3 at the N-1, N-3, and N-7 positions. Acrolein 171-174 caffeine susceptibility Mus musculus 138-141 33253558-5 2020 After oral administration of TP or CAF, the ACR adducts of TP and the metabolites of TP or CAF (e.g., mono- and di-ACR-TP, mono-ACR-1,3-DMU, and mono-ACR-1-MU) were detected in urinary samples obtained from both TP- and CAF-treated mouse groups by using ultra-performance liquid chromatography-tandem mass spectrometry. Acrolein 44-47 caffeine susceptibility Mus musculus 91-94 33253558-5 2020 After oral administration of TP or CAF, the ACR adducts of TP and the metabolites of TP or CAF (e.g., mono- and di-ACR-TP, mono-ACR-1,3-DMU, and mono-ACR-1-MU) were detected in urinary samples obtained from both TP- and CAF-treated mouse groups by using ultra-performance liquid chromatography-tandem mass spectrometry. Acrolein 44-47 caffeine susceptibility Mus musculus 91-94 33253558-8 2020 Those results indicated that dietary TP or CAF has the potential capacity to scavenge ACR in vivo. Acrolein 86-89 caffeine susceptibility Mus musculus 43-46 32588239-17 2020 Transcellular ion transport pathways via the ENaC, CFTR, and Na/K-ATPase are interrupted by both thermal stress and acrolein, one of the most potent smoke toxins. Acrolein 116-124 sodium channel, nonvoltage-gated 1 alpha Mus musculus 45-49 32588239-17 2020 Transcellular ion transport pathways via the ENaC, CFTR, and Na/K-ATPase are interrupted by both thermal stress and acrolein, one of the most potent smoke toxins. Acrolein 116-124 cystic fibrosis transmembrane conductance regulator Mus musculus 51-55 33244022-2 2020 Acrolein-treated fibrinogen was subjected to tissue plasminogen activator-induced fibrinolysis assay and the effect of lysine residue carbonylation in fibrinogen on fibrinolysis was analyzed. Acrolein 0-8 fibrinogen beta chain Homo sapiens 17-27 33244022-3 2020 The acrolein-treated fibrinogen-derived fibrin clot appeared more resistant to fibrinolysis and the N-acetyl 3-formyl-3,4-dehydropiperidino (FDP)-Lysine levels in the lysed solution were positively correlated with the duration of clot lysis. Acrolein 4-12 fibrinogen beta chain Homo sapiens 21-31 33244022-6 2020 These results suggest that fibrinogen carbonylation by acrolein to generate N-acetyl FDP-Lysine resulted in the generation of fibrinolysis-resistant fibrin by attenuating the C-terminal lysine-dependent activation of the Glu1-plasminogen. Acrolein 55-63 fibrinogen beta chain Homo sapiens 27-37 32879145-6 2020 The CSE- and ACR-induced decrease in the phosphorylation and expression of eNOS was counteracted by glutathione (reduced form), an antioxidant. Acrolein 13-16 nitric oxide synthase 3 Homo sapiens 75-79 32738274-0 2020 Acrolein in cigarette smoke attenuates the innate immune responses mediated by surfactant protein D. BACKGROUND: Surfactant proteins (SP) A and D belong to collectin family proteins, which play important roles in innate immune response in the lung. Acrolein 0-8 surfactant associated protein A1 Mus musculus 113-145 32738274-1 2020 We previously demonstrated that cigarette smoke (CS) increases the acrolein modification of SP-A, thereby impairing the innate immune abilities of this protein. Acrolein 67-75 surfactant associated protein A1 Mus musculus 92-96 32738274-4 2020 The structural changes in CS extract (CSE) or acrolein-exposed recombinant human (h)SP-D were determined by western blot, liquid chromatography-electrospray ionization tandem mass spectrometry, and blue native-polyacrylamide gel electrophoresis analyses. Acrolein 46-54 surfactant protein D Homo sapiens 84-88 32738274-7 2020 Exposure of hSP-D to CSE or acrolein induced an increased higher-molecular -weight of hSP-D and acrolein induced modification of five lysine residues in hSP-D. Acrolein 28-36 surfactant protein D Homo sapiens 12-17 32738274-7 2020 Exposure of hSP-D to CSE or acrolein induced an increased higher-molecular -weight of hSP-D and acrolein induced modification of five lysine residues in hSP-D. Acrolein 28-36 surfactant protein D Homo sapiens 86-91 32738274-7 2020 Exposure of hSP-D to CSE or acrolein induced an increased higher-molecular -weight of hSP-D and acrolein induced modification of five lysine residues in hSP-D. Acrolein 28-36 surfactant protein D Homo sapiens 86-91 32738274-7 2020 Exposure of hSP-D to CSE or acrolein induced an increased higher-molecular -weight of hSP-D and acrolein induced modification of five lysine residues in hSP-D. Acrolein 96-104 surfactant protein D Homo sapiens 12-17 32738274-9 2020 CONCLUSION: CS induced acrolein modification in SP-D, which in turn induced structural and functional defects in SP-D. Acrolein 23-31 surfactant associated protein D Mus musculus 48-52 32738274-9 2020 CONCLUSION: CS induced acrolein modification in SP-D, which in turn induced structural and functional defects in SP-D. Acrolein 23-31 surfactant associated protein D Mus musculus 113-117 33070462-0 2020 Structural change and degradation of cytoskeleton due to the acrolein conjugation with vimentin and actin during brain infarction. Acrolein 61-69 vimentin Mus musculus 87-95 33110918-13 2020 Acrolein exposure resulted in an increased expression of IL-17A, C, and D; IL-1B; IL-22; and RAR-related orphan receptor A in the PBEC-ALI model. Acrolein 0-8 interleukin 17A Mus musculus 57-73 33110918-13 2020 Acrolein exposure resulted in an increased expression of IL-17A, C, and D; IL-1B; IL-22; and RAR-related orphan receptor A in the PBEC-ALI model. Acrolein 0-8 interleukin 1 beta Mus musculus 75-80 33110918-13 2020 Acrolein exposure resulted in an increased expression of IL-17A, C, and D; IL-1B; IL-22; and RAR-related orphan receptor A in the PBEC-ALI model. Acrolein 0-8 interleukin 22 Mus musculus 82-87 33110918-15 2020 Altered expression of IL-17 pathway genes following acrolein exposure in the PBEC-ALI models indicates that it has a central role in chemical irritant toxicity. Acrolein 52-60 interleukin 17A Mus musculus 22-27 32659531-5 2020 Co-exposure to formaldehyde and acrolein mixtures showed significantly synergistic interaction on DNA strands breakage and chromosome damage in a concentration/time-dependent manner, while antagonism was shown on the late genotoxic endpoints (e.g. cytoplasmic block micronucleus (CBMN) and HPRT gene mutation). Acrolein 32-40 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 290-294 33070462-4 2020 It was found that vimentin was conjugated with acrolein, and the conjugated amino acid residue was Cys328, which is the only Cys residue in vimentin. Acrolein 47-55 vimentin Mus musculus 18-26 33070462-6 2020 The structure and localization of vimentin and actin filaments were changed greatly in infarct brain in photochemically induced thrombosis (PIT) model mice and in acrolein-treated Neuro2a cells. Acrolein 163-171 vimentin Mus musculus 34-42 32436179-4 2020 In primary neurons, acrolein induced an increase in mitochondrial fragmentation, loss of mitochondrial membrane potential, generation of reactive oxidative species, and release of mitochondrial cytochrome c. Mechanistically, acrolein facilitated the translocation of dynamin-related protein1 (Drp1) from the cytoplasm onto the mitochondrial membrane and led to excessive mitochondrial fission. Acrolein 20-28 dynamin 1-like Mus musculus 267-291 32436179-0 2020 Acrolein Aggravates Secondary Brain Injury After Intracerebral Hemorrhage Through Drp1-Mediated Mitochondrial Oxidative Damage in Mice. Acrolein 0-8 dynamin 1-like Mus musculus 82-86 32436179-4 2020 In primary neurons, acrolein induced an increase in mitochondrial fragmentation, loss of mitochondrial membrane potential, generation of reactive oxidative species, and release of mitochondrial cytochrome c. Mechanistically, acrolein facilitated the translocation of dynamin-related protein1 (Drp1) from the cytoplasm onto the mitochondrial membrane and led to excessive mitochondrial fission. Acrolein 20-28 dynamin 1-like Mus musculus 293-297 32436179-4 2020 In primary neurons, acrolein induced an increase in mitochondrial fragmentation, loss of mitochondrial membrane potential, generation of reactive oxidative species, and release of mitochondrial cytochrome c. Mechanistically, acrolein facilitated the translocation of dynamin-related protein1 (Drp1) from the cytoplasm onto the mitochondrial membrane and led to excessive mitochondrial fission. Acrolein 225-233 dynamin 1-like Mus musculus 267-291 32436179-4 2020 In primary neurons, acrolein induced an increase in mitochondrial fragmentation, loss of mitochondrial membrane potential, generation of reactive oxidative species, and release of mitochondrial cytochrome c. Mechanistically, acrolein facilitated the translocation of dynamin-related protein1 (Drp1) from the cytoplasm onto the mitochondrial membrane and led to excessive mitochondrial fission. Acrolein 225-233 dynamin 1-like Mus musculus 293-297 32436179-5 2020 Further studies found that treatment with hydralazine (an acrolein scavenger) significantly reversed Drp1 translocation and the morphological damage of mitochondria after ICH. Acrolein 58-66 dynamin 1-like Mus musculus 101-105 32436179-8 2020 Meanwhile, we uncovered a novel mechanism by which Drp1-mediated mitochondrial oxidative damage is involved in acrolein-induced brain injury. Acrolein 111-119 dynamin 1-like Mus musculus 51-55 32515247-7 2020 The overexpression of ATPGD1 prevented the accumulation of acrolein and 4-hydroxy trans-2-nonenal-protein adducts in ischemic hearts and delayed acrolein or 4-hydroxy trans-2-nonenal-induced hypercontracture in isolated cardiac myocytes. Acrolein 59-67 carnosine synthase 1 Mus musculus 22-28 32707767-9 2020 Together, our data suggest that CPA, once metabolized to acrolein, causes urothelial ATP-mediated, redox-dependent HMGB1 release from macrophages, which in turn causes RAGE-mediated CSE upregulation and subsequent H2S-targeted Cav3.2-dependent nociceptor excitation, resulting in bladder pain. Acrolein 57-65 high mobility group box 1 Mus musculus 115-120 32707767-9 2020 Together, our data suggest that CPA, once metabolized to acrolein, causes urothelial ATP-mediated, redox-dependent HMGB1 release from macrophages, which in turn causes RAGE-mediated CSE upregulation and subsequent H2S-targeted Cav3.2-dependent nociceptor excitation, resulting in bladder pain. Acrolein 57-65 MOK protein kinase Mus musculus 168-172 32707767-9 2020 Together, our data suggest that CPA, once metabolized to acrolein, causes urothelial ATP-mediated, redox-dependent HMGB1 release from macrophages, which in turn causes RAGE-mediated CSE upregulation and subsequent H2S-targeted Cav3.2-dependent nociceptor excitation, resulting in bladder pain. Acrolein 57-65 cystathionase (cystathionine gamma-lyase) Mus musculus 182-185 32707767-9 2020 Together, our data suggest that CPA, once metabolized to acrolein, causes urothelial ATP-mediated, redox-dependent HMGB1 release from macrophages, which in turn causes RAGE-mediated CSE upregulation and subsequent H2S-targeted Cav3.2-dependent nociceptor excitation, resulting in bladder pain. Acrolein 57-65 calcium channel, voltage-dependent, T type, alpha 1H subunit Mus musculus 227-233 31715629-9 2020 We also established that the e-cigarette product acrolein, a reactive aldehyde, recapitulated many of the NOX-2-dependent effects of e-cigarette vapour using in vitro blood vessel incubation. Acrolein 49-57 cytochrome b-245, beta polypeptide Mus musculus 106-111 32530271-0 2020 Albumin Protects Lung Cells against Acrolein Cytotoxicity and Acrolein-adducted Albumin Increases Heme Oxygenase 1 Transcripts. Acrolein 62-70 heme oxygenase 1 Homo sapiens 98-114 32530271-6 2020 In addition, albumin inhibited acrolein-induced increase of transcripts associated with cellular stress response, activating transcription factor 3 (ATF3), and antioxidant response, heme oxygenase 1 (HMOX1) in HAEC cells. Acrolein 31-39 activating transcription factor 3 Homo sapiens 114-147 32530271-6 2020 In addition, albumin inhibited acrolein-induced increase of transcripts associated with cellular stress response, activating transcription factor 3 (ATF3), and antioxidant response, heme oxygenase 1 (HMOX1) in HAEC cells. Acrolein 31-39 activating transcription factor 3 Homo sapiens 149-153 32530271-6 2020 In addition, albumin inhibited acrolein-induced increase of transcripts associated with cellular stress response, activating transcription factor 3 (ATF3), and antioxidant response, heme oxygenase 1 (HMOX1) in HAEC cells. Acrolein 31-39 heme oxygenase 1 Homo sapiens 182-198 32530271-6 2020 In addition, albumin inhibited acrolein-induced increase of transcripts associated with cellular stress response, activating transcription factor 3 (ATF3), and antioxidant response, heme oxygenase 1 (HMOX1) in HAEC cells. Acrolein 31-39 heme oxygenase 1 Homo sapiens 200-205 32530271-7 2020 Acrolein-adducted albumin itself increased HMOX1 transcripts but not ATF3 transcripts. Acrolein 0-8 heme oxygenase 1 Homo sapiens 43-48 32530271-8 2020 The HMOX1 transcript increase was inhibited by hydralazine, a carbonyl scavenger, suggesting that the carbonyl group of acrolein-adducted albumin mediated HMOX1 transcript increase. Acrolein 120-128 heme oxygenase 1 Homo sapiens 4-9 32530271-8 2020 The HMOX1 transcript increase was inhibited by hydralazine, a carbonyl scavenger, suggesting that the carbonyl group of acrolein-adducted albumin mediated HMOX1 transcript increase. Acrolein 120-128 heme oxygenase 1 Homo sapiens 155-160 33583791-7 2020 Furthermore, treatment with acrolein could markedly increase the levels of reactive oxygen species (ROS) and expression of cleavage of caspase-9 and caspase-3 in H9c2 cardiomyocytes, which were significantly reversed by co-treatment with PEF (100uM). Acrolein 28-36 caspase 9 Homo sapiens 135-144 33583791-7 2020 Furthermore, treatment with acrolein could markedly increase the levels of reactive oxygen species (ROS) and expression of cleavage of caspase-9 and caspase-3 in H9c2 cardiomyocytes, which were significantly reversed by co-treatment with PEF (100uM). Acrolein 28-36 caspase 3 Homo sapiens 149-158 32515247-7 2020 The overexpression of ATPGD1 prevented the accumulation of acrolein and 4-hydroxy trans-2-nonenal-protein adducts in ischemic hearts and delayed acrolein or 4-hydroxy trans-2-nonenal-induced hypercontracture in isolated cardiac myocytes. Acrolein 145-153 carnosine synthase 1 Mus musculus 22-28 32579679-3 2020 In the present study, we investigated the role and regulation of spermine oxidase (SMOX), one of the enzymes related to acrolein generation, in retinal glial cells under hypoxic condition. Acrolein 120-128 spermine oxidase Rattus norvegicus 65-81 32526913-1 2020 The Transient Receptor Potential Ankyrin 1 (TRPA1) cation channel expressed on capsaicin-sensitive afferents, immune and endothelial cells is activated by inflammatory mediators and exogenous irritants, e.g., endotoxins, nicotine, crotonaldehyde and acrolein. Acrolein 250-258 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 4-42 32526913-1 2020 The Transient Receptor Potential Ankyrin 1 (TRPA1) cation channel expressed on capsaicin-sensitive afferents, immune and endothelial cells is activated by inflammatory mediators and exogenous irritants, e.g., endotoxins, nicotine, crotonaldehyde and acrolein. Acrolein 250-258 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 44-49 32526913-1 2020 The Transient Receptor Potential Ankyrin 1 (TRPA1) cation channel expressed on capsaicin-sensitive afferents, immune and endothelial cells is activated by inflammatory mediators and exogenous irritants, e.g., endotoxins, nicotine, crotonaldehyde and acrolein. Acrolein 250-258 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 51-65 32579679-3 2020 In the present study, we investigated the role and regulation of spermine oxidase (SMOX), one of the enzymes related to acrolein generation, in retinal glial cells under hypoxic condition. Acrolein 120-128 spermine oxidase Rattus norvegicus 83-87 32291330-6 2020 In LDL(-) fractions, acrolein adducts were identified at all lysine residues in apoA1, with only a small number of acrolein-modified residues were identified in apoB. Acrolein 21-29 apolipoprotein A1 Homo sapiens 80-85 32145024-5 2020 Acrolein induced stomatal closure and triggered cytosolic alkalization in wild type (WT), tgg1-3 single mutants and in tgg2-1 single mutants, but not in tgg1-3 tgg2-1 double mutants. Acrolein 0-8 thioglucoside glucohydrolase 1 Arabidopsis thaliana 90-94 32255634-8 2020 Those identified from the unimolecular decay of syn-MACR-oxide and subsequent reaction of O2 are acetaldehyde (37 +- 7%), vinyl alcohol (9 +- 1%), methylketene (2 +- 1%), and acrolein (52 +- 5%). Acrolein 175-183 synemin Homo sapiens 48-51 32145024-5 2020 Acrolein induced stomatal closure and triggered cytosolic alkalization in wild type (WT), tgg1-3 single mutants and in tgg2-1 single mutants, but not in tgg1-3 tgg2-1 double mutants. Acrolein 0-8 glucoside glucohydrolase 2 Arabidopsis thaliana 119-123 31864078-0 2020 Acrolein-induced apoptosis of smooth muscle cells through NEAT1-Bmal1/Clock pathway and a protection from asparagus extract. Acrolein 0-8 nuclear paraspeckle assembly transcript 1 Homo sapiens 58-63 32084513-3 2020 This result led us to decipher CatS resistance to major and representative CSE oxidants: hydrogen peroxide, formaldehyde, acrolein and peroxynitrite. Acrolein 122-130 cathepsin S Felis catus 31-35 32084513-4 2020 CatS was inactivated by hydrogen peroxide, peroxynitrite and acrolein in a time- and dose-dependent manner, while formaldehyde was a weaker oxidant. Acrolein 61-69 cathepsin S Felis catus 0-4 32084513-5 2020 Hydrogen peroxide, but not CSE, formaldehyde, and peroxynitrite impaired the autocatalytic maturation of pro-CatS, whereas acrolein prevented the formation of mature CatS without hindering the initial step of the two-step autocatalytic process. Acrolein 123-131 cathepsin S Felis catus 166-170 31888849-4 2020 It was also found that the carbazate modified CMs could selectively remove carbonylated proteins from acrolein treated bovine serum albumin (BSA) or ESRD patient"s blood serum in PBS buffer. Acrolein 102-110 albumin Homo sapiens 126-139 31864078-0 2020 Acrolein-induced apoptosis of smooth muscle cells through NEAT1-Bmal1/Clock pathway and a protection from asparagus extract. Acrolein 0-8 aryl hydrocarbon receptor nuclear translocator like Homo sapiens 64-69 31864078-0 2020 Acrolein-induced apoptosis of smooth muscle cells through NEAT1-Bmal1/Clock pathway and a protection from asparagus extract. Acrolein 0-8 clock circadian regulator Homo sapiens 70-75 31864078-4 2020 However, whether acrolein, an environmental pollutant, affects the apoptosis of VSMCs by regulating NEAT1 and clock genes is still elusive. Acrolein 17-25 nuclear paraspeckle assembly transcript 1 Homo sapiens 100-105 31864078-4 2020 However, whether acrolein, an environmental pollutant, affects the apoptosis of VSMCs by regulating NEAT1 and clock genes is still elusive. Acrolein 17-25 clock circadian regulator Homo sapiens 110-115 31864078-6 2020 Acrolein exposure reduced survival rate of VSMCs, and raised apoptosis percentage through upregulating the expression of Bax, Cytochrome c and Cleaved caspase-3 and downregulating Bcl-2. Acrolein 0-8 BCL2 associated X, apoptosis regulator Homo sapiens 121-124 31864078-6 2020 Acrolein exposure reduced survival rate of VSMCs, and raised apoptosis percentage through upregulating the expression of Bax, Cytochrome c and Cleaved caspase-3 and downregulating Bcl-2. Acrolein 0-8 cytochrome c, somatic Homo sapiens 126-138 31864078-6 2020 Acrolein exposure reduced survival rate of VSMCs, and raised apoptosis percentage through upregulating the expression of Bax, Cytochrome c and Cleaved caspase-3 and downregulating Bcl-2. Acrolein 0-8 caspase 3 Homo sapiens 151-160 31864078-6 2020 Acrolein exposure reduced survival rate of VSMCs, and raised apoptosis percentage through upregulating the expression of Bax, Cytochrome c and Cleaved caspase-3 and downregulating Bcl-2. Acrolein 0-8 BCL2 apoptosis regulator Homo sapiens 180-185 31864078-8 2020 Expression of NEAT1, Bmal1 and Clock was decreased by acrolein, while was ameliorated by AE. Acrolein 54-62 nuclear paraspeckle assembly transcript 1 Homo sapiens 14-19 31864078-8 2020 Expression of NEAT1, Bmal1 and Clock was decreased by acrolein, while was ameliorated by AE. Acrolein 54-62 aryl hydrocarbon receptor nuclear translocator like Homo sapiens 21-26 31864078-8 2020 Expression of NEAT1, Bmal1 and Clock was decreased by acrolein, while was ameliorated by AE. Acrolein 54-62 clock circadian regulator Homo sapiens 31-36 31864078-12 2020 In this study, we demonstrated that VSMCs apoptosis induced by acrolein was associated with downregulation of NEAT1 and Bmal1/Clock. Acrolein 63-71 nuclear paraspeckle assembly transcript 1 Homo sapiens 110-115 31864078-12 2020 In this study, we demonstrated that VSMCs apoptosis induced by acrolein was associated with downregulation of NEAT1 and Bmal1/Clock. Acrolein 63-71 aryl hydrocarbon receptor nuclear translocator like Homo sapiens 120-125 31864078-12 2020 In this study, we demonstrated that VSMCs apoptosis induced by acrolein was associated with downregulation of NEAT1 and Bmal1/Clock. Acrolein 63-71 clock circadian regulator Homo sapiens 126-131 31804737-0 2020 Acrolein and Copper as Competitive Effectors of alpha-Synuclein. Acrolein 0-8 synuclein alpha Homo sapiens 48-63 31804737-3 2020 alphaSyn is modified by reactive carbonyl species, including acrolein (ACR). Acrolein 61-69 synuclein alpha Homo sapiens 0-8 31804737-3 2020 alphaSyn is modified by reactive carbonyl species, including acrolein (ACR). Acrolein 71-74 synuclein alpha Homo sapiens 0-8 31804737-5 2020 Therefore, we explored more thoroughly the effects of ACR on alphaSyn using an approach based on LC-MS/MS analysis. Acrolein 54-57 synuclein alpha Homo sapiens 61-69 31629858-9 2020 The induction of acrolein in neuronal cells during OGD occurred due to the increased expression of spermidine/spermine N1-acetyltransferase (SSAT) by NF-kB pathway activation. Acrolein 17-25 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 99-139 31634544-9 2020 High doses of acrolein led to HUVEC death and loss of vWF production. Acrolein 14-22 von Willebrand factor Homo sapiens 54-57 31629858-9 2020 The induction of acrolein in neuronal cells during OGD occurred due to the increased expression of spermidine/spermine N1-acetyltransferase (SSAT) by NF-kB pathway activation. Acrolein 17-25 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 141-145 31629858-13 2020 The mechanism underlying the role of acrolein in stroke-related neuronal damage occurs through SSAT-induced polyamine oxidation by NF-kB pathway activation. Acrolein 37-45 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 95-99 31654382-5 2020 Our results showed that not only acrolein reduced cell differentiation and cell viability, but also altered the expression of markers of synaptic communication (synapsin I), energy metabolism (AMPK-alpha, Sirt I and glucose uptake), and cytoskeleton (beta-III-tubulin). Acrolein 33-41 synapsin I Rattus norvegicus 161-171 31786775-3 2020 In the present study, the effect of AZD6244 (an ATP non-competitive MEK1/2 inhibitor) on acrolein-induced neuroinflammation was investigated using BV-2 cells and primary cultured microglia. Acrolein 89-97 mitogen-activated protein kinase kinase 1 Mus musculus 68-74 31786775-5 2020 Similar elevation in co-localized immunoreactivities of phosphorylated ERK and ED-1 was detected in the acrolein-treated BV-2 cells. Acrolein 104-112 mitogen-activated protein kinase 1 Mus musculus 71-74 31786775-5 2020 Similar elevation in co-localized immunoreactivities of phosphorylated ERK and ED-1 was detected in the acrolein-treated BV-2 cells. Acrolein 104-112 ectodysplasin-A Mus musculus 79-83 31786775-6 2020 Furthermore, Western blot assay showed increases in phosphorylated ERK in BV-2 cells subjected to LPS (1 mug/mL) or acrolein (30 muM); these increases were blocked by AZD6244 (10 muM). Acrolein 116-124 mitogen-activated protein kinase 1 Mus musculus 67-70 31786775-9 2020 In addition, AZD6244 inhibited acrolein-induced increases in activated caspase 1 (a biomarker of inflammasome activation) and heme oxygenase-1 (a redox-regulated chaperone protein) in BV-2 cells. Acrolein 31-39 caspase 1 Mus musculus 71-80 31786775-9 2020 In addition, AZD6244 inhibited acrolein-induced increases in activated caspase 1 (a biomarker of inflammasome activation) and heme oxygenase-1 (a redox-regulated chaperone protein) in BV-2 cells. Acrolein 31-39 heme oxygenase 1 Mus musculus 126-142 31786775-11 2020 In conclusion, our study shows that acrolein is capable of inducing neuroinflammation which involved ERK activation in microglia. Acrolein 36-44 mitogen-activated protein kinase 1 Mus musculus 101-104 31786775-13 2020 Our study suggests that ERK inhibition may be a neuroprotective target against acrolein-induced neuroinflammation in the CNS neurodegenerative diseases. Acrolein 79-87 mitogen-activated protein kinase 1 Mus musculus 24-27 31665823-0 2020 Translating In Vitro Acrolein-Trapping Capacities of Tea Polyphenol and Soy Genistein to In Vivo Situation is Mediated by the Bioavailability and Biotransformation of Individual Polyphenols. Acrolein 21-29 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 Mus musculus 53-56 31665823-7 2020 Tea EGCG exerted much higher capacity to capture acrolein than soy genistein in vitro. Acrolein 49-57 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 Mus musculus 0-3 31654382-6 2020 Treatment with p-BTX-I increased the percentage of differentiation in cells treated with acrolein and significantly attenuated cell viability loss, besides counteracting the negative effects of acrolein on synapsin I, AMPK-alpha, Sirt I, glucose uptake, and beta-III-tubulin. Acrolein 194-202 synapsin I Rattus norvegicus 206-216 31639409-0 2020 Involvement of ADAM10 in acrolein-induced astrocytic inflammation. Acrolein 25-33 ADAM metallopeptidase domain 10 Homo sapiens 15-21 31639409-4 2020 It was found that acrolein increased the levels of NLRP3 and cleaved caspase-1, which led to the maturation of interleukin-1beta (IL-1beta). Acrolein 18-26 NLR family pyrin domain containing 3 Homo sapiens 51-56 31639409-4 2020 It was found that acrolein increased the levels of NLRP3 and cleaved caspase-1, which led to the maturation of interleukin-1beta (IL-1beta). Acrolein 18-26 caspase 1 Homo sapiens 69-78 31639409-4 2020 It was found that acrolein increased the levels of NLRP3 and cleaved caspase-1, which led to the maturation of interleukin-1beta (IL-1beta). Acrolein 18-26 interleukin 1 beta Homo sapiens 111-128 31639409-4 2020 It was found that acrolein increased the levels of NLRP3 and cleaved caspase-1, which led to the maturation of interleukin-1beta (IL-1beta). Acrolein 18-26 interleukin 1 alpha Homo sapiens 130-138 31639409-5 2020 ELISA assay results, which showed that acrolein increased the secreted IL-1beta, further supported acrolein-induced astrocytic inflammation. Acrolein 39-47 interleukin 1 alpha Homo sapiens 71-79 31639409-5 2020 ELISA assay results, which showed that acrolein increased the secreted IL-1beta, further supported acrolein-induced astrocytic inflammation. Acrolein 99-107 interleukin 1 alpha Homo sapiens 71-79 31639409-8 2020 Furthermore, we found that acrolein activated p38 MAPK and NF-kappaB p65, while pretreatment with p38 MAPK inhibitor, SB203580 and GI 254023X inhibited NF-kappaB p65 activation and NLRP3 inflammasome. Acrolein 27-35 RELA proto-oncogene, NF-kB subunit Homo sapiens 59-72 31639409-8 2020 Furthermore, we found that acrolein activated p38 MAPK and NF-kappaB p65, while pretreatment with p38 MAPK inhibitor, SB203580 and GI 254023X inhibited NF-kappaB p65 activation and NLRP3 inflammasome. Acrolein 27-35 RELA proto-oncogene, NF-kB subunit Homo sapiens 69-72 31639409-8 2020 Furthermore, we found that acrolein activated p38 MAPK and NF-kappaB p65, while pretreatment with p38 MAPK inhibitor, SB203580 and GI 254023X inhibited NF-kappaB p65 activation and NLRP3 inflammasome. Acrolein 27-35 NLR family pyrin domain containing 3 Homo sapiens 181-186 31639409-10 2020 Finally, we showed that acrolein induced cell toxicity and decrease of EAAT1 expression, suggesting that acrolein may induce a loss of glutamate uptake function. Acrolein 24-32 solute carrier family 1 member 3 Homo sapiens 71-76 31639409-10 2020 Finally, we showed that acrolein induced cell toxicity and decrease of EAAT1 expression, suggesting that acrolein may induce a loss of glutamate uptake function. Acrolein 105-113 solute carrier family 1 member 3 Homo sapiens 71-76 31639409-11 2020 In conclusion, we demonstrate that acrolein induces astrocytic inflammation through NLRP3 inflammasome, which is regulated by ADAM10 and attributed to p38 MAPK-activated NF-kappaB p65 activity. Acrolein 35-43 NLR family pyrin domain containing 3 Homo sapiens 84-89 31639409-11 2020 In conclusion, we demonstrate that acrolein induces astrocytic inflammation through NLRP3 inflammasome, which is regulated by ADAM10 and attributed to p38 MAPK-activated NF-kappaB p65 activity. Acrolein 35-43 ADAM metallopeptidase domain 10 Homo sapiens 126-132 31639409-11 2020 In conclusion, we demonstrate that acrolein induces astrocytic inflammation through NLRP3 inflammasome, which is regulated by ADAM10 and attributed to p38 MAPK-activated NF-kappaB p65 activity. Acrolein 35-43 RELA proto-oncogene, NF-kB subunit Homo sapiens 170-183 31652327-9 2019 Results: At a high concentration, acrolein (100 muM) significantly decreased cell viability. Acrolein 34-42 latexin Homo sapiens 48-51 31652327-10 2019 However, in moderate, sublethal concentrations (25-50 muM), acrolein induced cell migration and substantially increased the production of CXCL1 in TR-MUL5 cells. Acrolein 60-68 latexin Homo sapiens 54-57 31652327-10 2019 However, in moderate, sublethal concentrations (25-50 muM), acrolein induced cell migration and substantially increased the production of CXCL1 in TR-MUL5 cells. Acrolein 60-68 C-X-C motif chemokine ligand 1 Rattus norvegicus 138-143 31652327-13 2019 Conclusions: Our data demonstrate that acrolein promotes retinal Muller glial cell migration by enhancing CXCL1 production. Acrolein 39-47 C-X-C motif chemokine ligand 1 Homo sapiens 106-111 31533203-9 2019 However, incubation with anti-scavenger receptor class B type I (SRB1) antibody abolished internalization of acrolein modified apoE3. Acrolein 109-117 scavenger receptor class B, member 1 Mus musculus 65-69 31361128-8 2019 Our preliminary data show that DNA adducts of acrolein, 6-hydroxy-1,N2-propano-2"-deoxyguanosine (6-OH-PdG) and 8-hydroxy-1,N2-propano-2"-deoxyguanosine (8-OH-PdG) (4-20 adducts per 107 nucleotides) are more prominent than etheno (epsilon) adducts (<0.5 adducts per 108 nucleotides). Acrolein 46-54 phosphoglycerate dehydrogenase Homo sapiens 103-106 31361128-8 2019 Our preliminary data show that DNA adducts of acrolein, 6-hydroxy-1,N2-propano-2"-deoxyguanosine (6-OH-PdG) and 8-hydroxy-1,N2-propano-2"-deoxyguanosine (8-OH-PdG) (4-20 adducts per 107 nucleotides) are more prominent than etheno (epsilon) adducts (<0.5 adducts per 108 nucleotides). Acrolein 46-54 phosphoglycerate dehydrogenase Homo sapiens 159-162 31533203-9 2019 However, incubation with anti-scavenger receptor class B type I (SRB1) antibody abolished internalization of acrolein modified apoE3. Acrolein 109-117 scavenger receptor class B, member 1 Mus musculus 30-63 31533203-10 2019 Taken together, our studies suggest that acrolein modification of apoE3 at lysine residues leads to increase in net negative charge, and as a consequence, results in clearance by LOX1 and SRB1 on endothelial cells. Acrolein 41-49 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 179-183 31533203-10 2019 Taken together, our studies suggest that acrolein modification of apoE3 at lysine residues leads to increase in net negative charge, and as a consequence, results in clearance by LOX1 and SRB1 on endothelial cells. Acrolein 41-49 scavenger receptor class B, member 1 Mus musculus 188-192 31265956-5 2019 Interestingly, acrolein exposure contributed to the increased MMP9, decreased Clock and Bmal1, and activated MAPK pathways in human umbilical vein endothelial cells (HUVECs). Acrolein 15-23 matrix metallopeptidase 9 Homo sapiens 62-66 31265956-5 2019 Interestingly, acrolein exposure contributed to the increased MMP9, decreased Clock and Bmal1, and activated MAPK pathways in human umbilical vein endothelial cells (HUVECs). Acrolein 15-23 clock circadian regulator Homo sapiens 78-83 31265956-5 2019 Interestingly, acrolein exposure contributed to the increased MMP9, decreased Clock and Bmal1, and activated MAPK pathways in human umbilical vein endothelial cells (HUVECs). Acrolein 15-23 aryl hydrocarbon receptor nuclear translocator like Homo sapiens 88-93 31265956-11 2019 Therefore, our findings indicated that acrolein increased the expression of MMP9 through MAPK regulating circadian clock, which was associated with gut microbiota regulation in atherosclerosis. Acrolein 39-47 matrix metallopeptidase 9 Homo sapiens 76-80 31265956-11 2019 Therefore, our findings indicated that acrolein increased the expression of MMP9 through MAPK regulating circadian clock, which was associated with gut microbiota regulation in atherosclerosis. Acrolein 39-47 clock circadian regulator Homo sapiens 115-120 30700647-3 2019 Our previous data showed that acrolein changed the levels of key AD-associated proteins, including advanced glycation end products (RAGE), A-disintegrin and metalloprotease (ADAM-10), and beta-site amyloid-beta peptide cleaving enzyme 1 (BACE-1). Acrolein 30-38 advanced glycosylation end product-specific receptor Mus musculus 132-136 30576219-7 2019 Vaporizing e-cigarette liquid produced reactive aldehydes, including acrolein (shown to induce acquired CFTR dysfunction), as quantified by mass spectrometry, demonstrating that respiratory toxicants in cigarette smoke can also be found in e-cigarette vapor (30 min air, 224.5 +- 15.99; unvaporized liquid, 284.8 +- 35.03; vapor, 54,468 +- 3,908 ng/ml; P < 0.0001). Acrolein 69-77 CF transmembrane conductance regulator Homo sapiens 104-108 30842129-3 2019 Acrolein is a major cigarette-related carcinogen that preferentially causes p53 mutations and inhibits DNA repair function in lung cancer. Acrolein 0-8 tumor protein p53 Homo sapiens 76-79 30735434-2 2019 The transient receptor potential ankyrin 1 (TRPA1) mediates pain signaling and is activated by unsaturated aldehydes, including acrolein and 4-hydroxynonenal. Acrolein 128-136 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 4-42 30735434-2 2019 The transient receptor potential ankyrin 1 (TRPA1) mediates pain signaling and is activated by unsaturated aldehydes, including acrolein and 4-hydroxynonenal. Acrolein 128-136 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 44-49 30735434-8 2019 A role of TRPA1 in cardiomyocyte toxicity was demonstrated in isolated cardiomyocytes exposed to acrolein, an I/R-associated toxin that induces Ca2+ accumulation and hypercontraction, effects significantly blunted by HC-030031, a TRPA1 antagonist. Acrolein 97-105 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 10-15 30735434-8 2019 A role of TRPA1 in cardiomyocyte toxicity was demonstrated in isolated cardiomyocytes exposed to acrolein, an I/R-associated toxin that induces Ca2+ accumulation and hypercontraction, effects significantly blunted by HC-030031, a TRPA1 antagonist. Acrolein 97-105 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 230-235 30735434-13 2019 Functional TRPA1 in cardiomyocytes was enriched in intercalated disks and contributed to acrolein-induced Ca2+ overload and hypercontraction. Acrolein 89-97 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 11-16 31035147-8 2019 Besides, formaldehyde could significantly potentiated the activation of environmental stress sensitive Nrf2 pathway induced by acrolein, even at doses at which formaldehyde treatment alone had no any response. Acrolein 127-135 NFE2 like bZIP transcription factor 2 Homo sapiens 103-107 31035147-9 2019 Furthermore, as the downstream components of Nrf2 pathway, catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPX) and heme oxygenase-1 (HO-1) were significantly synergistically induced by formaldehyde and acrolein mixtures. Acrolein 226-234 NFE2 like bZIP transcription factor 2 Homo sapiens 45-49 31035147-9 2019 Furthermore, as the downstream components of Nrf2 pathway, catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPX) and heme oxygenase-1 (HO-1) were significantly synergistically induced by formaldehyde and acrolein mixtures. Acrolein 226-234 heme oxygenase 1 Homo sapiens 139-155 31201929-5 2019 Acrolein elevation is accompanied by heightened alpha-synuclein oligomerization, dopaminergic dysregulation, and acrolein/alpha-synuclein interaction in the same brain regions. Acrolein 0-8 synuclein alpha Rattus norvegicus 48-63 31201929-5 2019 Acrolein elevation is accompanied by heightened alpha-synuclein oligomerization, dopaminergic dysregulation, and acrolein/alpha-synuclein interaction in the same brain regions. Acrolein 0-8 synuclein alpha Rattus norvegicus 122-137 31201929-7 2019 Taken together, our data suggests acrolein likely plays an important role in inducing PD pathology following bTBI by encouraging alpha-synuclein aggregation. Acrolein 34-42 synuclein alpha Rattus norvegicus 129-144 30857888-4 2019 It inhibits gamma-aminobutyric acid (GABA) transaminase, resulting in elevated brain GABA levels, inhibits both MAO and primary amine oxidase and, due to its hydrazine-containing structure, reacts chemically to sequester a number of reactive aldehydes (e.g. acrolein and 4-hydroxy-2-nonenal) proposed to be implicated in oxidative stress in a number of neurodegenerative disorders. Acrolein 258-266 4-aminobutyrate aminotransferase Rattus norvegicus 12-55 30700647-3 2019 Our previous data showed that acrolein changed the levels of key AD-associated proteins, including advanced glycation end products (RAGE), A-disintegrin and metalloprotease (ADAM-10), and beta-site amyloid-beta peptide cleaving enzyme 1 (BACE-1). Acrolein 30-38 a disintegrin and metallopeptidase domain 10 Mus musculus 174-181 30700647-3 2019 Our previous data showed that acrolein changed the levels of key AD-associated proteins, including advanced glycation end products (RAGE), A-disintegrin and metalloprotease (ADAM-10), and beta-site amyloid-beta peptide cleaving enzyme 1 (BACE-1). Acrolein 30-38 beta-site APP cleaving enzyme 1 Mus musculus 188-236 30700647-3 2019 Our previous data showed that acrolein changed the levels of key AD-associated proteins, including advanced glycation end products (RAGE), A-disintegrin and metalloprotease (ADAM-10), and beta-site amyloid-beta peptide cleaving enzyme 1 (BACE-1). Acrolein 30-38 beta-site APP cleaving enzyme 1 Mus musculus 238-244 30700647-6 2019 Inhibitors of MAPKs signaling pathways attenuated the cells death and restored the proteins levels of ADAM-10, BACE-1 and RAGE in varying degrees induced by acrolein. Acrolein 157-165 a disintegrin and metallopeptidase domain 10 Mus musculus 102-109 30700647-6 2019 Inhibitors of MAPKs signaling pathways attenuated the cells death and restored the proteins levels of ADAM-10, BACE-1 and RAGE in varying degrees induced by acrolein. Acrolein 157-165 beta-site APP cleaving enzyme 1 Mus musculus 111-117 30700647-6 2019 Inhibitors of MAPKs signaling pathways attenuated the cells death and restored the proteins levels of ADAM-10, BACE-1 and RAGE in varying degrees induced by acrolein. Acrolein 157-165 advanced glycosylation end product-specific receptor Mus musculus 122-126 31216970-3 2019 Substances that activate TRPA1, e.g., allyl isothiocyanates (pungent components of mustard, horseradish, and wasabi), cinnamaldehyde from cinnamon, organosulfur compounds from garlic and onion, tear gas, acrolein and crotonaldehyde from cigarette smoke, etc., cause burning, mechanical and thermal hypersensitivity, cough, eye irritation, sneezing, mucus secretion, and neurogenic inflammation. Acrolein 204-212 transient receptor potential cation channel subfamily A member 1 Homo sapiens 25-30 30934946-6 2019 Acrolein was also shown to induce granulocyte TLR4 expression. Acrolein 0-8 toll like receptor 4 Homo sapiens 46-50 30644728-2 2019 Acrolein reacts directly with DNA to form primarily Acr-dGuo adducts, which serve as important biomarkers for the assessment of exposure to acrolein and its potential role in smoking-related lung cancer. Acrolein 140-148 acrosin Homo sapiens 0-3 30378754-11 2019 Over-expression of the constitutively active form of Akt in myoblasts during differentiation prevented the inhibitory effects of acrolein (1 muM) on myogenesis (MHC and myogenin protein expression: acrolein with or without constitutively active Akt, 64.65% and 105.21% control and 69.14% and 102.02% control, respectively, n = 5, P < 0.05). Acrolein 129-137 thymoma viral proto-oncogene 1 Mus musculus 53-56 30653821-5 2019 Unexpectedly, disruption of Nox1 as well as Nox4 significantly exacerbated cytotoxicity induced by acrolein or MVK. Acrolein 99-107 NADPH oxidase 1 Rattus norvegicus 28-32 30653821-5 2019 Unexpectedly, disruption of Nox1 as well as Nox4 significantly exacerbated cytotoxicity induced by acrolein or MVK. Acrolein 99-107 NADPH oxidase 4 Rattus norvegicus 44-48 30653821-6 2019 Compared with Nox4-disrupted cells, Nox1-disrupted cells were more vulnerable to acrolein and MVK at lower concentrations. Acrolein 81-89 NADPH oxidase 1 Rattus norvegicus 36-40 30653821-11 2019 The augmented toxicity of acrolein and MVK in these cells was partially but significantly blunted in the presence of an MRP1 inhibitor, reversan. Acrolein 26-34 ATP binding cassette subfamily C member 1 Rattus norvegicus 120-124 30378754-11 2019 Over-expression of the constitutively active form of Akt in myoblasts during differentiation prevented the inhibitory effects of acrolein (1 muM) on myogenesis (MHC and myogenin protein expression: acrolein with or without constitutively active Akt, 64.65% and 105.21% control and 69.14% and 102.02% control, respectively, n = 5, P < 0.05). Acrolein 198-206 thymoma viral proto-oncogene 1 Mus musculus 53-56 30378754-12 2019 Oral administration of acrolein for 4 weeks reduced muscle weights (5 mg/kg/day: 65.52% control, n = 6, P < 0.05) and cross-sectional area of myofibers in soleus muscles (5 mg/kg/day: 79.92% control, n = 6, P < 0.05) with an up-regulation of atrogin-1 and a down-regulation of phosphorylated Akt protein expressions. Acrolein 23-31 F-box protein 32 Mus musculus 242-251 30378754-12 2019 Oral administration of acrolein for 4 weeks reduced muscle weights (5 mg/kg/day: 65.52% control, n = 6, P < 0.05) and cross-sectional area of myofibers in soleus muscles (5 mg/kg/day: 79.92% control, n = 6, P < 0.05) with an up-regulation of atrogin-1 and a down-regulation of phosphorylated Akt protein expressions. Acrolein 23-31 thymoma viral proto-oncogene 1 Mus musculus 292-295 30378754-16 2019 CONCLUSIONS: Low-dose acrolein significantly inhibited myogenic differentiation in vitro, which might be through inhibition of Akt signalling. Acrolein 22-30 thymoma viral proto-oncogene 1 Mus musculus 127-130 30500380-6 2019 Upon 10 mM CPA exposure, we were able to detect its metabolites 4-hydroxy-cyclophosphamide and acrolein in CYP3A4- and CYP2C19-expressing cell clones, but not in parental HepG2 cell line. Acrolein 95-103 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 107-113 30351402-0 2019 Ambient Particulate Matter and Acrolein Co-Exposure Increases Myocardial Dyssynchrony in Mice via TRPA1. Acrolein 31-39 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 98-103 30500380-6 2019 Upon 10 mM CPA exposure, we were able to detect its metabolites 4-hydroxy-cyclophosphamide and acrolein in CYP3A4- and CYP2C19-expressing cell clones, but not in parental HepG2 cell line. Acrolein 95-103 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 119-126 31582651-9 2019 Representative ingredients, such as acrolein and crotonaldehyde present in CSE, could stimulate PPAR isoforms even at the toxicological concentrations and might possibly contribute to stimulatory effects. Acrolein 36-44 peroxisome proliferator activated receptor alpha Homo sapiens 96-100 30784351-8 2019 TRPA1 message levels were significantly increased in meningeal cell populations following acrolein exposure compared to room air exposure. Acrolein 90-98 transient receptor potential cation channel subfamily A member 1 Homo sapiens 0-5 30204913-4 2018 A single 10-min exposure to buffered saline containing acrolein significantly induced oxidative stress and inflammatory responses, with changes in protein oxidation and GSH depletion occurring immediately after the treatment whereas responses in inflammation requiring a manifestation time of at least 24 h. Repeated exposure to acrolein for 10 consecutive days resulted in structural and functional changes that recapitulate the pathological lesions of COPD, including alterations in the beating frequency and structures of ciliated cells, inhibition of mucin expression and secretion apparatus, and development of squamous differentiation. Acrolein 55-63 LOC100508689 Homo sapiens 555-560 30205151-0 2018 Acrolein induces NLRP3 inflammasome-mediated pyroptosis and suppresses migration via ROS-dependent autophagy in vascular endothelial cells. Acrolein 0-8 NLR family pyrin domain containing 3 Homo sapiens 17-22 30205151-4 2018 In addition, exposure to acrolein resulted in NLRP3 inflammasome activation as evidenced by cleavage of caspase-1 and downstream mature interleukin (IL)-1beta and IL-18 secretion. Acrolein 25-33 NLR family pyrin domain containing 3 Homo sapiens 46-51 30205151-4 2018 In addition, exposure to acrolein resulted in NLRP3 inflammasome activation as evidenced by cleavage of caspase-1 and downstream mature interleukin (IL)-1beta and IL-18 secretion. Acrolein 25-33 caspase 1 Homo sapiens 104-113 30205151-4 2018 In addition, exposure to acrolein resulted in NLRP3 inflammasome activation as evidenced by cleavage of caspase-1 and downstream mature interleukin (IL)-1beta and IL-18 secretion. Acrolein 25-33 interleukin 1 beta Homo sapiens 136-158 30205151-4 2018 In addition, exposure to acrolein resulted in NLRP3 inflammasome activation as evidenced by cleavage of caspase-1 and downstream mature interleukin (IL)-1beta and IL-18 secretion. Acrolein 25-33 interleukin 18 Homo sapiens 163-168 30205151-5 2018 Knockdown of NLRP3 by small interfering RNA remarkably suppressed acrolein-induced pyroptosis and increased cell migration. Acrolein 66-74 NLR family pyrin domain containing 3 Homo sapiens 13-18 30205151-9 2018 Besides, we found damaged mitochondrion accentuated NLRP3 inflammasome and pyroptosis in acrolein-treated cells. Acrolein 89-97 NLR family pyrin domain containing 3 Homo sapiens 52-57 29902662-6 2018 Following treatment of EAhy926 cells with acrolein for 6 h, lysosomal permeabilization changed, and cathepsin B (CB) was released. Acrolein 42-50 cathepsin B Homo sapiens 100-111 30153066-2 2018 The multifunctional GST pi-isoform (GSTP) catalyzes the conjugation of glutathione with acrolein and inhibits c-Jun NH2-terminal kinase (JNK) activation. Acrolein 88-96 glutathione S-transferase pi 1 Homo sapiens 36-40 30144665-11 2018 In addition, acrolein-induced reduction in A-disintegrin and metalloprotease, and the increase of amyloid precursor protein, beta-secretase, and receptor for advanced glycation end products were reversed either, and most of them were nearly restored to the control levels by curcumin. Acrolein 13-21 amyloid beta (A4) precursor protein Mus musculus 98-123 29984447-9 2018 Work is underway to identify which canine GSTs detoxify acrolein and phosphoramide, so that better tools are available to predict the risk of CP toxicity in dogs. Acrolein 56-64 glutathione S-transferase theta-1 Canis lupus familiaris 42-46 29902662-6 2018 Following treatment of EAhy926 cells with acrolein for 6 h, lysosomal permeabilization changed, and cathepsin B (CB) was released. Acrolein 42-50 cathepsin B Homo sapiens 113-115 29902662-7 2018 Additionally, acrolein induced the collapse of mitochondrial transmembrane potential, and cytochrome c was released. Acrolein 14-22 cytochrome c, somatic Homo sapiens 90-102 29902662-8 2018 Furthermore, caspase-3 and caspase-9 activation showed that acrolein induced EAhy926 cell apoptosis. Acrolein 60-68 caspase 3 Homo sapiens 13-22 29902662-8 2018 Furthermore, caspase-3 and caspase-9 activation showed that acrolein induced EAhy926 cell apoptosis. Acrolein 60-68 caspase 9 Homo sapiens 27-36 29902662-9 2018 Autophagy inhibitor 3MA and CB inhibitor CA-074 Me (CA) attenuated acrolein-induced apoptosis. Acrolein 67-75 cathepsin B Homo sapiens 28-30 29564938-6 2018 We showed that pyruvate supplementation in combination with lowered oxygen culturing significantly attenuated acrolein-induced viability loss at 24 h. Poly(ADP-ribose) polymerase inhibition and EGTA preferentially provided partial rescue to low oxygen cultures, but not for standard cultures. Acrolein 110-118 poly (ADP-ribose) polymerase 1 Rattus norvegicus 151-178 32002947-10 2018 The findings also suggested curcumin"s potential in protecting HT22 cells against acrolein through regulating the BDNF/TrkB signaling. Acrolein 82-90 brain derived neurotrophic factor Mus musculus 114-118 32002947-10 2018 The findings also suggested curcumin"s potential in protecting HT22 cells against acrolein through regulating the BDNF/TrkB signaling. Acrolein 82-90 neurotrophic tyrosine kinase, receptor, type 2 Mus musculus 119-123 32002947-11 2018 In addition, acrolein-induced reduction in A-disintegrin and metalloprotease, and the increase of amyloid precursor protein, beta-secretase, and receptor for advanced glycation end products were reversed either, and most of them were nearly restored to the control levels by curcumin. Acrolein 13-21 amyloid beta (A4) precursor protein Mus musculus 98-123 29427351-5 2018 RESULTS: The overall allergenic effects of acrolein-treated TM were evaluated using female BALB/c mice and a mediator-releasing RBL-2H3 cell line. Acrolein 43-51 RB transcriptional corepressor like 2 Rattus norvegicus 128-133 29852243-4 2018 It has been shown that acrolein is involved in post-SCI hyperalgesia through elevated activation, upregulating, and sensitizing transient receptor potential ankyrin 1 (TRPA1) in sensory neurons in dorsal root ganglia. Acrolein 23-31 transient receptor potential cation channel subfamily A member 1 Homo sapiens 128-166 29852243-4 2018 It has been shown that acrolein is involved in post-SCI hyperalgesia through elevated activation, upregulating, and sensitizing transient receptor potential ankyrin 1 (TRPA1) in sensory neurons in dorsal root ganglia. Acrolein 23-31 transient receptor potential cation channel subfamily A member 1 Homo sapiens 168-173 29981795-7 2018 Furthermore, accumulation of toxic aldehydes such as acrolein and 4-HNE and reactive oxygen species (ROS) in the myocardium were significantly elevated after CY in ALDH2 KO mice. Acrolein 53-61 aldehyde dehydrogenase 2, mitochondrial Mus musculus 164-169 29427351-6 2018 Acrolein-treated TM significantly decreased TM-specific immunoglobulin E/G1 levels, and histamine and mMCP-1 release in mouse serum. Acrolein 0-8 mast cell protease 1 Mus musculus 102-108 29799837-6 2018 PTEN-deficient livers showed significantly increased cell-specific oxidative damage, as detected by 4-hydroxy-2-nonenal (4-HNE) and acrolein staining. Acrolein 132-140 phosphatase and tensin homolog Mus musculus 0-4 29627347-2 2018 We previously showed that a single exposure to acrolein, a ubiquitous gaseous component of air pollution, not only causes autonomic imbalance, but also increases arrhythmia through transient receptor potential A1 (TRPA1) cation channels. Acrolein 47-55 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 181-212 29580947-3 2018 Lysozyme and human serum albumin (HSA) were used as model proteins to investigate lipoxidation products formed by two short-chain aldehydes, acrolein and pentanal, which are unsaturated and saturated aldehydes respectively. Acrolein 141-149 albumin Homo sapiens 19-32 29627347-2 2018 We previously showed that a single exposure to acrolein, a ubiquitous gaseous component of air pollution, not only causes autonomic imbalance, but also increases arrhythmia through transient receptor potential A1 (TRPA1) cation channels. Acrolein 47-55 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 214-219 29627347-3 2018 Thus, the goal of this study was to characterize acrolein-induced autonomic changes in both normal and TRPA1-knockout mice (KO). Acrolein 49-57 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 103-108 29844863-3 2018 We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein. Acrolein 223-231 monoamine oxidase B Homo sapiens 78-82 29844863-3 2018 We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein. Acrolein 223-231 peptidylglycine alpha-amidating monooxygenase Homo sapiens 102-105 29844863-3 2018 We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein. Acrolein 223-231 monoamine oxidase B Homo sapiens 57-76 29844863-3 2018 We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein. Acrolein 223-231 monoamine oxidase B Homo sapiens 139-143 29844863-3 2018 We have designed and tested both in vitro and in vivo, a monoamine oxidase B (MAOB) specific prodrug, PAM-OBG, that is converted by glioma MAOB into the MGMT inhibitor O6-benzylguanine (O6BG) and the DNA crosslinking agent acrolein. Acrolein 223-231 O-6-methylguanine-DNA methyltransferase Homo sapiens 153-157 29627295-7 2018 Deficiency of AR decreased urinary levels of the acrolein metabolite, 3-hydroxypropylmercapturic acid. Acrolein 49-57 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 14-16 28826042-3 2018 In this study, we report the beneficial effect of carnosine (beta-alanyl-l-histidine), a special antioxidant with acrolein-sequestering ability, on CTX-induced bone marrow cell suppression. Acrolein 114-122 V-set and immunoglobulin domain containing 2 Mus musculus 148-151 29414104-6 2018 We also show that acrolein can promote the aggregation of alpha-synuclein, suggesting that alpha-synuclein self-assembly, a key pathological phenomenon in human PD, could play a role in neurotoxic effects of acrolein in PD models. Acrolein 18-26 synuclein alpha Homo sapiens 58-73 29414104-6 2018 We also show that acrolein can promote the aggregation of alpha-synuclein, suggesting that alpha-synuclein self-assembly, a key pathological phenomenon in human PD, could play a role in neurotoxic effects of acrolein in PD models. Acrolein 18-26 synuclein alpha Homo sapiens 91-106 29414104-6 2018 We also show that acrolein can promote the aggregation of alpha-synuclein, suggesting that alpha-synuclein self-assembly, a key pathological phenomenon in human PD, could play a role in neurotoxic effects of acrolein in PD models. Acrolein 208-216 synuclein alpha Homo sapiens 58-73 29414104-6 2018 We also show that acrolein can promote the aggregation of alpha-synuclein, suggesting that alpha-synuclein self-assembly, a key pathological phenomenon in human PD, could play a role in neurotoxic effects of acrolein in PD models. Acrolein 208-216 synuclein alpha Homo sapiens 91-106 29661478-7 2018 Capsaicin- and acrolein-induced CGRP release was measured with enzyme-linked immunoassay in an ex vivo dura mater preparation. Acrolein 15-23 calcitonin-related polypeptide alpha Rattus norvegicus 32-36 29355571-8 2018 Further study suggested that 30% CR showed protective effects against acrolein by modulating BDNF/TrkB signaling pathways. Acrolein 70-78 brain-derived neurotrophic factor Rattus norvegicus 93-97 29248694-0 2018 Sirt3 confers protection against acrolein-induced oxidative stress in cochlear nucleus neurons. Acrolein 33-41 sirtuin 3 Homo sapiens 0-5 29248694-3 2018 In this study, we investigated the mechanisms on acrolein-induced toxicity in primary cultured cochlear nucleus neurons with focus on Sirt3, a mitochondrial deacetylase. Acrolein 49-57 sirtuin 3 Homo sapiens 134-139 29248694-5 2018 Acrolein exposure also significantly reduced the mitochondrial membrane potential (MMP) levels, promoted cytochrome c release and decreased mitochondrial ATP production. Acrolein 0-8 cytochrome c, somatic Homo sapiens 105-117 29248694-9 2018 These results demonstrated that acrolein induces mitochondrial dysfunction and ER stress in cochlear nucleus neurons, and Sirt3 acts as an endogenous protective factor in acrolein-induced ototoxicity. Acrolein 171-179 sirtuin 3 Homo sapiens 122-127 29355571-8 2018 Further study suggested that 30% CR showed protective effects against acrolein by modulating BDNF/TrkB signaling pathways. Acrolein 70-78 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 98-102 29200178-7 2018 Acrolein inhalation exposure produced long-lasting potentiation of blood flow responses to a subsequent TRPA1 agonist and sensitized cutaneous responses to mechanical stimulation. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 104-109 29200178-8 2018 C-Fos expression in response to touch was increased in trigeminal nucleus caudalis in animals exposed to acrolein compared with room air. Acrolein 105-113 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 0-5 29414845-6 2018 Results showed that the expression levels of GRP78 and CHOP, two major components of endoplasmic reticulum (ER) stress were higher in the combination of acrolein and ISO than those in ISO treatment. Acrolein 153-161 heat shock protein family A (Hsp70) member 5 Rattus norvegicus 45-50 29414845-12 2018 Results showed that GRP78, CHOP and Bax expression were upregulated, while Bcl2 expression was downregulated both at the protein and mRNA levels, when the H9c2 cells were treated with acrolein. Acrolein 184-192 BCL2 associated X, apoptosis regulator Rattus norvegicus 36-39 29414845-6 2018 Results showed that the expression levels of GRP78 and CHOP, two major components of endoplasmic reticulum (ER) stress were higher in the combination of acrolein and ISO than those in ISO treatment. Acrolein 153-161 DNA-damage inducible transcript 3 Rattus norvegicus 55-59 29414845-12 2018 Results showed that GRP78, CHOP and Bax expression were upregulated, while Bcl2 expression was downregulated both at the protein and mRNA levels, when the H9c2 cells were treated with acrolein. Acrolein 184-192 BCL2, apoptosis regulator Rattus norvegicus 75-79 29414845-12 2018 Results showed that GRP78, CHOP and Bax expression were upregulated, while Bcl2 expression was downregulated both at the protein and mRNA levels, when the H9c2 cells were treated with acrolein. Acrolein 184-192 heat shock protein family A (Hsp70) member 5 Rattus norvegicus 20-25 29414845-12 2018 Results showed that GRP78, CHOP and Bax expression were upregulated, while Bcl2 expression was downregulated both at the protein and mRNA levels, when the H9c2 cells were treated with acrolein. Acrolein 184-192 DNA-damage inducible transcript 3 Rattus norvegicus 27-31 29048608-8 2018 Acrolein, an environmental irritant and known activator of TRPA1, and all extracts induced concentration-dependent locomotor responses whose potencies ranked as follows: polar F3 > weakly polar F2 > C-DEP > highly polar F4 > nonpolar F1, indicating that polar and weakly polar fractions that included nitro- and oxy-polyaromatic hydrocarbons (PAHs), drove C-DEP responses. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1a Danio rerio 59-64 29249019-5 2018 Acrolein inactivated several proteins such as GAPDH (glycelaldehyde-3-phosphate dehydrogenase), and also stimulated MMP-9 (matrix metalloproteinase-9) activity. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 46-51 29249019-5 2018 Acrolein inactivated several proteins such as GAPDH (glycelaldehyde-3-phosphate dehydrogenase), and also stimulated MMP-9 (matrix metalloproteinase-9) activity. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 53-93 29249019-5 2018 Acrolein inactivated several proteins such as GAPDH (glycelaldehyde-3-phosphate dehydrogenase), and also stimulated MMP-9 (matrix metalloproteinase-9) activity. Acrolein 0-8 matrix metallopeptidase 9 Homo sapiens 116-121 29249019-5 2018 Acrolein inactivated several proteins such as GAPDH (glycelaldehyde-3-phosphate dehydrogenase), and also stimulated MMP-9 (matrix metalloproteinase-9) activity. Acrolein 0-8 matrix metallopeptidase 9 Homo sapiens 123-149 29249019-6 2018 Acrolein-conjugated GAPDH translocated to nucleus, and caused apoptosis like nitrosylated GAPDH. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 20-25 29249019-6 2018 Acrolein-conjugated GAPDH translocated to nucleus, and caused apoptosis like nitrosylated GAPDH. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 90-95 29048608-10 2018 Pharmacologic inhibition of TRPA1 blocked locomotor responses to acrolein and the extracts. Acrolein 65-73 transient receptor potential cation channel, subfamily A, member 1a Danio rerio 28-33 29375273-0 2018 Proteomic identification of moesin upon exposure to acrolein. Acrolein 52-60 moesin Mus musculus 28-34 29375273-9 2018 Moesin was expressed in endothelium, epithelium, and inflammatory cells and increased in lung tissues of acrolein exposed mice compared with sham treated mice. Acrolein 105-113 moesin Mus musculus 0-6 29093526-1 2017 Spermine oxidase (SMOX) catalyzes oxidation of spermine to generate spermidine, hydrogen peroxide (H2O2) and 3-aminopropanal, which is spontaneously converted to acrolein. Acrolein 162-170 spermine oxidase Homo sapiens 0-16 29953618-0 2018 Acrolein-induced atherogenesis by stimulation of hepatic flavin containing monooxygenase 3 and a protection from hydroxytyrosol. Acrolein 0-8 flavin containing monooxygenase 3 Mus musculus 49-90 29953618-8 2018 However, ATP-binding cassette transporters subfamily A member 1 (ABCA1), a major transporter in RCT process, was repressed by acrolein. Acrolein 126-134 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 65-70 29953618-12 2018 Therefore, our findings indicated that acrolein-enhanced atherogenesis by increasing FMO3 which increased inflammatory responses and decreased ABCA1 in vitro can be alleviated by HT, which may have a therapeutic potential for the treatment of atherosclerosis. Acrolein 39-47 flavin containing monooxygenase 3 Mus musculus 85-89 29953618-12 2018 Therefore, our findings indicated that acrolein-enhanced atherogenesis by increasing FMO3 which increased inflammatory responses and decreased ABCA1 in vitro can be alleviated by HT, which may have a therapeutic potential for the treatment of atherosclerosis. Acrolein 39-47 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 143-148 28866823-5 2018 Furthermore, baicalein reduced acrolein-induced elevations in glial fibrillary acidic protein (a biomarker of activated astrocytes), ED-1 (a biomarker of activated microglia), and mature cathepsin B levels (a cysteine lysosomal protease), suggesting that baicalein attenuated acrolein-induced neuroinflammation. Acrolein 31-39 cathepsin B Rattus norvegicus 187-198 28866823-6 2018 Moreover, baicalein attenuated acrolein-induced caspase 1 activation (a pro-inflammatory caspase) and interleukin-1beta levels, indicating that baicalein prevented acrolein-induced inflammasome activation. Acrolein 31-39 caspase 1 Rattus norvegicus 48-57 28866823-6 2018 Moreover, baicalein attenuated acrolein-induced caspase 1 activation (a pro-inflammatory caspase) and interleukin-1beta levels, indicating that baicalein prevented acrolein-induced inflammasome activation. Acrolein 31-39 interleukin 1 beta Rattus norvegicus 102-119 28866823-6 2018 Moreover, baicalein attenuated acrolein-induced caspase 1 activation (a pro-inflammatory caspase) and interleukin-1beta levels, indicating that baicalein prevented acrolein-induced inflammasome activation. Acrolein 164-172 interleukin 1 beta Rattus norvegicus 102-119 28866823-7 2018 In addition, baicalein significantly attenuated acrolein-induced caspase 3 activation (a biomarker of apoptosis) as well as acrolein-induced elevation in receptor interacting protein kinase (RIPK) 3 levels (an initiator of necroptosis), indicating that baicalein attenuated apoptosis and necroptosis. Acrolein 48-56 caspase 3 Rattus norvegicus 65-74 29226874-5 2018 We found that the levels of acrolein-conjugated protein (Acr-PC) in the plasma (p = 0.00012) and CSF (p = 0.00161) of AD patients were significantly higher than those of control subjects, whereas the levels of a urinary acrolein metabolite, 3-hydroxypropyl mercapturic acid (3-HPMA), were markedly decreased (p = 0.00882) in AD patients. Acrolein 28-36 acrosin Homo sapiens 57-60 29226874-5 2018 We found that the levels of acrolein-conjugated protein (Acr-PC) in the plasma (p = 0.00012) and CSF (p = 0.00161) of AD patients were significantly higher than those of control subjects, whereas the levels of a urinary acrolein metabolite, 3-hydroxypropyl mercapturic acid (3-HPMA), were markedly decreased (p = 0.00882) in AD patients. Acrolein 220-228 acrosin Homo sapiens 57-60 28935573-7 2017 Acrolein also caused the down-regulation and/or redistribution of three representative tight junction proteins (ie, zonula occludens-1, Occludin, Claudin-1) that critically regulate epithelial paracellular permeability. Acrolein 0-8 occludin Homo sapiens 136-144 28935573-7 2017 Acrolein also caused the down-regulation and/or redistribution of three representative tight junction proteins (ie, zonula occludens-1, Occludin, Claudin-1) that critically regulate epithelial paracellular permeability. Acrolein 0-8 claudin 1 Homo sapiens 146-155 29129206-6 2017 The TRPA1-agonists acrolein, carvacrol and capsazepine all induced cytotoxicity, but this effect is independent of TRPA1. Acrolein 19-27 transient receptor potential cation channel subfamily A member 1 Homo sapiens 4-9 29093526-0 2017 Spermine oxidase promotes bile canalicular lumen formation through acrolein production. Acrolein 67-75 spermine oxidase Homo sapiens 0-16 29093526-1 2017 Spermine oxidase (SMOX) catalyzes oxidation of spermine to generate spermidine, hydrogen peroxide (H2O2) and 3-aminopropanal, which is spontaneously converted to acrolein. Acrolein 162-170 spermine oxidase Homo sapiens 18-22 29093526-11 2017 Our results suggest that SMOX plays a central role in the formation of bile canalicular lumen in liver cells by activating Akt pathway through acrolein production. Acrolein 143-151 spermine oxidase Homo sapiens 25-29 29093526-11 2017 Our results suggest that SMOX plays a central role in the formation of bile canalicular lumen in liver cells by activating Akt pathway through acrolein production. Acrolein 143-151 AKT serine/threonine kinase 1 Homo sapiens 123-126 28244642-7 2017 Further analysis using cultured urothelial cells revealed that acrolein, the major metabolite of CYP, caused protein oxidation, p38 activation, and urothelial injury. Acrolein 63-71 mitogen-activated protein kinase 14 Mus musculus 128-131 28244642-8 2017 These effects of acrolein were reproduced by TRPV4 agonists and significantly prevented by antioxidant NAC, p38 inhibitor SB203580, TRPV4 antagonist RN-1734, and CBX. Acrolein 17-25 transient receptor potential cation channel, subfamily V, member 4 Mus musculus 132-137 28244642-8 2017 These effects of acrolein were reproduced by TRPV4 agonists and significantly prevented by antioxidant NAC, p38 inhibitor SB203580, TRPV4 antagonist RN-1734, and CBX. Acrolein 17-25 transient receptor potential cation channel, subfamily V, member 4 Mus musculus 45-50 28244642-8 2017 These effects of acrolein were reproduced by TRPV4 agonists and significantly prevented by antioxidant NAC, p38 inhibitor SB203580, TRPV4 antagonist RN-1734, and CBX. Acrolein 17-25 mitogen-activated protein kinase 14 Mus musculus 108-111 28814727-4 2017 Indeed, acrolein-modified SP-A was detected in the lungs of mice exposed to CS for 1 week. Acrolein 8-16 surfactant associated protein A1 Mus musculus 26-30 28499912-3 2017 The mechanism by which CTX and/or its main metabolite, acrolein, affect female fertility remains unclear, but it is thought to be caused by an overproduction of reactive oxygen species (ROS). Acrolein 55-63 V-set and immunoglobulin domain containing 2 Mus musculus 23-26 28326554-7 2017 In parallel to the wild-type, the LHCSR3-deficient npq4 mutant was high light-treated, which in photoautotrophic conditions exhibited particular sensitivity under elevated oxygen, the treatment that induced the highest RES levels, including acrolein. Acrolein 241-249 uncharacterized protein Chlamydomonas reinhardtii 34-40 28814727-5 2017 To further confirm this finding, recombinant human SP-A (hSP-A) was incubated with CS extract (CSE) or acrolein and then analysed by western blotting and nanoscale liquid chromatography-matrix-assisted laser desorption/ionisation time-of-flight tandem mass spectrometry. Acrolein 103-111 surfactant protein A1 Homo sapiens 51-55 28814727-5 2017 To further confirm this finding, recombinant human SP-A (hSP-A) was incubated with CS extract (CSE) or acrolein and then analysed by western blotting and nanoscale liquid chromatography-matrix-assisted laser desorption/ionisation time-of-flight tandem mass spectrometry. Acrolein 103-111 surfactant protein A1 Homo sapiens 57-62 28814727-6 2017 These analyses revealed that CSE and acrolein induced hSP-A oligomerisation and that acrolein induced the modification of six residues in hSP-A: His39, His116, Cys155, Lys180, Lys221, and Cys224. Acrolein 37-45 heat shock protein 90 beta family member 2, pseudogene Homo sapiens 54-57 28814727-6 2017 These analyses revealed that CSE and acrolein induced hSP-A oligomerisation and that acrolein induced the modification of six residues in hSP-A: His39, His116, Cys155, Lys180, Lys221, and Cys224. Acrolein 37-45 surfactant protein A1 Homo sapiens 54-59 28814727-8 2017 CSE- or acrolein-induced modification of hSP-A significantly decreased hSP-A"s ability to inhibit bacterial growth and to enhance macrophage phagocytosis. Acrolein 8-16 surfactant protein A1 Homo sapiens 41-46 28814727-8 2017 CSE- or acrolein-induced modification of hSP-A significantly decreased hSP-A"s ability to inhibit bacterial growth and to enhance macrophage phagocytosis. Acrolein 8-16 surfactant protein A1 Homo sapiens 71-76 28716263-7 2017 The previously determined ability of acrolein to bind to and activate the TRPA1 channel and elicit algesic responses may be a mechanism of the phenomenon seen in this study. Acrolein 37-45 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 74-79 28376311-0 2017 Contribution of PPARgamma in modulation of acrolein-induced inflammatory signaling in gp91phox knock-out mice. Acrolein 43-51 peroxisome proliferator activated receptor gamma Mus musculus 16-25 28807058-10 2017 We measured ALDH activity after exposure to HCY or acrolein and the same with pre-treatment with NAC. Acrolein 51-59 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 12-16 28807058-14 2017 Less ALDH activity was observed after exposure to HCY or acrolein. Acrolein 57-65 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 5-9 28807058-16 2017 CONCLUSIONS: Increased ROS generation and decreased ALDH activity confirmed that CY metabolites HCY and acrolein are strongly implicated in cardiotoxicity. Acrolein 104-112 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 52-56 28376311-3 2017 We investigated the contribution of PPARgamma ligand GW1929 to the attenuation of oxidative stress in acrolein-induced insult. Acrolein 102-110 peroxisome proliferator activated receptor gamma Mus musculus 36-45 28376311-6 2017 Acrolein significantly increased 8-isoprostane and reduced PPARgamma activity (P < 0.05) in the wild type (WT) and KO mice. Acrolein 0-8 peroxisome proliferator activated receptor gamma Mus musculus 59-68 28560422-6 2017 Notably, in utero exposure of 5 mg/kg acrolein significantly decreased the testicular testosterone level and downregulated the expression levels of steroidogenic acute regulatory protein (StAR) and 3beta-hydroxysteroid dehydrogenase (3beta-HSD), whereas the levels of other steroidogenic enzymes, including scavenger receptor class B, cholesterol side-chain cleavage enzyme and steroid 17 alpha-hydroxylase/17,20 lyase, were unaffected. Acrolein 38-46 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Rattus norvegicus 198-232 28482051-5 2017 Acrolein exposure in mice led to a 2- to 3-fold increase in its urinary metabolite 3-hydroxypropyl mercapturic acid (3-HPMA) with an attendant increase in pulmonary levels of the acrolein-metabolizing enzymes, glutathione S-transferase P and aldose reductase, as well as several Nrf2-regulated antioxidant proteins. Acrolein 0-8 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 210-258 28482051-5 2017 Acrolein exposure in mice led to a 2- to 3-fold increase in its urinary metabolite 3-hydroxypropyl mercapturic acid (3-HPMA) with an attendant increase in pulmonary levels of the acrolein-metabolizing enzymes, glutathione S-transferase P and aldose reductase, as well as several Nrf2-regulated antioxidant proteins. Acrolein 0-8 nuclear factor, erythroid derived 2, like 2 Mus musculus 279-283 28482051-7 2017 Exposure to acrolein suppressed circulating levels of endothelial progenitor cells (EPCs) and specific leukocyte subsets (eg, GR-1+ cells, CD19+ B-cells, CD4+ T-cells; CD11b+ monocytes) whilst other subsets (eg, CD8+ cells, NK1.1+ cells, Ly6C+ monocytes) were unchanged. Acrolein 12-20 CD19 molecule Homo sapiens 139-143 28482051-7 2017 Exposure to acrolein suppressed circulating levels of endothelial progenitor cells (EPCs) and specific leukocyte subsets (eg, GR-1+ cells, CD19+ B-cells, CD4+ T-cells; CD11b+ monocytes) whilst other subsets (eg, CD8+ cells, NK1.1+ cells, Ly6C+ monocytes) were unchanged. Acrolein 12-20 integrin subunit alpha M Homo sapiens 168-173 28359953-8 2017 Among thiol-reactive CSE components, H2O2 had no effect on exosome release, whereas acrolein imitated the NAC-reversible exosome induction. Acrolein 84-92 X-linked Kx blood group Homo sapiens 106-109 28560422-6 2017 Notably, in utero exposure of 5 mg/kg acrolein significantly decreased the testicular testosterone level and downregulated the expression levels of steroidogenic acute regulatory protein (StAR) and 3beta-hydroxysteroid dehydrogenase (3beta-HSD), whereas the levels of other steroidogenic enzymes, including scavenger receptor class B, cholesterol side-chain cleavage enzyme and steroid 17 alpha-hydroxylase/17,20 lyase, were unaffected. Acrolein 38-46 steroidogenic acute regulatory protein Rattus norvegicus 148-186 28560422-6 2017 Notably, in utero exposure of 5 mg/kg acrolein significantly decreased the testicular testosterone level and downregulated the expression levels of steroidogenic acute regulatory protein (StAR) and 3beta-hydroxysteroid dehydrogenase (3beta-HSD), whereas the levels of other steroidogenic enzymes, including scavenger receptor class B, cholesterol side-chain cleavage enzyme and steroid 17 alpha-hydroxylase/17,20 lyase, were unaffected. Acrolein 38-46 steroidogenic acute regulatory protein Rattus norvegicus 188-192 28483671-0 2017 Activation of MMP-9 activity by acrolein in saliva from patients with primary Sjogren"s syndrome and its mechanism. Acrolein 32-40 matrix metallopeptidase 9 Homo sapiens 14-19 28483671-5 2017 Under the conditions studied, Cys99, located in the propeptide, was conjugated with acrolein together with Cys230, 244, 302, 314, 329, 347, 361, 373, 388 and 516, which are located in fibronectin repeats and glycosyl domains, but not on the active site of MMP-9. Acrolein 84-92 matrix metallopeptidase 9 Homo sapiens 256-261 28483671-7 2017 The results suggest that acrolein conjugation at Cys99 caused the active site of MMP-9 to be exposed. Acrolein 25-33 matrix metallopeptidase 9 Homo sapiens 81-86 28483671-8 2017 Activation of MMP-9 by acrolein was inhibited by cysteine, and slightly by lysine, because these amino acids inhibited acrolein conjugation with MMP-9. Acrolein 23-31 matrix metallopeptidase 9 Homo sapiens 14-19 28483671-8 2017 Activation of MMP-9 by acrolein was inhibited by cysteine, and slightly by lysine, because these amino acids inhibited acrolein conjugation with MMP-9. Acrolein 23-31 matrix metallopeptidase 9 Homo sapiens 145-150 28483671-8 2017 Activation of MMP-9 by acrolein was inhibited by cysteine, and slightly by lysine, because these amino acids inhibited acrolein conjugation with MMP-9. Acrolein 119-127 matrix metallopeptidase 9 Homo sapiens 14-19 28483671-9 2017 Conversely, MMP-9 activity in the presence of 50muM acrolein was enhanced by 100muM histidine. Acrolein 52-60 matrix metallopeptidase 9 Homo sapiens 12-17 28483671-10 2017 This was due to the inhibition of acrolein conjugation with His405 and 411 located at the Zn2+ binding site of MMP-9. Acrolein 34-42 matrix metallopeptidase 9 Homo sapiens 111-116 28483671-11 2017 These results suggest that activation of 92kDa MMP-9 by acrolein is involved in tissue damage in pSS patients and is regulated by cysteine and histidine, and slightly by lysine. Acrolein 56-64 matrix metallopeptidase 9 Homo sapiens 47-52 28560422-6 2017 Notably, in utero exposure of 5 mg/kg acrolein significantly decreased the testicular testosterone level and downregulated the expression levels of steroidogenic acute regulatory protein (StAR) and 3beta-hydroxysteroid dehydrogenase (3beta-HSD), whereas the levels of other steroidogenic enzymes, including scavenger receptor class B, cholesterol side-chain cleavage enzyme and steroid 17 alpha-hydroxylase/17,20 lyase, were unaffected. Acrolein 38-46 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Rattus norvegicus 234-243 28560422-7 2017 Furthermore, the 3beta-HSD immunoreactive area in the interstitial region of the fetal testes was reduced at a 5 mg/kg dose, whereas the protein expression levels of 4-hydroxynonenalwere dose-dependently increased following maternal exposure to acrolein. Acrolein 245-253 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Rattus norvegicus 17-26 27696135-4 2017 Atherosclerotic apolipoprotein E-deficient (apoE-/-) mice that were fed acrolein (3 mg/kg/day) for 1 month showed significant increases in serum and aortic cholesterol, triglycerides, and lipid peroxides. Acrolein 72-80 apolipoprotein E Mus musculus 44-48 27746315-13 2017 These data demonstrate that a single exposure to acrolein causes cardiac dysfunction through TRPA1 activation and autonomic imbalance characterized by a shift toward parasympathetic modulation. Acrolein 49-57 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 93-98 28532411-3 2017 ALDH2 has the lowest Km for acetaldehyde among ALDH isozymes and detoxifies acetaldehydes in addition to other reactive aldehydes, such as 4-hydroxy-nonenal, malondialdehyde and acrolein produced from lipid peroxidation by reactive oxygen species (ROS). Acrolein 178-186 aldehyde dehydrogenase 2, mitochondrial Mus musculus 0-5 28532411-3 2017 ALDH2 has the lowest Km for acetaldehyde among ALDH isozymes and detoxifies acetaldehydes in addition to other reactive aldehydes, such as 4-hydroxy-nonenal, malondialdehyde and acrolein produced from lipid peroxidation by reactive oxygen species (ROS). Acrolein 178-186 aldehyde dehydrogenase family 3, subfamily A1 Mus musculus 0-4 28204886-4 2017 An acrolein permeation tube at 326.25 ng min-1 rate was used to generate gaseous standards. Acrolein 3-11 CD59 molecule (CD59 blood group) Homo sapiens 41-46 27592100-0 2017 Role of TRPA1 in acute cardiopulmonary toxicity of inhaled acrolein. Acrolein 59-67 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 8-13 27592100-2 2017 Because the transient receptor potential ankyrin 1 (TRPA1) channel mediates tobacco smoke-induced lung injury, we assessed its role in high-level acrolein-induced toxicity in mice. Acrolein 146-154 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 52-57 27592100-5 2017 Both male and female TRPA1-null mice were more sensitive to acrolein-induced mortality than age- and sex-matched WT mice. Acrolein 60-68 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 21-26 27592100-6 2017 Acrolein exposure increased lung weight:body weight ratios and lung albumin and decreased plasma albumin to a greater extent in TRPA1-null than in WT mice. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 128-133 27592100-11 2017 These data show TRPA1 protects against high-level acrolein-induced toxicity in a sex-dependent manner. Acrolein 50-58 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 16-21 27592100-12 2017 Post-exposure TRPA1 antagonism also protected against acrolein-induced mortality attesting to a complex role of TRPA1 in cardiopulmonary injury. Acrolein 54-62 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 14-19 27592100-12 2017 Post-exposure TRPA1 antagonism also protected against acrolein-induced mortality attesting to a complex role of TRPA1 in cardiopulmonary injury. Acrolein 54-62 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 112-117 27746315-0 2017 TRPA1 mediates changes in heart rate variability and cardiac mechanical function in mice exposed to acrolein. Acrolein 100-108 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 0-5 27746315-4 2017 Thus, this study examines the role of TRPA1, an irritant sensory receptor found in the airways, in the cardiac response of mice to acrolein and ozone. Acrolein 131-139 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 38-43 27977070-7 2017 Acrolein was also effective in releasing CGRP from the dura of TRPV1-/- but not of TRPA1-/- mice. Acrolein 0-8 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 41-45 27977070-7 2017 Acrolein was also effective in releasing CGRP from the dura of TRPV1-/- but not of TRPA1-/- mice. Acrolein 0-8 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 63-68 28401906-0 2017 Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of alpha-synuclein aggregation and programmed cell death. Acrolein 0-8 synuclein alpha Rattus norvegicus 94-109 28401906-5 2017 Acrolein was pro-oxidative by increasing 4-hydroxy-2-nonenal and heme oxygenase-1 levels. Acrolein 0-8 heme oxygenase 1 Rattus norvegicus 65-81 28401906-6 2017 Furthermore, acrolein conjugated with proteins at lysine residue and induced alpha-synuclein aggregation in the infused SN. Acrolein 13-21 synuclein alpha Rattus norvegicus 77-92 28109747-8 2017 Adaptation to acrolein is related to Nrf2 translocation, increased mRNA expression of gammaGCS, HO-1 and increased GSH levels and the increased GSH levels can explain the hormetic effect. Acrolein 14-22 NFE2 like bZIP transcription factor 2 Homo sapiens 37-41 28109747-8 2017 Adaptation to acrolein is related to Nrf2 translocation, increased mRNA expression of gammaGCS, HO-1 and increased GSH levels and the increased GSH levels can explain the hormetic effect. Acrolein 14-22 heme oxygenase 1 Homo sapiens 96-100 28332605-0 2017 Janus-faced Acrolein prevents allergy but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse model for passive respiratory exposure. Acrolein 12-20 forkhead box P3 Mus musculus 97-102 29260020-8 2017 The results suggest that acrolein becomes a trigger for the production of IL-6 and CRP, as previously observed in a mouse model of stroke and in cell culture systems. Acrolein 25-33 interleukin 6 Mus musculus 74-86 28188272-4 2017 The feasibility of the detoxification of aldehydes in siliques via oxidation by AAO4 was demonstrated, first, by its ability to efficiently oxidize an array of aromatic and aliphatic aldehydes, including the reactive carbonyl species (RCS) acrolein, hydroxyl-2-nonenal, and malondialdehyde. Acrolein 240-248 aldehyde oxidase 4 Arabidopsis thaliana 80-84 28332605-6 2017 Results from reporter cell lines suggested that acrolein acts via the aryl-hydrocarbon receptor which could be inhibited by resveratrol and 3"-methoxy-4"-nitroflavone Acrolein- stimulation of human PBMCs increased Foxp3+ expression by T cells which could be antagonized by resveratrol. Acrolein 48-56 aryl hydrocarbon receptor Homo sapiens 70-95 28332605-6 2017 Results from reporter cell lines suggested that acrolein acts via the aryl-hydrocarbon receptor which could be inhibited by resveratrol and 3"-methoxy-4"-nitroflavone Acrolein- stimulation of human PBMCs increased Foxp3+ expression by T cells which could be antagonized by resveratrol. Acrolein 48-56 forkhead box P3 Homo sapiens 214-219 28332605-7 2017 Our mouse and human data thus revealed that acrolein exerts systemic immunosuppression by promoting Foxp3+ regulatory cells. Acrolein 44-52 forkhead box P3 Homo sapiens 100-105 28076424-1 2017 The TRPA1 ion channel is expressed in nociceptive (pain-sensitive) somatosensory neurons and is activated by a wide variety of chemical irritants, such as acrolein in smoke or isothiocyanates in mustard. Acrolein 155-163 transient receptor potential cation channel subfamily A member 1 Homo sapiens 4-9 27249374-12 2017 Sublethal concentration of acrolein upregulated HO-1 mRNA expression in retinal microvascular endothelial cells. Acrolein 27-35 heme oxygenase 1 Homo sapiens 48-52 27865847-8 2017 Using the perfusion-superfusion system, acute exposure to acrolein caused a dose-dependent reduction in the levels of PAS-positive mucin stores induced by LPS, consistent with mucin secretion. Acrolein 58-66 toll-like receptor 4 Mus musculus 155-158 29456784-0 2017 Idh2 Deficiency Exacerbates Acrolein-Induced Lung Injury through Mitochondrial Redox Environment Deterioration. Acrolein 28-36 isocitrate dehydrogenase 2 (NADP+), mitochondrial Mus musculus 0-4 26969882-5 2017 SiRNA-mediated silencing of AKR1B10 in colon cancer cells HCT-8 enhanced cytotoxicity of acrolein and HNE, whereas ectopic expression of AKR1B10 in colon cancer cells RKO prevented the host cells against carbonyl cytotoxicity. Acrolein 89-97 aldo-keto reductase family 1 member B10 Homo sapiens 28-35 29430557-3 2017 It has been shown in rat models that repeated exposure to acrolein induces trigeminovascular sensitization to both TRPA1 and TRP vanilloid 1 (TRPV1) agonists, a phenomenon linked to headache. Acrolein 58-66 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 115-120 29430557-3 2017 It has been shown in rat models that repeated exposure to acrolein induces trigeminovascular sensitization to both TRPA1 and TRP vanilloid 1 (TRPV1) agonists, a phenomenon linked to headache. Acrolein 58-66 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 125-140 29430557-3 2017 It has been shown in rat models that repeated exposure to acrolein induces trigeminovascular sensitization to both TRPA1 and TRP vanilloid 1 (TRPV1) agonists, a phenomenon linked to headache. Acrolein 58-66 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 142-147 29430557-4 2017 In this study, we test the hypothesis that the sensitization of trigeminovascular responses in rats after acrolein exposure via inhalation is associated with changes in levels of endogenous lipids, including TRPV1 agonists, in the trigeminal ganglia, trigeminal nucleus, and cerebellum. Acrolein 106-114 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 208-213 29430557-8 2017 This increase in TRPV1 ligands by acrolein exposure may indicate further downstream signaling, in that we also show here that a combination of these TRPV1 endogenous agonists increases the potency of the individual ligands in TRPV1-HEK cells. Acrolein 34-42 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 17-22 29430557-8 2017 This increase in TRPV1 ligands by acrolein exposure may indicate further downstream signaling, in that we also show here that a combination of these TRPV1 endogenous agonists increases the potency of the individual ligands in TRPV1-HEK cells. Acrolein 34-42 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 149-154 29430557-8 2017 This increase in TRPV1 ligands by acrolein exposure may indicate further downstream signaling, in that we also show here that a combination of these TRPV1 endogenous agonists increases the potency of the individual ligands in TRPV1-HEK cells. Acrolein 34-42 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 149-154 29430557-9 2017 In addition to these TRPV1 agonists, 3 TRPV3 antagonists, 4 TRPV4 agonists, and 25 orphan lipids were up and down regulated after acrolein exposure. Acrolein 130-138 transient receptor potential cation channel, subfamily V, member 1 Rattus norvegicus 21-26 29430557-9 2017 In addition to these TRPV1 agonists, 3 TRPV3 antagonists, 4 TRPV4 agonists, and 25 orphan lipids were up and down regulated after acrolein exposure. Acrolein 130-138 transient receptor potential cation channel, subfamily V, member 3 Rattus norvegicus 39-44 29430557-9 2017 In addition to these TRPV1 agonists, 3 TRPV3 antagonists, 4 TRPV4 agonists, and 25 orphan lipids were up and down regulated after acrolein exposure. Acrolein 130-138 transient receptor potential cation channel, subfamily V, member 4 Rattus norvegicus 60-65 29456784-5 2017 Downregulation of idh2 expression increased susceptibility to acrolein via induction of apoptotic cell death due to elevated mitochondrial oxidative stress. Acrolein 62-70 isocitrate dehydrogenase 2 (NADP+), mitochondrial Mus musculus 18-22 29456784-6 2017 Idh2 deficiency also promoted acrolein-induced lung injury in idh2 knockout mice through the disruption of mitochondrial redox status. Acrolein 30-38 isocitrate dehydrogenase 2 (NADP+), mitochondrial Mus musculus 62-66 29456784-7 2017 In addition, acrolein-induced toxicity in idh2 shRNA-transfected LLC cells and in idh2 knockout mice was ameliorated by the antioxidant, N-acetylcysteine, through attenuation of oxidative stress resulting from idh2 deficiency. Acrolein 13-21 isocitrate dehydrogenase (NADP(+)) 2 Homo sapiens 42-46 29456784-7 2017 In addition, acrolein-induced toxicity in idh2 shRNA-transfected LLC cells and in idh2 knockout mice was ameliorated by the antioxidant, N-acetylcysteine, through attenuation of oxidative stress resulting from idh2 deficiency. Acrolein 13-21 isocitrate dehydrogenase 2 (NADP+), mitochondrial Mus musculus 82-86 29456784-7 2017 In addition, acrolein-induced toxicity in idh2 shRNA-transfected LLC cells and in idh2 knockout mice was ameliorated by the antioxidant, N-acetylcysteine, through attenuation of oxidative stress resulting from idh2 deficiency. Acrolein 13-21 isocitrate dehydrogenase 2 (NADP+), mitochondrial Mus musculus 82-86 29456784-8 2017 In conclusion, idh2 deficiency leads to mitochondrial redox environment deterioration, which causes acrolein-mediated apoptosis of LLC cells and acrolein-induced lung injury in idh2-/- mice. Acrolein 100-108 isocitrate dehydrogenase 2 (NADP+), mitochondrial Mus musculus 15-19 29456784-9 2017 The present study supports the central role of idh2 deficiency in inducing oxidative stress resulting from acrolein-induced disruption of mitochondrial redox status in the lung. Acrolein 107-115 isocitrate dehydrogenase 2 (NADP+), mitochondrial Mus musculus 47-51 27995963-6 2016 Elevated recruitment of Dnmt1 and Dnmt3b to the Ogg1 promoter in acrolein treated bladder muscle cells was validated by the pattern of CpG methylation revealed by bisulfite sequencing. Acrolein 65-73 DNA methyltransferase (cytosine-5) 1 Mus musculus 24-29 27995963-6 2016 Elevated recruitment of Dnmt1 and Dnmt3b to the Ogg1 promoter in acrolein treated bladder muscle cells was validated by the pattern of CpG methylation revealed by bisulfite sequencing. Acrolein 65-73 DNA methyltransferase 3B Mus musculus 34-40 27995963-6 2016 Elevated recruitment of Dnmt1 and Dnmt3b to the Ogg1 promoter in acrolein treated bladder muscle cells was validated by the pattern of CpG methylation revealed by bisulfite sequencing. Acrolein 65-73 8-oxoguanine DNA-glycosylase 1 Mus musculus 48-52 27995963-8 2016 Histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), restored Ogg1 expression in cells treated with acrolein and mice treated with cyclophosphamide superior to the standard of care, mesna or nicotinamide-induced DNA demethylation. Acrolein 125-133 8-oxoguanine DNA-glycosylase 1 Mus musculus 87-91 27307078-6 2016 ABSTRACT: The TRPA1 ion channel is expressed in nociceptive (pain-sensitive) neurons and responds to a wide variety of chemical irritants, such as acrolein in smoke or isothiocyanates in mustard. Acrolein 147-155 transient receptor potential cation channel subfamily A member 1 Homo sapiens 14-19 27633142-3 2016 The whole blood from Nrf2-/- mice exhibited decreased antioxidant capacities, while the bone marrow cells, peripheral blood mononuclear cells and granulocytes from Nrf2-/- mice were more susceptible to acrolein-induced cytotoxicity than those from wild type mice. Acrolein 202-210 nuclear factor, erythroid derived 2, like 2 Mus musculus 164-168 27799370-2 2016 In this study, we show that TRPA1 (activated by allyl isothiocyanate, acrolein, and 4-hydroxynonenal) elevates the intracellular Ca2+ concentration ([Ca2+]i) in dorsal root ganglion (DRG) neurons in the presence and absence of extracellular Ca2+ Pharmacological and immunocytochemical analyses revealed the presence of TRPA1 channels both on the plasma membrane and in endolysosomes. Acrolein 70-78 transient receptor potential cation channel subfamily A member 1 Homo sapiens 28-33 27669733-4 2016 Accordingly, the association of H3/H4 with the histone chaperone ASF1 and importin 4 is disrupted and the translocation of green fluorescent protein-tagged H3 is inhibited in cells exposed to acrolein. Acrolein 192-200 importin 4 Homo sapiens 74-84 27799370-2 2016 In this study, we show that TRPA1 (activated by allyl isothiocyanate, acrolein, and 4-hydroxynonenal) elevates the intracellular Ca2+ concentration ([Ca2+]i) in dorsal root ganglion (DRG) neurons in the presence and absence of extracellular Ca2+ Pharmacological and immunocytochemical analyses revealed the presence of TRPA1 channels both on the plasma membrane and in endolysosomes. Acrolein 70-78 transient receptor potential cation channel subfamily A member 1 Homo sapiens 319-324 27138068-6 2016 We now report for the first time that thrombin dose-dependently induces formation of HNEPA in NSC34 mouse motor neuron cells using anti-HNE and anti-acrolein monoclonal antibodies. Acrolein 149-157 coagulation factor II Mus musculus 38-46 27612966-0 2016 Acrolein and thiol-reactive electrophiles suppress allergen-induced innate airway epithelial responses by inhibition of DUOX1 and EGFR. Acrolein 0-8 dual oxidase 1 Mus musculus 120-125 27612966-0 2016 Acrolein and thiol-reactive electrophiles suppress allergen-induced innate airway epithelial responses by inhibition of DUOX1 and EGFR. Acrolein 0-8 epidermal growth factor receptor Mus musculus 130-134 27612966-5 2016 Acrolein and other thiol-reactive electrophiles were found to dramatically prevent allergen-induced activation of DUOX1 as well as EGFR, and acrolein was capable of inhibiting EGFR tyrosine kinase activity via modification of C797. Acrolein 0-8 dual oxidase 1 Mus musculus 114-119 27612966-5 2016 Acrolein and other thiol-reactive electrophiles were found to dramatically prevent allergen-induced activation of DUOX1 as well as EGFR, and acrolein was capable of inhibiting EGFR tyrosine kinase activity via modification of C797. Acrolein 0-8 epidermal growth factor receptor Mus musculus 131-135 27612966-5 2016 Acrolein and other thiol-reactive electrophiles were found to dramatically prevent allergen-induced activation of DUOX1 as well as EGFR, and acrolein was capable of inhibiting EGFR tyrosine kinase activity via modification of C797. Acrolein 141-149 epidermal growth factor receptor Mus musculus 176-180 27612966-6 2016 Biotin-labeling strategies indicated increased cysteine modification and carbonylation of Src, EGFR, as well as DUOX1, in response to acrolein exposure in vitro and in vivo, suggesting that direct alkylation of these proteins on accessible cysteine residues may be responsible for their inhibition. Acrolein 134-142 Rous sarcoma oncogene Mus musculus 90-93 27612966-6 2016 Biotin-labeling strategies indicated increased cysteine modification and carbonylation of Src, EGFR, as well as DUOX1, in response to acrolein exposure in vitro and in vivo, suggesting that direct alkylation of these proteins on accessible cysteine residues may be responsible for their inhibition. Acrolein 134-142 epidermal growth factor receptor Mus musculus 95-99 27612966-6 2016 Biotin-labeling strategies indicated increased cysteine modification and carbonylation of Src, EGFR, as well as DUOX1, in response to acrolein exposure in vitro and in vivo, suggesting that direct alkylation of these proteins on accessible cysteine residues may be responsible for their inhibition. Acrolein 134-142 dual oxidase 1 Mus musculus 112-117 27612966-7 2016 Collectively, our findings indicate a novel anti-inflammatory mechanism of CS-derived acrolein and other thiol-reactive electrophiles, by directly inhibiting DUOX1- and EGFR-mediated airway epithelial responses to airborne allergens. Acrolein 86-94 dual oxidase 1 Mus musculus 158-163 27612966-7 2016 Collectively, our findings indicate a novel anti-inflammatory mechanism of CS-derived acrolein and other thiol-reactive electrophiles, by directly inhibiting DUOX1- and EGFR-mediated airway epithelial responses to airborne allergens. Acrolein 86-94 epidermal growth factor receptor Mus musculus 169-173 27590852-0 2016 Decrease in acrolein toxicity based on the decline of polyamine oxidases. Acrolein 12-20 spermine oxidase Mus musculus 54-72 27590852-5 2016 In the Neuro2a-ATD2 cells, the IC50 of acrolein increased from 4.2 to 6.8muM, and the levels of FosB and C/EBPbeta - transcription factors involved in the transcription of AcPAO and SMO genes - were reduced. Acrolein 39-47 spermine oxidase Mus musculus 182-185 27590852-9 2016 Furthermore, transfection of the cDNA for AcPAO or SMO into Neuro2a cells increased the toxicity of acrolein. Acrolein 100-108 spermine oxidase Mus musculus 51-54 27590852-10 2016 These results suggest that acrolein is mainly produced from polyamines by PAO. Acrolein 27-35 spermine oxidase Mus musculus 74-77 27238871-0 2016 Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine. Acrolein 0-8 Fas ligand Homo sapiens 44-48 27238871-5 2016 Our data demonstrate that acrolein markedly enhanced AZT-induced transcriptionally permissive histone modifications (H3K9Ac and H3K9Me3) allowing the recruitment of transcription factor NF-kB and RNA polymerase II at the FasL gene promoter, resulting in FasL upregulation and apoptosis in hepatocytes. Acrolein 26-34 Fas ligand Homo sapiens 221-225 27238871-5 2016 Our data demonstrate that acrolein markedly enhanced AZT-induced transcriptionally permissive histone modifications (H3K9Ac and H3K9Me3) allowing the recruitment of transcription factor NF-kB and RNA polymerase II at the FasL gene promoter, resulting in FasL upregulation and apoptosis in hepatocytes. Acrolein 26-34 Fas ligand Homo sapiens 254-258 27238871-6 2016 Notably, the acrolein scavenger, hydralazine prevented these promoter-associated epigenetic changes and inhibited FasL upregulation and apoptosis induced by the combination of AZT and acrolein, as well as AZT alone. Acrolein 13-21 Fas ligand Homo sapiens 114-118 27238871-6 2016 Notably, the acrolein scavenger, hydralazine prevented these promoter-associated epigenetic changes and inhibited FasL upregulation and apoptosis induced by the combination of AZT and acrolein, as well as AZT alone. Acrolein 184-192 Fas ligand Homo sapiens 114-118 27478470-0 2016 Sulforaphane protects against acrolein-induced oxidative stress and inflammatory responses: modulation of Nrf-2 and COX-2 expression. Acrolein 30-38 NFE2 like bZIP transcription factor 2 Homo sapiens 106-111 27478470-0 2016 Sulforaphane protects against acrolein-induced oxidative stress and inflammatory responses: modulation of Nrf-2 and COX-2 expression. Acrolein 30-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 27478470-3 2016 MATERIAL AND METHODS: Acrolein-induced oxidative stress was determined through evaluating the levels of reactive oxygen species, protein carbonyl and sulfhydryl content, thiobarbituric acid reactive species, total oxidant status and antioxidant status (total antioxidant capacity, glutathione, superoxide dismutase, catalase, glutathione peroxidase, glutathione-S-transferase activity). Acrolein 22-30 catalase Homo sapiens 316-324 27478470-5 2016 Acrolein-induced inflammation was determined through analyzing expression of cyclooxygenase-2 by western blot and PGE2 levels by ELISA. Acrolein 0-8 prostaglandin-endoperoxide synthase 2 Homo sapiens 77-93 27478470-7 2016 RESULTS: Acrolein showed a significant (p < 0.001) increase in the levels of oxidative stress parameters and down-regulated Nrf-2 expression. Acrolein 9-17 NFE2 like bZIP transcription factor 2 Homo sapiens 127-132 27478470-8 2016 Acrolein-induced inflammation was observed through upregulation (p < 0.001) of COX-2 and PGE2 levels. Acrolein 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 27478470-10 2016 Acrolein-induced inflammation was significantly inhibited through suppression of COX-2 (p < 0.001) and PGE2 levels (p < 0.001). Acrolein 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 26991531-6 2016 Diabetes as well as insulin resistance (defined as HOMA-IR>2.6) were positively associated with the 3-HPMA, CEMA and Acrolein with evidence of a dose-response relationship (p<0.05). Acrolein 121-129 insulin Homo sapiens 20-27 26991531-8 2016 The highest 3rd quartile of 3-HPMA and Acrolein were positively and significantly associated with HOMA-IR, HOMA-beta and fasting insulin. Acrolein 40-48 insulin Homo sapiens 130-137 27060873-3 2016 One such target is acrolein, a highly reactive aldehyde produced as a byproduct of oxidative stress and inflammation that is capable of activating the transient receptor potential ankyrin 1 (TRPA1) cation channel, known to be involved in the transmission and propagation of chronic neuropathic pain. Acrolein 19-27 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 151-189 27060873-3 2016 One such target is acrolein, a highly reactive aldehyde produced as a byproduct of oxidative stress and inflammation that is capable of activating the transient receptor potential ankyrin 1 (TRPA1) cation channel, known to be involved in the transmission and propagation of chronic neuropathic pain. Acrolein 19-27 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 191-196 27036235-1 2016 The acrolein derived cyclic 1,N(2)-propanodeoxyguanosine adduct (Acr-dG), formed primarily from omega-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA) under oxidative conditions, while proven to be mutagenic, is potentially involved in DHA-induced apoptosis. Acrolein 4-12 acrosin Homo sapiens 65-68 27036235-8 2016 These results clearly demonstrate that NER deficiency induces higher levels of Acr-dG in cells treated with DHA or acrolein and sensitizes cells to undergo apoptosis in a correlative manner. Acrolein 115-123 acrosin Homo sapiens 79-82 27143379-7 2016 Incubation in vitro of erythrocytes of donors and PD patients with acrolein increased the methemoglobin content, while incubation with carnosine normalized the methemoglobin content in erythrocytes of PD patients. Acrolein 67-75 hemoglobin subunit gamma 2 Homo sapiens 90-103 26980145-11 2016 Moreover, acrolein enhanced the stimulatory effects of Ang II and 8-bromo-cyclic AMP on aldosterone secretion from ZG cells prepared in both A-1 and A-3 groups. Acrolein 10-18 angiotensinogen Rattus norvegicus 55-61 26980145-11 2016 Moreover, acrolein enhanced the stimulatory effects of Ang II and 8-bromo-cyclic AMP on aldosterone secretion from ZG cells prepared in both A-1 and A-3 groups. Acrolein 10-18 UDP glucuronosyltransferase family 1 member A6 Rattus norvegicus 141-152 26980145-12 2016 Furthermore, the enzyme activity of P450scc, the rate-limiting step of aldosterone synthesis, was elevated after acrolein injection. Acrolein 113-121 cytochrome P450, family 11, subfamily a, polypeptide 1 Rattus norvegicus 36-43 26980145-14 2016 These results suggested that acrolein exposure increased aldosterone production, at least in part, through elevating the level of plasma Ang II and stimulating steroidogenesis pathways. Acrolein 29-37 angiotensinogen Rattus norvegicus 137-143 26996390-8 2016 Further investigating the steroidogenic pathway, the protein expressions of steroidogenic acute regulatory protein (StAR) and the upper receptor-melanocortin 2 receptor (MC2R) were attenuated in acrolein-treated groups. Acrolein 195-203 steroidogenic acute regulatory protein Rattus norvegicus 76-114 26996390-8 2016 Further investigating the steroidogenic pathway, the protein expressions of steroidogenic acute regulatory protein (StAR) and the upper receptor-melanocortin 2 receptor (MC2R) were attenuated in acrolein-treated groups. Acrolein 195-203 steroidogenic acute regulatory protein Rattus norvegicus 116-120 26996390-8 2016 Further investigating the steroidogenic pathway, the protein expressions of steroidogenic acute regulatory protein (StAR) and the upper receptor-melanocortin 2 receptor (MC2R) were attenuated in acrolein-treated groups. Acrolein 195-203 melanocortin 2 receptor Rattus norvegicus 136-168 26996390-8 2016 Further investigating the steroidogenic pathway, the protein expressions of steroidogenic acute regulatory protein (StAR) and the upper receptor-melanocortin 2 receptor (MC2R) were attenuated in acrolein-treated groups. Acrolein 195-203 melanocortin 2 receptor Rattus norvegicus 170-174 26996390-9 2016 Another experiment using trilostane showed less activity of P450scc in zona fasciculata-reticularis (ZFR) cells in acrolein-treated groups. Acrolein 115-123 cytochrome P450, family 11, subfamily a, polypeptide 1 Rattus norvegicus 60-67 26996390-14 2016 These results suggested that acrolein decreased the releasing ability of corticosterone via an inhibition on the response of ZFR cells to ACTH and the reduction of protein expressions of StAR and MC2R as well as the activity of P450scc in rat ZFR cells. Acrolein 29-37 steroidogenic acute regulatory protein Rattus norvegicus 187-191 26996390-14 2016 These results suggested that acrolein decreased the releasing ability of corticosterone via an inhibition on the response of ZFR cells to ACTH and the reduction of protein expressions of StAR and MC2R as well as the activity of P450scc in rat ZFR cells. Acrolein 29-37 melanocortin 2 receptor Rattus norvegicus 196-200 26996390-14 2016 These results suggested that acrolein decreased the releasing ability of corticosterone via an inhibition on the response of ZFR cells to ACTH and the reduction of protein expressions of StAR and MC2R as well as the activity of P450scc in rat ZFR cells. Acrolein 29-37 cytochrome P450, family 11, subfamily a, polypeptide 1 Rattus norvegicus 228-235 27143379-8 2016 Prophylactic (i.e. before acrolein addition) and therapeutic administration of carnosine to the incubation system with acrolein decreased the methemoglobin content to its initial level. Acrolein 119-127 hemoglobin subunit gamma 2 Homo sapiens 142-155 26890747-10 2016 Moreover, MAF1401 prevented glutathione depletion and positively modulated, in the presence of acrolein, some oxidative stress-sensitive pathways including the transcription factors NF-kappaB and Nrf2, the proteins gamma-GCS and GSK3beta, and the protein adaptator p66Shc. Acrolein 95-103 MAF bZIP transcription factor Homo sapiens 10-13 26419886-8 2016 There is indirect evidence to suggest that nicotine and acrolein may lead to CFTR dysfunction thereby influencing ductal secretion. Acrolein 56-64 CF transmembrane conductance regulator Homo sapiens 77-81 26728460-7 2016 Exposure to AC, HQ, PN, and CS resulted in cysteine and tyrosine nitrosylation leading to an altered three-dimensional structure of the PDI due to a decrease in helical content and formation of a more random coil structure, resulting in protein unfolding, inhibition of PDI reductase and isomerase activity in vitro and in vivo, and subsequent induction of endoplasmic reticulum stress response. Acrolein 12-14 prolyl 4-hydroxylase, beta polypeptide Mus musculus 136-139 26728460-7 2016 Exposure to AC, HQ, PN, and CS resulted in cysteine and tyrosine nitrosylation leading to an altered three-dimensional structure of the PDI due to a decrease in helical content and formation of a more random coil structure, resulting in protein unfolding, inhibition of PDI reductase and isomerase activity in vitro and in vivo, and subsequent induction of endoplasmic reticulum stress response. Acrolein 12-14 prolyl 4-hydroxylase, beta polypeptide Mus musculus 270-273 26365991-0 2015 Acrolein contributes to TRPA1 up-regulation in peripheral and central sensory hypersensitivity following spinal cord injury. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 24-29 26208604-5 2015 Meanwhile, LTA4H levels and triaminopeptidase activity declined with increasing concentrations of acrolein thereby sparing PGP from enzymatic destruction. Acrolein 98-106 leukotriene A4 hydrolase Homo sapiens 11-16 26365991-2 2015 Acrolein can directly activate a pro-algesic transient receptor protein ankyrin 1 (TRPA1) channel that exists in sensory neurons. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 45-81 26365991-2 2015 Acrolein can directly activate a pro-algesic transient receptor protein ankyrin 1 (TRPA1) channel that exists in sensory neurons. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 83-88 26365991-6 2015 Furthermore, we show that acrolein alone, in the absence of physical trauma, could lead to the elevation of TRPA1 mRNA at various locations when injected to the spinal cord. Acrolein 26-34 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 108-113 26365991-7 2015 In addition, post-SCI elevation of TRPA1 mRNA could be mitigated using acrolein scavengers. Acrolein 71-79 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 35-40 26365991-9 2015 Taken together, these data indicate that acrolein is likely a critical causal factor in heightening pain sensation post-SCI, through both the direct binding of TRPA1 receptor, and also by boosting the expression of TRPA1. Acrolein 41-49 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 160-165 26365991-9 2015 Taken together, these data indicate that acrolein is likely a critical causal factor in heightening pain sensation post-SCI, through both the direct binding of TRPA1 receptor, and also by boosting the expression of TRPA1. Acrolein 41-49 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 215-220 25724913-7 2015 RESULTS: Acrolein inhalation exposure potentiated blood flow responses both to TRPA1 and TRPV1 agonists compared to room air. Acrolein 9-17 transient receptor potential cation channel subfamily A member 1 Homo sapiens 79-84 26457480-4 2015 Acrolein reacted with resveratrol at the C-2 and C-3 positions through nucleophilic addition and formed an additional heterocyclic ring. Acrolein 0-8 complement C2 Homo sapiens 41-44 26457480-4 2015 Acrolein reacted with resveratrol at the C-2 and C-3 positions through nucleophilic addition and formed an additional heterocyclic ring. Acrolein 0-8 complement C3 Homo sapiens 49-52 26262998-7 2015 Acrolein, a by-product of MPO catalysis, formed a covalent adduct with the phosphatase tensin homolog (PTEN) tumor suppressor and enhanced the activity of the Akt kinase proto-oncogene in vitro and in vivo. Acrolein 0-8 myeloperoxidase Mus musculus 26-29 26262998-7 2015 Acrolein, a by-product of MPO catalysis, formed a covalent adduct with the phosphatase tensin homolog (PTEN) tumor suppressor and enhanced the activity of the Akt kinase proto-oncogene in vitro and in vivo. Acrolein 0-8 phosphatase and tensin homolog Mus musculus 103-107 26262998-8 2015 Thus, MPO may be an important determinant of diet and inflammation on colon cancer risk via its effect on endogenous exposure to oxidants and acrolein. Acrolein 142-150 myeloperoxidase Mus musculus 6-9 25724913-7 2015 RESULTS: Acrolein inhalation exposure potentiated blood flow responses both to TRPA1 and TRPV1 agonists compared to room air. Acrolein 9-17 transient receptor potential cation channel subfamily V member 1 Homo sapiens 89-94 25724913-9 2015 Acrolein sensitization of trigeminovascular responses to a TRPA1 agonist was attenuated by pre-treatment with AP-18. Acrolein 0-8 transient receptor potential cation channel subfamily A member 1 Homo sapiens 59-64 26472811-6 2015 In contrast, the gas phase acted like a sheer TRPA1 agonist, consistent with its composition, among other compounds, of volatile reactive carbonyls like formaldehyde and acrolein. Acrolein 170-178 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 46-51 25504014-6 2015 Acrolein also rapidly depleted intracellular glutathione (GSH), GSH-linked glutathione-S-transferases, and aldose reductase, three critical cellular defenses that detoxify reactive aldehydes. Acrolein 0-8 aldo-keto reductase family 1 member B Homo sapiens 107-123 26301996-4 2015 We also found that autoantibody activities recognizing SSA (Ro) and SSB (La) proteins increased after acrolein treatment of saliva from control subjects. Acrolein 102-110 small RNA binding exonuclease protection factor La Homo sapiens 68-71 26301996-5 2015 When an antibody against human serum albumin was treated with acrolein, the ability to recognize albumin was reduced but the ability to recognize other proteins was increased. Acrolein 62-70 albumin Homo sapiens 31-44 26832697-0 2015 [Changes of CD(4)(+) Foxp3+ regulatory T cells and CD(4)(+)IL-17+T cells in acrolein exposure rats]. Acrolein 76-84 interleukin 17A Rattus norvegicus 59-64 26832697-10 2015 Foxp3 mRNA was increased in the acrolein exposure groups [ (26.37 +- 3.24), (33.19 +- 2.98)] (24.4 +- 2.7), (30.3 +- 2.7) compared with the control groups [(12.37 +- 2.56), (13.12 +- 3.08)]. Acrolein 32-40 forkhead box P3 Rattus norvegicus 0-5 26480658-1 2015 OBJECTIVE: To investigate expressional changes of brain derived neurotrophic factor (BDNF) in the trachea of rats with acrolein inhalation. Acrolein 119-127 brain-derived neurotrophic factor Rattus norvegicus 50-83 26480658-1 2015 OBJECTIVE: To investigate expressional changes of brain derived neurotrophic factor (BDNF) in the trachea of rats with acrolein inhalation. Acrolein 119-127 brain-derived neurotrophic factor Rattus norvegicus 85-89 26480658-7 2015 The expression of BDNF mRNA in the trachea was increased at 1 week after acrolein inhalation (P < 0.05, vs. control group), then decreased along with the time and reached to the same level as control group at 3 weeks, then last to 6 weeks (P > 0.05). Acrolein 73-81 brain-derived neurotrophic factor Rattus norvegicus 18-22 24376112-0 2015 alpha,beta-Unsaturated aldehyde pollutant acrolein suppresses cardiomyocyte contractile function: Role of TRPV1 and oxidative stress. Acrolein 42-50 transient receptor potential cation channel subfamily V member 1 Homo sapiens 106-111 26480658-8 2015 CONCLUSION: The inflammatory injury in trachea induced by acrolein exposure could be associated with the increased expression of BDNF. Acrolein 58-66 brain-derived neurotrophic factor Rattus norvegicus 129-133 26480658-9 2015 BDNF may be one of the crucial inflammatory factors in the process of inflammatory reaction in trachea with acrolein stimulation. Acrolein 108-116 brain-derived neurotrophic factor Rattus norvegicus 0-4 25868843-8 2015 Acrolein induced similar hypotension in GSTP-null and WT mice. Acrolein 0-8 glutathione S-transferase pi 1 Homo sapiens 40-44 25868843-9 2015 GSTP-null mice also were more susceptible than WT mice to mortality associated with high-dose acrolein (10-20 mg/kg). Acrolein 94-102 glutathione S-transferase pi 1 Homo sapiens 0-4 25868843-10 2015 Collectively, these results suggest that CY cardiotoxicity is regulated, in part, by GSTP, which prevents CY toxicity by detoxifying acrolein. Acrolein 133-141 glutathione S-transferase pi 1 Homo sapiens 85-89 24376112-8 2015 However, the acrolein-induced cardiomyocyte contractile and intracellular Ca(2+) anomalies, as well as apoptosis (as evidenced by Bcl-2, Bax, FasL, Caspase-3 and -8), were negated by the reactive oxygen species (ROS) scavenger glutathione or the TRPV1 antagonist capsazepine. Acrolein 13-21 BCL2 apoptosis regulator Homo sapiens 130-135 24376112-8 2015 However, the acrolein-induced cardiomyocyte contractile and intracellular Ca(2+) anomalies, as well as apoptosis (as evidenced by Bcl-2, Bax, FasL, Caspase-3 and -8), were negated by the reactive oxygen species (ROS) scavenger glutathione or the TRPV1 antagonist capsazepine. Acrolein 13-21 BCL2 associated X, apoptosis regulator Homo sapiens 137-140 24376112-8 2015 However, the acrolein-induced cardiomyocyte contractile and intracellular Ca(2+) anomalies, as well as apoptosis (as evidenced by Bcl-2, Bax, FasL, Caspase-3 and -8), were negated by the reactive oxygen species (ROS) scavenger glutathione or the TRPV1 antagonist capsazepine. Acrolein 13-21 Fas ligand Homo sapiens 142-146 24376112-8 2015 However, the acrolein-induced cardiomyocyte contractile and intracellular Ca(2+) anomalies, as well as apoptosis (as evidenced by Bcl-2, Bax, FasL, Caspase-3 and -8), were negated by the reactive oxygen species (ROS) scavenger glutathione or the TRPV1 antagonist capsazepine. Acrolein 13-21 caspase 3 Homo sapiens 148-164 24376112-8 2015 However, the acrolein-induced cardiomyocyte contractile and intracellular Ca(2+) anomalies, as well as apoptosis (as evidenced by Bcl-2, Bax, FasL, Caspase-3 and -8), were negated by the reactive oxygen species (ROS) scavenger glutathione or the TRPV1 antagonist capsazepine. Acrolein 13-21 transient receptor potential cation channel subfamily V member 1 Homo sapiens 246-251 25144495-4 2015 Acrolein at 100 muM inhibited plasma membrane inward-rectifying potassium (Kin) channels in guard cells. Acrolein 0-8 Kin17 DNA and RNA binding protein Homo sapiens 75-78 26019375-0 2015 SCGB3A2 Inhibits Acrolein-Induced Apoptosis through Decreased p53 Phosphorylation. Acrolein 17-25 secretoglobin, family 3A, member 2 Mus musculus 0-7 26019375-0 2015 SCGB3A2 Inhibits Acrolein-Induced Apoptosis through Decreased p53 Phosphorylation. Acrolein 17-25 transformation related protein 53, pseudogene Mus musculus 62-65 26019375-7 2015 Acrolein increased the production of ROS and phosphorylation of p53 and induced apoptosis in MLg cells. Acrolein 0-8 transformation related protein 53, pseudogene Mus musculus 64-67 25395196-0 2015 Acrolein-Induced Oxidative Stress and Cell Death Exhibiting Features of Apoptosis in the Yeast Saccharomyces cerevisiae Deficient in SOD1. Acrolein 0-8 superoxide dismutase SOD1 Saccharomyces cerevisiae S288C 133-137 25395196-2 2015 The study was aimed at elucidation of the cytotoxic effect of acrolein on the yeast deficient in SOD1, Cu, Zn-superoxide dismutase which is hypersensitive to aldehydes. Acrolein 62-70 superoxide dismutase SOD1 Saccharomyces cerevisiae S288C 97-101 26232997-5 2015 We showed that acrolein decreased concentration of glutathione (GSH) and increased levels of malondialdehyde (MDA), Amyloid-beta (Abeta) and phospho-tau in the brain. Acrolein 15-23 amyloid beta precursor protein Rattus norvegicus 130-135 26491656-2 2015 ALDH2 also metabolizes other reactive aldehydes such as 4-hydroxy-2-nonenal and acrolein. Acrolein 80-88 aldehyde dehydrogenase 2 family member Homo sapiens 0-5 25144495-5 2015 Acrolein at 100 muM inhibited Kin channel KAT1 expressed in a heterologous system using Xenopus leaves oocytes. Acrolein 0-8 Kin17 DNA and RNA binding protein S homeolog Xenopus laevis 30-33 25144495-5 2015 Acrolein at 100 muM inhibited Kin channel KAT1 expressed in a heterologous system using Xenopus leaves oocytes. Acrolein 0-8 kynurenine aminotransferase 1 L homeolog Xenopus laevis 42-46 25144495-6 2015 These results suggest that acrolein inhibits light-induced stomatal opening through inhibition of Kin channels in guard cells. Acrolein 27-35 Kin17 DNA and RNA binding protein Homo sapiens 98-101 25600140-9 2015 The CSE inhibitor prevented the cardiovascular effects of acrolein exposure. Acrolein 58-66 cystathionine gamma-lyase Rattus norvegicus 4-7 25600140-10 2015 DISCUSSION AND CONCLUSION: Pretreatment with the CSE inhibitor prevented the cardiovascular effects of acrolein, suggesting that the cardiovascular responses with acrolein may be mediated by carotid body-triggered changes in autonomic tone. Acrolein 103-111 cystathionine gamma-lyase Rattus norvegicus 49-52 25600140-10 2015 DISCUSSION AND CONCLUSION: Pretreatment with the CSE inhibitor prevented the cardiovascular effects of acrolein, suggesting that the cardiovascular responses with acrolein may be mediated by carotid body-triggered changes in autonomic tone. Acrolein 163-171 cystathionine gamma-lyase Rattus norvegicus 49-52 26461383-11 2014 Moreover, MAF prevented glutathione depletion induced by acrolein. Acrolein 57-65 MAF bZIP transcription factor Homo sapiens 10-13 25821552-0 2015 Enhancement of the acrolein-induced production of reactive oxygen species and lung injury by GADD34. Acrolein 19-27 protein phosphatase 1, regulatory subunit 15A Mus musculus 93-99 25821552-4 2015 Here we investigated the effects of GADD34 on acrolein-induced lung injury. Acrolein 46-54 protein phosphatase 1, regulatory subunit 15A Mus musculus 36-42 25821552-5 2015 The intranasal exposure of acrolein induced the expression of GADD34, developing the pulmonary damage with inflammation and increase of reactive oxygen species (ROS). Acrolein 27-35 protein phosphatase 1, regulatory subunit 15A Mus musculus 62-68 25821552-7 2015 Acrolein-induced phosphorylation of eIF2alpha in GADD34-knockout epithelial cells by shRNA protected cell death by reducing misfolded protein-caused oxidative stress. Acrolein 0-8 eukaryotic translation initiation factor 2A Mus musculus 36-45 25821552-7 2015 Acrolein-induced phosphorylation of eIF2alpha in GADD34-knockout epithelial cells by shRNA protected cell death by reducing misfolded protein-caused oxidative stress. Acrolein 0-8 protein phosphatase 1, regulatory subunit 15A Mus musculus 49-55 25821552-8 2015 These data indicate that GADD34 participates in the development of acrolein-induced lung injury. Acrolein 67-75 protein phosphatase 1, regulatory subunit 15A Mus musculus 25-31 26461383-12 2014 Our results also showed that MAF prevented the expression of ?-glutamylcystein synthetase, the nuclear translocation of Nrf2, the activation of both NF-?B and p66HSC by acrolein. Acrolein 169-177 MAF bZIP transcription factor Homo sapiens 29-32 25187385-2 2014 In this study, we have found that the apparent activation energy for propene oxidation to acrolein over scheelite-structured, multicomponent, mixed metal oxides (Bi3FeMo2O12, Bi2Mo2.5W0.5O12, and Bi1-x/3V1-xMoxO4, where 0 <= x <= 1) correlates with the band gap of the catalyst measured at reaction temperature. Acrolein 90-98 transmembrane BAX inhibitor motif containing 6 Homo sapiens 196-199 25157679-0 2014 Mechanism of repair of acrolein- and malondialdehyde-derived exocyclic guanine adducts by the alpha-ketoglutarate/Fe(II) dioxygenase AlkB. Acrolein 23-31 alkB homolog 1, histone H2A dioxygenase Homo sapiens 133-137 25157679-8 2014 Taken together, this study provides a detailed mechanism by which three-carbon bridge exocyclic guanine adducts can be processed by AlkB and suggests an important role for the AlkB family of dioxygenases in protecting against the deleterious biological consequences of acrolein and MDA. Acrolein 269-277 alkB homolog 1, histone H2A dioxygenase Homo sapiens 132-136 25157679-8 2014 Taken together, this study provides a detailed mechanism by which three-carbon bridge exocyclic guanine adducts can be processed by AlkB and suggests an important role for the AlkB family of dioxygenases in protecting against the deleterious biological consequences of acrolein and MDA. Acrolein 269-277 alkB homolog 1, histone H2A dioxygenase Homo sapiens 176-180 24747221-0 2014 Acrolein-exposed normal human lung fibroblasts in vitro: cellular senescence, enhanced telomere erosion, and degradation of Werner"s syndrome protein. Acrolein 0-8 WRN RecQ like helicase Homo sapiens 124-149 25152401-0 2014 Reductive detoxification of acrolein as a potential role for aldehyde reductase (AKR1A) in mammals. Acrolein 28-36 aldo-keto reductase family 1, member B7 Mus musculus 61-79 24800887-7 2014 Furthermore, statil enhanced the susceptibility of cells to acrolein, an active substrate of AKR1B10. Acrolein 60-68 aldo-keto reductase family 1 member B10 Homo sapiens 93-100 24999835-4 2014 Our results showed that intranasal exposure of mice to acrolein increased CD11c(+)F4/80(high) macrophages in the lungs and increased ROS formation via induction of NF-kappaB signaling. Acrolein 55-63 integrin alpha X Mus musculus 74-79 24999835-6 2014 In in vitro studies, acrolein treatment of bone marrow-derived GM-CSF-dependent immature macrophages (GM-IMs), activated the cells and led to their increased production of ROS and expression of several key pro-inflammatory cytokines. Acrolein 21-29 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 63-69 24747221-6 2014 RESULTS: We found that acrolein induced cellular senescence by increasing both p53 and p21. Acrolein 23-31 tumor protein p53 Homo sapiens 79-82 24747221-6 2014 RESULTS: We found that acrolein induced cellular senescence by increasing both p53 and p21. Acrolein 23-31 H3 histone pseudogene 16 Homo sapiens 87-90 24816802-6 2014 RESULTS: In the highest quintile of outdoor acrolein exposure (0.05-0.46 microg/m3), there was a marginally significant increase in the asthma attack pOR (prevalence-odds ratio [95% CI] = 1.08 [0.98:1.19]) relative to the lowest quintile. Acrolein 44-52 cytochrome p450 oxidoreductase Homo sapiens 150-153 24747221-9 2014 Acrolein-induced down-regulation of WRN protein was rescued by p53 knockdown or proteasome inhibition. Acrolein 0-8 WRN RecQ like helicase Homo sapiens 36-39 24747221-9 2014 Acrolein-induced down-regulation of WRN protein was rescued by p53 knockdown or proteasome inhibition. Acrolein 0-8 tumor protein p53 Homo sapiens 63-66 24747221-11 2014 CONCLUSIONS: These results suggest that acrolein induces p53-mediated cellular senescence accompanied by enhanced telomere attrition and WRN protein down-regulation. Acrolein 40-48 tumor protein p53 Homo sapiens 57-60 24747221-11 2014 CONCLUSIONS: These results suggest that acrolein induces p53-mediated cellular senescence accompanied by enhanced telomere attrition and WRN protein down-regulation. Acrolein 40-48 WRN RecQ like helicase Homo sapiens 137-140 24987934-0 2014 Theoretical study of the gas-phase reactions of NO3 radical with a series of trans-2-unsaturated aldehydes: from acrolein to trans-2-octenal. Acrolein 113-121 NBL1, DAN family BMP antagonist Homo sapiens 48-51 24594012-0 2014 Airborne acrolein induces keratin-8 (Ser-73) hyperphosphorylation and intermediate filament ubiquitination in bronchiolar lung cell monolayers. Acrolein 9-17 keratin 8 Homo sapiens 26-35 24594012-7 2014 Use of antibody arrays to monitor protein expression in exposed monolayers identified strong upregulation of phospho-keratin-8 (Ser(73)) as an early consequence of acrolein exposure. Acrolein 164-172 keratin 8 Homo sapiens 117-126 24812010-0 2014 Acrolein decreases endothelial cell migration and insulin sensitivity through induction of let-7a. Acrolein 0-8 insulin Homo sapiens 50-57 24812010-0 2014 Acrolein decreases endothelial cell migration and insulin sensitivity through induction of let-7a. Acrolein 0-8 microRNA let7a-1 Mus musculus 91-97 24812010-7 2014 Exposure to acrolein attenuated beta3 integrin-dependent migration and reduced Akt phosphorylation in response to insulin. Acrolein 12-20 insulin Homo sapiens 114-121 24812010-8 2014 These effects of acrolein on endothelial cell migration and insulin signaling were reversed by expression of a let-7a inhibitor. Acrolein 17-25 insulin Homo sapiens 60-67 24812010-8 2014 These effects of acrolein on endothelial cell migration and insulin signaling were reversed by expression of a let-7a inhibitor. Acrolein 17-25 microRNA let7a-1 Mus musculus 111-117 24812010-9 2014 Also, inhalation exposure of mice to acrolein (1 ppm x 6 h/day x 4 days) upregulated let-7a and led to a decrease in insulin-stimulated Akt phosphorylation in the aorta. Acrolein 37-45 microRNA let7a-1 Mus musculus 85-91 24812010-9 2014 Also, inhalation exposure of mice to acrolein (1 ppm x 6 h/day x 4 days) upregulated let-7a and led to a decrease in insulin-stimulated Akt phosphorylation in the aorta. Acrolein 37-45 insulin Homo sapiens 117-124 24874071-11 2014 Acrolein modifies LTA4H and inhibits aminopeptidase activity to the same extent as cigarette smoke. Acrolein 0-8 leukotriene A4 hydrolase Mus musculus 18-23 24874071-13 2014 We highlight a mechanism by which acrolein potentiates neutrophilic inflammation through selective inhibition of LTA4H aminopeptidase activity. Acrolein 34-42 leukotriene A4 hydrolase Mus musculus 113-118 24373849-5 2014 The exposure of cells to acrolein (15-50muM) for shorter times of 15 to 30min activated several ER stress markers. Acrolein 25-33 latexin Homo sapiens 40-43 24373849-7 2014 Acrolein (25-50muM) caused apoptotic cell death mediated by the ER after 2h, which was characterised by the induction of CHOP and activation of ER proteases calpain and caspase-4. Acrolein 0-8 DNA damage inducible transcript 3 Homo sapiens 121-125 24373849-7 2014 Acrolein (25-50muM) caused apoptotic cell death mediated by the ER after 2h, which was characterised by the induction of CHOP and activation of ER proteases calpain and caspase-4. Acrolein 0-8 caspase 4 Homo sapiens 169-178 24561178-0 2014 Acrolein relaxes mouse isolated tracheal smooth muscle via a TRPA1-dependent mechanism. Acrolein 0-8 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 61-66 24561178-12 2014 Pharmacologic studies indicate that acrolein-induced relaxation likely involves interplay between TRPA1-expressing airway sensory C-fibres, NK1 receptor-expressing epithelial cells, and EP2-receptor expressing airway smooth muscle cells. Acrolein 36-44 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 98-103 24561178-12 2014 Pharmacologic studies indicate that acrolein-induced relaxation likely involves interplay between TRPA1-expressing airway sensory C-fibres, NK1 receptor-expressing epithelial cells, and EP2-receptor expressing airway smooth muscle cells. Acrolein 36-44 tachykinin receptor 1 Mus musculus 140-152 24373849-8 2014 Calpain and caspase-7 were the initiating factors for caspase-4 activation in acrolein-induced apoptosis. Acrolein 78-86 caspase 7 Homo sapiens 12-21 24561178-12 2014 Pharmacologic studies indicate that acrolein-induced relaxation likely involves interplay between TRPA1-expressing airway sensory C-fibres, NK1 receptor-expressing epithelial cells, and EP2-receptor expressing airway smooth muscle cells. Acrolein 36-44 prostaglandin E receptor 2 (subtype EP2) Mus musculus 186-198 24561178-2 2014 TRPA1 likely plays an intermediary role in eliciting a range of effects induced by acrolein including cough and neurogenic inflammation. Acrolein 83-91 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 0-5 24561178-3 2014 Currently, it is not known whether acrolein-induced activation of TRPA1 produces other airway effects including relaxation of mouse airway smooth muscle. Acrolein 35-43 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 66-71 24373849-8 2014 Calpain and caspase-7 were the initiating factors for caspase-4 activation in acrolein-induced apoptosis. Acrolein 78-86 caspase 4 Homo sapiens 54-63 24594943-5 2014 Reports on mammals have indicated that allyl alcohol requires activation by alcohol dehydrogenases (Adh) to form the highly reactive and toxic metabolite acrolein, which shows similar toxicity in zebrafish embryos and adults. Acrolein 154-162 alcohol dehydrogenase 5 Danio rerio 100-103 24667599-4 2014 At high doses of acrolein (>=10 muM) the capacity of the cellular protection by GSH is overwhelmed and GSH is not able to quench all the acrolein, resulting in cytotoxicity. Acrolein 17-25 latexin Homo sapiens 35-38 24667599-5 2014 At a relatively low dose of acrolein (3 muM), no cytotoxicity is observed due to protection by GSH. Acrolein 28-36 latexin Homo sapiens 40-43 24667599-7 2014 The adaptation to acrolein is induced via Nrf2 mediated gene expression of gamma-glutamylcysteine synthetase leading to elevated GSH levels. Acrolein 18-26 NFE2 like bZIP transcription factor 2 Homo sapiens 42-46 24667599-7 2014 The adaptation to acrolein is induced via Nrf2 mediated gene expression of gamma-glutamylcysteine synthetase leading to elevated GSH levels. Acrolein 18-26 glutamate-cysteine ligase catalytic subunit Homo sapiens 75-108 24648011-0 2014 Vocal fold ion transport and mucin expression following acrolein exposure. Acrolein 56-64 LOC100508689 Homo sapiens 29-34 24648011-3 2014 The objective of this study was to investigate the effect of the pollutant acrolein on two vocal fold epithelial mechanisms: ion transport and mucin (MUC) synthesis. Acrolein 75-83 LOC100508689 Homo sapiens 143-148 24648011-3 2014 The objective of this study was to investigate the effect of the pollutant acrolein on two vocal fold epithelial mechanisms: ion transport and mucin (MUC) synthesis. Acrolein 75-83 LOC100508689 Homo sapiens 150-153 24581246-8 2014 Acrolein was pro-inflammatory for the PNEC cultures (30 muM exposure for 4 h inducing a 2.0 fold increase in IL-8 release) and also increased IL-8 release after stimulation with PA LPS. Acrolein 0-8 latexin Homo sapiens 56-59 24581246-8 2014 Acrolein was pro-inflammatory for the PNEC cultures (30 muM exposure for 4 h inducing a 2.0 fold increase in IL-8 release) and also increased IL-8 release after stimulation with PA LPS. Acrolein 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 109-113 24581246-8 2014 Acrolein was pro-inflammatory for the PNEC cultures (30 muM exposure for 4 h inducing a 2.0 fold increase in IL-8 release) and also increased IL-8 release after stimulation with PA LPS. Acrolein 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 142-146 24147766-4 2014 Concurrent with injury-induced increases in acrolein concentration is an increased expression of TRPA1 in the lumbar (L3-L6) sensory ganglia. Acrolein 44-52 transient receptor potential cation channel, subfamily A, member 1 Rattus norvegicus 97-102 24325674-11 2014 Overall, disruption of the structural and functional integrity of apoE by oxidative modification of essential lysine residues by acrolein is expected to affect its role in maintaining plasma cholesterol homeostasis and lead to dysregulation in lipid metabolism. Acrolein 129-137 apolipoprotein E Rattus norvegicus 66-70 24370185-8 2014 Isolated treatment with unsaturated-aldehydes (acrolein, 10mumol) caused a 61% reduction, while saturated-aldehydes (acetaldehyde, 200mumol), peroxynitrite (200muM) and RNS donor (SIN-1, 2mM) caused no substantial effect. Acrolein 47-55 MAPK associated protein 1 Homo sapiens 180-185 24325674-0 2014 Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry. Acrolein 0-8 apolipoprotein E Rattus norvegicus 61-77 24040746-11 2013 Acrolein, a component of cigarette smoke, was higher in smokers, blocked CFTR by inhibiting channel gating, and was attenuated by antioxidant N-acetylcysteine, a known scavenger of acrolein. Acrolein 0-8 cystic fibrosis transmembrane conductance regulator Mus musculus 73-77 24325674-3 2014 The objective of this study is to examine the effect of acrolein modification on the structure and function of rat apoE and to determine the sites and nature of modification by mass spectrometry. Acrolein 56-64 apolipoprotein E Rattus norvegicus 115-119 24325674-8 2014 Treatment of recombinant rat apoE with a 10-fold molar excess of acrolein resulted in (i) a significant decrease in lipid-binding and cholesterol efflux abilities, (ii) impairment in the LDLr- and heparin-binding capabilities, and (iii) significant alterations in the overall stability of the protein. Acrolein 65-73 apolipoprotein E Rattus norvegicus 29-33 24325674-8 2014 Treatment of recombinant rat apoE with a 10-fold molar excess of acrolein resulted in (i) a significant decrease in lipid-binding and cholesterol efflux abilities, (ii) impairment in the LDLr- and heparin-binding capabilities, and (iii) significant alterations in the overall stability of the protein. Acrolein 65-73 low density lipoprotein receptor Rattus norvegicus 187-191 24558308-0 2014 Korean Red Ginseng water extract inhibits COX-2 expression by suppressing p38 in acrolein-treated human endothelial cells. Acrolein 81-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 24558308-0 2014 Korean Red Ginseng water extract inhibits COX-2 expression by suppressing p38 in acrolein-treated human endothelial cells. Acrolein 81-89 mitogen-activated protein kinase 14 Homo sapiens 74-77 24558308-5 2014 Acrolein-induced COX-2 expression was accompanied by increased levels of phosphorylated p38 in HUVECs and KRG inhibited COX-2 expression in HUVECs. Acrolein 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 24558308-5 2014 Acrolein-induced COX-2 expression was accompanied by increased levels of phosphorylated p38 in HUVECs and KRG inhibited COX-2 expression in HUVECs. Acrolein 0-8 mitogen-activated protein kinase 14 Homo sapiens 88-91 24558308-5 2014 Acrolein-induced COX-2 expression was accompanied by increased levels of phosphorylated p38 in HUVECs and KRG inhibited COX-2 expression in HUVECs. Acrolein 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 120-125 24558308-6 2014 These results suggest that KRG suppresses acrolein-induced COX-2 expression via inhibition of the p38 mitogen-activated protein kinase signaling pathway. Acrolein 42-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 24558308-6 2014 These results suggest that KRG suppresses acrolein-induced COX-2 expression via inhibition of the p38 mitogen-activated protein kinase signaling pathway. Acrolein 42-50 mitogen-activated protein kinase 14 Homo sapiens 98-101 24558308-7 2014 In addition, KRG exhibited an inhibitory effect on acrolein-induced apoptosis, as demonstrated by annexin V-propidium iodide staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay. Acrolein 51-59 annexin A5 Homo sapiens 98-107 23981515-10 2013 The concentrations of acrolein, MVK and CPO in the CSE were 3368+-334, 2429+-123 and 392.9+-31.8muM (n=4), respectively, which were higher than the cytotoxic concentrations. Acrolein 22-30 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 51-54 23981515-13 2013 These results show that acrolein and MVK are responsible for the acute cytotoxicity of the CSE through PKC/NOX-dependent and -independent mechanisms, whereas CPO is responsible for the delayed cytotoxicity of the CSE through a PKC/NOX-independent mechanism. Acrolein 24-32 choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity) Homo sapiens 91-94 24040746-13 2013 Acrolein present in cigarette smoke mediates CFTR defects in extrapulmonary tissues in smokers. Acrolein 0-8 cystic fibrosis transmembrane conductance regulator Mus musculus 45-49 23792774-9 2013 However, exposure to acrolein caused increased generation of free radicals, activation of p38 MAPK, upregulation of the muscle-specific E3 ligases atrogin-1 and MuRF1, degradation of myosin heavy chain, and atrophy of myotubes. Acrolein 21-29 mitogen-activated protein kinase 14 Homo sapiens 90-93 23792774-10 2013 Inhibition of p38 MAPK by SB203580 abolished acrolein-induced muscle catabolism. Acrolein 45-53 mitogen-activated protein kinase 14 Homo sapiens 14-17 23792774-9 2013 However, exposure to acrolein caused increased generation of free radicals, activation of p38 MAPK, upregulation of the muscle-specific E3 ligases atrogin-1 and MuRF1, degradation of myosin heavy chain, and atrophy of myotubes. Acrolein 21-29 tripartite motif containing 63 Homo sapiens 161-166 23770200-0 2013 Aldose reductase regulates acrolein-induced cytotoxicity in human small airway epithelial cells. Acrolein 27-35 aldo-keto reductase family 1 member B Homo sapiens 0-16 24157358-3 2013 Here, we demonstrate that acrolein rapidly inactivates the seleno-enzyme thioredoxin reductase (TrxR) in human bronchiolar epithelial HBE1 cells, which recovered over 4-8h by a mechanism depending on the presence of cellular GSH and thioredoxin 1 (Trx1), and corresponding with reversal of protein-acrolein adduction. Acrolein 26-34 peroxiredoxin 5 Homo sapiens 73-94 23770200-3 2013 We have investigated the role of AR in acrolein-induced cytotoxicity in primary human small airway epithelial cells (SAECs). Acrolein 39-47 aldo-keto reductase family 1 member B Homo sapiens 33-35 23770200-6 2013 AR inhibition protected SAECs from low-dose (5 microM) acrolein-induced cellular reactive oxygen species (ROS). Acrolein 55-63 aldo-keto reductase family 1 member B Homo sapiens 0-2 23770200-8 2013 Further, fidarestat inhibited acrolein-induced translocation of the proapoptotic proteins Bax and Bad from the cytosol to the mitochondria and that of Bcl2 and BclXL from the mitochondria to the cytosol. Acrolein 30-38 BCL2 associated X, apoptosis regulator Homo sapiens 90-93 23770200-8 2013 Further, fidarestat inhibited acrolein-induced translocation of the proapoptotic proteins Bax and Bad from the cytosol to the mitochondria and that of Bcl2 and BclXL from the mitochondria to the cytosol. Acrolein 30-38 BCL2 apoptosis regulator Homo sapiens 151-155 23770200-8 2013 Further, fidarestat inhibited acrolein-induced translocation of the proapoptotic proteins Bax and Bad from the cytosol to the mitochondria and that of Bcl2 and BclXL from the mitochondria to the cytosol. Acrolein 30-38 BCL2 like 1 Homo sapiens 160-165 23770200-10 2013 The mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinases 1 and 2, stress-activated protein kinase/c-Jun NH2-terminal kinase, and p38MAPK, and c-Jun were transiently activated in airway epithelial cells by acrolein in a concentration- and time-dependent fashion, which was significantly prevented by AR inhibition. Acrolein 242-250 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 179-184 23770200-11 2013 These results suggest that AR inhibitors could prevent acrolein-induced cytotoxicity in the lung epithelial cells. Acrolein 55-63 aldo-keto reductase family 1 member B Homo sapiens 27-29 23763486-0 2013 Acrolein stimulates the synthesis of IL-6 and C-reactive protein (CRP) in thrombosis model mice and cultured cells. Acrolein 0-8 interleukin 6 Mus musculus 37-41 23763486-0 2013 Acrolein stimulates the synthesis of IL-6 and C-reactive protein (CRP) in thrombosis model mice and cultured cells. Acrolein 0-8 C-reactive protein, pentraxin-related Mus musculus 46-64 23763486-0 2013 Acrolein stimulates the synthesis of IL-6 and C-reactive protein (CRP) in thrombosis model mice and cultured cells. Acrolein 0-8 C-reactive protein, pentraxin-related Mus musculus 66-69 23763486-3 2013 In mice with photochemically induced thrombosis, acrolein produced at the locus of infarction increased the level of IL-6 and then CRP in plasma. Acrolein 49-57 interleukin 6 Mus musculus 117-121 23763486-3 2013 In mice with photochemically induced thrombosis, acrolein produced at the locus of infarction increased the level of IL-6 and then CRP in plasma. Acrolein 49-57 C-reactive protein, pentraxin-related Mus musculus 131-134 23763486-4 2013 This was confirmed in cell culture systems - acrolein stimulated the production of IL-6 in mouse neuroblastoma Neuro-2a cells, mouse macrophage-like J774.1 cells, and human umbilical vein endothelial cells (HUVEC), and IL-6 in turn stimulated the production of CRP in human hepatocarcinoma cells. Acrolein 45-53 interleukin 6 Mus musculus 83-87 23763486-4 2013 This was confirmed in cell culture systems - acrolein stimulated the production of IL-6 in mouse neuroblastoma Neuro-2a cells, mouse macrophage-like J774.1 cells, and human umbilical vein endothelial cells (HUVEC), and IL-6 in turn stimulated the production of CRP in human hepatocarcinoma cells. Acrolein 45-53 interleukin 6 Homo sapiens 219-223 23763486-4 2013 This was confirmed in cell culture systems - acrolein stimulated the production of IL-6 in mouse neuroblastoma Neuro-2a cells, mouse macrophage-like J774.1 cells, and human umbilical vein endothelial cells (HUVEC), and IL-6 in turn stimulated the production of CRP in human hepatocarcinoma cells. Acrolein 45-53 C-reactive protein Homo sapiens 261-264 23763486-7 2013 IL-6 functioned as a protective factor against acrolein toxicity in Neuro-2a cells and HUVEC. Acrolein 47-55 interleukin 6 Mus musculus 0-4 23763486-8 2013 These results show that acrolein stimulates the synthesis of IL-6 and CRP, which function as protecting factors against acrolein toxicity, and that the combined measurement of PC-Acro, IL-6, and CRP is effective for identification of silent brain infarction. Acrolein 24-32 interleukin 6 Mus musculus 61-73 23763486-8 2013 These results show that acrolein stimulates the synthesis of IL-6 and CRP, which function as protecting factors against acrolein toxicity, and that the combined measurement of PC-Acro, IL-6, and CRP is effective for identification of silent brain infarction. Acrolein 24-32 interleukin 6 Mus musculus 61-65 23763486-8 2013 These results show that acrolein stimulates the synthesis of IL-6 and CRP, which function as protecting factors against acrolein toxicity, and that the combined measurement of PC-Acro, IL-6, and CRP is effective for identification of silent brain infarction. Acrolein 24-32 C-reactive protein, pentraxin-related Mus musculus 70-73 23763486-8 2013 These results show that acrolein stimulates the synthesis of IL-6 and CRP, which function as protecting factors against acrolein toxicity, and that the combined measurement of PC-Acro, IL-6, and CRP is effective for identification of silent brain infarction. Acrolein 120-128 interleukin 6 Mus musculus 61-65 23763486-10 2013 The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis. Acrolein 47-55 interleukin 6 Mus musculus 87-91 23763486-10 2013 The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis. Acrolein 47-55 C-reactive protein, pentraxin-related Mus musculus 96-99 23763486-10 2013 The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis. Acrolein 112-120 interleukin 6 Mus musculus 131-135 23763486-10 2013 The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis. Acrolein 112-120 interleukin 6 Mus musculus 131-135 23763486-10 2013 The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis. Acrolein 112-120 C-reactive protein, pentraxin-related Mus musculus 173-176 23763486-11 2013 Furthermore, IL-6 decreased acrolein toxicity in several cell lines. Acrolein 28-36 interleukin 6 Mus musculus 13-17 24157358-3 2013 Here, we demonstrate that acrolein rapidly inactivates the seleno-enzyme thioredoxin reductase (TrxR) in human bronchiolar epithelial HBE1 cells, which recovered over 4-8h by a mechanism depending on the presence of cellular GSH and thioredoxin 1 (Trx1), and corresponding with reversal of protein-acrolein adduction. Acrolein 26-34 peroxiredoxin 5 Homo sapiens 96-100 24157358-3 2013 Here, we demonstrate that acrolein rapidly inactivates the seleno-enzyme thioredoxin reductase (TrxR) in human bronchiolar epithelial HBE1 cells, which recovered over 4-8h by a mechanism depending on the presence of cellular GSH and thioredoxin 1 (Trx1), and corresponding with reversal of protein-acrolein adduction. Acrolein 26-34 thioredoxin Homo sapiens 233-246 24157358-3 2013 Here, we demonstrate that acrolein rapidly inactivates the seleno-enzyme thioredoxin reductase (TrxR) in human bronchiolar epithelial HBE1 cells, which recovered over 4-8h by a mechanism depending on the presence of cellular GSH and thioredoxin 1 (Trx1), and corresponding with reversal of protein-acrolein adduction. Acrolein 26-34 thioredoxin Homo sapiens 248-252 24157358-4 2013 Our findings indicate that acrolein-induced protein alkylation is not necessarily a feature of irreversible protein damage, but may reflect a reversible signaling mechanism that is regulated by GSH and Trx1. Acrolein 27-35 thioredoxin Homo sapiens 202-206 24056970-3 2013 RLE-6TN, H441, and primary alveolar type II (pAT2) cells were exposed to acrolein for 4 h, and its effect on mitochondrial oxygen consumption rates was studied by XF Extracellular Flux analysis. Acrolein 73-81 solute carrier family 36 (proton/amino acid symporter), member 2 Mus musculus 45-49 24056970-5 2013 Acrolein inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, leading to decreased substrate availability for mitochondrial respiration in RLE-6TN, H441, and pAT2 cells; the reduced GAPDH activity was compensated in pAT2 cells by an increase in the activity of glucose-6-phosphate dehydrogenase, the regulatory control of the pentose phosphate pathway. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Rattus norvegicus 19-59 24056970-5 2013 Acrolein inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, leading to decreased substrate availability for mitochondrial respiration in RLE-6TN, H441, and pAT2 cells; the reduced GAPDH activity was compensated in pAT2 cells by an increase in the activity of glucose-6-phosphate dehydrogenase, the regulatory control of the pentose phosphate pathway. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Rattus norvegicus 61-66 24056970-5 2013 Acrolein inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, leading to decreased substrate availability for mitochondrial respiration in RLE-6TN, H441, and pAT2 cells; the reduced GAPDH activity was compensated in pAT2 cells by an increase in the activity of glucose-6-phosphate dehydrogenase, the regulatory control of the pentose phosphate pathway. Acrolein 0-8 solute carrier family 36 (proton/amino acid symporter), member 2 Mus musculus 174-178 24056970-5 2013 Acrolein inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, leading to decreased substrate availability for mitochondrial respiration in RLE-6TN, H441, and pAT2 cells; the reduced GAPDH activity was compensated in pAT2 cells by an increase in the activity of glucose-6-phosphate dehydrogenase, the regulatory control of the pentose phosphate pathway. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 198-203 24056970-5 2013 Acrolein inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, leading to decreased substrate availability for mitochondrial respiration in RLE-6TN, H441, and pAT2 cells; the reduced GAPDH activity was compensated in pAT2 cells by an increase in the activity of glucose-6-phosphate dehydrogenase, the regulatory control of the pentose phosphate pathway. Acrolein 0-8 solute carrier family 36 (proton/amino acid symporter), member 2 Mus musculus 232-236 24056970-8 2013 Accordingly, a decrease in phosphatidylcholine levels and an increase in phospholipase A2 activity were found in the alveolar cells after acrolein exposure. Acrolein 138-146 phospholipase A2, group IB, pancreas Mus musculus 73-89 23953484-3 2013 Acrolein has been shown to cause cytotoxicity in the airways and induce inflammation and mucin production in pulmonary cells. Acrolein 0-8 LOC100508689 Homo sapiens 89-94 24152914-7 2013 It is suggested that the modification and inactivation of Cu,Zn-SOD by acrolein could be produced by more oxidative cell environments. Acrolein 71-79 superoxide dismutase 1 Homo sapiens 64-67 24172941-3 2013 Using behavioral testing, we found that TRPA1 knockout mice failed to avoid entering a chamber filled with vapor of formalin, allyl isothiocyanate, and acrolein. Acrolein 152-160 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 40-45 24152914-0 2013 Modification and inactivation of Cu,Zn-superoxide dismutase by the lipid peroxidation product, acrolein. Acrolein 95-103 superoxide dismutase 1 Homo sapiens 33-59 24152914-2 2013 The effects of acrolein on the structure and function of human Cu,Zn-superoxide dismutase (SOD) were examined. Acrolein 15-23 superoxide dismutase 1 Homo sapiens 63-89 24152914-3 2013 When Cu,Zn-SOD was incubated with acrolein, the covalent crosslinking of the protein was increased, and the loss of enzymatic activity was increased in a dose-dependent manner. Acrolein 34-42 superoxide dismutase 1 Homo sapiens 11-14 24152914-6 2013 When Cu,Zn-SOD that has been exposed to acrolein was subsequently analyzed by amino acid analysis, serine, histidine, arginine, threonine and lysine residues were particularly sensitive. Acrolein 40-48 superoxide dismutase 1 Homo sapiens 11-14 24012931-0 2013 The potential interaction of MARCKS-related peptide and diltiazem on acrolein-induced airway mucus hypersecretion in rats. Acrolein 69-77 myristoylated alanine rich protein kinase C substrate Rattus norvegicus 29-35 24012931-3 2013 To investigate the potential interaction of myristoylated alanine-rich C kinase substrate (MARCKS)-related peptide and diltiazem on acrolein-induced airway mucus hypersecretion in rats, rat model of airway mucus hypersecretion was established by inhalation of acrolein on 12 consecutive days. Acrolein 132-140 myristoylated alanine rich protein kinase C substrate Rattus norvegicus 91-97 24012931-9 2013 RESULTS: Instillation of MARCKS-related peptide attenuated the release of Muc5ac in BALF induced by acrolein(p<0.05). Acrolein 100-108 myristoylated alanine rich protein kinase C substrate Rattus norvegicus 25-31 24012931-9 2013 RESULTS: Instillation of MARCKS-related peptide attenuated the release of Muc5ac in BALF induced by acrolein(p<0.05). Acrolein 100-108 mucin 5AC, oligomeric mucus/gel-forming Rattus norvegicus 74-80 24241266-0 2013 Acrolein-induced oxidative stress in NAD(P)H Oxidase Subunit gp91phox knock-out mice and its modulation of NFkappaB and CD36. Acrolein 0-8 2,4-dienoyl CoA reductase 1, mitochondrial Mus musculus 37-44 24241266-0 2013 Acrolein-induced oxidative stress in NAD(P)H Oxidase Subunit gp91phox knock-out mice and its modulation of NFkappaB and CD36. Acrolein 0-8 paired Ig-like receptor B Mus musculus 61-65 24241266-0 2013 Acrolein-induced oxidative stress in NAD(P)H Oxidase Subunit gp91phox knock-out mice and its modulation of NFkappaB and CD36. Acrolein 0-8 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 107-115 24241266-3 2013 We examined the involvement of NAD(P)H oxidase and other oxidant system in acrolein toxicity using gp91phox knockout mice. Acrolein 75-83 2,4-dienoyl CoA reductase 1, mitochondrial Mus musculus 31-38 24131734-8 2013 RESULTS: Exposure to acrolein following OVA challenge of OVA-sensitized mice resulted in markedly attenuated allergic airway inflammation, demonstrated by decreased inflammatory cell infiltrates, mucus hyperplasia and Th2 cytokines. Acrolein 21-29 heart and neural crest derivatives expressed 2 Mus musculus 218-221 24131734-9 2013 Acrolein exposure rapidly depleted lung tissue glutathione (GSH) levels, and induced activation of the Nrf2 pathway, indicated by accumulation of Nrf2, increased alkylation of Keap1, and induction of Nrf2-target genes such as HO-1. Acrolein 0-8 nuclear factor, erythroid derived 2, like 2 Mus musculus 103-107 24131734-9 2013 Acrolein exposure rapidly depleted lung tissue glutathione (GSH) levels, and induced activation of the Nrf2 pathway, indicated by accumulation of Nrf2, increased alkylation of Keap1, and induction of Nrf2-target genes such as HO-1. Acrolein 0-8 nuclear factor, erythroid derived 2, like 2 Mus musculus 146-150 24131734-9 2013 Acrolein exposure rapidly depleted lung tissue glutathione (GSH) levels, and induced activation of the Nrf2 pathway, indicated by accumulation of Nrf2, increased alkylation of Keap1, and induction of Nrf2-target genes such as HO-1. Acrolein 0-8 kelch-like ECH-associated protein 1 Mus musculus 176-181 24131734-9 2013 Acrolein exposure rapidly depleted lung tissue glutathione (GSH) levels, and induced activation of the Nrf2 pathway, indicated by accumulation of Nrf2, increased alkylation of Keap1, and induction of Nrf2-target genes such as HO-1. Acrolein 0-8 nuclear factor, erythroid derived 2, like 2 Mus musculus 146-150 24131734-10 2013 Additionally, analysis of inflammatory signaling pathways showed suppressed activation of NF-kappaB and marginally reduced activation of JNK in acrolein-exposed lungs, associated with increased carbonylation of RelA and JNK. Acrolein 144-152 mitogen-activated protein kinase 8 Mus musculus 137-140 24131734-10 2013 Additionally, analysis of inflammatory signaling pathways showed suppressed activation of NF-kappaB and marginally reduced activation of JNK in acrolein-exposed lungs, associated with increased carbonylation of RelA and JNK. Acrolein 144-152 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 211-215 24131734-10 2013 Additionally, analysis of inflammatory signaling pathways showed suppressed activation of NF-kappaB and marginally reduced activation of JNK in acrolein-exposed lungs, associated with increased carbonylation of RelA and JNK. Acrolein 144-152 mitogen-activated protein kinase 8 Mus musculus 220-223 24131734-11 2013 CONCLUSION: Acrolein inhalation suppresses Th2-driven allergic inflammation in sensitized animals, due to direct protein alkylation resulting in activation of Nrf2 and anti-inflammatory gene expression, and inhibition of NF-kappaB or JNK signaling. Acrolein 12-20 heart and neural crest derivatives expressed 2 Mus musculus 43-46 24131734-11 2013 CONCLUSION: Acrolein inhalation suppresses Th2-driven allergic inflammation in sensitized animals, due to direct protein alkylation resulting in activation of Nrf2 and anti-inflammatory gene expression, and inhibition of NF-kappaB or JNK signaling. Acrolein 12-20 nuclear factor, erythroid derived 2, like 2 Mus musculus 159-163 24131734-11 2013 CONCLUSION: Acrolein inhalation suppresses Th2-driven allergic inflammation in sensitized animals, due to direct protein alkylation resulting in activation of Nrf2 and anti-inflammatory gene expression, and inhibition of NF-kappaB or JNK signaling. Acrolein 12-20 mitogen-activated protein kinase 8 Mus musculus 234-237 22970857-0 2013 Identification of a role for a mouse sperm surface aldo-keto reductase (AKR1B7) and its human analogue in the detoxification of the reactive aldehyde, acrolein. Acrolein 151-159 aldo-keto reductase family 1, member B7 Mus musculus 72-78 22970857-3 2013 Further functional characterisation of a recombinant form of AKR1B7 showed that the likely role of AKR1B7 is the reduction of the reactive aldehyde, acrolein, a by-product of spermine catabolism in the reproductive tract. Acrolein 149-157 aldo-keto reductase family 1, member B7 Mus musculus 61-67 22970857-3 2013 Further functional characterisation of a recombinant form of AKR1B7 showed that the likely role of AKR1B7 is the reduction of the reactive aldehyde, acrolein, a by-product of spermine catabolism in the reproductive tract. Acrolein 149-157 aldo-keto reductase family 1, member B7 Mus musculus 99-105 23953484-9 2013 Acrolein at 5-50 mug/mL increased expression of TNF-alpha and COX-2, as shown by RT-PCR and Western blotting. Acrolein 0-8 tumor necrosis factor Homo sapiens 48-57 23953484-9 2013 Acrolein at 5-50 mug/mL increased expression of TNF-alpha and COX-2, as shown by RT-PCR and Western blotting. Acrolein 0-8 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 23953484-10 2013 Acrolein exposure at 5-50 mug/mL for 2-24h increased MUC5AC expression, as determined by RT-PCR. Acrolein 0-8 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 53-59 23953484-11 2013 CONCLUSION: Acrolein decreased cell viability, induced an inflammatory response, and increased mucin gene expression in HMEECs. Acrolein 12-20 LOC100508689 Homo sapiens 95-100 23707493-9 2013 An increase of acrolein by acetaldehyde was SMO dependent. Acrolein 15-23 spermine oxidase Homo sapiens 44-47 23901044-5 2013 Acrolein induced the activity of Nrf2, NF-kappaB, and Sirt1. Acrolein 0-8 NFE2 like bZIP transcription factor 2 Homo sapiens 33-37 23901044-5 2013 Acrolein induced the activity of Nrf2, NF-kappaB, and Sirt1. Acrolein 0-8 nuclear factor kappa B subunit 1 Homo sapiens 39-48 23901044-5 2013 Acrolein induced the activity of Nrf2, NF-kappaB, and Sirt1. Acrolein 0-8 sirtuin 1 Homo sapiens 54-59 24024160-0 2013 Acrolein-induced activation of mitogen-activated protein kinase signaling is mediated by alkylation of thioredoxin reductase and thioredoxin 1. Acrolein 0-8 peroxiredoxin 5 Homo sapiens 103-124 23404573-5 2013 The results showed that acrolein induced SH-SY5Y cell apoptosis by activating mitochondria/caspase and MEK/ERK signaling pathways. Acrolein 24-32 mitogen-activated protein kinase kinase 7 Homo sapiens 103-106 23404573-5 2013 The results showed that acrolein induced SH-SY5Y cell apoptosis by activating mitochondria/caspase and MEK/ERK signaling pathways. Acrolein 24-32 mitogen-activated protein kinase 1 Homo sapiens 107-110 23305793-10 2013 Acrolein interacted with apolipoprotein B in LDL and Acro-LDL uptake by THP-1 macrophage was a more effective inducer of cholesterol accumulation than oxidized LDL uptake. Acrolein 0-8 apolipoprotein B Homo sapiens 25-41 23305793-10 2013 Acrolein interacted with apolipoprotein B in LDL and Acro-LDL uptake by THP-1 macrophage was a more effective inducer of cholesterol accumulation than oxidized LDL uptake. Acrolein 0-8 GLI family zinc finger 2 Homo sapiens 72-77 23220588-9 2013 Inhibiting ALDH or depleting GSH in hepatocytes increased cytotoxicity by about 3-fold in acrolein-treated hepatocytes. Acrolein 90-98 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 11-15 24024160-6 2013 Acrolein exposure of HBE1 cells induced dose-dependent activation of the MAP kinases, extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, and activation of JNK was markedly enhanced after selenite-mediated induction of TrxR1, and was associated with increased alkylation of TrxR1. Acrolein 0-8 mitogen-activated protein kinase 8 Homo sapiens 124-147 24024160-6 2013 Acrolein exposure of HBE1 cells induced dose-dependent activation of the MAP kinases, extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, and activation of JNK was markedly enhanced after selenite-mediated induction of TrxR1, and was associated with increased alkylation of TrxR1. Acrolein 0-8 mitogen-activated protein kinase 8 Homo sapiens 149-152 24024160-6 2013 Acrolein exposure of HBE1 cells induced dose-dependent activation of the MAP kinases, extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, and activation of JNK was markedly enhanced after selenite-mediated induction of TrxR1, and was associated with increased alkylation of TrxR1. Acrolein 0-8 mitogen-activated protein kinase 14 Homo sapiens 159-162 24024160-6 2013 Acrolein exposure of HBE1 cells induced dose-dependent activation of the MAP kinases, extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, and activation of JNK was markedly enhanced after selenite-mediated induction of TrxR1, and was associated with increased alkylation of TrxR1. Acrolein 0-8 mitogen-activated protein kinase 8 Homo sapiens 182-185 22964642-9 2013 Pre-treatment of Keap1(-/-) MEFs or A549 cells with the LY294002 PI3K inhibitor or the MK-2206 PKB/Akt inhibitor increased their sensitivity to acrolein, chlorambucil and cisplatin between 1.9-fold and 3.1-fold, and this was substantially attenuated by simultaneous pre-treatment with the GSK-3 inhibitor CT99021. Acrolein 144-152 kelch-like ECH-associated protein 1 Mus musculus 17-22 23633528-0 2013 Acrolein, an alpha,beta-unsaturated aldehyde, irreversibly inhibits the acetylation of aromatic amine xenobiotics by human arylamine N-acetyltransferase 1. Acrolein 0-8 N-acetyltransferase 1 Homo sapiens 123-154 23828398-3 2013 The oxidative products of spermine oxidase activity are spermidine, H2O2 and the aldehyde 3-aminopropanal that spontaneously turns into acrolein. Acrolein 136-144 spermine oxidase Homo sapiens 26-42 23515618-3 2013 We investigated whether treatment with the CB2 agonist GP1a alters severity of experimental cystitis induced by acrolein and referred mechanical hyperalgesia associated with cystitis. Acrolein 112-120 cannabinoid receptor 2 Homo sapiens 43-46 23515618-3 2013 We investigated whether treatment with the CB2 agonist GP1a alters severity of experimental cystitis induced by acrolein and referred mechanical hyperalgesia associated with cystitis. Acrolein 112-120 GTP binding protein 1 Homo sapiens 55-58 23515618-5 2013 We found that treatment with the selective CB2 agonist GP1a (1-10 mg/kg, ip) inhibited the severity of bladder inflammation 3 h after intravesical instillation of acrolein in a dose-dependent manner, and inhibition reached significance at a dose of 10 mg/kg (P < 0.05). Acrolein 163-171 cannabinoid receptor 2 Homo sapiens 43-46 23296102-8 2013 Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex. Acrolein 10-18 beta-secretase 1 Rattus norvegicus 74-80 23296102-8 2013 Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex. Acrolein 10-18 ADAM metallopeptidase domain 10 Rattus norvegicus 114-121 23313590-8 2013 Further study suggested that CA/CAPE showed protective effects against acrolein by modulating MAPKs and Akt/GSK3beta signaling pathways. Acrolein 71-79 thymoma viral proto-oncogene 1 Mus musculus 104-107 23313590-8 2013 Further study suggested that CA/CAPE showed protective effects against acrolein by modulating MAPKs and Akt/GSK3beta signaling pathways. Acrolein 71-79 glycogen synthase kinase 3 beta Mus musculus 108-116 24024160-6 2013 Acrolein exposure of HBE1 cells induced dose-dependent activation of the MAP kinases, extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, and activation of JNK was markedly enhanced after selenite-mediated induction of TrxR1, and was associated with increased alkylation of TrxR1. Acrolein 0-8 thioredoxin reductase 1 Homo sapiens 245-250 24024160-6 2013 Acrolein exposure of HBE1 cells induced dose-dependent activation of the MAP kinases, extracellular regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, and activation of JNK was markedly enhanced after selenite-mediated induction of TrxR1, and was associated with increased alkylation of TrxR1. Acrolein 0-8 thioredoxin reductase 1 Homo sapiens 300-305 24024160-7 2013 Conversely, siRNA silencing of TrxR1 significantly suppressed the ability of acrolein to activate JNK, and also appeared to attenuate acrolein-dependent activation of ERK and p38. Acrolein 77-85 thioredoxin reductase 1 Homo sapiens 31-36 24024160-7 2013 Conversely, siRNA silencing of TrxR1 significantly suppressed the ability of acrolein to activate JNK, and also appeared to attenuate acrolein-dependent activation of ERK and p38. Acrolein 77-85 mitogen-activated protein kinase 8 Homo sapiens 98-101 24024160-8 2013 Alteration of initial TrxR1 levels by siRNA or selenite supplementation also affected initial Trx1 redox status and acrolein-mediated alkylation of Trx1, but did not significantly affect acrolein-mediated activation of HO-1 or cytotoxicity. Acrolein 116-124 thioredoxin reductase 1 Homo sapiens 22-27 24024160-0 2013 Acrolein-induced activation of mitogen-activated protein kinase signaling is mediated by alkylation of thioredoxin reductase and thioredoxin 1. Acrolein 0-8 thioredoxin Homo sapiens 103-114 24024160-8 2013 Alteration of initial TrxR1 levels by siRNA or selenite supplementation also affected initial Trx1 redox status and acrolein-mediated alkylation of Trx1, but did not significantly affect acrolein-mediated activation of HO-1 or cytotoxicity. Acrolein 116-124 thioredoxin Homo sapiens 148-152 24024160-9 2013 Collectively, our findings indicate that alkylation of TrxR1 and/or Trx1 may contribute directly to acrolein-mediated activation of MAP kinases such as JNK, and may therefore be important in acrolein-induced alterations in airway epithelial function, as a contributing mechanism in tobacco-related respiratory disease. Acrolein 100-108 thioredoxin reductase 1 Homo sapiens 55-60 24024160-9 2013 Collectively, our findings indicate that alkylation of TrxR1 and/or Trx1 may contribute directly to acrolein-mediated activation of MAP kinases such as JNK, and may therefore be important in acrolein-induced alterations in airway epithelial function, as a contributing mechanism in tobacco-related respiratory disease. Acrolein 100-108 thioredoxin Homo sapiens 68-72 24024160-9 2013 Collectively, our findings indicate that alkylation of TrxR1 and/or Trx1 may contribute directly to acrolein-mediated activation of MAP kinases such as JNK, and may therefore be important in acrolein-induced alterations in airway epithelial function, as a contributing mechanism in tobacco-related respiratory disease. Acrolein 100-108 mitogen-activated protein kinase 8 Homo sapiens 152-155 23261472-3 2013 Acrolein-conjugated proteins were separated by gel electrophoresis with subsequent determination of their amino acid sequence, and it was found that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was one of the major acrolein-conjugated proteins in cells. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 149-189 23261472-3 2013 Acrolein-conjugated proteins were separated by gel electrophoresis with subsequent determination of their amino acid sequence, and it was found that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was one of the major acrolein-conjugated proteins in cells. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 191-196 23261472-3 2013 Acrolein-conjugated proteins were separated by gel electrophoresis with subsequent determination of their amino acid sequence, and it was found that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was one of the major acrolein-conjugated proteins in cells. Acrolein 219-227 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 149-189 23261472-3 2013 Acrolein-conjugated proteins were separated by gel electrophoresis with subsequent determination of their amino acid sequence, and it was found that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was one of the major acrolein-conjugated proteins in cells. Acrolein 219-227 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 191-196 23261472-4 2013 Acrolein interacted with cysteine-150 at the active site of GAPDH, and also with cysteine-282. Acrolein 0-8 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 60-65 23261472-5 2013 When cells were treated with 8 muM acrolein, the activity of acrolein-conjugated GAPDH was greatly reduced, and the ATP content in cells was thus significantly reduced. Acrolein 35-43 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 81-86 23261472-6 2013 In addition, it was shown that acrolein-conjugated GAPDH translocated to the nucleus, and the level of acetylated GAPDH and the number of TUNEL positive cells was increased, indicating that cell death is enhanced by acrolein-conjugated GAPDH. Acrolein 31-39 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 51-56 23261472-6 2013 In addition, it was shown that acrolein-conjugated GAPDH translocated to the nucleus, and the level of acetylated GAPDH and the number of TUNEL positive cells was increased, indicating that cell death is enhanced by acrolein-conjugated GAPDH. Acrolein 216-224 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 51-56 23261472-6 2013 In addition, it was shown that acrolein-conjugated GAPDH translocated to the nucleus, and the level of acetylated GAPDH and the number of TUNEL positive cells was increased, indicating that cell death is enhanced by acrolein-conjugated GAPDH. Acrolein 216-224 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 114-119 23261472-6 2013 In addition, it was shown that acrolein-conjugated GAPDH translocated to the nucleus, and the level of acetylated GAPDH and the number of TUNEL positive cells was increased, indicating that cell death is enhanced by acrolein-conjugated GAPDH. Acrolein 216-224 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 114-119 23261472-7 2013 Inhibition of cell growth by acrolein was partially reversed when the cDNA encoding GAPDH was transformed into cells. Acrolein 29-37 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 84-89 23261472-8 2013 These results indicate that inactivation of GAPDH is one mechanism that underlies cell toxicity caused by acrolein. Acrolein 106-114 glyceraldehyde-3-phosphate dehydrogenase Mus musculus 44-49